Drug;Gene;Genotype;Alleles;Outcome;Variation;Effect;Entity
NIFEDIPINE;CYP3A4;CYP3A4*1, CYP3A4*17;*17;OTHER, LADME-PK;DECREASED_METABOLISM;;
SITAGLIPTIN;DPP4;rs2909451;TT;EFFICACY;DECREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;;
SITAGLIPTIN;KCNJ11;rs2285676;GG;EFFICACY;INCREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
WARFARIN;CYP2C9;CYP2C9*11;*11/*11;DOSAGE;DECREASED_DOSE;;
SITAGLIPTIN;KCNQ1;rs163184;GG;EFFICACY;DECREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*18;*1/*18;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
SITAGLIPTIN;DPP4;rs4664443;GG;EFFICACY;DECREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
CODEINE;CYP2D6;CYP2D6*1xN;*1xN;LADME-PK;INCREASED_METABOLISM;;
SITAGLIPTIN;CYP2C9;rs1799853;TT;EFFICACY;DECREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
SITAGLIPTIN;GLP1R;rs3765467;AG;EFFICACY;INCREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
IVACAFTOR / LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
FLUOXETINE;CYP2C19;CYP2C19 intermediate metabolizer;;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER
PAROXETINE;CYP2C19;CYP2C19 ultrarapid metabolizer;;EFFICACY;DECREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER
SITAGLIPTIN;GLP1R;rs6923761;AA;EFFICACY;DECREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
CODEINE;CYP2D6;CYP2D6*2, CYP2D6*2xN;*2/*2xN;LADME-PK;INCREASED_METABOLISM;;
EXENATIDE, LIRAGLUTIDE;GLP1R;rs3765467;GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
 CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;CYP2C19;CYP2C19 poor metabolizer;;EFFICACY;DECREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER
ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;GLP1R;rs6923761;A;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
EXENATIDE;TCF7L2;rs7903146;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
RIFAPENTINE;NAT2;NAT2 slow acetylator;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE
EFAVIRENZ;CYP2B6;CYP2B6 poor metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;LADME-PK;DECREASED_EXPOSURE;OTHER;HISTORY OF GASTRIC BYPASS SURGERY
ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;ARRB1;rs140226575;A;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
EFAVIRENZ;NAT2;NAT2 slow acetylator;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE
PROPAFENONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;CARDIAC RHYTHM DISEASE
PROPAFENONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;EFFICACY;INCREASED_RESPONSE;DISEASE;CARDIAC RHYTHM DISEASE
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4, CYP2D6*6;*4/*6;LADME-PK;DECREASED_METABOLISM;;
NEVIRAPINE;NAT2;NAT2 slow acetylator;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE
ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;ARRB1;rs78979036;A;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
METHADONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*2xN;*1/*2xN + *2/*2xN;EFFICACY;INCREASED_RESPONSE;OTHER;OPIOID-RELATED DISORDERS
LURBINECTEDIN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*1;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION
ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;ARRB1;rs78052828;T;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
METHYLMERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;SEVERE CUTANEOUS ADVERSE REACTIONS
ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;ARRB1;rs58428187;C;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*36;*10/*36;DOSAGE;INCREASED_DOSE;OTHER;BREAST NEOPLASMS
RALOXIFENE 6-GLUCURONIDE, RALOXIFENE-4â€²-GLUCURONIDE;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;OSTEOPOROSIS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION, DISEASE:HIV INFECTIOUS DISEASE
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*17;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;LADME-PK;DECREASED_CLEARANCE;;
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;CYP1A2*35;*35;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED_EXPOSURE;OTHER;LACTATION
LURBINECTEDIN;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME-PK;INCREASED_CLEARANCE;OTHER;NEOPLASMS
LURBINECTEDIN;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;NEOPLASMS
LEFLUNOMIDE;PON1;rs705379;GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;DOSAGE;DECREASED_DOSE;DISEASE;COLORECTAL NEOPLASMS
LETROZOLE;CYP2A6;rs56113850;T;;INCREASED_CONCENTRATIONS;OTHER;BREAST NEOPLASMS
TRAMADOL;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED_EXPOSURE;;
(S)-METHADONE;CYP2B6;CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7;*6/*6;LADME-PK;INCREASED_CONCENTRATIONS;;
ANTIEPILEPTICS;SCN1A;rs2298771;C;EFFICACY;INCREASED_RESISTANCE;OTHER;EPILEPSY
ANTIEPILEPTICS;SCN1A;rs10167228;T;EFFICACY;INCREASED_RESISTANCE;OTHER;EPILEPSY
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10;*3/*4 + *4/*4;LADME-PK;DECREASED_CONCENTRATIONS;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;DOSAGE;DECREASED_DOSE;;
CODEINE;CYP2D6;CYP2D6*2, CYP2D6*2xN;*2/*2xN;LADME-PK;INCREASED_METABOLISM;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*5;*1/*5;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*11;*1/*11;DOSAGE;DECREASED_DOSE;;
METHADONE;;low activity;;LADME-PK;INCREASED_TROUGH CONCENTRATION;;
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;LADME-PK;DECREASED_METABOLISM;OTHER;NEOPLASMS
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;LADME-PK;DECREASED_METABOLISM;OTHER;NEOPLASMS
CARVEDILOL;UGT1A1;UGT1A1*1, UGT1A1*28;*28;LADME-PK;INCREASED_METABOLISM;OTHER;ANGINA PECTORIS
LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;;
ACENOCOUMAROL;VKORC1;rs9934438;A;DOSAGE;DOSE;OTHER;A STABLE MAINTENANCE DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3 + *1/*3;DOSAGE;DECREASED_DOSE;;
LIRAGLUTIDE;CNR1;rs1049353;CT + TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2, OTHER:OBESITY
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;DECREASED_CONCENTRATIONS;;
FLUVOXAMINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
CLONIDINE;ADRA2C;rs11269124;GGGGAGCTTTCCCAGAGACCC/del + del/del;EFFICACY;INCREASED_RESPONSE;DISEASE;LIVER CIRRHOSIS
SIMVASTATIN ACID;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;CARDIOVASCULAR DISEASE, OTHER:DYSLIPIDAEMIA
SIMVASTATIN ACID;SLCO1B1;rs2306283;AG + GG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;CARDIOVASCULAR DISEASE, OTHER:DYSLIPIDAEMIA
DEXTROMETHORPHAN;CYP2D6;CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5;*4/*2xN;LADME-PK;INCREASED_METABOLISM;OTHER;HYPERCHOLESTEROLEMIA
ASPIRIN;P2RY1;rs1371097;T;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;STROKE
ASPIRIN;ABCB1;rs1045642;GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;STROKE
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*28;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;COLONIC NEOPLASMS
DEXTROMETHORPHAN;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;;
SIROLIMUS;CYP3A4;CYP3A4*8, CYP3A4*20;*8/*20;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;SEIZURES, OTHER:INTESTINAL DISEASES, OTHER:CONGENITAL ABNORMALITIES
DEXTROMETHORPHAN;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;;
RIBAVIRIN, SOFOSBUVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION
RIFAMPIN;SLCO1B1;rs4149032;TT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;TUBERCULOSIS
MODAFINIL;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;OTHER;METHAMPHETAMINE DEPENDENCE
ISONIAZID;;rs1495741;AA;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;TUBERCULOSIS
VALSARTAN;AGT;rs699;GG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;HYPERTENSION
NALTREXONE;OPRM1;rs1799971;G;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;ALCOHOL ABUSE
IVACAFTOR;CFTR;rs113993960;del;EFFICACY;INCREASED_RESPONSE;;
IVACAFTOR;CFTR;rs113993960;del;EFFICACY;INCREASED_RESPONSE;;
IVACAFTOR;CFTR;rs113993960;del;EFFICACY;INCREASED_RESPONSE;;
IVACAFTOR;CFTR;rs113993960;del;EFFICACY;INCREASED_RESPONSE;DISEASE;CYSTIC FIBROSIS
ELEXACAFTOR;CFTR;CFTR deficiency;;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;CYSTIC FIBROSIS
REMIFENTANIL;ADRA2A;rs1800544;CG + GG;DOSAGE;INCREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
WARFARIN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;DOSAGE;INCREASED_DOSE;OTHER;THROMBOEMBOLISM
REMIFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
ELIGLUSTAT;CYP2D6;CYP2D6 ultrarapid metabolizer;;DOSAGE;INCREASED_DOSE;OTHER;GAUCHER DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;OTHER;LIVER TRANSPLANTATION
POSACONAZOLE, TACROLIMUS;ABCB1;rs1045642;GG;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*6;*6;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
LACOSAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY
TACROLIMUS;CYP3A5;CYP3A5*3;*3;DOSAGE;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*7;*7;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;DEPRESSIVE DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;DEPRESSIVE DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_DOSE;DISEASE;ORGAN TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;DECREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;ULCERATIVE COLITIS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;CONCENTRATIONS;;
COUMARIN;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*10;*4/*4 + *4/*10;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2;*1/*2 + *2/*2;DOSAGE;DECREASED_DOSE;DISEASE;TOBACCO USE DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
BELINOSTAT;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*60;*28/*28 + *1/*60 + *60/*60;DOSAGE;DECREASED_DOSE;OTHER;NEOPLASMS
MOXIFLOXACIN;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*36, UGT1A1*37;*1/*36;LADME-PK;DECREASED_CLEARANCE;DISEASE;TUBERCULOSIS
DEXTROMETHORPHAN;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;OTHER;BREAST NEOPLASMS
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*46;*46/*46;LADME-PK;INCREASED_CLEARANCE;;
BUPRENORPHINE;SLC39A10;rs149319538;C;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;OPIOID-RELATED DISORDERS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE, LADME-PK;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2/*2;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;HEART DISEASES
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;DISEASE;VENOUS THROMBOEMBOLISM
SIMVASTATIN, WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE, LADME-PK;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE, LADME-PK;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;DISEASE;ATRIAL FIBRILLATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*4;*4;LADME-PK;DECREASED_METABOLISM;;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE, LADME-PK;DOSE;;
LETROZOLE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12;*1/*1;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
LETROZOLE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*46;*1/*46 + *1/*46 + *46/*46;LADME-PK;INCREASED_CLEARANCE;;
WARFARIN;CYP4F2;CYP4F2*3;*3;DOSAGE;DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT, OTHER:ATRIAL FIBRILLATION, OTHER:STROKE, OTHER:PULMONARY EMBOLISM, OTHER:VENOUS THROMBOSIS
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT, OTHER:ATRIAL FIBRILLATION, OTHER:STROKE, OTHER:PULMONARY EMBOLISM, OTHER:VENOUS THROMBOSIS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;;
ARIPIPRAZOLE;DRD2;rs1799732;G/del;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOAFFECTIVE DISORDER
RIVAROXABAN;ABCB1;rs4148738;CC;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION
RIVAROXABAN;ABCB1;rs1128503;AA;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION
METHOTREXATE;TYMS;rs2853542;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A;*1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*33, TPMT*34;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;DOSAGE;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
METHOTREXATE;ATIC;rs4673993;TT;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
FLUOXETINE;HTR1A;rs6295;GG;EFFICACY;INCREASED_RESPONSE;EFFICACY;MAJOR DEPRESSIVE DISORDER
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*41;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER;SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE DISORDER, OTHER:BIPOLAR DISORDER, OTHER:DEPRESSIVE DISORDER
SN-38;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28, UGT1A1*60;*6/*60 + *6/*28;LADME-PK;DECREASED_METABOLISM;DISEASE;NEOPLASMS
TAMOXIFEN;CYP2D6;rs16947;A;EFFICACY, TOXICITY;INCREASED_DISCONTINUATION;OTHER;BREAST NEOPLASMS
DIHYDROPYRIDINE DERIVATIVES;NUMA1;rs10898815;AA + AG;OTHER;INCREASED_DISCONTINUATION;;
TAMOXIFEN;ABCC2;rs3740065;G;EFFICACY, TOXICITY;INCREASED_DISCONTINUATION;OTHER;BREAST NEOPLASMS
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;DOSAGE;DECREASED_DOSE;;
HYDRALAZINE;NAT2;NAT2 rapid acetylator;;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;HYPERTENSION
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;DISEASE;HEART TRANSPLANTATION
LANSOPRAZOLE;CYP2C19;CYP2C19 poor metabolizer;;LADME-PK;DECREASED_CLEARANCE;OTHER;GASTROESOPHAGEAL REFLUX
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17;LADME-PK;DECREASED_METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE
SULFONAMIDES, UREA DERIVATIVES;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2  + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
CORTICOSTEROIDS;NR3C1;rs10482634;GG;EFFICACY;INCREASED_RESISTANCE;OTHER;NEPHROTIC SYNDROME
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*10, CYP2C9*11;*11 + *2 + *3 + *5 + *6;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_DOSE;DISEASE;HEART TRANSPLANTATION
VALPROIC ACID;UGT1A6;rs6759892;TT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;EPILEPSY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE;LIVER TRANSPLANTATION
METHYLPHENIDATE;SYT1;rs2251214;AA + AG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE;LIVER TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE;LIVER TRANSPLANTATION
VORICONAZOLE;CYP2C19;CYP2C19*17;*17/*17;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;SEVERE COMBINED IMMUNODEFICIENCY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
HYDRALAZINE;NAT2;NAT2 slow acetylator;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HYPERTENSION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION
CHOP, RITUXIMAB;CBR3;rs8133052;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER;NON-HODGKIN LYMPHOMA
CHOP, RITUXIMAB;ABCC2;rs8187710;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER;NON-HODGKIN LYMPHOMA
N-DESMETHYLTAMOXIFEN;SEPTIN3;rs11914200;AG;LADME-PK;DECREASED_METABOLISM;;
FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;NEOPLASMS, DISEASE:PAIN
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;rs34130495;A;EFFICACY, LADME-PK;DECREASED_RESPONSE;;
N-DESMETHYLTAMOXIFEN;SREBF2;rs133290;AC;LADME-PK;DECREASED_METABOLISM;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;DISEASE;VENOUS THROMBOEMBOLISM
N-DESMETHYLTAMOXIFEN;TCF20;rs5751251;GG;LADME-PK;INCREASED_METABOLISM;;
N-DESMETHYLTAMOXIFEN;SREBF2;rs2267439;TT;LADME-PK;INCREASED_METABOLISM;;
N-DESMETHYLTAMOXIFEN;SREBF2;rs9607850;TT;LADME-PK;INCREASED_METABOLISM;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE, LADME-PK;DECREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION
N-DESMETHYLTAMOXIFEN;CENPM, SMIM45;rs8140869;AG;LADME-PK;DECREASED_METABOLISM;;
RIBAVIRIN, SOFOSBUVIR;IFNL4;rs11322783;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
VARENICLINE;CYP2A6;CYP2A6 high activity;;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*24;*2/*24;DOSAGE;DECREASED_CLEARANCE;OTHER;CARDIOMYOPATHIES
ETOPOSIDE;;rs446112;AA;OTHER;INCREASED_RESISTANCE;;
ROSUVASTATIN;ABCG2;rs2231142;GT + TT;LADME-PK;INCREASED_EXPOSURE;OTHER;DIABETES MELLITUS, OTHER:HYPERCHOLESTEROLEMIA
FLUVOXAMINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
PAROXETINE;CYP2D6;CYP2D6*2;*2/*2;LADME-PK;INCREASED_CLEARANCE;DISEASE;MAJOR DEPRESSIVE DISORDER
OPIOIDS;CYP2D6;CYP2D6 poor and ultrarapid metabolizers;;EFFICACY;DECREASED_RESPONSE;DISEASE;PAIN
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*24;*2/*24;DOSAGE;DECREASED_DOSE;OTHER;CARDIOMYOPATHIES
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE;PANIC DISORDER
IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;;
AFATINIB;EGFR;rs28929495;GG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;NON-SMALL CELL LUNG CARCINOMA
HYDROMORPHONE;CYP2D6;CYP2D6*5, CYP2D6*17;*5/*17;LADME-PK;DECREASED_CONCENTRATIONS;;
IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
3-AMINOISOBUTYRATE;DPYD;rs3918290;TT;LADME-PK;DECREASED_CONCENTRATIONS;;
HYDRALAZINE;NAT2;NAT2 rapid acetylator;;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;HYPERTENSION
MEXILETINE;CYP2D6;CYP2D6*41;*41;EFFICACY;DECREASED_RESPONSE;OTHER;MYOTONIC DYSTROPHY, OTHER:NONDYSTROPHIC MYOTONIA
HYDROCODONE, TRAMADOL;CYP2D6;CYP2D6*5, CYP2D6*17;*5/*17;EFFICACY;DECREASED_RESPONSE;;
3-AMINOISOBUTYRATE;UPB1;rs143493067;AA;LADME-PK;DECREASED_CONCENTRATIONS;;
3-AMINOISOBUTYRATE;AGXT2;rs114286107;TT;LADME-PK;INCREASED_CONCENTRATIONS;;
FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;PAIN, POSTOPERATIVE
URACIL;DPYD;rs3918290;TT;LADME-PK;INCREASED_CONCENTRATIONS;;
2-AMINOHEPTANOATE, 2-AMINOOCTANOIC ACID, 2-HYDROXYLAURATE;ACAD11;rs41272317;AA;LADME-PK;INCREASED_CONCENTRATIONS;;
CYSTEINE-S-SULFATE, L-ORNITHINE;NPC2;rs140130028;TT;LADME-PK;INCREASED_CONCENTRATIONS;;
HYDRALAZINE;NAT2;NAT2 slow acetylator;;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION
5,6-DIHYDROTHYMINE;UPB1;rs143493067;AA;LADME-PK;INCREASED_CONCENTRATIONS;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
HYDRALAZINE;NAT2;NAT2 slow acetylator;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HYPERTENSION
10-MONOHYDROXY OXCARBAZEPINE;ABCC2;rs2273697;G;LADME-PK;INCREASED_CLEARANCE;OTHER;EPILEPSY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;;
RIVAROXABAN;CYP3A5;rs776746;TT;TOXICITY;DECREASED_CONCENTRATIONS;OTHER;VENOUS THROMBOEMBOLISM
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT
CYTARABINE;SLC29A1;rs2396243;T;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;LEUKEMIA, MYELOID, ACUTE
CYTARABINE;NME4;rs5841;CT + TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;LEUKEMIA, MYELOID, ACUTE
PRAZIQUANTEL;CYP1A2;CYP1A2*1, CYP1A2*30;*1/*30 + *30/*30;LADME-PK;INCREASED_METABOLISM;OTHER;SCHISTOSOMIASIS
PRAZIQUANTEL;CYP2C9;CYP2C9*1, CYP2C9*9;*1/*9 + *9/*9;LADME-PK;INCREASED_METABOLISM;OTHER;SCHISTOSOMIASIS
CYTARABINE;CDA;rs10916819;AG + GG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;LEUKEMIA, MYELOID, ACUTE
CYTARABINE;CMPK1;rs17103168;AG + GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;LEUKEMIA, MYELOID, ACUTE
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
CYTARABINE;CTPS1;rs12067645;A;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;LEUKEMIA, MYELOID, ACUTE
CYTARABINE;RRM1;rs11030918;CC;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;LEUKEMIA, MYELOID, ACUTE
CYTARABINE;DCK;rs4643786;C;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;LEUKEMIA, MYELOID, ACUTE
CYTARABINE;RRM2;rs1138729;AG + GG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;LEUKEMIA, MYELOID, ACUTE
CYTARABINE;CMPK1;rs1044457;CT + TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;LEUKEMIA, MYELOID, ACUTE
CYTARABINE;SLC28A3;rs17343066;AA;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;LEUKEMIA, MYELOID, ACUTE
ARIPIPRAZOLE;CYP2D6;rs1065852;AA + AG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;TIC DISORDERS
ARIPIPRAZOLE;CYP2D6;rs1080989;CT + TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;TIC DISORDERS
QUINAPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;;
ARIPIPRAZOLE;CYP2D6;rs1080989;CT + TT;EFFICACY;DECREASED_CLEARANCE;OTHER;TIC DISORDERS
CYCLOPHOSPHAMIDE;CYP3A4;rs2740574;CC + CT;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*1, CYP3A5*3;*3;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
WARFARIN;CYP2C9;rs72558189;A;DOSAGE;DOSE;;
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES
WARFARIN;CYP2C9;rs28371686;C;DOSAGE;DOSE;;
WARFARIN;CYP2C9;rs1057910;A;DOSAGE;DOSE;;
WARFARIN;CYP4F2;rs2108622;C;DOSAGE;DOSE;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION
TACROLIMUS;UGT1A4;rs2011425;TT;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION
TACROLIMUS;CYP3A4;rs35599367;GG;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION
ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_EXPOSURE;OTHER;DIABETES MELLITUS, OTHER:HYPERCHOLESTEROLEMIA
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*22;DOSAGE;DECREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;DECREASED_DOSE;DISEASE;LIVER TRANSPLANTATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2/*3;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*28;*28;LADME-PK;INCREASED_EXPOSURE;DISEASE;HIV INFECTIOUS DISEASE
ALOGLIPTIN;PNPLA3;rs738409;CG + GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2, OTHER:FATTY LIVER DISEASE, OTHER:BODY WEIGHT CHANGES
AMLODIPINE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HYPERTENSION
IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;CTT/del;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
SERTRALINE;DRD3;rs167770;AG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;OBSESSIVE-COMPULSIVE DISORDER
SERTRALINE;DRD3;rs11721264;AG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;OBSESSIVE-COMPULSIVE DISORDER
ILOPERIDONE, ILOPERIDONE METABOLITE P88;CYP2D6;rs1065852;AA;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;DECREASED_RESPONSE;;
IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*4;*1/*4;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
VALPROIC ACID;CACNA1H;rs3751664;T;EFFICACY;INCREASED_RESISTANCE;OTHER;EPILEPSY
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;DISEASE;DEPRESSIVE DISORDER
PENICILLIN G;IFNG;rs1861494;CC;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;SYPHILIS
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE;DISEASE;ACUTE CORONARY SYNDROME
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE;;
PENICILLIN G;IFNG;rs2430561;TT;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;SYPHILIS
IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
IMIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN;*1/*1xN + *1/*2xN;DOSAGE;INCREASED_DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER
ISONIAZID;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7;*6/*6 + *6/*7 + *7/*7;LADME-PK;DECREASED_METABOLISM;OTHER;TUBERCULOSIS
SIMVASTATIN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HYPERCHOLESTEROLEMIA
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE, LADME-PK;DECREASED_METABOLISM;DISEASE;LIVER TRANSPLANTATION
IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME-PK;DECREASED_METABOLISM;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5;*3 + *5 + *2 + *1;DOSAGE;DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE;;
VENETOCLAX;CYP3A5;rs776746;CC;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LEUKEMIA, MYELOID, ACUTE
CLOZAPINE;NFIB;rs28379954;CT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;SCHIZOPHRENIA
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A4;rs2740574;TT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME-PK;INCREASED_METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX
METHYLPHENIDATE;SLC6A2;rs998424;GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME-PK;DECREASED_METABOLISM;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;LUPUS NEPHRITIS
LITHIUM;;rs7405404;T;EFFICACY;INCREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
NICOTINE;CYP2A6;rs28399454;CT + TT;LADME-PK;DECREASED_METABOLISM;;
3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*41;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2 + *2/*2;DOSAGE;DECREASED_DOSE;;
EFAVIRENZ;CYP2B6;rs28399499;C;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;rs35167514;del;EFFICACY, LADME-PK;DECREASED_RESPONSE;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;;
FENTANYL;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;DOSAGE;INCREASED_DOSE;OTHER;GASTROINTESTINAL NEOPLASMS, OTHER:PAIN, POSTOPERATIVE
VARENICLINE;HYKK;rs7164594;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER
SIROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
VORICONAZOLE;CYP2C19;CYP2C19*17;*17/*17;EFFICACY;DECREASED_RESPONSE;DISEASE;FUNGAL INFECTIOUS DISEASE
4-HYDROXYTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
CAPTOPRIL;ACE;rs1799752;del/del;EFFICACY;DECREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*41;*4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;;
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5;*1/*1;LADME-PK;INCREASED_METABOLISM;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
VENLAFAXINE;CYP2D6;CYP2D6*4, CYP2D6*5;*4/*5;LADME-PK;DECREASED_METABOLISM;;
ENALAPRIL, LOSARTAN;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_RESPONSE;DISEASE;CORONARY DISEASE
VENLAFAXINE;CYP2C19;CYP2C19*2;*2/*2;LADME-PK;DECREASED_METABOLISM;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
BENAZEPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;DISEASE;ESSENTIAL HYPERTENSION
BUPROPION;CYP2B6;rs8109525;GG;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5;*1/*1;DOSAGE;INCREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;DECREASED_CLEARANCE;DISEASE;NEPHROTIC SYNDROME
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*41;*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
MESALAZINE, THIOGUANINE;NAT1;NAT1*3, NAT1*4, NAT1*10;*10;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;ULCERATIVE COLITIS, DISEASE:CROHN DISEASE, DISEASE:INFLAMMATORY BOWEL DISEASES
PIOGLITAZONE;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME-PK;INCREASED_METABOLISM;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;ULCERATIVE COLITIS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;ORGAN TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_TROUGH CONCENTRATION;DISEASE;ORGAN TRANSPLANTATION
EXEMESTANE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
WARFARIN;CYP4F2;CYP4F2*1, CYP4F2*3;*3;DOSAGE;INCREASED_DOSE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DISEASE;HEART TRANSPLANTATION
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*4 + *5;LADME-PK;DECREASED_METABOLISM;DISEASE;SCHIZOPHRENIA
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14;*4 + *5 + *10 +*14;LADME-PK;DECREASED_METABOLISM;DISEASE;SCHIZOPHRENIA
METOPROLOL;CYP2D6;CYP2D6*4;*4;DOSAGE;DECREASED_DOSE;DISEASE;HEART FAILURE
CETUXIMAB;VEGFA;rs144854329;del/del;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;LADME-PK;DECREASED_METABOLISM;OTHER;NEOPLASMS
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE;RHEUMATOID ARTHRITIS, DISEASE:ULCERATIVE COLITIS
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;INCREASED_TROUGH CONCENTRATION;DISEASE;ULCERATIVE COLITIS
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;LADME-PK;DECREASED_CLEARANCE;OTHER;NEOPLASMS
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*6;*1/*6;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;DOSAGE;INCREASED_TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DOSE;DISEASE;STROKE
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*3/*4 + *4/*4 + *4/*5;LADME-PK;DECREASED_METABOLISM;;
LETROZOLE;;rs7937;C;;INCREASED_CONCENTRATIONS;OTHER;BREAST NEOPLASMS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY
PROPOFOL;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*1 + *1/*2;LADME-PK;DECREASED_CONCENTRATIONS;;
WARFARIN;VKORC1;rs104894540;G;DOSAGE;INCREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME-PK;CLEARANCE;DISEASE;HEART DISEASES
CODEINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;DECREASED_RESPONSE;OTHER;PAIN
LANSOPRAZOLE, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
NOROXYCODONE, OXYCODONE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME-PK;INCREASED_CONCENTRATIONS;;
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, PAROXETINE, SERTRALINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;DEPRESSION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION
DISULFIRAM;SLC6A3;rs28363170;GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT/GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT;EFFICACY;INCREASED_RESPONSE;OTHER;COCAINE DEPENDENCE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;DOSAGE;INCREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY
BENAZEPRIL, PERINDOPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*4/*4;LADME-PK;DECREASED_CLEARANCE;DISEASE;PSYCHOTIC DISORDER
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;DOSAGE;DECREASED_DOSE;;
THIOGUANINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;CROHN DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME-PK;INCREASED_CLEARANCE;OTHER;HUMAN LIVER MICROSOMES
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;DISEASE;ULCERATIVE COLITIS
PROGUANIL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DISEASE;MALARIA
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C + *3A/*3A;DOSAGE;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
CITALOPRAM;CYP2C19;CYP2C19*17;*17/*17;EFFICACY;DECREASED_RESPONSE;DISEASE;OBSESSIVE-COMPULSIVE DISORDER
N-DESMETHYLCLOZAPINE;CYP2C19;CYP2C19*1, CYP2C19*17;*17;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;SCHIZOAFFECTIVE DISORDER, DISEASE:SCHIZOPHRENIA
CLOZAPINE;CYP2C19;CYP2C19*17;*17/*17;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOAFFECTIVE DISORDER, DISEASE:SCHIZOPHRENIA
WARFARIN;VKORC1;rs104894541;C;DOSAGE;INCREASED_DOSE;;
EFAVIRENZ;CYP2B6;rs36118214;GG;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
WARFARIN;VKORC1;rs104894539;A;DOSAGE;INCREASED_DOSE;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME-PK;DECREASED_METABOLISM;DISEASE;NON-HODGKIN LYMPHOMA
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*30;*1/*30;LADME-PK;DECREASED_METABOLISM;DISEASE;NON-HODGKIN LYMPHOMA
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*29;*1/*29;LADME-PK;DECREASED_METABOLISM;DISEASE;NON-HODGKIN LYMPHOMA
LANSOPRAZOLE, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
CYCLOPHOSPHAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME-PK;DECREASED_METABOLISM;DISEASE;NON-HODGKIN LYMPHOMA
QUINAPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del;EFFICACY;INCREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
CYCLOPHOSPHAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-HODGKIN LYMPHOMA
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;DISEASE;ATRIAL FIBRILLATION, DISEASE:VENOUS THROMBOEMBOLISM
TESTOSTERONE;UGT1A4;UGT1A4*1a, UGT1A4*3a;*3a;EFFICACY, LADME-PK;INCREASED_CLEARANCE;;
CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-HODGKIN LYMPHOMA
HYDRALAZINE;NAT2;NAT2 slow acetylator;;LADME-PK;DECREASED_METABOLISM;OTHER;HYPERTENSION
ACENOCOUMAROL;CYP2C9;CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DOSE;;
LAMOTRIGINE;UGT1A4;UGT1A4*1a, UGT1A4*2, UGT1A4*3a;*2 + *3a;EFFICACY, LADME-PK;DECREASED_CLEARANCE;;
CURCUMIN, IVACAFTOR;CFTR;rs77010898;AA + AG;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;MENTAL DISORDERS
3-HYDROXYCOTININE;CYP2A6;CYP2A6*1, CYP2A6*12;*1/*12;LADME-PK;DECREASED_CONCENTRATIONS;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME-PK;DECREASED_METABOLISM;DISEASE;MENTAL DISORDERS
CAPTOPRIL;ACE;rs1799752;del/del;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;LIVER TRANSPLANTATION
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;DOSAGE, LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE;LIVER TRANSPLANTATION
METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*45, CYP2D6*46;*9 + *29 + *45 + *46 + *17 + *10;TOXICITY, LADME-PK;DECREASED_METABOLISM;DISEASE;HYPERTENSION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_RESISTANCE;OTHER;CORONARY DISEASE
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_CLEARANCE;DISEASE;MAJOR DEPRESSIVE DISORDER
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;DOSAGE, LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
METHOTREXATE;HLA-G;rs371194629;del/del;EFFICACY;INCREASED_RESPONSE;EFFICACY;RHEUMATOID ARTHRITIS
METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*4 + *3 + *5  + *6;TOXICITY, LADME-PK;DECREASED_METABOLISM;DISEASE;HYPERTENSION
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;LADME-PK;DECREASED_METABOLISM;DISEASE;NEOPLASMS
ESOMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*17;EFFICACY;DECREASED_RESPONSE;OTHER;EOSINOPHILIC ESOPHAGITIS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;DOSAGE, LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;NEOPLASMS
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6/*6 + *28/*28 + *6/*28;DOSAGE;DECREASED_DOSE;DISEASE;NEOPLASMS
CAPTOPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;;
IVACAFTOR, TEZACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;LADME-PK;INCREASED_METABOLISM;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;DOSAGE;DECREASED_DOSE;;
LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;HYPERTENSION
CHIGLITAZAR;PPARA;rs1800234;CC + CT;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
LAMOTRIGINE;UGT1A4;UGT1A4*1a, UGT1A4*1b;*1b;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;EPILEPSY
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*5 + *10;LADME-PK;DECREASED_METABOLISM;DISEASE;SCHIZOPHRENIA
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3 + *4;LADME-PK;DECREASED_METABOLISM;DISEASE;SCHIZOPHRENIA
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*1/*4 + *3/*4;LADME-PK;DECREASED_METABOLISM;OTHER;SCHIZOPHRENIA
AZATHIOPRINE, MERCAPTOPURINE;TPMT;TPMT low activity;;LADME-PK;DECREASED_METABOLISM;;
O-DESMETHYLTRAMADOL;SLC22A1;SLC22A1 deficiency;;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;PAIN
MERCAPTOPURINE;TPMT;TPMT intermediate activity;;EFFICACY;INCREASED_RESPONSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
FENTANYL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
SULFASALAZINE;NAT2;NAT2 slow acetylator;;OTHER;INCREASED_DISCONTINUATION;DISEASE;RHEUMATOID ARTHRITIS
FENTANYL;CYP3A4;rs2242480;T/T;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;PAIN, POSTOPERATIVE
ETHANOL;OPRM1;rs1799971;G;DOSAGE;INCREASED_DOSE;;
SUFENTANIL;CYP3A4;rs2242480;T/T;EFFICACY;INCREASED_RESPONSE;OTHER;PAIN, POSTOPERATIVE
SUFENTANIL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE;DISEASE;PAIN
SUFENTANIL;CYP3A4;rs2242480;T/T;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;PAIN
TACROLIMUS;CYP3A4;rs2242480;C/C;OTHER, LADME-PK;DECREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
FENTANYL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
SUFENTANIL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
FENTANYL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
BETA BLOCKING AGENTS;GRK5;rs4752292;T;EFFICACY;DECREASED_RESPONSE;OTHER;CORONARY ARTERY DISEASE
INTERFERON BETA-1A;HLA-B;HLA-B*15:01;*15:01;EFFICACY;DECREASED_RESPONSE;DISEASE;MULTIPLE SCLEROSIS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DOSE;DISEASE;HEART DISEASES
RUBELLA VACCINES;HLA-B;HLA-B*35:03;*35:03;EFFICACY;INCREASED_RESPONSE;;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;HLA-B;HLA-B*38:01;*38:01;EFFICACY;DECREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);OPRM1;rs671531;GG;EFFICACY;DECREASED_RESPONSE;OTHER;HIV INFECTIOUS DISEASE
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*18;*1/*18;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*18;*18/*18;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
USTEKINUMAB;HLA-C;HLA-C*06:02;*06:02;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
METHOTREXATE;HLA-C;HLA-C*06:02;*06:02;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
FENTANYL;CYP3A4;CYP3A4*1, CYP3A4*18;*18/*18;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
RUBELLA VACCINES;HLA-C;HLA-C*15:02;*15:02;EFFICACY;INCREASED_RESPONSE;;
PEGINTERFERON ALFA-2B, RIBAVIRIN;HLA-C;HLA-C*01:02, HLA-C*02:02, HLA-C*03:02, HLA-C*04:01, HLA-C*05:01, HLA-C*06:02, HLA-C*07:01, HLA-C*08:01, HLA-C*12:02, HLA-C*14:02, HLA-C*15:02, HLA-C*16:01, HLA-C*17:01;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
MEASLES VACCINES;HLA-DQA1;HLA-DQA1*01:04;*01:04;EFFICACY;INCREASED_RESPONSE;;
MEASLES VACCINES;HLA-DRB1;HLA-DRB1*01:01;*01:01;EFFICACY;RESPONSE;;
CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*18;*1/*1;LADME-PK;INCREASED_CONCENTRATIONS;;
INTERFERON BETA-1A;HLA-DRB1;HLA-DRB1*04:01;*04:01;EFFICACY;INCREASED_RESPONSE;DISEASE;MULTIPLE SCLEROSIS
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;HLA-DRB1;HLA-DRB1*04:01;*04:01;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
HEPATITIS VACCINES;HLA-DRB1;HLA-DRB1*07:01;*07:01;EFFICACY;DECREASED_RESPONSE;;
INFLUENZA VACCINES;HLA-DRB1;HLA-DRB1*07:01;*07:01;EFFICACY;DECREASED_RESPONSE;;
MEASLES VACCINES;HLA-DRB1;HLA-DRB1*08:01;*08:01;EFFICACY;RESPONSE;;
INFLUENZA VACCINES;HLA-DRB1;HLA-DRB1*13:01;*13:01;EFFICACY;INCREASED_RESPONSE;;
TACROLIMUS;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3 + *3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
METHOTREXATE;GGH;rs11545078;AA + AG;TOXICITY;INCREASED_DISCONTINUATION;SIDE EFFECT;RHEUMATOID ARTHRITIS
IBUPROFEN;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3;DOSAGE;DECREASED_DOSE;;
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7, CYP2B6*18;*1/*6 + *1/*18 + *6/*6 + *6/*18;LADME-PK;DECREASED_METABOLISM;OTHER;OPIOID-RELATED DISORDERS
DISULFIRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;HTTLPR short form (S allele) / HTTLPR short form (S allele) + HTTLPR short form (S allele) / L allele-rs25531C + L allele-rs25531C / L allele-rs25531C;EFFICACY;INCREASED_RESPONSE;OTHER;COCAINE DEPENDENCE
SERTRALINE;CYP2B6;CYP2B6*1, CYP2B6*4;*1/*4 + *4/*4;LADME-PK;DECREASED_CONCENTRATIONS;;
SERTRALINE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*9;*6 + *9;LADME-PK;INCREASED_CONCENTRATIONS;;
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME-PK;DECREASED_CONCENTRATIONS;;
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4;*2 + *3 + *4;LADME-PK;INCREASED_CONCENTRATIONS;;
PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*1/*15;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERCHOLESTEROLEMIA
RIFAMPIN, WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*11;*2 + *3 + *11;EFFICACY;INCREASED_RESPONSE;OTHER;TUBERCULOSIS
ACYCLOVIR;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5;*2/*2 +*2/*3 +*3/*3 + *5/*5;EFFICACY;INCREASED_RESPONSE;;
TACROLIMUS;ABCB1;rs1045642;GG;LADME-PK;INCREASED_METABOLISM;DISEASE;LIVER TRANSPLANTATION
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;;
FLUVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*14;*14;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;;
METHADONE;CYP2B6;CYP2B6*6;*6/*6;TOXICITY;DECREASED_METABOLISM;OTHER;PAIN, POSTOPERATIVE, OTHER:SCOLIOSIS
METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*31, SLCO1B1*37;*31;LADME-PK;DECREASED_CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*20, SLCO1B1*37;*20;LADME-PK;INCREASED_CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
CONJUGATED ESTROGENS;SLCO1B1;rs4149056;TT;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;MENOPAUSE
METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*23, SLCO1B1*37;*23;LADME-PK;DECREASED_CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
ACENOCOUMAROL;CYP2C18;rs1998591;GG;DOSAGE;INCREASED_DOSE;;
ACENOCOUMAROL;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;;
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;INCREASED_RESISTANCE;OTHER;STROKE
METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;*15;LADME-PK;DECREASED_CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
ATORVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;*15;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HYPERCHOLESTEROLEMIA
ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*14, SLCO1B1*15, SLCO1B1*37;*15/*15 + *1/*15 + *15/*37 + *14/*37;LADME-PK;INCREASED_CONCENTRATIONS;;
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME-PK;DECREASED_CONCENTRATIONS;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_STEADY-STATE CONCENTRATION;OTHER;TRANSPLANTATION
3,4-DEHYDROCILOSTAZOL;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;CEREBRAL INFARCTION
BETA BLOCKING AGENTS;ADRA2C;rs61767072;del;EFFICACY;INCREASED_RESPONSE;OTHER;CARDIOMYOPATHY, DILATED
ARIPIPRAZOLE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;*3 + *4 + *4xN + *5 + *6 + *10 + *41;LADME-PK;INCREASED_CONCENTRATIONS;;
ATOMOXETINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
DOCETAXEL, THALIDOMIDE;SULT1C4;rs1402467;G;EFFICACY;INCREASED_RESPONSE;DISEASE;PROSTATIC NEOPLASMS
ATOMOXETINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;DOSAGE;DECREASED_DOSE;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
ATOMOXETINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
AMITRIPTYLINE, CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;OTHER;INCREASED_DISCONTINUATION;OTHER;BIPOLAR DISORDER
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;*1/*2 + *1/*3 + *1/*5 + *1/*6;DOSAGE;DECREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION
BREXPIPRAZOLE;CYP2D6;CYP2D6*1, CYP2D6*2;*2;LADME-PK;DECREASED_METABOLISM;;
BREXPIPRAZOLE;CYP2D6;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*14, CYP2D6*17, CYP2D6*29, CYP2D6*41;*9 +*10 + *14 + *17 + *29 + *41;LADME-PK;DECREASED_METABOLISM;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION
N-DESMETHYLTRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HEAD AND NECK NEOPLASMS
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;;
VENLAFAXINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER
VENLAFAXINE;SLC6A4;SLC6A4 L allele-rs25531T;L allele-rs25531T/L allele-rs25531T;EFFICACY;INCREASED_RESPONSE;OTHER;ANXIETY DISORDERS
VENLAFAXINE;SLC6A4;SLC6A4 L allele-rs25531T;L allele-rs25531T/L allele-rs25531T;EFFICACY;DECREASED_RESPONSE;OTHER;DEPRESSION
KETOROLAC;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;INCREASED_RESPONSE;OTHER;PAIN, POSTOPERATIVE
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4;EFFICACY;DECREASED_RESPONSE;OTHER;PAIN, POSTOPERATIVE
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC1;rs3212948;C;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;OTHER;PANIC DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION
ENDOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*22/*22;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;BREAST NEOPLASMS
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*22;DOSAGE;DECREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION
MIDAZOLAM;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_CLEARANCE;OTHER;NEOPLASMS
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*17, CYP2D6*29;*17/*29 + *17/*17;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;BREAST NEOPLASMS
LIRAGLUTIDE;GLP1R;rs10305420;TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME-PK;DECREASED_METABOLISM;;
N-DESMETHYLTAMOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME-PK;DECREASED_METABOLISM;;
TAMOXIFEN;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME-PK;DECREASED_METABOLISM;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
OXYCODONE;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;LADME-PK;DECREASED_METABOLISM;;
OXYCODONE;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;LADME-PK;DECREASED_METABOLISM;;
OXYCODONE;CYP3A4;CYP3A4*1, CYP3A4*22;*22;LADME-PK;DECREASED_METABOLISM;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;OTHER;LUNG TRANSPLANTATION
BEVACIZUMAB, CYCLOPHOSPHAMIDE;CXCL8;rs4073;AA + AT;EFFICACY;DECREASED_RESPONSE;DISEASE;OVARIAN NEOPLASMS
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*4;*4/*4;LADME-PK;DECREASED_METABOLISM;;
DULOXETINE;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;DEPRESSIVE DISORDER
N-DESMETHYLCLOZAPINE;CYP3A4;CYP3A4 low activity;;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
DIHYDROPYRIDINE DERIVATIVES;CYP3A5;rs776746;TT;OTHER;INCREASED_DISCONTINUATION;;
DESVENLAFAXINE;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;DEPRESSIVE DISORDER
N-DESMETHYLCLOZAPINE;CYP1A2;CYP1A2 low activity;;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
DESVENLAFAXINE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;DEPRESSIVE DISORDER
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*9, CYP2A6*17, CYP2A6*35;*1/*35 + *9/*35 + *17/*35;LADME-PK;DECREASED_METABOLISM;;
DISULFIRAM;ALDH2;ALDH2 deficiency;;EFFICACY;INCREASED_RESPONSE;OTHER;ALCOHOL ABUSE
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*46;*1/*46 + *46/*46;LADME-PK;INCREASED_METABOLISM;;
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*24, CYP2A6*25, CYP2A6*26, CYP2A6*27, CYP2A6*28, CYP2A6*35;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE
NICOTINE;CYP2A6;rs137904044;A;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*35;*35/*35;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;rs571335587;A;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;rs28399454;T;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;rs140471703;T;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;rs199515342;A;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;rs61605570;T;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;rs768416963;T;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;rs1302192284;C;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;rs111869995;A;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;rs200554095;A;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;rs772964366;G;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;rs145308399;T;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;rs758479488;T;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;rs145157460;T;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;rs148693084;G;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;rs1303839356;T;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;rs374515279;T;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;rs777098658;G;LADME-PK;DECREASED_METABOLISM;;
WARFARIN;VKORC1;rs11150606;C;DOSAGE;DECREASED_DOSE;;
NICOTINE;CYP2A6;rs5031016;G;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*14, CYP2A6*38, CYP2A6*46;*1 + *46 + *9 + *14 + *38;LADME-PK;INCREASED_METABOLISM;;
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*9, CYP2A6*12, CYP2A6*38, CYP2A6*46;*1 + *9 + *12 + *38;LADME-PK;DECREASED_METABOLISM;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;;
OXALIPLATIN;MTHFR;rs1801131;GG + GT;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
ALPRAZOLAM;CYP3A4;CYP3A4 low activity;;EFFICACY;INCREASED_RESPONSE;OTHER;ALCOHOL ABUSE, OTHER:ANXIETY DISORDERS
TACROLIMUS;CYP3A4;rs2242480;C/C;LADME-PK;DECREASED_METABOLISM;DISEASE;LIVER TRANSPLANTATION
TACROLIMUS;CYP3A4;rs2242480;C/C;LADME-PK;DECREASED_METABOLISM;DISEASE;LIVER TRANSPLANTATION
TACROLIMUS;CYP3A4;rs2242480;C/T + T/T;LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A4;rs2242480;C/C;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
FENTANYL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
ENDOXIFEN;CYP2D6;CYP2D6 intermediate metabolizer;;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;BREAST NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5 intermediate metabolizer and normal metabolizer;;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION
CLOZAPINE;ABCG2;rs2231142;GT + TT;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;SCHIZOPHRENIA
DOLUTEGRAVIR;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *6/*6;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTIONS AND DRUG-ELUTING STENTS
(S)-METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*7, CYP2B6*9, CYP2B6*18;*6 + *7 + *9 + *18;LADME-PK;DECREASED_CLEARANCE;OTHER;SCOLIOSIS
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;DOSAGE;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;DOSAGE;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7;*4/*4 + *4/*7;OTHER, LADME-PK;DECREASED_METABOLISM;;
HYDRALAZINE;NAT2;NAT2 rapid acetylator;;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;HYPERTENSION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*13;*1/*13;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION
L-METHYLFOLATE;MTHFR;rs1801133;AG;EFFICACY;INCREASED_RESPONSE;OTHER;BIPOLAR DISORDER, OTHER:DEPRESSION, OTHER:OBSESSIVE-COMPULSIVE DISORDER
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA, OTHER:LYMPHOMA, OTHER:LEUKEMIA, MYELOID, ACUTE
HYDRALAZINE;NAT2;NAT2 slow acetylator;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HYPERTENSION
VENLAFAXINE;CYP2D6;CYP2D6 intermediate metabolizer;;LADME-PK;DECREASED_METABOLISM;OTHER;ELDERLY ADULT
ESCITALOPRAM;CYP2C19;CYP2C19 intermediate metabolizer;;LADME-PK;DECREASED_METABOLISM;OTHER;ELDERLY ADULT
SOMATROPIN RECOMBINANT;COL1A1;rs1800012;AA;DOSAGE;DECREASED_DOSE;OTHER;GROWTH HORMONE DEFICIENCY
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10, CYP2A6*11, CYP2A6*13, CYP2A6*15, CYP2A6*17, CYP2A6*19, CYP2A6*20;*2 + *4 + *7 + *9 + *10 + *11 + *13 + *15 + *17 + *19 + *20;LADME-PK;DECREASED_METABOLISM;;
TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*11;*11/*4;LADME-PK;DECREASED_METABOLISM;OTHER;STOMACH NEOPLASMS
LETROZOLE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*35;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;LADME-PK;DECREASED_CLEARANCE;DISEASE;BREAST NEOPLASMS
L-METHYLFOLATE;MTHFR;rs1801131;GT;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*46;*1/*46;LADME-PK;INCREASED_CLEARANCE;;
COUMARIN;CYP2A6;CYP2A6*5, CYP2A6*47;*5/*47;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*24, CYP2A6*25, CYP2A6*26, CYP2A6*27, CYP2A6*28, CYP2A6*35, CYP2A6*46;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME-PK;DECREASED_METABOLISM;;
VITAMIN B-COMPLEX, INCL. COMBINATIONS;MTHFR;rs1801133;A;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DECREASED_DOSE;;
VITAMIN B-COMPLEX, INCL. COMBINATIONS;MTHFR;rs1801131;G;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER
WARFARIN;VKORC1;rs9923231;G;DOSAGE;DOSE;DISEASE;HEART DISEASES
ATOMOXETINE;SLC6A2;rs12708954;A;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
CYCLOSPORINE, TACROLIMUS;CYP3A4;rs2740574;C;LADME-PK;DECREASED_CONCENTRATIONS;SIDE EFFECT;KIDNEY TRANSPLANTATION
MERCAPTOPURINE;NUDT15;rs746071566;del;DOSAGE, TOXICITY;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;;
RIZATRIPTAN;DRD2;rs6275;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER;MIGRAINE WITHOUT AURA
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
WARFARIN;CYP2C9;rs1799853;C;DOSAGE;DOSE;;
WARFARIN;VKORC1;rs61162043;G;DOSAGE;INCREASED_DOSE;;
SULFONAMIDES, UREA DERIVATIVES;CYP2C9;rs1057910;CC;EFFICACY;INCREASED_RESPONSE;;
NICOTINE;OPRM1;rs1799971;AG + GG;EFFICACY;DECREASED_RESPONSE;OTHER;TOBACCO USE DISORDER
RISPERIDONE;DRD3;rs6280;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;AUTISM
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;;
SIROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME-PK;DECREASED_CONCENTRATIONS;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*3;DOSAGE;DECREASED_DOSE;;
CYSTEAMINE;CFTR;rs113993960;CTT/del + del/del;EFFICACY;INCREASED_RESPONSE;DISEASE;CYSTIC FIBROSIS
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;DISEASE;PANIC DISORDER
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2/*2;DOSAGE;DECREASED_DOSE;;
HYDRALAZINE;NAT2;NAT2 slow acetylator;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HYPERTENSION
FLUOROURACIL;DPYD;DPYD deficiency;;LADME-PK;DECREASED_METABOLISM;DISEASE;BREAST NEOPLASMS
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;DOSAGE;DECREASED_DOSE;DISEASE;TRANSPLANTATION
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;EFFICACY;DECREASED_RESPONSE;DISEASE;MYOCARDIAL INFARCTION
HYDRALAZINE;NAT2;NAT2 slow acetylator;;LADME-PK;DECREASED_METABOLISM;OTHER;HYPERTENSION
CODEINE;CYP2D6;CYP2D6*17;*17;LADME-PK;DECREASED_METABOLISM;DISEASE;ANEMIA, SICKLE CELL
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;DOSAGE;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *1/*2 + *17/*17;DOSAGE;DOSE;DISEASE;CYSTIC FIBROSIS, DISEASE:LUNG TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;LADME-PK;DECREASED_TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE, EFFICACY;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
ARIPIPRAZOLE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6;*4 + *5 + *6;LADME-PK;DECREASED_METABOLISM;;
RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *17/*17 + *1/*2;DOSAGE;DOSE;DISEASE;CYSTIC FIBROSIS, DISEASE:LUNG TRANSPLANTATION
PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*1 + *1/*17;LADME-PK;INCREASED_METABOLISM;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3;DOSAGE;DECREASED_DOSE;;
ANTHRACYCLINES AND RELATED SUBSTANCES, CAPECITABINE, CYCLOPHOSPHAMIDE, FLUOROURACIL, TAXANES;GSTM1;GSTM1 non-null, GSTM1 null;;EFFICACY;DECREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME-PK;INCREASED_METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_CLEARANCE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME-PK;INCREASED_CLEARANCE;DISEASE;LIVER TRANSPLANTATION
MIANSERIN;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*1/*10 + *5/*10;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;DEPRESSION
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME-PK;DECREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;DECREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
SALVIANOLIC ACID B;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_RESPONSE;OTHER;CORONARY DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
VALPROIC ACID;UGT1A6;UGT1A6*1a, UGT1A6*2a, UGT1A6*3a, UGT1A6*4a, UGT1A6*8;*1a;LADME-PK;METABOLISM;DISEASE;EPILEPSY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;MYASTHENIA GRAVIS
VALPROIC ACID;UGT1A6;UGT1A6*1a, UGT1A6*2a, UGT1A6*3a, UGT1A6*4a, UGT1A6*8;*1a;DOSAGE;DECREASED_DOSE;DISEASE;EPILEPSY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*8;*8/*8;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*1;LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
CAPECITABINE, FLUOROURACIL;DPYD;rs55886062;C;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
SIROLIMUS, TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE;LIVER TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;DOSAGE;DECREASED_DOSE;DISEASE;DEPRESSION
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*18;*18;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;EFFICACY;DECREASED_RESPONSE;DISEASE;FUNGAL INFECTIOUS DISEASE
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;LADME-PK;DECREASED_METABOLISM;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*17/*17;EFFICACY;DECREASED_RESPONSE;DISEASE;FUNGAL INFECTIOUS DISEASE
ENDOXIFEN;CYP2D6;CYP2D6 normal metabolizer and ultrarapid metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
IMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;LOW BACK PAIN, DISEASE:OSTEOARTHRITIS
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;DISEASE;DEPRESSIVE DISORDER
ISONIAZID;NAT2;NAT2 slow acetylator;;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;TUBERCULOSIS
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;DOSAGE;DECREASED_DOSE;DISEASE;COLORECTAL NEOPLASMS
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;DOSAGE;DECREASED_DOSE;DISEASE;COLORECTAL NEOPLASMS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;;
OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2;LADME-PK;DECREASED_METABOLISM;;
CORTICOSTEROIDS;NR1I2;rs3842689;del/del;EFFICACY;INCREASED_RESISTANCE;;
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28;DOSAGE;DECREASED_DOSE;DISEASE;COLORECTAL NEOPLASMS
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;LADME-PK;INCREASED_TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*26;*26;LADME-PK;DECREASED_METABOLISM;;
IRBESARTAN;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME-PK;DECREASED_EXPOSURE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4;*2 + *3 + *4;LADME-PK;INCREASED_EXPOSURE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;DISEASE;CARDIOVASCULAR DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;DISEASE;LIVER TRANSPLANTATION
SIPOGLITAZAR;UGT2B15;UGT2B15*1, UGT2B15*2;*2/*2;EFFICACY, LADME-PK;INCREASED_RESPONSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
SERTRALINE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*9;*6/*9 + *1/*6 + *6/*6;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER
CLOMIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;DEPRESSION
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10 + *1/*10;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;BREAST NEOPLASMS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_RESISTANCE;DISEASE;STROKE
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
NORTRIPTYLINE;CYP2D6;CYP2D6*1xN, CYP2D6*2;*2/*1xN;LADME-PK;INCREASED_METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;DISEASE;CEREBRAL SINOVENOUS THROMBOSIS
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*26;*1/*26 + *6/*6 + *6/*26;DOSAGE;DECREASED_DOSE;DISEASE;HIV INFECTIOUS DISEASE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;DISEASE;CEREBRAL SINOVENOUS THROMBOSIS
NORTRIPTYLINE;CYP2D6;CYP2D6*1xN, CYP2D6*2;*2/*1xN;DOSAGE, EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1;*1;LADME-PK;DECREASED_TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION
CLOPIDOGREL, PRASUGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1 + *1/*2 + *1/*3;EFFICACY;RESPONSE;DISEASE;MYOCARDIAL INFARCTION
CLOPIDOGREL;CYP2C19;CYP2C19*2, CYP2C19*3, CYP2C19*17;*2 + *3 + *17;DOSAGE;DOSE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
CLOMIPRAMINE;CYP2D6;CYP2D6*1xN, CYP2D6*2;*2/*1xN;DOSAGE, EFFICACY;DECREASED_RESPONSE;DISEASE;AGORAPHOBIA
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME-PK;DECREASED_METABOLISM;;
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;LADME-PK;INCREASED_METABOLISM;;
NICOTINE;CYP2A6;CYP2A6*4, CYP2A6*9, CYP2A6*17, CYP2A6*26;*4/*17 + *9/*26;LADME-PK;DECREASED_METABOLISM;;
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME-PK;DECREASED_METABOLISM;;
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED_RESISTANCE;DISEASE;STROKE
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*41;*3/*4 + *4/*4;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*4/*4 + *3/*4 + *4/*5 + *4/*6;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
MORPHINE;SLC22A1;rs72552763;GAT/del + del/del;LADME-PK;DECREASED_CLEARANCE;;
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*17, CYP2D6*41;*4/*41 + *4/*10 + *4/*17 + *5/*41;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
IMATINIB;GSTT1;GSTT1 non-null, GSTT1 null;null/null;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
GLUCOCORTICOIDS;HSD3B1;rs1047303;AA + AC;EFFICACY;INCREASED_RESISTANCE;OTHER;ASTHMA
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4xN, CYP2D6*12, CYP2D6*29, CYP2D6*84;*12/*84 + *4xN/*29;LADME-PK;DECREASED_METABOLISM;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME-PK;DECREASED_METABOLISM;;
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;LADME-PK;INCREASED_METABOLISM;;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME-PK;DECREASED_METABOLISM;;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*17/*17;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*1 + *1/*17;LADME-PK;INCREASED_METABOLISM;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;;
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
SIMVASTATIN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME-PK;CONCENTRATIONS;;
MORPHINE;SLC22A1;rs72552763;del/del;LADME-PK;DECREASED_CLEARANCE;OTHER;ADENOTONSILLECTOMY
METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*5, SLCO1B1*37;*5;LADME-PK;DECREASED_CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME-PK;DECREASED_METABOLISM;DISEASE;ACUTE CORONARY SYNDROME
FLUVOXAMINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;DISEASE;MOOD DISORDER
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;DECREASED_RESPONSE;DISEASE;ACUTE CORONARY SYNDROME
SILDENAFIL;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HEART FAILURE
EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;DOSAGE;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28 + *1/*28;LADME-PK;DECREASED_METABOLISM;DISEASE;NEOPLASMS
EFAVIRENZ;CYP2B6;CYP2B6*6;*6;LADME-PK;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;rs55918055;C;EFFICACY, LADME-PK;DECREASED_RESPONSE;;
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;EFFICACY;INCREASED_RESPONSE;DISEASE;RECTAL NEOPLASMS
BILIRUBIN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;NEOPLASMS
METHADONE;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;LADME-PK;INCREASED_CONCENTRATIONS;;
BILIRUBIN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;NEOPLASMS
METHADONE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_CONCENTRATIONS;;
METHADONE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_CONCENTRATIONS;;
METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*14, SLCO1B1*37;*14;LADME-PK;INCREASED_CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
WARFARIN;CYP2C9;CYP2C9*1;*1/*1;DOSAGE, LADME-PK;INCREASED_DOSE;;
SN-38;UGT1A1;UGT1A1*1, UGT1A1*6;*6/*6 + *1/*6;LADME-PK;DECREASED_METABOLISM;DISEASE;NEOPLASMS
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1;LADME-PK;INCREASED_CLEARANCE;DISEASE;MAJOR DEPRESSIVE DISORDER
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*1;LADME-PK;INCREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41;*3/*9 + *4/*17 +  *4/*41 + *4/*10;DOSAGE;DECREASED_DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER
PACLITAXEL;CYP2C8;CYP2C8*3;*3;LADME-PK;DECREASED_EXPOSURE;DISEASE;BREAST NEOPLASMS
PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME-PK;DECREASED_CLEARANCE;;
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME-PK;METABOLISM;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;;
GLATIRAMER ACETATE;CCR5;rs333;del;EFFICACY;DECREASED_RESPONSE;DISEASE;MULTIPLE SCLEROSIS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3, CYP2C9*13, CYP2C9*16, CYP2C9*60;*1/*13 + *1/*16 + *1/*60;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*1;LADME-PK;DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*3A/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;DISEASE;CROHN DISEASE
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A;*3A/*3A;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;DISEASE;CROHN DISEASE
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DOSE;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*9;*2 + *3 + *8 + *9;LADME-PK;DECREASED_METABOLISM;DISEASE;ASTHMA
GLIPIZIDE;TCF7L2;rs7903146;T;EFFICACY;INCREASED_RESPONSE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;;
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE;DISEASE;CAROTID ARTERY DISEASES
CLOPIDOGREL;SLC14A2;rs12456693;T;EFFICACY;INCREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS B VIRUS INFECTION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*1;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
CISPLATIN, FLUOROURACIL;TPMT;TPMT*3C;*3C;EFFICACY;DECREASED_RESPONSE;DISEASE;HEAD AND NECK NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;DOSAGE;INCREASED_DOSE;DISEASE;LIVER TRANSPLANTATION
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;;
CAVOSONSTAT;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
BUPROPION;CYP2B6;CYP2B6*6;*6;LADME-PK;DECREASED_METABOLISM;;
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*2;LADME-PK;DECREASED_METABOLISM;DISEASE;CORONARY ARTERY DISEASE
RISPERIDONE;CYP2D6;CYP2D6*5, CYP2D6*10;*10 + *5;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;SCHIZOPHRENIA
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2 + *3;LADME-PK;INCREASED_TROUGH CONCENTRATION;;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4;LADME-PK;DECREASED_METABOLISM;DISEASE;SCHIZOPHRENIA
NEVIRAPINE;NR1I2;rs3842689;GAGAAG/del + del/del;DOSAGE, LADME-PK;INCREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
IVACAFTOR / LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME-PK;DECREASED_TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE
MIDAZOLAM;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME-PK;DECREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
SN-38;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6 + *28;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;COLORECTAL NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;DOSAGE;DECREASED_DOSE;DISEASE;TRANSPLANTATION
IVACAFTOR / LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*5;*5;LADME-PK;DECREASED_METABOLISM;DISEASE;SCHIZOPHRENIA
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;DISEASE;ULCERATIVE COLITIS
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;ACUTE CORONARY SYNDROME
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;*1/*2 + *1/*8 + *2/*2 + *2/*3;LADME-PK;DECREASED_METABOLISM;DISEASE;CORONARY ARTERY DISEASE
MEASLES VACCINES;HLA-B;HLA-B*51:01;*51:01;EFFICACY;DECREASED_RESPONSE;;
BUCINDOLOL;ADRA2C;rs61767072;GGGGCGGGGCCG/GGGGCGGGGCCG;EFFICACY;INCREASED_RESPONSE;DISEASE;HEART FAILURE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;DOSAGE;DECREASED_DOSE;DISEASE;PSYCHOTIC DISORDER
MEASLES VACCINES;HLA-B;HLA-B*07:02;*07:02;EFFICACY;INCREASED_RESPONSE;;
MEASLES VACCINES;HLA-B;HLA-B*13:01;*13:01;EFFICACY;DECREASED_RESPONSE;;
MEASLES VACCINES;HLA-B;HLA-B*08:01;*08:01;EFFICACY;DECREASED_RESPONSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*3;DOSAGE;DECREASED_DOSE;;
INFLUENZA VACCINES;HLA-DQB1;HLA-DQB1*03:03;*03:03;EFFICACY;DECREASED_RESPONSE;;
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1 + *1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
MEASLES VACCINES;HLA-DQA1;HLA-DQA1*02:01;*02:01;EFFICACY;DECREASED_RESPONSE;;
MEASLES VACCINES;HLA-DRB1;HLA-DRB1*03:01;*03:01;EFFICACY;DECREASED_RESPONSE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*20;*1/*20;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;;
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
FLUOROURACIL;DPYD;DPYD poor metabolizer;;DOSAGE;DECREASED_DOSE;DISEASE;COLORECTAL NEOPLASMS, DISEASE:GASTROINTESTINAL NEOPLASMS, DISEASE:RECTAL NEOPLASMS
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;DOSAGE;INCREASED_DOSE;OTHER;HEART TRANSPLANTATION
CISPLATIN, FLUOROURACIL;TPMT;TPMT*3B;*3B;EFFICACY;DECREASED_RESPONSE;DISEASE;HEAD AND NECK NEOPLASMS
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;DECREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;OTHER;HEART TRANSPLANTATION
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;DISEASE;ULCERATIVE COLITIS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;DOSAGE;INCREASED_DOSE;DISEASE;LIVER TRANSPLANTATION
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10;*4/*5 + *4/*4;LADME-PK;DECREASED_METABOLISM;;
SIROLIMUS, TEMSIROLIMUS;ABCB1;rs1128503;GG;LADME-PK;DECREASED_EXPOSURE;DISEASE;URINARY BLADDER NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;OTHER;LUNG TRANSPLANTATION
AMITRIPTYLINE;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;INCREASED_CONCENTRATIONS;;
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;;
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1 + *1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*59;*1/*59;DOSAGE;DECREASED_DOSE;;
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME-PK;INCREASED_CONCENTRATIONS;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *3/*3 + *2/*3;DOSAGE;DECREASED_DOSE;;
GRANISETRON;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;DECREASED_CLEARANCE;;
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*40;*40;EFFICACY;DECREASED_RESPONSE;DISEASE;ANEMIA, SICKLE CELL
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*17;*17;EFFICACY;DECREASED_RESPONSE;DISEASE;ANEMIA, SICKLE CELL
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;OTHER;INCREASED_DISCONTINUATION;DISEASE;RHEUMATOID ARTHRITIS
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*6;*6;EFFICACY;DECREASED_RESPONSE;DISEASE;ANEMIA, SICKLE CELL
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4;EFFICACY;DECREASED_RESPONSE;DISEASE;ANEMIA, SICKLE CELL
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESPONSE;DISEASE;STROKE
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*5;*5;EFFICACY;DECREASED_RESPONSE;DISEASE;ANEMIA, SICKLE CELL
GRANISETRON;CYP1A1;CYP1A1*1, CYP1A1*2A;*2A;LADME-PK;INCREASED_CLEARANCE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;RHEUMATOID ARTHRITIS
CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME-PK;DECREASED_METABOLISM;DISEASE;MENTAL DISORDERS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
ROCURONIUM;SLCO1A2;rs7967354;CC;DOSAGE;DECREASED_DOSE;;
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *2/*3;DOSAGE;DECREASED_DOSE;;
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3 + *4 + *5 + *6;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;MENTAL DISORDERS
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;MENTAL DISORDERS
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*11;*11;LADME-PK;INCREASED_TROUGH CONCENTRATION;DISEASE;HIV INFECTIOUS DISEASE, DISEASE:TUBERCULOSIS
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;rs12208357;T;EFFICACY, LADME-PK;DECREASED_RESPONSE;;
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME-PK;INCREASED_TROUGH CONCENTRATION;DISEASE;HIV INFECTIOUS DISEASE, DISEASE:TUBERCULOSIS
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*3 + *2;DOSAGE;DECREASED_DOSE;;
CAPECITABINE, FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RESPONSE;DISEASE;RECTAL NEOPLASMS
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME-PK;DECREASED_METABOLISM;DISEASE;MENTAL DISORDERS
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME-PK;DECREASED_CLEARANCE;;
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
CARVEDILOL;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*10;*3/*10 + *4/*4;DOSAGE;INCREASED_DOSE;DISEASE;HEART FAILURE
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3 + *1/*3;DOSAGE;DECREASED_DOSE;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *3/*3 + *2/*3;DOSAGE;DECREASED_DOSE;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*58;*58;DOSAGE;DECREASED_DOSE;;
VORICONAZOLE;CYP3A4;CYP3A4*1, CYP3A4*22;*22;LADME-PK;INCREASED_EXPOSURE;;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;DOSAGE;INCREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;EFFICACY;INCREASED_RESPONSE;DISEASE;ULCERATIVE COLITIS
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME-PK;DECREASED_METABOLISM;DISEASE;MENTAL DISORDERS
IMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3 + *2/*2;DOSAGE;DECREASED_DOSE;;
VARENICLINE;CYP2A6;CYP2A6 normal metabolizer;;EFFICACY;INCREASED_RESPONSE;DISEASE;TOBACCO USE DISORDER
AZATHIOPRINE;GSTM1;GSTM1 non-null, GSTM1 null;;LADME-PK;INCREASED_DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *3/*3 + *2/*3;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*12;*1/*12;DOSAGE;DECREASED_DOSE;;
RALOXIFENE;UGT1A8;UGT1A8*1a, UGT1A8*2, UGT1A8*3;*1a/*3;LADME-PK;INCREASED_METABOLISM;;
PHENAZEPAM;CYP2C19;CYP2C19*1, CYP2C19*17;*17;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;ALCOHOL ABUSE, OTHER:ANXIETY DISORDERS
DAUNORUBICIN;G6PD;G6PD Mediterranean, Dallas, Panama, Sassari, Cagliari, Birmingham;Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham;LADME-PK;DECREASED_METABOLISM;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*5, CYP2C9*6, CYP2C9*11;*5 + *6 + *11;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;;
DOLUTEGRAVIR;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28, UGT1A1*36, UGT1A1*37;*28/*28 + *28/*37 + *1/*6 + *1/*28 + *1/*37 + *28/*36 + *36/*37;LADME-PK;DECREASED_CLEARANCE;;
NICOTINE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME-PK;DECREASED_METABOLISM;;
MERCAPTOPURINE;TPMT;TPMT*3A, TPMT*3C;*3A/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
DIMETHYL FUMARATE;GSTP1;rs1695;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
MERCAPTOPURINE;TPMT;TPMT*3A;*3A/*3A;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*1/*3 + *1/*4 + *1/*5;LADME-PK;DECREASED_METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;DECREASED_METABOLISM;DISEASE;ULCERATIVE COLITIS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;;
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C + *3A/*3A;OTHER;INCREASED_DISCONTINUATION;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*8, CYP2C9*11;*2 + *3 + *5 + *8 + *11;DOSAGE;DECREASED_DOSE;;
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 ultrarapid metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;LOW BACK PAIN, DISEASE:OSTEOARTHRITIS
TOREMIFENE;CYP2D6;CYP2D6*10;*10;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;BREAST NEOPLASMS
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;*4/*41 + *5/*6;EFFICACY;DECREASED_RESPONSE;DISEASE;MALARIA
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE;;
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;DECREASED_RESPONSE;;
TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME-PK;DECREASED_METABOLISM;DISEASE;BREAST NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;DECREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;EFFICACY;INCREASED_RESPONSE;;
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;rs34059508;A;EFFICACY, LADME-PK;DECREASED_RESPONSE;;
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;OTHER;INCREASED_RESISTANCE;DISEASE;CORONARY ARTERY DISEASE
CAPECITABINE, FLUOROURACIL;TYMP;rs11479;AA + AG;DOSAGE;DOSE;DISEASE;COLORECTAL NEOPLASMS
USTEKINUMAB;HLA-C;HLA-C*06:02;*06:02;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE;DISEASE;ATRIAL FIBRILLATION, DISEASE:PULMONARY EMBOLISM, DISEASE:STROKE, DISEASE:VENOUS THROMBOSIS
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE;;
DOXEPIN;CYP2D6;CYP2D6*3, CYP2D6*4;*3/*4;LADME-PK;DECREASED_METABOLISM;;
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
PHENYTOIN;CYP2C19;CYP2C19*2, CYP2C19*3;*2 + *3;DOSAGE;DOSE;DISEASE;EPILEPSY
CLOZAPINE;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;HTTLPR short form (S allele)/L allele-rs25531C;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
PHENYTOIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE;DISEASE;EPILEPSY
ANTIPSYCHOTICS, HALOPERIDOL, OLANZAPINE, RISPERIDONE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2;EFFICACY;DECREASED_RESPONSE;DISEASE;ACUTE CORONARY SYNDROME
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;DECREASED_RESPONSE;DISEASE;ACUTE CORONARY SYNDROME
FOLIC ACID, HYDROXYCHLOROQUINE, METHOTREXATE, SULFASALAZINE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME-PK;DECREASED_METABOLISM;DISEASE;CORONARY ARTERY DISEASE
FLUVASTATIN;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
ONDANSETRON;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;LADME-PK;INCREASED_METABOLISM;;
INTERFERON ALFA-2A, RECOMBINANT, RIBAVIRIN;HLA-B;HLA-B*44:02;*44:02;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
ONDANSETRON, TROPISETRON;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;EFFICACY;DECREASED_RESPONSE;DISEASE;NEOPLASMS
CYCLOSPORINE, TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
PRAVASTATIN;ACE;rs1799752;del/del;EFFICACY;RESPONSE;OTHER;NON-HYPERCHOLESTEROLAEMIC PATIENTS SCHEDULED FOR ANGIOPLASTY
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*6;*1/*2 + *1/*3 + *1/*4 + *1/*6;DOSAGE;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*18;*1/*18;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*9;*1/*9;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
FLUOXETINE, SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT;DOSAGE;DOSE;DISEASE;COLORECTAL NEOPLASMS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17;EFFICACY;DECREASED_RESPONSE;;
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
(S)-METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE;LIVER TRANSPLANTATION
METOPROLOL;ADRA2C;rs61767072;del;EFFICACY;INCREASED_RESPONSE;DISEASE;HEART FAILURE
ENDOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
IMATINIB;ABCG2;rs2231142;GT + TT;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;GASTROINTESTINAL STROMAL TUMORS
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;DOSAGE;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AT;DOSAGE;DOSE;DISEASE;COLORECTAL NEOPLASMS
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME-PK;DECREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME-PK;DECREASED_METABOLISM;;
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7;LADME-PK;DECREASED_METABOLISM;OTHER;LUNG TRANSPLANTATION
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
GEFITINIB;EGFR;rs121434568;GT;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
VINCRISTINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME-PK;INCREASED_METABOLISM;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
ENDOXIFEN;CYP2D6;CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41;*9/*4;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6;*1/*4 + *1/*5 + *1/*6;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*41;*9/*41 + *10/*10 + *41/*41;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*41;*1/*9 + *1/*10 + *1/*41;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;DOSAGE;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*81;*1/*81;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER
CAPECITABINE, FLUOROURACIL;DPYD;rs75017182;CG;DOSAGE;DOSE;DISEASE;COLORECTAL NEOPLASMS
SIROLIMUS, TEMSIROLIMUS;NR1I2;rs6785049;GG;LADME-PK;INCREASED_EXPOSURE;DISEASE;URINARY BLADDER NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;DISEASE;LAPAROSCOPIC SLEEVE GASTRECTOMY
TACROLIMUS;;rs4646458;G;DOSAGE;DOSE;DISEASE;KIDNEY TRANSPLANTATION
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;DOSAGE;DECREASED_DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER
ROCURONIUM;IAPP, SLCO1A2;rs11045995;CC;DOSAGE;DECREASED_DOSE;;
MEASLES VACCINES;HLA-B;HLA-B*44:02;*44:02;EFFICACY;RESPONSE;;
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3 + *4 + *5 + *6;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
NORTRIPTYLINE;CYP2D6;CYP2D6*1xN, CYP2D6*2;*2/*1xN;LADME-PK;INCREASED_DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;LAPAROSCOPIC SLEEVE GASTRECTOMY
METOPROLOL;CYP2D6;rs5030655;del/del;EFFICACY;INCREASED_RESPONSE;;
AMOXICILLIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;RESPONSE;;
AMOXICILLIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3;*2/*3;TOXICITY;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5;*1/*2 + *1/*3 + *1/*5;TOXICITY;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
HMG COA REDUCTASE INHIBITORS;CXCL5;rs352046;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;ACUTE CORONARY SYNDROME
AMOXICILLIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;DOSAGE, LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;DISEASE;VENOUS THROMBOEMBOLISM
DEBRISOQUINE;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*15;*4/*5 + *4/*15 + *4/*6 + *3/*4 + *4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;LEUKEMIA
DEXTROMETHORPHAN;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*15;*4/*5 + *4/*15 + *4/*6 + *3/*4 + *4/*4 + *3/*5;LADME-PK;DECREASED_METABOLISM;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;DOSAGE;DECREASED_DOSE;;
ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*36;*28/*28;TOXICITY;INCREASED_DISCONTINUATION;DISEASE;HIV INFECTIOUS DISEASE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;DISEASE;ATRIAL FIBRILLATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*5, CYP2C9*6, CYP2C9*11;*2 + *6 + *5 + *11;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*9, CYP2C9*11;*2 + *6 + *5 + *11;DOSAGE;DECREASED_DOSE;;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE;;
CYCLOSPORINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME-PK;DECREASED_CONCENTRATIONS;;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DOSE;;
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*6, CYP2D6*8;*4 + *6 + *8;LADME-PK;DECREASED_CONCENTRATIONS;;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DOSE;;
METFORMIN;CSMD1;rs2954625;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;DIABETES MELLITUS
ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_DISCONTINUATION;OTHER;HIV INFECTIOUS DISEASE
ESTRONE;SLCO1B1;SLCO1B1*1, SLCO1B1*5;*5/*5;EFFICACY;INCREASED_CONCENTRATIONS;OTHER;BREAST NEOPLASMS
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE;;
VORICONAZOLE;ABCB1;rs1045642;AA;LADME-PK;DECREASED_TROUGH CONCENTRATION;;
MERCAPTOPURINE;NT5C2;rs72846714;AA + AG;LADME-PK;DECREASED_METABOLISM;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*2;*2/*2;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;SCHIZOPHRENIA
CYCLOSPORINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;;
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A1;UGT1A1*60;*60;EFFICACY;DECREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*8;*1/*8 + *8/*8;LADME-PK;DECREASED_CLEARANCE;;
WARFARIN;VKORC1;rs7294;T;DOSAGE;INCREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DOSE;;
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C;*2 + *3A + *3B + *3C;DOSAGE;DECREASED_DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES
SERTRALINE;CYP2C18;rs11188059;GG;LADME-PK;DECREASED_CONCENTRATIONS;;
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
DONEPEZIL;CYP2D6;CYP2D6*4, CYP2D6*5;*4/*4 + *4/*5;LADME-PK;DECREASED_CLEARANCE;DISEASE;ALZHEIMER DISEASE
DEBRISOQUINE;CYP2D6;CYP2D6*4, CYP2D6*17;*4/*17;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;CYP2A6 high activity;;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*2, TPMT*3A;*1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES
FENTANYL;CYP2D6;CYP2D6*1, CYP2D6*29;*29;LADME-PK;DECREASED_CLEARANCE;OTHER;BURNS
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*41;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4xN, CYP2D6*56;*4xN/*56;LADME-PK;DECREASED_METABOLISM;;
LEVONORGESTREL;CYP2B6;rs3745274;GT + TT;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
ADALIMUMAB;;rs9828223;T;EFFICACY;DECREASED_RESPONSE;OTHER;CROHN DISEASE
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_RESPONSE;OTHER;COLORECTAL NEOPLASMS
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
PROGESTERONE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*17;LADME-PK;INCREASED_EXPOSURE;;
TACROLIMUS;CYP3A5;CYP3A5*3, CYP3A5*6, CYP3A5*7;*3 + *6 + *7;LADME-PK;DECREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
DONEPEZIL;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN + *1xN/*1xN;LADME-PK;INCREASED_CLEARANCE;DISEASE;ALZHEIMER DISEASE
CYCLOPHOSPHAMIDE, FLUDARABINE;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;EFFICACY;DECREASED_RESPONSE;DISEASE;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
LEVONORGESTREL;CYP2B6;rs4803419;CT;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
MERCAPTOPURINE;TPMT;TPMT poor metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;;
ATORVASTATIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;DECREASED_CLEARANCE;;
SORAFENIB;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;LADME-PK;INCREASED_EXPOSURE;DISEASE;NEOPLASMS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;;
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B;*1/*3A;DOSAGE, TOXICITY;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_DOSE;DISEASE;EPILEPSY
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME-PK;METABOLISM;DISEASE;EPILEPSY
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*2;LADME-PK;DECREASED_CLEARANCE;DISEASE;GASTROESOPHAGEAL REFLUX
ATENOLOL, ENALAPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESISTANCE;DISEASE;KIDNEY DISORDER
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME-PK;INCREASED_CONCENTRATIONS;;
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*3C + *1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME-PK;METABOLISM;DISEASE;EPILEPSY
BREXPIPRAZOLE;CYP2D6;CYP2D6 intermediate metabolizer;;LADME-PK;DECREASED_METABOLISM;OTHER;SCHIZOPHRENIA
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESISTANCE;DISEASE;EPILEPSY
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
LOPINAVIR;CYP3A4;CYP3A4*1, CYP3A4*22;*22/*22;LADME-PK;DECREASED_CLEARANCE;OTHER;HIV INFECTIOUS DISEASE
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME-PK;METABOLISM;DISEASE;EPILEPSY
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;DISEASE;EPILEPSY
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME-PK;METABOLISM;DISEASE;EPILEPSY
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*9;*4/*9 + *9/*9;LADME-PK;DECREASED_METABOLISM;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE;;
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME-PK;METABOLISM;DISEASE;EPILEPSY
EFAVIRENZ;ABCB1;rs3842;C;LADME-PK;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME-PK;METABOLISM;DISEASE;EPILEPSY
CITALOPRAM, FLUOXETINE;SERPINE1;rs2227631;G;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
PHENYTOIN;CYP2C9;rs12782374;AG;OTHER, LADME-PK;INCREASED_METABOLISM;;
PHENYTOIN;CYP2C9;rs71486745;GT/del + del/del;DOSAGE, LADME-PK;DECREASED_DOSE;DISEASE;EPILEPSY
ATENOLOL, HYDROCHLOROTHIAZIDE, METOPROLOL;SLC25A31;rs201279313;TTA/del;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME-PK;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
CAPTOPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28;DOSAGE;DECREASED_DOSE;OTHER;ADENOCARCINOMA, OTHER:GASTROINTESTINAL NEOPLASMS
TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;*1/*1;LADME-PK;INCREASED_METABOLISM;DISEASE;BILIARY TRACT NEOPLASM
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;DECREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*17;*17;EFFICACY, LADME-PK;DECREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*1;DOSAGE;INCREASED_DOSE;;
TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY, LADME-PK;INCREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
CAPTOPRIL;ACE;rs1799752;del/del;EFFICACY;DECREASED_RESPONSE;DISEASE;HEART FAILURE
MERCAPTOPURINE;CNNM2;rs58700372;CC + CT;LADME-PK;DECREASED_METABOLISM;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
OXYCODONE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;INCREASED_DOSE;DISEASE;NEOPLASMS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*1 + *1/*17;LADME-PK;DECREASED_TROUGH CONCENTRATION;DISEASE;HEMATOLOGIC DISORDER
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;LADME-PK;INCREASED_CONCENTRATIONS;;
FLUOROURACIL;TYMS;rs11280056;TTAAAGTTA/del;EFFICACY;DECREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;EFFICACY;DECREASED_RESPONSE;DISEASE;MALARIA
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_CONCENTRATIONS;;
SERTRALINE;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;DISEASE;DEPRESSIVE DISORDER
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE;;
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;*4/*41 + *5/*6;LADME-PK;DECREASED_CLEARANCE;DISEASE;MALARIA
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;DOSAGE, TOXICITY;INCREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;DOSAGE, TOXICITY;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 deficiency;;LADME-PK;DECREASED_EXPOSURE;DISEASE;PAIN
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*10;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
ESOMEPRAZOLE, PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
TACROLIMUS;CYP3A7;CYP3A7*1A, CYP3A7*1C;*1A/*1A;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;;
KETAMINE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME-PK;DECREASED_CLEARANCE;DISEASE;NEOPLASMS, DISEASE:PAIN
ESOMEPRAZOLE, PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;;
CLOMIPRAMINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;EFFICACY;DECREASED_RESPONSE;DISEASE;DEPRESSION
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME-PK;INCREASED_METABOLISM;DISEASE;CHRONIC GRANULOMATOUS DISEASE
CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;EFFICACY;DECREASED_RESPONSE;DISEASE;DEPRESSION
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;T;DOSAGE;DECREASED_DOSE;;
ETHANOL;DRD2;rs1800497;A;DOSAGE;INCREASED_DOSE;;
VARDENAFIL;CYP3A5;rs776746;TT;OTHER, LADME-PK;INCREASED_CLEARANCE;;
ETHANOL;OPRM1;rs1799971;G;DOSAGE;INCREASED_DOSE;;
IMATINIB;SLC22A1;rs683369;CC;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;GASTROINTESTINAL STROMAL TUMORS
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;INCREASED_RESISTANCE;DISEASE;GASTROESOPHAGEAL REFLUX
CAPECITABINE, FLUOROURACIL;DPYD;rs56038477;T;DOSAGE;DECREASED_DOSE;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESISTANCE;DISEASE;GASTROESOPHAGEAL REFLUX
ACETAMINOPHEN;UGT1A6;UGT1A6*1a, UGT1A6*2a;*2a;LADME-PK;INCREASED_CLEARANCE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;A;DOSAGE;DECREASED_DOSE;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;DISEASE;ATRIAL FIBRILLATION, DISEASE:ATRIAL FLUTTER, DISEASE:VENOUS THROMBOSIS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME-PK;DECREASED_METABOLISM;DISEASE;SCHIZOPHRENIA
METHADONE;OPRK1;rs3802281;TT;DOSAGE;DECREASED_DOSE;OTHER;HEROIN DEPENDENCE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;;
AZATHIOPRINE;TPMT;rs1142345;CT;DOSAGE;DECREASED_DOSE;OTHER;ULCERATIVE COLITIS, OTHER:CROHN DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
DEBRISOQUINE;CYP2D6;CYP2D6*17;*17/*17;LADME-PK;DECREASED_METABOLISM;;
TOLTERODINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3 + *4;LADME-PK;DECREASED_METABOLISM;;
CITALOPRAM, MIANSERIN, MIRTAZAPINE, NORTRIPTYLINE, PAROXETINE, VENLAFAXINE;CYP2D6;CYP2D6*1xN, CYP2D6*2xN;*1xN + *2xN;EFFICACY;DECREASED_RESPONSE;DISEASE;MOOD DISORDER
SPARTEINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*10;*10/*10 + *4/*10;LADME-PK;DECREASED_METABOLISM;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;AUTOIMMUNE DISEASES
HYDROXYUREA;SIN3A;rs7166737;GG;EFFICACY;DECREASED_RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES
RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME-PK;DECREASED_CLEARANCE;DISEASE;HELICOBACTER INFECTIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
HYDRALAZINE;NAT2;NAT2 slow acetylator;;LADME-PK;DECREASED_METABOLISM;OTHER;HYPERTENSION
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6;LADME-PK;INCREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799964;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;SPONDYLITIS, ANKYLOSING
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;EFFICACY;INCREASED_RESPONSE;;
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;;
CAPECITABINE, RALTITREXED;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*1;DOSAGE;INCREASED_DOSE;;
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;DECREASED_RESPONSE;DISEASE;ACUTE CORONARY SYNDROME
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;OTHER;ELDERLY ADULT
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DOSE;DISEASE;ATRIAL FIBRILLATION, DISEASE:VENOUS THROMBOEMBOLISM
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;G/TT + TT/TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
VENLAFAXINE;CYP2D6;CYP2D6 normal metabolizer;;LADME-PK;DECREASED_METABOLISM;OTHER;ELDERLY ADULT
DEBRISOQUINE, SPARTEINE;CYP2D6;CYP2D6*3, CYP2D6*4;*4/*4 + *3/*4;LADME-PK;DECREASED_METABOLISM;;
ESCITALOPRAM;CYP2C19;CYP2C19 normal metabolizer;;LADME-PK;DECREASED_METABOLISM;OTHER;ELDERLY ADULT
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;TOXICITY;INCREASED_CONCENTRATIONS;DISEASE;EPILEPSY
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME-PK;DECREASED_CONCENTRATIONS;;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3;LADME-PK;INCREASED_CONCENTRATIONS;;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME-PK;DECREASED_CLEARANCE;DISEASE;LYMPHOMA, B-CELL
SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;OTHER;POSTTRAUMATIC STRESS DISORDER
MIDAZOLAM;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;DISEASE;GASTROINTESTINAL NEOPLASMS
BUPROPION;HTR2A;rs2770296;CC;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER
CAPECITABINE, FLUOROURACIL;HLA-G;rs371194629;ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
VORICONAZOLE;CYP2C19;CYP2C19 ultrarapid metabolizer;*1/*17 + *17/*17;LADME-PK;DECREASED_CONCENTRATIONS;;
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizer;*2/*2 + *2/*3;LADME-PK;INCREASED_TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE
HYDRALAZINE;NAT2;NAT2 slow acetylator;;LADME-PK;DECREASED_METABOLISM;OTHER;NEOPLASMS
HYDRALAZINE;NAT2;NAT2 slow acetylator;;LADME-PK;DECREASED_METABOLISM;OTHER;NEOPLASMS
PRAVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;MYOCARDIAL INFARCTION
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*3 + *3/*3;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;;
DONEPEZIL;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;DISEASE;ALZHEIMER DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
FLUOXETINE;ABCB1;rs2032582;A;EFFICACY;INCREASED_RESPONSE;DISEASE;DEPRESSIVE DISORDER
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*4/*4 + *4/*5;LADME-PK;DECREASED_CONCENTRATIONS;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_EXPOSURE;OTHER;KIDNEY TRANSPLANTATION
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER
COLCHICINE;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*1;EFFICACY;INCREASED_RESPONSE;DISEASE;FAMILIAL MEDITERRANEAN FEVER
FLUOXETINE, SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*1/*4 + *4/*4 + *4/*7 + *4/*9;LADME-PK;DECREASED_METABOLISM;DISEASE;NON-SMALL CELL LUNG CARCINOMA
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
AZATHIOPRINE;GSTM1;GSTM1 non-null, GSTM1 null;;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;ULCERATIVE COLITIS, OTHER:CROHN DISEASE
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10;*4/*10 + *5/*10;LADME-PK;DECREASED_METABOLISM;;
OXYCODONE;CYP2D6;CYP2D6*4;*4;LADME-PK;INCREASED_CONCENTRATIONS;;
NILOTINIB;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*27, UGT1A1*28;*6/*6 + *6/*28;DOSAGE;DECREASED_DOSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5;DOSAGE;DECREASED_DOSE;;
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME-PK;DECREASED_CLEARANCE;DISEASE;OPIOID-RELATED DISORDERS
BUPROPION;DBH;rs2873804;CC;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;RHEUMATOID ARTHRITIS, DISEASE:SYSTEMIC LUPUS ERYTHEMATOSUS
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_RESPONSE;DISEASE;NEOPLASM OF ESOPHAGUS, DISEASE:STOMACH NEOPLASMS
HYDRALAZINE;NAT2;NAT2 slow acetylator;;LADME-PK;DECREASED_METABOLISM;OTHER;HYPERTENSION
PACLITAXEL, PLATINUM COMPOUNDS;GSTM1;GSTM1 non-null, GSTM1 null;non-null;EFFICACY;DECREASED_RESPONSE;DISEASE;OVARIAN NEOPLASMS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3, CYP2C9*13;*3/*13;DOSAGE;DECREASED_DOSE;;
BLEOMYCIN, DACARBAZINE, DOXORUBICIN, VINBLASTINE;GSTM1;GSTM1 non-null, GSTM1 null;non-null/non-null;EFFICACY;INCREASED_RESPONSE;DISEASE;HODGKIN DISEASE
METHADONE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME-PK;DECREASED_CONCENTRATIONS;;
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DOSE;;
S-EDDP;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME-PK;INCREASED_CONCENTRATIONS;;
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME-PK;DECREASED_METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER
ENALAPRIL, LISINOPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;HYPERTENSION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
BUPROPION;SLC18A2;rs363225;CC;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER
RALTEGRAVIR;UGT1A9;UGT1A9*3a;*3a;LADME-PK;INCREASED_EXPOSURE;DISEASE;HIV INFECTIOUS DISEASE
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*9;*1/*2 + *1/*9;LADME-PK;DECREASED_METABOLISM;;
SERTRALINE;CYP2C18;rs2860840;TT;LADME-PK;DECREASED_CONCENTRATIONS;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DOSE;DISEASE;HEART DISEASES
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;DISEASE;RHEUMATIC HEART DISEASE
ARIPIPRAZOLE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;DISEASE;SCHIZOAFFECTIVE DISORDER, DISEASE:SCHIZOPHRENIA
4-HYDROXYTAMOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*22;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
TAMOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*22;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RESPONSE;OTHER;RECTAL NEOPLASMS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_CONCENTRATIONS;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*14;*1/*14;DOSAGE;DECREASED_DOSE;;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME-PK;DECREASED_TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;SPONDYLITIS, ANKYLOSING
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE;;
ACETYLCYSTEINE;EPHX1;EPHX1 poor metabolizer;;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC OBSTRUCTIVE PULMONARY DISEASE
BUPROPION;SLC18A2;rs363226;GG;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;;
METHOTREXATE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
ISONIAZID;NAT2;NAT2*4;*4;LADME-PK;INCREASED_METABOLISM;DISEASE;TUBERCULOSIS
LEVODOPA, METHYLPHENIDATE;SLC6A3;rs3836790;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;EFFICACY;INCREASED_RESPONSE;DISEASE;PARKINSON DISEASE
ATOMOXETINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*29, CYP2D6*41;*4/*4xN + *4/*4;LADME-PK;DECREASED_CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;HEART DISEASES
LEVODOPA;SLC6A3;rs3836790;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;EFFICACY;INCREASED_RESPONSE;DISEASE;PARKINSON DISEASE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*3;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;HEART DISEASES
FLUOROURACIL;DPYD;DPYD deficiency;;LADME-PK;CLEARANCE;DISEASE;HEAD AND NECK NEOPLASMS
ATOMOXETINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*41;*4/*4xN + *4/*4;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
BUPROPION;FKBP5;rs17614642;TT;EFFICACY;DECREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;HEART DISEASES
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;HEART DISEASES
INTERFERON BETA-1A;ACE;rs1799752;del/del;EFFICACY;DECREASED_RESPONSE;DISEASE;MULTIPLE SCLEROSIS
ETHANOL;OPRM1;rs1799971;AG;EFFICACY;INCREASED_RESPONSE;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;;
WARFARIN;EPHX1;rs2260863;CG;DOSAGE;INCREASED_DOSE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION
CAPTOPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;DISEASE;ESOPHAGITIS, DISEASE:GASTROESOPHAGEAL REFLUX
LOSARTAN;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
TACROLIMUS;CYP3A4;rs35599367;GG;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
THALIDOMIDE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;DOSAGE;INCREASED_DOSE;DISEASE;ERYTHEMA NODOSUM, DISEASE:LEPROSY
CARVEDILOL;CYP2D6;CYP2D6*10;*10;LADME-PK;DECREASED_METABOLISM;DISEASE;ANGINA PECTORIS
EFAVIRENZ;CYP2B6;CYP2B6*1;*1/*1;LADME-PK;INCREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE, LADME-PK;DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION, OTHER:PULMONARY EMBOLISM, OTHER:VENOUS THROMBOSIS
WARFARIN;CYP2C9;CYP2C9*8;*8;DOSAGE, LADME-PK;DOSE;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME-PK;INCREASED_METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE
DIHYDROCODEINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME-PK;DECREASED_METABOLISM;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6;*1/*1 + *1/*3 + *1/*6;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
NICOTINE;CYP2A6;CYP2A6 low activity;;DOSAGE;DECREASED_DOSE;DISEASE;TOBACCO USE DISORDER
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME-PK;DECREASED_METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3;DOSAGE;DECREASED_DOSE;;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;;
IMATINIB;CYP3A5;rs776746;CC;LADME-PK;INCREASED_TROUGH CONCENTRATION;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX
PACLITAXEL;SLCO1B1;SLCO1B1*5, SLCO1B1*15;*5 + *15;LADME-PK;INCREASED_EXPOSURE;DISEASE;BREAST NEOPLASMS
IMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*3 + *2/*2;LADME-PK;DECREASED_METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER
RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX
LAMOTRIGINE;UGT2B7;rs7668258;CC;DOSAGE, LADME-PK;INCREASED_CLEARANCE;;
RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME-PK;INCREASED_METABOLISM;DISEASE;GASTROESOPHAGEAL REFLUX
BUPRENORPHINE;UGT2B7;UGT2B7;*2;EFFICACY;DECREASED_RESPONSE;DISEASE;PAIN
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;DOSAGE;INCREASED_DOSE;DISEASE;FUNGAL INFECTIOUS DISEASE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME-PK;INCREASED_TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE
IMATINIB;ABCB1;rs1045642;AG;LADME-PK;DECREASED_TROUGH CONCENTRATION;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME-PK;DECREASED_TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME-PK;CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HEPATITIS C VIRUS INFECTION, DISEASE:LYMPHOMA, DISEASE:SHOCK, SEPTIC
NELFINAVIR;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME-PK;DECREASED_METABOLISM;;
HYDROXYBUPROPION;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME-PK;DECREASED_CONCENTRATIONS;;
NELFINAVIR;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;PANCREATIC NEOPLASMS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;;
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*18, CYP2B6*22;*1/*6 + *1/*18;LADME-PK;DECREASED_METABOLISM;DISEASE;TOBACCO USE DISORDER
IVACAFTOR, TEZACAFTOR;CFTR;rs113993960;del/del;EFFICACY;INCREASED_RESPONSE;DISEASE;CYSTIC FIBROSIS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*18, CYP2B6*22;*6/*6 + *6/*18;LADME-PK;DECREASED_METABOLISM;DISEASE;TOBACCO USE DISORDER
IVACAFTOR, TEZACAFTOR;CFTR;rs113993960;CTT/del;EFFICACY;INCREASED_RESPONSE;DISEASE;CYSTIC FIBROSIS
WARFARIN;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE;ATRIAL FIBRILLATION
WARFARIN;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;DOSAGE;INCREASED_DOSE;DISEASE;ATRIAL FIBRILLATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6;*1/*1 + *1/*3 + *1/*6;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
ATOMOXETINE;CYP2D6;CYP2D6 poor metabolizer;;DOSAGE;DECREASED_DOSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
GEMCITABINE;CDA;rs60369023;A;OTHER, LADME-PK;DECREASED_METABOLISM;DISEASE;NEOPLASMS
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;ABCB1;rs1045642;GG;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;THROMBOEMBOLISM
ATAZANAVIR;NR1I2;rs2472677;TT;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
IMATINIB;ABCB1;rs2032582;A;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
ANTIDEPRESSANTS;FKBP5;rs1360780;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
IMATINIB;ABCB1;rs1128503;A;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
TACROLIMUS;CYP3A5;rs776746;TT;LADME-PK;INCREASED_METABOLISM;DISEASE;LIVER TRANSPLANTATION
ANTIDEPRESSANTS;GNB3;rs5443;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
IMATINIB;ABCB1;rs1045642;A;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
ANTIDEPRESSANTS;FKBP5;rs3800373;AC + CC;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;;
METHADONE;OPRK1;rs963549;CC;DOSAGE;DECREASED_DOSE;OTHER;HEROIN DEPENDENCE
ANTIPSYCHOTICS;ABCB1;rs1128503;AA;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;SCHIZOPHRENIA
IMATINIB;ABCG2;rs2231142;T;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;EFFICACY;DECREASED_RESISTANCE;DISEASE;HIV INFECTIOUS DISEASE
TACROLIMUS;PPARA;rs4823613;G;LADME-PK;DECREASED_METABOLISM;OTHER;KIDNEY TRANSPLANTATION
INFLIXIMAB;SLCO1C1;rs3794271;G;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;POR;rs1057868;T;LADME-PK;INCREASED_METABOLISM;OTHER;KIDNEY TRANSPLANTATION
DALCETRAPIB;ADCY9;rs1967309;AA;EFFICACY;INCREASED_RESPONSE;;
ANTIDEPRESSANTS;BDNF;rs6265;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
BETA BLOCKING AGENTS, FLECAINIDE;ADRB1;rs1801253;G;EFFICACY;DECREASED_RESPONSE;DISEASE;TACHYCARDIA
METHOTREXATE;ABCC2;rs717620;T;LADME-PK;DECREASED_CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
RITUXIMAB;FCGR3A;rs396991;AA;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;NEUROMYELITIS OPTICA
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*18;*18;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
DRUGS USED IN ALCOHOL DEPENDENCE;GATA4;rs13273672;CC;EFFICACY;DECREASED_CLINICAL_BENEFIT;DISEASE;ALCOHOL ABUSE
CHORIONIC GONADOTROPIN;FSHR;rs6166;CC;DOSAGE;INCREASED_DOSE;;
BEPRIDIL;CYP2D6;CYP2D6*10;*10;LADME-PK;INCREASED_CLEARANCE;DISEASE;CARDIAC RHYTHM DISEASE
TACROLIMUS;CYP3A4;rs35599367;GG;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
NICARDIPINE, NIMODIPINE;CACNA1B;rs2739260;AG + GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;BIPOLAR DISORDER
CITALOPRAM, ESCITALOPRAM;GLDC;rs10975641;G;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DOSE;OTHER;A STABLE MAINTENANCE DOSE
CORTISONE ACETATE;CYP3A7;CYP3A7*1A, CYP3A7*1C;*1C;DOSAGE;DECREASED_DOSE;DISEASE;ADRENAL HYPERPLASIA, CONGENITAL
DAUNORUBICIN;G6PD;G6PD A- 202A_376G;A-202A_376G;LADME-PK;DECREASED_METABOLISM;;
TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7;*4/*4 + *4/*7 + *7/*7;LADME-PK;DECREASED_CLEARANCE;DISEASE;NEOPLASMS
EFAVIRENZ;CYP2A6;CYP2A6*2;*2;OTHER, LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE, EFFICACY;DECREASED_DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE;OTHER;A STABLE MAINTENANCE DOSE
METFORMIN;HNF1B;rs11868513;AA + AG;EFFICACY;INCREASED_RESPONSE;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;;
ATORVASTATIN;CYP3A4;rs2242480;C/C;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERLIPIDEMIAS
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;;
GLATIRAMER ACETATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;EFFICACY;DECREASED_RESPONSE;DISEASE;MULTIPLE SCLEROSIS
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE, LADME-PK;DECREASED_CLEARANCE;DISEASE;CARDIOVASCULAR DISEASE
WARFARIN;CYP2C9;CYP2C9*1;*1/*1;DOSAGE, LADME-PK;INCREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*3;*3;LADME-PK;DECREASED_DOSE;DISEASE;CARDIOVASCULAR DISEASE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*1 + *1/*17 + *2/*17 + *3/*17;EFFICACY;INCREASED_RESPONSE;DISEASE;ANGINA PECTORIS
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;;
ATORVASTATIN;CYP3A4;rs2242480;C/C;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERLIPIDEMIAS
DIAZEPAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;OTHER, LADME-PK;DECREASED_METABOLISM;;
INTERFERON ALFA-2A, RECOMBINANT, INTERFERON ALFA-2B, RECOMBINANT, INTERFERONS, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IL18;rs1946518;T;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
FLUOXETINE, PAROXETINE;SLC6A4;rs57098334;(CCCACCCGA)12/(CCCACCCGA)12;EFFICACY;INCREASED_RESPONSE;DISEASE;DEPRESSION
VENLAFAXINE;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;DECREASED_METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;EFFICACY;INCREASED_RESPONSE;;
THIOGUANOSINE DIPHOSPHATE, THIOGUANOSINE MONOPHOSPHATE, THIOGUANOSINE TRIPHOSPHATE;TPMT;TPMT poor metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;INFLAMMATORY BOWEL DISEASES
COUMARIN;CYP2A6;CYP2A6*1, CYP2A6*12;*12;OTHER, LADME-PK;DECREASED_METABOLISM;;
VALPROIC ACID;CYP2A6;CYP2A6*1, CYP2A6*4;*4;LADME-PK;DECREASED_METABOLISM;DISEASE;EPILEPSY
TEGAFUR;CYP2A6;CYP2A6*4;*4;LADME-PK;DECREASED_METABOLISM;DISEASE;STOMACH NEOPLASMS
TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4;*4;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*7;*1/*7;LADME-PK;DECREASED_METABOLISM;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;DOSAGE;DECREASED_DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2/*2;DOSAGE;DECREASED_DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;DECREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
WARFARIN;CYP4F2;CYP4F2*1, CYP4F2*3;*3/*3;DOSAGE;INCREASED_DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*3;DOSAGE;DECREASED_DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE
PACLITAXEL;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
CAFFEINE;CYP2A6;CYP2A6*1, CYP2A6*7, CYP2A6*10, CYP2A6*11;*7 + *10 + *11;OTHER, LADME-PK;DECREASED_METABOLISM;;
CAFFEINE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*9;*1/*4 + *1/*9 + *4/*4 + *4/*9;OTHER, LADME-PK;DECREASED_METABOLISM;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE, LADME-PK;DECREASED_DOSE;DISEASE;THROMBOEMBOLISM
TOCILIZUMAB;IL6R;rs4845625;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
ATORVASTATIN;CYP3A4;rs2242480;T/T;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERLIPIDEMIAS
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;CARDIOVASCULAR DISEASE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;OTHER, LADME-PK;DECREASED_CLEARANCE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;OTHER, LADME-PK;DECREASED_CLEARANCE;;
LETROZOLE;CYP2A6;CYP2A6*1, CYP2A6*26;*1/*26;LADME-PK;METABOLISM;DISEASE;BREAST NEOPLASMS
LETROZOLE;CYP2A6;CYP2A6*1, CYP2A6*35;*1/*35;;METABOLISM;DISEASE;BREAST NEOPLASMS
MIRTAZAPINE;CYP2B6;CYP2B6*6;*6/*6;EFFICACY;INCREASED_RESPONSE;DISEASE;DEPRESSION
METHOTREXATE;SLC19A1;rs1051266;CT;EFFICACY;DECREASED_RESPONSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE, LADME-PK;DECREASED_CLEARANCE;DISEASE;CARDIOVASCULAR DISEASE
WARFARIN;CYP2C9;CYP2C9*2;*2;LADME-PK;DECREASED_DOSE;DISEASE;CARDIOVASCULAR DISEASE
INTERFERON ALFA-2A, RECOMBINANT, INTERFERON ALFA-2B, RECOMBINANT, INTERFERONS, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IL18;rs187238;C;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME-PK;DECREASED_METABOLISM;OTHER;HUMAN LIVER MICROSOMES
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*1;DOSAGE;INCREASED_DOSE;;
ISONIAZID;NAT2;NAT2*4;*4/*4;LADME-PK;INCREASED_METABOLISM;DISEASE;TUBERCULOSIS
ISONIAZID;NAT2;NAT2*4;*4/*4;LADME-PK;INCREASED_METABOLISM;DISEASE;TUBERCULOSIS
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*1;DOSAGE;INCREASED_DOSE;;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME-PK;TROUGH CONCENTRATION;;
LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3;EFFICACY;DECREASED_RESPONSE;DISEASE;KIDNEY DISORDER
TROPISETRON;CYP2D6;CYP2D6*3;*3/*3;EFFICACY;DECREASED_METABOLISM;DISEASE;NEOPLASMS
LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2;EFFICACY;DECREASED_RESPONSE;DISEASE;KIDNEY DISORDER
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE;DISEASE;MYOCARDIAL ISCHEMIA
TACROLIMUS;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;DOSAGE;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
METOPROLOL;CYP2D6;CYP2D6*10;*10;LADME-PK;DECREASED_CLEARANCE;;
SIMVASTATIN;CYP3A4;CYP3A4*1, CYP3A4*4;*1/*4;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERLIPIDEMIAS
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;LADME-PK;DECREASED_METABOLISM;;
ONDANSETRON;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2xN;*1xN + *2xN;EFFICACY;DECREASED_RESPONSE;;
PHENPROCOUMON;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;;
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;;
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME-PK;DECREASED_METABOLISM;DISEASE;SCHIZOPHRENIA
DEBRISOQUINE;CYP2D6;CYP2D6*2xN;*2xN;LADME-PK;INCREASED_METABOLISM;;
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME-PK;DECREASED_METABOLISM;DISEASE;SCHIZOPHRENIA
CARVEDILOL;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;LADME-PK;DECREASED_CLEARANCE;DISEASE;HEART DISEASES
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX
CARVEDILOL;CYP2D6;CYP2D6*4, CYP2D6*5, CYP2D6*6;*4/*5 + *4/*6;DOSAGE;INCREASED_DOSE;DISEASE;HEART FAILURE
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;INCREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
OMEPRAZOLE, PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;EFFICACY;INCREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
CARVEDILOL;CYP2D6;CYP2D6*10;*10/*10;LADME-PK;DECREASED_CLEARANCE;DISEASE;HEART DISEASES
CARVEDILOL;CYP2D6;CYP2D6*1, CYP2D6*5;*1/*5;LADME-PK;DECREASED_CLEARANCE;DISEASE;HEART DISEASES
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*3;*3;LADME-PK;DECREASED_METABOLISM;DISEASE;SCHIZOPHRENIA
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
FLUOXETINE;CYP2D6;rs3892097;CC;EFFICACY;INCREASED_RESPONSE;EFFICACY;ALCOHOL ABUSE, EFFICACY:MAJOR DEPRESSIVE DISORDER
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;DEPRESSION
SUFENTANIL;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;DOSAGE;INCREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
METFORMIN;;rs6719578;CG;EFFICACY;INCREASED_RESPONSE;;
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10;EFFICACY, LADME-PK;DECREASED_METABOLISM;DISEASE;SCHIZOPHRENIA
AMITRIPTYLINE;CYP2D6;CYP2D6*4;*4/*4;TOXICITY, LADME-PK;DECREASED_CLEARANCE;OTHER;ONE SUICIDE CASE
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME-PK;DECREASED_METABOLISM;DISEASE;SCHIZOPHRENIA
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4;*4;LADME-PK;DECREASED_METABOLISM;DISEASE;SCHIZOPHRENIA
METHOTREXATE;ATIC;rs4673993;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;ULCER
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
CLOPIDOGREL;CYP2C19;CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESPONSE;DISEASE;CARDIOVASCULAR DISEASE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME-PK;DECREASED_METABOLISM;;
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *2/*3;DOSAGE;DECREASED_DOSE;;
HYDROMORPHONE, KETOROLAC, MORPHINE, OPIOIDS, OXYCODONE;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;DECREASED_RESPONSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE;;
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*22;*1/*22;LADME-PK;INCREASED_METABOLISM;;
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME-PK;DECREASED_METABOLISM;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
WARFARIN;CYP2C9;CYP2C9*1;*1/*1;DOSAGE, LADME-PK;INCREASED_DOSE;;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2;DOSAGE;DECREASED_DOSE;DISEASE;CYSTIC FIBROSIS, DISEASE:LUNG TRANSPLANTATION
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE;PANIC DISORDER
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;;
FLUOXETINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
HYDRALAZINE;NAT2;NAT2 slow acetylator;;LADME-PK;DECREASED_METABOLISM;OTHER;HYPERTENSION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;EFFICACY;INCREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY, TOXICITY;DECREASED_RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;HLA-A;HLA-A*01:01;*01:01;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
CITALOPRAM, FLUOXETINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;;
ACENOCOUMAROL;VKORC1;rs104894542;AC + CC;DOSAGE;INCREASED_DOSE;;
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;EFFICACY;DECREASED_RESPONSE;DISEASE;ACUTE CORONARY SYNDROME
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;;
MEPHENYTOIN;CYP2C19;rs28399504;G;LADME-PK;DECREASED_METABOLISM;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *3/*3;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;;
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*5;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3 + *3/*3 + *2/*2;DOSAGE;DECREASED_DOSE;;
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_CLEARANCE;DISEASE;EPILEPSY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2 + *2/*2;DOSAGE;DECREASED_DOSE;;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;;
LAMIVUDINE, NEVIRAPINE, STAVUDINE;HLA-B;HLA-B*40:01;*40:01;EFFICACY;RESPONSE;DISEASE;HIV INFECTIOUS DISEASE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME-PK;INCREASED_CONCENTRATIONS;;
BELINOSTAT;UGT1A1;UGT1A1*1, UGT1A1*60;*1/*60 + *60/*60;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;NEOPLASMS
BELINOSTAT;UGT1A1;UGT1A1*1, UGT1A1*60;*1/*60 + *60/*60;LADME-PK;DECREASED_METABOLISM;DISEASE;NEOPLASMS
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER
BOCEPREVIR, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;rs11322783;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*11;*2 + *3 + *5 + *6 + *11;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;;
ACENOCOUMAROL, PHENPROCOUMON;CYP2C19;CYP2C19*2, CYP2C19*3;*2 + *3;DOSAGE;DOSE;;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE;DISEASE;STROKE
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DOSE;;
COUMARIN;CYP2A6;CYP2A6*1, CYP2A6*6;*6;LADME-PK;DECREASED_METABOLISM;;
ECULIZUMAB;C5;rs56040400;CT;EFFICACY;DECREASED_RESPONSE;OTHER;PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
DEFERASIROX;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;ANEMIA
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DOSE;;
CLOPIDOGREL, PRASUGREL, TICAGRELOR;CYP2C19;rs4244285;A;EFFICACY;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME
WARFARIN;CYP2C9;rs9332131;A;DOSAGE;DOSE;;
WARFARIN;CYP2C9;rs28371685;C;DOSAGE;DOSE;;
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;EFFICACY;INCREASED_RESISTANCE;DISEASE;ACUTE CORONARY SYNDROME, DISEASE:STROKE
VALPROIC ACID;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;DOSAGE;DECREASED_DOSE;DISEASE;BIPOLAR DISORDER, DISEASE:PSYCHOTIC DISORDER
WARFARIN;POR;rs41301394;CT + TT;DOSAGE;INCREASED_DOSE;;
METHADONE;DRD2;rs6275;AA + AG;;INCREASED_DOSE;OTHER;TREATMENT FOR HEROIN ADDICTION
CARBOPLATIN, PACLITAXEL;GSTP1;rs1695;G;TOXICITY;DECREASED_RESPONSE;OTHER;OVARIAN NEOPLASMS
VORICONAZOLE;CYP2C19;CYP2C19 ultrarapid metabolizer;;LADME-PK;DECREASED_TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28;DOSAGE;DECREASED_DOSE;DISEASE;COLORECTAL NEOPLASMS
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;DISEASE;ATRIAL FIBRILLATION
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*18;*1/*1;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
CISPLATIN;MIR335;rs3807348;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;MESOTHELIOMA
HYDROCODONE;CYP2D6;CYP2D6*2, CYP2D6*41;*2/*41;LADME-PK;INCREASED_CONCENTRATIONS;;
CYCLOPHOSPHAMIDE, DOXORUBICIN;ALDH1A1;rs6151031;CTGGTGAGGAGAGAACC/del;EFFICACY;DECREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
BUPRENORPHINE, METHADONE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;DISEASE;OPIOID-RELATED DISORDERS
DESVENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER
WARFARIN;VKORC1;VKORC1 low activity;;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;;
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*2 + *2/*17;EFFICACY;DECREASED_RESPONSE;;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17;LADME-PK;DECREASED_METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE
CLOMIPRAMINE;CYP2D6;CYP2D6*4, CYP2D6*5;*4/*5;LADME-PK;DECREASED_METABOLISM;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_TROUGH CONCENTRATION;DISEASE;LIVER TRANSPLANTATION
CLOZAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;DOSAGE;DECREASED_CONCENTRATIONS;DISEASE;SCHIZOAFFECTIVE DISORDER, DISEASE:SCHIZOPHRENIA
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE;OTHER;HEART TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;DECREASED_TROUGH CONCENTRATION;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION
SIROLIMUS, TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;DECREASED_CLEARANCE;DISEASE;HEART TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE;ULCERATIVE COLITIS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
CARBAMAZEPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;DECREASED_CLEARANCE;DISEASE;EPILEPSY
FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;NEOPLASMS, DISEASE:PAIN
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION
FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;DECREASED_CLEARANCE;DISEASE;PAIN, POSTOPERATIVE
MIDAZOLAM;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME-PK;INCREASED_METABOLISM;DISEASE;NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_METABOLISM;DISEASE;LIVER TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
CYCLOSPORINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3;DOSAGE;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
FENTANYL;CYP2D6;CYP2D6*1, CYP2D6*9;*9;LADME-PK;DECREASED_CLEARANCE;OTHER;BURNS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
SIMVASTATIN;F3;rs3917643;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;MYOCARDIAL ISCHEMIA
IVACAFTOR / LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;INCREASED_RESPONSE;DISEASE;CYSTIC FIBROSIS
FLUVASTATIN;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
IVACAFTOR;CFTR;rs113993960;CTT/del;EFFICACY;INCREASED_RESPONSE;DISEASE;CYSTIC FIBROSIS
ENALAPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del;EFFICACY;INCREASED_RESPONSE;DISEASE;ARTERIOSCLEROSIS
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE;DISEASE;STOMACH NEOPLASMS
IMATINIB;CYP3A5;rs776746;C;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;DOSAGE;DECREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
FENTANYL, MEPERIDINE, MIDAZOLAM;CYP3A5;CYP3A5 poor metabolizer;;LADME-PK;DECREASED_DOSE;OTHER;SEDATION
FENTANYL, MEPERIDINE, MIDAZOLAM;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;LADME-PK;DECREASED_DOSE;OTHER;SEDATION
FENTANYL, MEPERIDINE, MIDAZOLAM;UGT1A1;UGT1A1 poor metabolizer;;LADME-PK;DECREASED_DOSE;OTHER;SEDATION
BELZUTIFAN;UGT2B17;UGT2B17 poor metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;VON HIPPEL-LINDAU DISEASE, OTHER:RENAL CELL CARCINOMA
BELZUTIFAN;CYP2C19;CYP2C19 poor metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;VON HIPPEL-LINDAU DISEASE, OTHER:RENAL CELL CARCINOMA
TACROLIMUS;CYP3A4;rs35599367;AG;LADME-PK;DECREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;PAIN
4-HYDROXYTAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;BREAST NEOPLASMS
TAMSULOSIN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41;*1/*4 + *4/*10;EFFICACY;INCREASED_CLINICAL_BENEFIT;;
IMATINIB;CYP3A4;rs2242480;C;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
FULVESTRANT;CYP2C9;CYP2C9 poor metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;BREAST NEOPLASMS, OTHER:METASTATIC NEOPLASM
ANASTROZOLE;CYP2C9;CYP2C9 intermediate metabolizer;;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;BREAST NEOPLASMS, OTHER:METASTATIC NEOPLASM
ANASTROZOLE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;BREAST NEOPLASMS, OTHER:METASTATIC NEOPLASM
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE;;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LEUKEMIA
ABATACEPT;HLA-DRB1;HLA-DRB1*04:05;*04:05;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
ETANERCEPT;SLCO1C1;rs3794271;G;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
APATINIB;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_CLEARANCE;OTHER;NEOPLASMS
ESCITALOPRAM;CYP2C19;CYP2C19 rapid metabolizer;;LADME-PK;INCREASED_CLEARANCE;;
ESCITALOPRAM;CYP2C19;CYP2C19 poor metabolizer;;LADME-PK;DECREASED_CLEARANCE;;
SERTRALINE;CYP2C19;CYP2C19 poor metabolizer;;LADME-PK;DECREASED_CLEARANCE;;
DULOXETINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;;
AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE;VDR;rs7975232;A;EFFICACY;INCREASED_RESPONSE;OTHER;HELICOBACTER INFECTIONS
AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE;VDR;rs2228570;A;EFFICACY;INCREASED_RESPONSE;OTHER;HELICOBACTER INFECTIONS
BUPROPION, NALTREXONE;ANKK1, DRD2;rs1800497;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;OBESITY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;DECREASED_CLEARANCE;OTHER;HEART TRANSPLANTATION
RISPERIDONE;CYP2D6;CYP2D6 intermediate metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;AUTISM SPECTRUM DISORDER
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*1;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
DOCETAXEL, THALIDOMIDE;PPARD;rs6922548;G;EFFICACY;INCREASED_RESPONSE;DISEASE;PROSTATIC NEOPLASMS
SN-38;UGT1A1;UGT1A1*1, UGT1A1*6;*6;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;RECTAL NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1;*1;LADME-PK;INCREASED_TIME TO RESPONSE;OTHER;KIDNEY TRANSPLANTATION
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 intermediate metabolizer;;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;PAIN, POSTOPERATIVE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
NALDEMEDINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;NEOPLASMS, OTHER:PAIN, OTHER:CONSTIPATION
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;;
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*41, CYP2D6*65;*10/*10 + *10/*65 + *10/*41;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
DOCETAXEL, THALIDOMIDE;PPARD;rs7769719;G;EFFICACY;INCREASED_RESPONSE;DISEASE;PROSTATIC NEOPLASMS
TACROLIMUS;CYP3A5;rs776746;TT;LADME-PK;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;NEDD4;rs2288344;G;DOSAGE;INCREASED_DOSE;;
QUETIAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;DECREASED_CLEARANCE;OTHER;BIPOLAR DISORDER
TACROLIMUS;CYP3A5;rs776746;TT;LADME-PK;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;DDHD1;rs17126068;G;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;CYP3A5 intermediate metabolizer;;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LUNG TRANSPLANTATION
CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
DESVENLAFAXINE, VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED_EXPOSURE;OTHER;MAJOR DEPRESSIVE DISORDER
TACROLIMUS;CYP3A5;rs776746;CT;LADME-PK;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*22;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
SALBUTAMOL;;rs7903366;T;EFFICACY;DECREASED_RESPONSE;OTHER;ASTHMA
PRAZIQUANTEL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3;LADME-PK;INCREASED_EXPOSURE;OTHER;SCHISTOSOMIASIS
LOSARTAN;CYP2C9;rs1057910;C;LADME-PK;DECREASED_METABOLISM;PK;NO DISEASE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESPONSE;DISEASE;STROKE
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME-PK;INCREASED_EXPOSURE;DISEASE;BIPOLAR DISORDER, DISEASE:DEPRESSION, DISEASE:PSYCHOTIC DISORDER, DISEASE:SUBSTANCE-RELATED DISORDERS
ISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;LADME-PK;DECREASED_METABOLISM;DISEASE;SYSTEMIC LUPUS ERYTHEMATOSUS
ISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *6/*6 + *6/*7 + *7/*7;LADME-PK;DECREASED_METABOLISM;DISEASE;TUBERCULOSIS
SALBUTAMOL;;rs7081864;A;EFFICACY;DECREASED_RESPONSE;OTHER;ASTHMA
SULFINPYRAZONE;UGT1A9;rs72551330;T;LADME-PK;INCREASED_METABOLISM;;
SULFAMETHOXAZOLE;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*4/*4;LADME-PK;INCREASED_METABOLISM;OTHER;KIDNEY TRANSPLANTATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;rs1051792;AA;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;SPONDYLARTHROPATHIES
WARFARIN;VKORC1;rs9923231;GG;DOSAGE;INCREASED_DOSE;OTHER;ATRIAL FIBRILLATION, OTHER:PULMONARY EMBOLISM, OTHER:VENOUS THROMBOSIS
METHADONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*2xN;*1/*2xN + *2/*2xN;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS
LITHIUM;GSK3B;rs6438552;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
TACROLIMUS;ABCB1;rs1045642;AA;DOSAGE;DECREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION
LITHIUM;NR1D1, THRA;rs2071427;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
TACROLIMUS;CYP3A5;CYP3A5 poor metabolizers;;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
MORPHINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME-PK;DECREASED_EXPOSURE;;
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
ARIPIPRAZOLE;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;PSYCHOTIC DISORDER
ATOMOXETINE;CYP2C19;CYP2C19 poor metabolizers;;LADME-PK;INCREASED_CONCENTRATIONS;;
CAFFEINE;NAT2;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*16;*4/*5 + *1/*16 + *4/*6 + *4/*7;LADME-PK;INCREASED_METABOLISM;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEART TRANSPLANTATION
ISONIAZID;NAT2;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*7G, NAT2*39;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;LADME-PK;DECREASED_CLEARANCE;DISEASE;TUBERCULOSIS
TACROLIMUS;ABCB1;rs1045642;GG;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
INFLIXIMAB;HLA-DQA1;HLA-DQA1*05;*05;EFFICACY;INCREASED_DISCONTINUATION;EFFICACY;CROHN DISEASE
TACROLIMUS;ABCB1;rs1045642;AA;LADME-PK;DECREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
ENZYME INHIBITORS;CYP19A1;rs700518;CC;OTHER;RESPONSE;DISEASE;BREAST NEOPLASMS
TACROLIMUS;ABCB1;rs1128503;AA;LADME-PK;DECREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
CORTICOSTEROIDS;FCER2;rs28364072;G;DOSAGE;INCREASED_DOSE;DISEASE;ASTHMA
TACROLIMUS;ABCB1;rs2032582;AA;LADME-PK;DECREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
ISONIAZID;NAT2;NAT2*1, NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16 + *6 + *7 + *14;LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
TACROLIMUS;ABCB1;rs1045642;AG + GG;LADME-PK;INCREASED_CLEARANCE;DISEASE;LIVER TRANSPLANTATION
HYDRALAZINE;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*4/*16 + *4/*6 + *4/*7;LADME-PK;INCREASED_METABOLISM;OTHER;HYPERTENSION, OTHER:PREGNANCY
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4, CYP2D6*59;*4/*59;LADME-PK;DECREASED_METABOLISM;;
HALOPERIDOL;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;PSYCHOTIC DISORDER
ESCITALOPRAM;;rs12154537;G;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER
MORPHINE;ABCB1;rs1128503;AG + GG;LADME-PK;DECREASED_CONCENTRATIONS;;
ISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16, NAT2*19;*4/*4;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;TUBERCULOSIS
DOCETAXEL;SLCO1B3;rs11045585;G;OTHER, LADME-PK;DECREASED_CLEARANCE;DISEASE;NASOPHARYNGEAL NEOPLASMS
DOCETAXEL;SLCO1B3;rs7311358;A;OTHER, LADME-PK;DECREASED_CLEARANCE;DISEASE;NASOPHARYNGEAL NEOPLASMS
DOCETAXEL;SLCO1B3;rs4149118;G;OTHER, LADME-PK;DECREASED_CLEARANCE;DISEASE;NASOPHARYNGEAL NEOPLASMS
CAFFEINE;NAT2;NAT2*5, NAT2*6, NAT2*7, NAT2*16, NAT2*34;*16/*5 + *5/*5 + *5/*6 + *5/*34 + *5/*7 + *6/*6 + *6/*7;LADME-PK;DECREASED_METABOLISM;;
ISONIAZID;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*7G;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;LADME-PK;DECREASED_METABOLISM;DISEASE;TUBERCULOSIS
WARFARIN;VKORC1;rs9934438;A;DOSAGE, LADME-PK;DECREASED_DOSE;;
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEART TRANSPLANTATION
MIDAZOLAM;VDR;rs1544410;C;LADME-PK;INCREASED_CLEARANCE;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;KLRC4;rs1154831;GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;SPONDYLARTHROPATHIES
TACROLIMUS;CYP3A5;CYP3A5*1;*1;DOSAGE;INCREASED_DOSE;OTHER;LUNG TRANSPLANTATION
ESCITALOPRAM;CYP2C19;CYP2C19 intermediate metabolizer;;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;DEPRESSION, OTHER:ANXIETY DISORDERS
METHADONE;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;EFFICACY;DECREASED_RESPONSE;OTHER;HEROIN DEPENDENCE
FLUOXETINE;CYP2D6;CYP2D6 ultrarapid metabolizer;;EFFICACY;DECREASED_CLINICAL_BENEFIT;EFFICACY;MAJOR DEPRESSIVE DISORDER, EFFICACY:OBSESSIVE-COMPULSIVE DISORDER
HYDRALAZINE;NAT2;NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *7/*6;EFFICACY;INCREASED_RESPONSE;OTHER;RESISTANT HYPERTENSION
ISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;TUBERCULOSIS
ACETYLISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;TUBERCULOSIS
ACETAMINOPHEN;CYP2D6;CYP2D6*10;*10;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;PATENT DUCTUS ARTERIOSUS
BUPROPION;CYP2B6;CYP2B6*6;*6;LADME-PK;INCREASED_EXPOSURE;OTHER;MAJOR DEPRESSIVE DISORDER
WARFARIN;VKORC1;rs7294;T;DOSAGE, LADME-PK;INCREASED_DOSE;;
PARAMETHOXYMETHAMPHETAMINE;CYP2D6;CYP2D6 normal metabolizer genotype;;LADME-PK;INCREASED_METABOLISM;DISEASE;SUBSTANCE-RELATED DISORDERS
VORICONAZOLE;CYP2C19;CYP2C19 intermediate metabolizers;*1/*2 + *1/*3 + *2/*17;LADME-PK;INCREASED_CONCENTRATIONS;;
MARAVIROC;CYP3A5;CYP3A5 intermediate metabolizers;;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;DECREASED_RESPONSE;;
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;DECREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME-PK;DECREASED_TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE
CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17;LADME-PK;INCREASED_EXPOSURE;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
NORTRIPTYLINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;LADME-PK;INCREASED_METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER
HALOPERIDOL, OLANZAPINE, PERPHENAZINE, QUETIAPINE, RISPERIDONE;DRD2;rs1799978;C;EFFICACY;INCREASED_RESISTANCE;OTHER;SCHIZOPHRENIA
MARAVIROC;CYP3A5;CYP3A5 poor metabolizers;;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;LADME-PK;DECREASED_EXPOSURE;;
TACROLIMUS;CYP3A5;CYP3A5 intermediate metabolizer and normal metabolizer;;DOSAGE, LADME-PK;INCREASED_TIME TO RESPONSE;OTHER;KIDNEY TRANSPLANTATION
RISPERIDONE;CYP2D6;CYP2D6 ultrarapid metabolizer;;LADME-PK;INCREASED_METABOLISM;DISEASE;SCHIZOPHRENIA
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;DISEASE;SCHIZOPHRENIA
NORTRIPTYLINE;CYP2D6;CYP2D6 intermediate metabolizers;;LADME-PK;DECREASED_METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER
IMIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;DOSAGE;DECREASED_DOSE;DISEASE;DIABETIC NEUROPATHIES
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
HYDROCODONE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;;
ATOMOXETINE;CYP2C19;CYP2C19 poor metabolizers;;LADME-PK;DECREASED_CLEARANCE;;
IMIPRAMINE;CYP2C19;CYP2C19 poor metabolizers;;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;PSYCHOTIC DISORDER
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*8, CYP2C19*17;*1/*2 + *1/*8 + *2/*2;EFFICACY, LADME-PK;DECREASED_METABOLISM;DISEASE;CORONARY ARTERY DISEASE
TAMOXIFEN;CYP2D6;CYP2D6 intermediate metabolizers;;LADME-PK;INCREASED_DOSE;DISEASE;BREAST NEOPLASMS
PROPAFENONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*36;*1/*5 + *2/*36 + *5/*10 + *5/*5;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;TACHYCARDIA
IMIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5;*4/*4 + *4/*5;DOSAGE;DECREASED_DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER
CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME-PK;DECREASED_EXPOSURE;;
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*8, CYP2C19*17;*1/*2 + *1/*8 + *2/*2;EFFICACY, LADME-PK;DECREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
METHAMPHETAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*18, CYP2D6*36;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;LADME-PK;INCREASED_CONCENTRATIONS;;
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME-PK;INCREASED_EXPOSURE;OTHER;PSYCHOTIC DISORDER, OTHER:SCHIZOPHRENIA
NORTRIPTYLINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;DOSAGE, EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
DESVENLAFAXINE;CYP2D6;CYP2D6*99;*99;LADME-PK;DECREASED_CONCENTRATIONS;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4, CYP2D6*4x2, CYP2D6*36;*4/*36 + *4x2/*36;LADME-PK;DECREASED_METABOLISM;;
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*5/*10 + *4/*10 + *10/*10 + *10/*41;LADME-PK;DECREASED_METABOLISM;;
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME-PK;DECREASED_METABOLISM;;
METHADONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*2xN;*1/*2xN + *2/*2xN;DOSAGE;INCREASED_DOSE;OTHER;OPIOID-RELATED DISORDERS
VENLAFAXINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;EFFICACY;INCREASED_RESPONSE;;
DESIPRAMINE, IMIPRAMINE;CYP2D6;CYP2D6*4, CYP2D6*5;*4/*4 + *4/*5;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER
TRANS 4-HYDROXYPRAZIQUANTEL;CYP2J2;rs890293;AA + AC;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;SCHISTOSOMIASIS
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME-PK;DECREASED_METABOLISM;;
PERPHENAZINE;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME-PK;INCREASED_CONCENTRATIONS;;
TACROLIMUS;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 +*2/*3;DOSAGE, LADME-PK;DECREASED_DOSE;OTHER;HEART TRANSPLANTATION
VORTIOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;TOXICITY;INCREASED_DISCONTINUATION;;
DEBRISOQUINE;CYP2D6;CYP2D6*4, CYP2D6*38;*4/*38;LADME-PK;DECREASED_METABOLISM;;
NORTRIPTYLINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER
FENTANYL;;poor metabolizers;;LADME-PK;DECREASED_METABOLISM;DISEASE;PAIN
ESCITALOPRAM;CYP2C19;CYP2C19 ultrarapid metabolizer phenotype;;LADME-PK;INCREASED_METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER
NORTRIPTYLINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER
ESCITALOPRAM;CYP2C19;CYP2C19 poor metabolizers;;LADME-PK;DECREASED_METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER
ETHANOL;OPRM1;rs2075572;G;EFFICACY;INCREASED_RESPONSE;;
PROTON PUMP INHIBITORS;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;HELICOBACTER INFECTIONS
DEXAMETHASONE;CHRM3;rs2165870;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;POSTOPERATIVE NAUSEA AND VOMITING
METOPROLOL;CYP2D6;CYP2D6 poor metabolizers;;DOSAGE;DECREASED_DOSE;;
ETHANOL;OPRM1;rs548646;T;EFFICACY;INCREASED_RESPONSE;;
GLICLAZIDE;KCNQ1;rs2237892;T;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4, CYP2D6*31;*4/*31;LADME-PK;DECREASED_METABOLISM;;
NORTRIPTYLINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;LADME-PK;INCREASED_METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER
NICOTINE;DRD2;rs1799732;G/del + del/del;EFFICACY;INCREASED_RESPONSE;DISEASE;TOBACCO USE DISORDER
LINAGLIPTIN;TCF7L2;rs7903146;CC + CT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
DEXTROMETHORPHAN;CYP2D6;CYP2D6*5, CYP2D6*13;*5/*13;LADME-PK;DECREASED_METABOLISM;;
CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19 poor metabolizer phenotype;;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
PAROXETINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_CLEARANCE;DISEASE;MAJOR DEPRESSIVE DISORDER
ETHANOL;OPRM1;rs681243;T;EFFICACY;INCREASED_RESPONSE;;
DEXTROMETHORPHAN;CYP2D6;CYP2D6 normal metabolizer genotype;;LADME-PK;INCREASED_METABOLISM;;
AMOXICILLIN, CLARITHROMYCIN, ESOMEPRAZOLE;CYP2C19;CYP2C19 normal metabolizer genotype;;EFFICACY;DECREASED_RESPONSE;DISEASE;GASTRITIS
ESCITALOPRAM;CYP2C19;CYP2C19 poor metabolizers;;LADME-PK;DECREASED_METABOLISM;;
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizers;;EFFICACY;DECREASED_RESPONSE;EFFICACY;MAJOR DEPRESSIVE DISORDER
BUPROPION;COMT;rs4680;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER
ARIPIPRAZOLE;CYP2D6;CYP2D6 intermediate metabolizer phenotype;;LADME-PK;DECREASED_METABOLISM;;
CODEINE, FENTANYL, HYDROCODONE, HYDROMORPHONE, METHADONE, MORPHINE, OXYCODONE, TRAMADOL;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY;DECREASED_RESPONSE;OTHER;NEOPLASMS, OTHER:PAIN
TRIMIPRAMINE;CYP2C19;CYP2C19 poor metabolizers;;LADME-PK;DECREASED_METABOLISM;DISEASE;SCHIZOPHRENIA
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_METABOLISM;OTHER;MAJOR DEPRESSIVE DISORDER
ETHANOL;OPRM1;rs1461773;A;EFFICACY;INCREASED_RESPONSE;;
3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*41;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;;
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
ETHANOL;OPRM1;rs3778148;T;EFFICACY;INCREASED_RESPONSE;;
AMOXICILLIN, CLARITHROMYCIN, LANSOPRAZOLE;CYP2C19;CYP2C19 normal metabolizer genotype;;EFFICACY;DECREASED_CLINICAL_BENEFIT;EFFICACY;HELICOBACTER INFECTIONS
AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE;CYP2C19;CYP2C19 normal metabolizer genotype;;EFFICACY;DECREASED_CLINICAL_BENEFIT;EFFICACY;HELICOBACTER INFECTIONS
MIDAZOLAM;VDR;rs4516035;T;LADME-PK;INCREASED_CLEARANCE;;
DESIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;DOSAGE;DECREASED_DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER
AMITRIPTYLINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;DECREASED_RESPONSE;OTHER;PHANTOM LIMB SYNDROME
TRAMADOL;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;INCREASED_RESPONSE;OTHER;PHANTOM LIMB SYNDROME
MORPHINE;COMT;rs4680;A;EFFICACY;INCREASED_RESPONSE;DISEASE;LOW BACK PAIN
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizers;;EFFICACY;INCREASED_RESPONSE;;
ANTIDEPRESSANTS;FKBP5;rs3800373;AC + CC;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME-PK;DECREASED_CLEARANCE;;
DESIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;LADME-PK;INCREASED_TROUGH CONCENTRATION;;
TRIMIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_METABOLISM;DISEASE;SCHIZOPHRENIA
OPIOIDS;COMT;rs4680;GG;DOSAGE;INCREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
ATENOLOL, METOPROLOL;ADRB2;rs1042714;CC;EFFICACY;INCREASED_RESPONSE;OTHER;TACHYCARDIA
GLICLAZIDE;KCNQ1;rs2237895;C;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
WARFARIN;CYP2C9;CYP2C9 normal metabolizers;;DOSAGE;INCREASED_DOSE;;
SOLANIDINE;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME-PK;DECREASED_METABOLISM;OTHER;DEPRESSION
FLECAINIDE;CYP2D6;CYP2D6 normal metabolizer genotype;;LADME-PK;CONCENTRATIONS;DISEASE;TACHYCARDIA, SUPRAVENTRICULAR
NOROXYCODONE, OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;NEOPLASMS, OTHER:PAIN
OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;DECREASED_RESPONSE;OTHER;NEOPLASMS, OTHER:PAIN
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizers;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE
VORICONAZOLE;CYP2C19;CYP2C19*2;*2/*2;LADME-PK;INCREASED_CONCENTRATIONS;;
PIMOZIDE;CYP2D6;CYP2D6 poor metabolizers;;DOSAGE;DECREASED_DOSE;;
PERPHENAZINE;CYP2D6;CYP2D6 normal metabolizer genotype;;LADME-PK;INCREASED_CLEARANCE;;
BUPROPION;CYP2C19;CYP2C19*2, CYP2C19*3, CYP2C19*17;*2 + *3;LADME-PK;DECREASED_METABOLISM;DISEASE;PREGNANCY
(R)-METHADONE, (S)-METHADONE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*1/*1xN;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;HEROIN DEPENDENCE
METHADONE;OPRM1;rs1799971;AA;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;OPIOID-RELATED DISORDERS
ARSENIC COMPOUNDS;CBS;rs4920037;AA + AG;TOXICITY, LADME-PK;INCREASED_METABOLISM;;
(R)-METHADONE, (S)-METHADONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3/*4 + *4/*4 + *4/*6;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HEROIN DEPENDENCE
VORICONAZOLE;CYP2C19;CYP2C19*2;*2/*2;LADME-PK;INCREASED_CONCENTRATIONS;;
MORPHINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
CODEINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_METABOLISM;;
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;NEOPLASMS, OTHER:PAIN
(S)-METHADONE;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS
WARFARIN;VKORC1;rs9934438;GG;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;INCREASED_CLINICAL_BENEFIT;;
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*9;*4/*4;LADME-PK;DECREASED_METABOLISM;;
METHOTREXATE;FOXP3;rs3761548;G;OTHER;DECREASED_RESPONSE;DISEASE;PSORIASIS
ATENOLOL, METOPROLOL;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RESPONSE;OTHER;TACHYCARDIA
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME-PK;INCREASED_TROUGH CONCENTRATION;DISEASE;FUNGAL INFECTIOUS DISEASE
N-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;NEOPLASMS, OTHER:PAIN
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
GEMCITABINE;NT5C2;rs11598702;TT;LADME-PK;DECREASED_CLEARANCE;;
GEMCITABINE;CDA;rs1048977;TT;LADME-PK;DECREASED_METABOLISM;;
VORICONAZOLE;CYP2C19;CYP2C19*17;*17/*17;LADME-PK;DECREASED_CONCENTRATIONS;;
METHADONE;ABCB1;rs1045642;AG;LADME-PK;DECREASED_CONCENTRATIONS;;
CLOMIPRAMINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER
OXYMORPHONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*17, CYP2D6*41;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;LADME-PK;INCREASED_EXPOSURE;;
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CTRB1, CTRB2;rs7202877;GG + GT;EFFICACY;DECREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
LANSOPRAZOLE, OMEPRAZOLE;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;HELICOBACTER INFECTIONS
SERTRALINE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*9;*6/*6 + *6/*9;LADME-PK;INCREASED_CONCENTRATIONS;;
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;*3 + *4 + *5 + *6 + *9 + *10 + *17 + *29 + *41;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
ARSENIC COMPOUNDS;CBS;rs234709;CT + TT;TOXICITY, LADME-PK;INCREASED_METABOLISM;;
3-HYDROXYCOTININE, 3-HYDROXYCOTININE GLUCURONIDE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*9, CYP2A6*10;*1 + *2;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;TOBACCO USE DISORDER
RISPERIDONE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;LADME-PK;INCREASED_CLEARANCE;DISEASE;PSYCHOTIC DISORDER
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_METABOLISM;;
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;VDR;rs2239179;C;EFFICACY;DECREASED_RESPONSE;DISEASE;ASTHMA
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41;*1/*1 + *2/*2 + *1/*2;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
AMITRIPTYLINE;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_METABOLISM;DISEASE;DEPRESSION
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;VDR;rs1540339;C;EFFICACY;DECREASED_RESPONSE;DISEASE;ASTHMA
ENDOXIFEN;CYP2C9;CYP2C9 poor metabolizers;;LADME-PK;DECREASED_CONCENTRATIONS;;
CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;DOSAGE, EFFICACY;INCREASED_RESPONSE;DISEASE;ACUTE CORONARY SYNDROME
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3;LADME-PK;INCREASED_TROUGH CONCENTRATION;DISEASE;HEMATOLOGIC DISORDER, DISEASE:INFECTIOUS DISEASE
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
IMIPRAMINE;CYP2C19;CYP2C19 poor metabolizers;;LADME-PK;DECREASED_METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER
DEBRISOQUINE;CYP2D6;CYP2D6*21, CYP2D6*36xN;*21/*36xN;LADME-PK;DECREASED_METABOLISM;;
GEMIGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN;GLP1R;rs3765467;AA + AG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
METHADONE;ABCB1;rs1045642;AA;LADME-PK;INCREASED_CONCENTRATIONS;;
FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6;*1/*3 + *1/*6 + *3/*3 + *3/*6 + *6/*6;LADME-PK;DECREASED_CLEARANCE;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
NORQUETIAPINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME-PK;INCREASED_EXPOSURE;;
CODEINE;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;INCREASED_RESPONSE;OTHER;PAIN
VORICONAZOLE;CYP2C19;CYP2C19 intermediate metabolizers;*1/*2 + *1/*3;LADME-PK;DECREASED_METABOLISM;DISEASE;FUNGAL INFECTIOUS DISEASE
CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *3/*3 + *2/*3;LADME-PK;INCREASED_EXPOSURE;;
INDOMETHACIN;CYP2C9;rs2153628;G;EFFICACY;INCREASED_RESPONSE;;
GEMCITABINE;CDA;rs2072671;AA;LADME-PK;DECREASED_METABOLISM;DISEASE;NON-SMALL CELL LUNG CARCINOMA
TACROLIMUS;CYP3A5;CYP3A5 poor metabolizer genotype;;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
VENLAFAXINE;SLC6A4;rs25531;TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;DISEASE;ANXIETY DISORDERS
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
ENDOXIFEN;CYP2D6;CYP2D6 intermediate metabolizers;;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
TRAMADOL;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;LADME-PK;INCREASED_METABOLISM;;
CODEINE;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;INCREASED_RESPONSE;OTHER;PAIN
MARAVIROC;CYP3A5;CYP3A5 poor metabolizers;;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
VENLAFAXINE;GABRQ;rs3810651;AA + AT;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
METOPROLOL;CYP2D6;CYP2D6 normal metabolizers;;LADME-PK;INCREASED_CLEARANCE;OTHER;PREGNANCY
CYTARABINE, IDARUBICIN;DCK;rs80143932;G;EFFICACY;INCREASED_RESPONSE;DISEASE;LEUKEMIA, MYELOID, ACUTE
CLOMIPRAMINE;CYP1A2;rs762551;AA;EFFICACY;INCREASED_DOSE;DISEASE;DEPRESSION
FENTANYL, HYDROMORPHONE, OPIOIDS, OXYCODONE, TRAMADOL;CYP2D6;CYP2D6 ultrarapid metabolizer;;DOSAGE;INCREASED_DOSE;OTHER;SURGERY
CLOZAPINE, N-DESMETHYLCLOZAPINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
IBOGAINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_CLEARANCE;OTHER;OPIOID-RELATED DISORDERS
ATOMOXETINE;CYP2D6;CYP2D6*10;*10/*10;LADME-PK;INCREASED_EXPOSURE;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
ATOMOXETINE;CYP2D6;CYP2D6*10;*10/*10;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
AMPHETAMINE, LISDEXAMFETAMINE;CYP2D6;CYP2D6 poor metabolizer;;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;GRIA3;rs502434;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*41;*41;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*55;*55;LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*39;*39;LADME-PK;DECREASED_METABOLISM;;
ISONIAZID;NAT2;NAT2 slow acetylator;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;TUBERCULOSIS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;INCREASED_EXPOSURE;OTHER;KIDNEY TRANSPLANTATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;HLA-DQA1;HLA-DQA1*05;*05;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;INFLAMMATORY BOWEL DISEASES, OTHER:INFLAMMATION
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;DOSAGE, EFFICACY;DOSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME-PK;DECREASED_CONCENTRATIONS;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;GRIA3;rs3761554;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
WARFARIN;CALU;rs339097;G;DOSAGE;INCREASED_DOSE;;
ISONIAZID;NAT2;NAT2 intermediate acetylator;;LADME-PK;INCREASED_CLEARANCE;OTHER;TUBERCULOSIS
OPIOIDS;OPRM1;rs1799971;GG;DOSAGE;INCREASED_DOSE;OTHER;PAIN
DIHYDROARTEMISININ;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*18;*6/*6 + *18/*18 + *1/*6;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;MALARIA, FALCIPARUM
DESBUTYL LUMEFANTRINE;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6;*1/*3;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;MALARIA, FALCIPARUM
SERTRALINE;CYP2D6;CYP2D6*1, CYP2D6*2;*2;LADME-PK;DECREASED_CLEARANCE;OTHER;SUBSTANCE-RELATED DISORDERS, OTHER:MAJOR DEPRESSIVE DISORDER, OTHER:ANXIETY DISORDERS, OTHER:BORDERLINE PERSONALITY DISORDER
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*2 + *2/*17;LADME-PK;DECREASED_CLEARANCE;OTHER;SUBSTANCE-RELATED DISORDERS, OTHER:MAJOR DEPRESSIVE DISORDER, OTHER:ANXIETY DISORDERS, OTHER:BORDERLINE PERSONALITY DISORDER
TACROLIMUS;ABCC2;rs3740066;TT;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
LEVONORGESTREL;CYP2B6;CYP2B6 poor metabolizer;;LADME-PK;INCREASED_CLEARANCE;OTHER;HIV INFECTIOUS DISEASE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;GRIA3;rs3761555;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
WARFARIN;NKX2-6;rs310279;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT
CYTARABINE, IDARUBICIN;DCK;rs2306744;T;EFFICACY;INCREASED_RESPONSE;DISEASE;LEUKEMIA, MYELOID, ACUTE
VENLAFAXINE;HTR2A;rs7997012;AG + GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;DISEASE;ANXIETY DISORDERS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;THERAPEUTIC DRUG MONITORING ANALYSES
ANTIEPILEPTICS;;rs16935279;CC + CT;LADME-PK;DECREASED_METABOLISM;DISEASE;BIPOLAR DISORDER, DISEASE:PSYCHOTIC DISORDER
FOLLITROPIN BETA, UROFOLLITROPIN;FSHR;rs6166;CC + CT;DOSAGE;INCREASED_DOSE;;
PAROXETINE;CYP2D6;CYP2D6 ultrarapid metabolizer;;LADME-PK;DECREASED_STEADY-STATE CONCENTRATION;OTHER;MAJOR DEPRESSIVE DISORDER, OTHER:ANXIETY DISORDERS, OTHER:PANIC DISORDER
PAROXETINE;CYP2D6;CYP2D6 ultrarapid metabolizer;;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER
CLOMIPRAMINE;CYP2D6;CYP2D6*1xN, CYP2D6*2;*2/*1xN;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;AGORAPHOBIA
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
CLOMIPRAMINE;CYP2D6;CYP2D6*4, CYP2D6*6;*4/*6;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER
WARFARIN;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *17/*17;LADME-PK;INCREASED_CLEARANCE;;
ATORVASTATIN;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4, CYP2C19*8, CYP2C19*11;*2 + *4 + *8;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;CARDIOVASCULAR DISEASE
CISPLATIN, IRINOTECAN;UBE2I;rs9597;CG;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
WARFARIN;FRAS1;rs4386623;AA + AG;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;GASTROESOPHAGEAL REFLUX
WARFARIN;FAM201A;rs1890109;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
VALPROIC ACID;SCN1A;rs3812718;T;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;EPILEPSY
PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE;ULCER
PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;DISEASE;ULCER
CAPECITABINE;DPYD;rs1801159;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;GASTROESOPHAGEAL CANCER
NICOTINE;DRD2;rs6277;A;EFFICACY;INCREASED_RESPONSE;;
CAPTOPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESISTANCE;DISEASE;DIABETES MELLITUS
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;CYP3A5;rs776746;CC;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;THROMBOEMBOLISM
BUPROPION;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER
ETHANOL;OPRM1;rs648007;A;EFFICACY;INCREASED_RESPONSE;;
MIDAZOLAM;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME-PK;DECREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
CLOZAPINE;NFIB;rs28379954;CT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;TOBACCO USE DISORDER
ETHANOL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RESPONSE;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;INCREASED_EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;*4/*41 + *5/*6;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;MALARIA
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE;;
NICOTINE;UGT2B10;rs61750900;T;OTHER, LADME-PK;DECREASED_METABOLISM;;
NICOTINE;CHRNA7;rs2337980;CC;EFFICACY;INCREASED_RESPONSE;;
BUPROPION;DRD2;rs1799732;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;TOBACCO USE DISORDER
WARFARIN;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_DOSE;;
CLOZAPINE;CYP1A1;rs2472297;CT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;TOBACCO USE DISORDER
SIMVASTATIN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME-PK;CONCENTRATIONS;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE
QUETIAPINE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;PSYCHOTIC DISORDER
WARFARIN;EPHX1;rs1131873;A;DOSAGE;DECREASED_DOSE;;
CLOZAPINE;CYP1A1;rs2472297;CT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;;
METFORMIN;SLC2A2;rs8192675;C;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS
WARFARIN;CYP2C9;rs28371686;G;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;DISEASE;CONNECTIVE TISSUE DISEASES
WARFARIN;CYP2C9;rs28371685;T;DOSAGE;DECREASED_DOSE;;
DULOXETINE;CYP2D6;rs3892097;CC;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;ALCOHOL ABUSE, OTHER:DEPRESSIVE DISORDER
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;NEOPLASMS
WARFARIN;CYP2C9;rs9332131;del;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_CONCENTRATIONS;;
CLOZAPINE;NFIB;rs28379954;CT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;;
HYDROXYUREA;BCL11A;rs4671393;A;EFFICACY;INCREASED_RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
WARFARIN;CYP2C9;rs7900194;A;DOSAGE;DECREASED_DOSE;;
ROSIGLITAZONE;CYP2C8;CYP2C8*1, CYP2C8*3;*3;EFFICACY;DECREASED_RESPONSE;DISEASE;DIABETES MELLITUS
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;EPILEPSY
BETA BLOCKING AGENTS;KL;rs36217263;A/del + del/del;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6 + *1/*6;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *1/*2 + *1/*3;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE
GEMCITABINE;RRM1;rs12806698;AC;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
FLUOXETINE, SERTRALINE;SLC6A4;rs57098334;(CCCACCCGA)12/(CCCACCCGA)12;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
BUPROPION;ACE;rs8075924;TT;EFFICACY;DECREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;OTHER;KIDNEY TRANSPLANTATION
SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
SUNITINIB;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME-PK;DECREASED_CLEARANCE;;
HYDROXYCHLOROQUINE;CYP3A4;rs3735451;CC;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;RHEUMATOID ARTHRITIS, OTHER:SYSTEMIC LUPUS ERYTHEMATOSUS
FLUOROURACIL;XRCC1;rs25487;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;RECTAL NEOPLASMS
MIRTAZAPINE;CYP2B6;CYP2B6*6;*6/*6;LADME-PK;INCREASED_METABOLISM;DISEASE;DEPRESSION
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;DISEASE;EPILEPSY
GEMCITABINE;RRM1;rs11030918;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
TACROLIMUS;ABCB1;rs1045642;AG + GG;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3;LADME-PK;DECREASED_CLEARANCE;;
RISPERIDONE;CYP2D6;CYP2D6 intermediate metabolizer phenotype;;LADME-PK;DECREASED_METABOLISM;;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;DOSAGE, EFFICACY;DECREASED_RESPONSE;OTHER;PERCUTANEOUS CORONARY INTERVENTION
PACLITAXEL;CYP2C8;rs11572080;T;OTHER, LADME-PK;DECREASED_METABOLISM;;
PACLITAXEL;CYP2C8;rs10509681;C;OTHER, LADME-PK;DECREASED_METABOLISM;;
CYCLOSPORINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME-PK;DECREASED_CONCENTRATIONS;;
CYCLOSPORINE;CYP3A4;rs35599367;A;LADME-PK;DECREASED_METABOLISM;OTHER;KIDNEY TRANSPLANTATION
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*10;*1/*1 + *10/*10 + *1/*4 + *1/*10;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;ANXIETY DISORDERS, OTHER:DEPRESSION, OTHER:MAJOR DEPRESSIVE DISORDER
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME-PK;DECREASED_METABOLISM;DISEASE;CHRONIC KIDNEY FAILURE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME-PK;INCREASED_METABOLISM;OTHER;PATIENTS WITH DECREASED CONCENTRATIONS OF VORICONAZOLE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
DOCETAXEL, THALIDOMIDE;PPARD;rs3734254;T;EFFICACY;INCREASED_RESPONSE;DISEASE;PROSTATIC NEOPLASMS
ATENOLOL, METOPROLOL;OR10P1;rs17117817;G;LADME-PD;DECREASED_RESPONSE;OTHER;HYPERTENSION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;DOSAGE;DECREASED_DOSE;;
CARBOPLATIN, GEMCITABINE;RRM1;rs12806698;AC;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
METFORMIN;C11orf65;rs11212617;C;EFFICACY;INCREASED_CLINICAL_BENEFIT;DISEASE;DIABETES MELLITUS, TYPE 2
ABATACEPT;HLA-DRB1;HLA-DRB1*04:01, HLA-DRB1*04:04, HLA-DRB1*04:05, HLA-DRB1*04:10, HLA-DRB1*10:01;*04:01 + *04:04 + *04:05 + *04:10 + *10:01;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
METHADONE;;rs17180299;AG + GG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS
WARFARIN;CALU;rs339097;G;DOSAGE;INCREASED_DOSE;;
VINCRISTINE;;rs1247117;G;LADME-PD;INCREASED_RESISTANCE;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;DISEASE;LIVER TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
ATENOLOL, METOPROLOL;SNX9;rs2364349;A;LADME-PD;DECREASED_RESPONSE;OTHER;HYPERTENSION
TACROLIMUS;;rs11265572;GT + TT;LADME-PK;DECREASED_METABOLISM;DISEASE;LIVER TRANSPLANTATION
WARFARIN;STX4;rs10871454;T;DOSAGE;DECREASED_DOSE;;
SIROLIMUS, TEMSIROLIMUS;CYP3A5;rs776746;CT;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;URINARY BLADDER NEOPLASMS
PERAMPANEL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
VORICONAZOLE;CYP2C19;CYP2C19*17;*17;LADME-PK;DECREASED_CONCENTRATIONS;;
ENALAPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;DISEASE;ESSENTIAL HYPERTENSION
URACIL;DPYD;DPYD c.295_298delTCAT (*7), DPYD Reference;c.295_298delTCAT (*7);LADME-PK;INCREASED_CONCENTRATIONS;;
URACIL;DPYD;DPYD c.2846A>T, DPYD Reference;c.2846A>T;LADME-PK;INCREASED_CONCENTRATIONS;;
URACIL;DPYD;DPYD c.1679T>G (*13), DPYD Reference;c.1679T>G (*13);LADME-PK;INCREASED_CONCENTRATIONS;;
URACIL;DPYD;DPYD c.1905+1G>A (*2A), DPYD Reference;c.1905+1G>A (*2A);LADME-PK;INCREASED_CONCENTRATIONS;;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*29, CYP2D6*35, CYP2D6*41;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;LADME-PK;DECREASED_METABOLISM;DISEASE;BREAST NEOPLASMS
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;LADME-PK;DECREASED_METABOLISM;DISEASE;BREAST NEOPLASMS
ATORVASTATIN;CYP3A5;CYP3A5*3;*3/*3;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10 + *1/*10;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
ESCITALOPRAM;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;;
ESCITALOPRAM;CYP2D6;CYP2D6 intermediate metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;;
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2 + *1/*2;TOXICITY, LADME-PK;DECREASED_METABOLISM;SIDE EFFECT;POSTMORTEM TOXICOLOGY CASES
EFAVIRENZ;CYP2B6;CYP2B6 poor metabolizer;;LADME-PK;INCREASED_EXPOSURE;;
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;HLA-A*03:01;*03:01;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;HLA-A*23:17;*23:17;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-B;HLA-B*57:03;*57:03;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*7;*1/*1 + *1/*3;LADME-PK;INCREASED_CLEARANCE;OTHER;KIDNEY TRANSPLANTATION
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*41;*2 + *9 + *10 + *35 + *41;LADME-PK;DECREASED_CLEARANCE;;
ANTIDEPRESSANTS;CYP2C19;CYP2C19 poor metabolizer;;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER
SUMATRIPTAN;SLC22A1;rs1349294037;TAAGTTGT/TAAGTTGT;OTHER;INCREASED_CONCENTRATIONS;;
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*18;*6 + *18;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS
LAMOTRIGINE;UGT1A4;UGT1A4*3b;*3b;EFFICACY;DECREASED_CLINICAL_BENEFIT;;
DOCETAXEL, THALIDOMIDE;PPARD;rs2016520;C;EFFICACY;INCREASED_RESPONSE;DISEASE;PROSTATIC NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION
INFLIXIMAB;HLA-DQA1;HLA-DQA1*05;*05;EFFICACY;DECREASED_RESPONSE;OTHER;CROHN DISEASE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4, CYP2C19*17;*2 + *4;EFFICACY;DECREASED_RESPONSE;;
DOCETAXEL, THALIDOMIDE;CHST3;rs1871450;A;EFFICACY;INCREASED_RESPONSE;DISEASE;PROSTATIC NEOPLASMS
WARFARIN;VKORC1;rs9923231;T;DOSAGE, LADME-PK;DECREASED_DOSE;;
PROPOFOL;CYP2B6;CYP2B6*1, CYP2B6*6;*6;TOXICITY;DECREASED_RESPONSE;OTHER;BRAIN INJURY
TILDRAKIZUMAB;PDE4D;rs10556657;CT/CT;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;PSORIASIS
BUPRENORPHINE, DIHYDROCODEINE, FENTANYL, HYDROMORPHONE, METHADONE, MORPHINE, OXYCODONE, PIRITRAMIDE, TILIDINE, TRAMADOL;ABCB1;rs1045642;A;DOSAGE;DECREASED_DOSE;DISEASE;PAIN
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME-PK;DECREASED_CLEARANCE;OTHER;KIDNEY TRANSPLANTATION
SIROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
DOCETAXEL, THALIDOMIDE;PPARD;rs1883322;C;EFFICACY;INCREASED_RESPONSE;DISEASE;PROSTATIC NEOPLASMS
PHENYTOIN;CYP2C19;CYP2C19 intermediate metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;;
VALPROIC ACID;CYP2C19;CYP2C19 intermediate metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;;
CARBAMAZEPINE;CYP3A5;CYP3A5 poor metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;;
VALPROIC ACID;CYP2C9;CYP2C9 intermediate metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;;
VALPROIC ACID;UGT1A6;UGT1A6*1a, UGT1A6*2a;*2a;LADME-PK;DECREASED_CONCENTRATIONS;;
PHENYTOIN;CYP2C9;CYP2C9 intermediate metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;;
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;COLORECTAL NEOPLASMS, OTHER:METASTATIC NEOPLASM
DOCETAXEL, THALIDOMIDE;CHST3;rs12418;A;EFFICACY;INCREASED_RESPONSE;DISEASE;PROSTATIC NEOPLASMS
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*60;*28 + *60;DOSAGE;DECREASED_DOSE;OTHER;COLORECTAL NEOPLASMS
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28 + *1/*28;DOSAGE;DECREASED_DOSE;OTHER;COLORECTAL NEOPLASMS, OTHER:METASTATIC NEOPLASM
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME-PK;INCREASED_METABOLISM;OTHER;PEPTIC ULCER DISEASE, OTHER:GASTROESOPHAGEAL REFLUX, OTHER:ESOPHAGITIS
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*8;*1/*8;LADME-PK;DECREASED_METABOLISM;;
ABROCITINIB;CYP2C19;CYP2C19 poor metabolizer;;LADME-PK;INCREASED_EXPOSURE;;
WARFARIN;CYP2C9;CYP2C9*1;*1/*1;DOSAGE;INCREASED_DOSE;;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*8;*2 + *3 + *8;DOSAGE;DECREASED_DOSE;;
OPIOIDS;OPRM1;rs1799971;GG;DOSAGE;INCREASED_DOSE;OTHER;CAESARIAN SECTION, OTHER:PAIN
DULOXETINE;DRD3;rs963468;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;ANXIETY DISORDERS
SIMVASTATIN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME-PK;INCREASED_EXPOSURE;;
METFORMIN;C11orf65;rs11212617;C;EFFICACY;INCREASED_CLINICAL_BENEFIT;DISEASE;DIABETES MELLITUS, TYPE 2
CYCLOSPORINE;CYP3A5;rs776746;CC;DOSAGE, LADME-PK;DECREASED_DOSE;;
EFAVIRENZ, NEVIRAPINE;NR1I3;rs2307424;AA + AG;EFFICACY;INCREASED_RESPONSE;EFFICACY;HIV INFECTIOUS DISEASE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*1 + *1/*2;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEMATOLOGIC NEOPLASMS, OTHER:HEMATOPOIETIC STEM CELL TRANSPLANTATION
ARIPIPRAZOLE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME-PK;INCREASED_CONCENTRATIONS;;
ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;;
PIMOZIDE;CYP3A4;CYP3A4*1, CYP3A4*22;*22;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;PSYCHOTIC DISORDER
DOCETAXEL, THALIDOMIDE;CHST3;rs4148943;C;EFFICACY;INCREASED_RESPONSE;DISEASE;PROSTATIC NEOPLASMS
RISPERIDONE;CYP2D6;CYP2D6 ultrarapid metabolizer;;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
DOCETAXEL, THALIDOMIDE;CHST3;rs4148945;C;EFFICACY;INCREASED_RESPONSE;DISEASE;PROSTATIC NEOPLASMS
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs80034486;CG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CYSTIC FIBROSIS
GLYBURIDE;ABCB11;rs4148776;G;EFFICACY;INCREASED_RESPONSE;;
IMATINIB;SLCO1B3;rs7311358;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
IMATINIB;SLCO1B3;rs4149117;GG + GT;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
PRAZIQUANTEL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *2/*2 + *1/*3 + *3/*3;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;SCHISTOSOMIASIS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA, OTHER:LYMPHOMA, OTHER:LEUKEMIA, MYELOID, ACUTE
GLYBURIDE;CHST13;rs1054097;C;EFFICACY;INCREASED_RESPONSE;;
LACOSAMIDE;CYP2C19;CYP2C19 normal metabolizer;;LADME-PK;DECREASED_EXPOSURE;OTHER;EPILEPSY
LACOSAMIDE;ABCC2;rs717620;T;LADME-PK;DECREASED_EXPOSURE;OTHER;EPILEPSY
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*1/*3 + *1/*4;LADME-PK;INCREASED_CONCENTRATIONS;;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*4/*4;LADME-PK;INCREASED_CONCENTRATIONS;;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*1;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SURGERY
CLOZAPINE;CYP2D6;CYP2D6 normal metabolizer;;DOSAGE;INCREASED_DOSE;OTHER;SCHIZOPHRENIA, OTHER:PSYCHOTIC DISORDER
EFAVIRENZ;CYP2B6;CYP2B6 intermediate metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE
MERCAPTOPURINE;TPMT;TPMT deficiency;;DOSAGE;DECREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
THIOGUANOSINE DIPHOSPHATE, THIOGUANOSINE MONOPHOSPHATE, THIOGUANOSINE TRIPHOSPHATE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*3A + *3B + *3C;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
TOLTERODINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;;
METOPROLOL;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;;
CLOZAPINE;ITIH3;rs2535629;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
ATOMOXETINE;CYP2D6;CYP2D6 poor metabolizer;;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
EFAVIRENZ;CYP2B6;CYP2B6 poor metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE, DISEASE:TUBERCULOSIS
EFAVIRENZ;NAT2;NAT2 slow acetylator;;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE, DISEASE:TUBERCULOSIS
COTININE;CYP2A6;CYP2A6 low activity;;LADME-PK;INCREASED_METABOLISM;OTHER;TOBACCO USE DISORDER
COTININE;CYP2A6;CYP2A6 low activity;;LADME-PK;INCREASED_CONCENTRATIONS;;
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*24, CYP2A6*25, CYP2A6*26, CYP2A6*27, CYP2A6*28, CYP2A6*35;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;LADME-PK;DECREASED_METABOLISM;;
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER
DEOXY-THIOGUANOSINE TRIPHOSPHATE, THIOGUANOSINE TRIPHOSPHATE;TPMT;TPMT deficiency;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;BREAST NEOPLASMS
CAFFEINE;ADORA1;rs10920573;CC;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;APNEA OF PREMATURITY
NORQUETIAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_CONCENTRATIONS;;
QUETIAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME-PK;INCREASED_CONCENTRATIONS;;
AMLODIPINE;CACNA1D;rs312481;GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;HYPERTENSION
PEGINTERFERON ALFA-2A;ZHX2;rs17289471;C;EFFICACY;INCREASED_RESPONSE;OTHER;HEPATITIS B VIRUS INFECTION
BERBERINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;;
CLOPIDOGREL;CYP2C19;rs12248560;T;EFFICACY, OTHER;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME
RANIBIZUMAB;VEGFA;rs833069;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;MACULAR DEGENERATION
TACROLIMUS;CYP3A5;rs4646449;CC;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
ONDANSETRON;CYP2D6;CYP2D6 poor metabolizer;;DOSAGE;INCREASED_DOSE;OTHER;SURGERY
IMATINIB;ABCA3;rs150929;GG + GT;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
METFORMIN;CBARP, STK11;rs2301759;TT;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
METFORMIN;SLC22A3;rs3127602;T;EFFICACY;INCREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
METFORMIN;PRKAA1;rs11749180;A;EFFICACY;DECREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
METFORMIN;SLC29A4;rs10234709;A;EFFICACY;DECREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
METFORMIN;PRKAG2;rs4725434;T;EFFICACY;INCREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
METFORMIN;SLC47A1;rs2120274;A;EFFICACY;INCREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
METFORMIN;STK11;rs2301759;C;EFFICACY;INCREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
METFORMIN;SLC47A2;rs4621031;C;EFFICACY;DECREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;CFTR 3849+10kbC->T;3849+10kbC->T;;INCREASED_CLINICAL_BENEFIT;OTHER;CYSTIC FIBROSIS
ALECTINIB;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;NON-SMALL CELL LUNG CARCINOMA
METFORMIN;TCF7L2;rs7903146;T;EFFICACY;INCREASED_RESPONSE;;
METHADONE;OPRK1;rs3802279;CC;DOSAGE;DECREASED_DOSE;OTHER;HEROIN DEPENDENCE
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs80034486;GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CYSTIC FIBROSIS
LACOSAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;rs41267797;AG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;DEATH
N,N-DIDESMETHYLTRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*41, CYP2D6*45;*4/*6 + *4/*5;LADME-PK;INCREASED_CONCENTRATIONS;;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;IMMUNOGLOBULIN A VASCULITIS
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs75961395;AA;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CYSTIC FIBROSIS
TOCILIZUMAB;IL6R;rs35717427;AG + GG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;ABCC2;rs17216317;CT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;DEATH
TOCILIZUMAB;IL6R;rs6690230;CG + GG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
TOCILIZUMAB;IL6R;rs11265621;AA + AG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
TOCILIZUMAB;;rs10108210;AA;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
TOCILIZUMAB;CLEC2D;rs1560011;GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
TOCILIZUMAB;KCNMB1;rs703505;AA + AG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ELDERLY ADULT, OTHER:MAJOR DEPRESSIVE DISORDER
MORPHINE;CCL11;rs17809012;AA;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;NEOPLASMS, OTHER:PAIN
MORPHINE;IL16;rs4778889;TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;NEOPLASMS, OTHER:PAIN
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;rs35235578;CT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;DEATH
VALPROIC ACID;SLC16A1;rs7169;GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;EPILEPSY
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;rs9457841;C;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;DEATH
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;rs34134157;CC;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;DEATH
TENOFOVIR;ABCC4;rs3742106;AC + CC;TOXICITY;INCREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE
ANTIDEPRESSANTS;FKBP5;rs1360780;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
ACETAMINOPHEN SULFATE;CYP2E1;CYP2E1*1, CYP2E1*5B;*1/*5B;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;PATENT DUCTUS ARTERIOSUS, OTHER:PREMATURE BIRTH
FENTANYL;ABCC1;rs58572178;(A)14;LADME-PK;INCREASED_CLEARANCE;OTHER;PAIN, OTHER:PREMATURE BIRTH
VORICONAZOLE;CYP2C19;CYP2C19*2, CYP2C19*17;*2 + *17;DOSAGE;DOSE;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION
ACETAMINOPHEN;CYP1A2;rs2069514;A;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;PATENT DUCTUS ARTERIOSUS
DOXORUBICIN;CBR1;rs20572;T;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;BREAST NEOPLASMS
SUNITINIB;KDR;rs34231037;AG;EFFICACY;INCREASED_CLINICAL_BENEFIT;;
ANTIDEPRESSANTS;FKBP5;rs3800373;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;DEPRESSIVE DISORDER
GLICLAZIDE, GLIMEPIRIDE, GLIPIZIDE, GLYBURIDE;KCNQ1;rs163184;GT + TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
ISONIAZID;NAT2;NAT2 slow acetylator;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;TUBERCULOSIS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION
MORPHINE;CYP2D6;CYP2D6*10, CYP2D6*41;*41;LADME-PK;INCREASED_EXPOSURE;OTHER;PAIN, POSTOPERATIVE
DULOXETINE;DRD3;rs324026;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE;ANXIETY DISORDERS
CYTARABINE, DAUNORUBICIN;RAD50;rs2299014;AA + AC;EFFICACY;INCREASED_RESISTANCE;OTHER;LEUKEMIA, MYELOID, ACUTE
TENOFOVIR;ABCC4;rs1751034;TT;TOXICITY;INCREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE
DULOXETINE;DRD3;rs324023;CT;EFFICACY;DECREASED_RESPONSE;DISEASE;ANXIETY DISORDERS
EFAVIRENZ, NEVIRAPINE;NR1I2;rs1523127;AA + AC;EFFICACY;DECREASED_RESPONSE;EFFICACY;HIV INFECTIOUS DISEASE
EZETIMIBE;ABCG8;ABCG8 deficiency;;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;FAMILIAL HYPERCHOLESTEROLEMIA
EZETIMIBE;ABCG5;ABCG5 deficiency;;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;FAMILIAL HYPERCHOLESTEROLEMIA
RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
DULOXETINE;DRD3;rs167770;AG;EFFICACY;DECREASED_RESPONSE;DISEASE;ANXIETY DISORDERS
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BIPOLAR DISORDER, DISEASE:SCHIZOAFFECTIVE DISORDER, DISEASE:SCHIZOPHRENIA
TAMSULOSIN;CYP2D6;CYP2D6*10, CYP2D6*41;*10 + *41;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;PROSTATIC HYPERPLASIA
HYDROXYUREA;HBG2;rs7482144;AG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;BETA-THALASSEMIA AND RELATED DISEASES, OTHER:ALPHA-THALASSEMIA
HYDROXYUREA;HBG2;rs7482144;AA + AG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;BETA-THALASSEMIA AND RELATED DISEASES
HYDROXYUREA;HBG2;rs7482144;AA;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;BETA-THALASSEMIA AND RELATED DISEASES
HYDROXYUREA;BCL11A;rs766432;C;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;BETA-THALASSEMIA AND RELATED DISEASES
IMATINIB;PDGFRB;rs201866603;CT;EFFICACY;DECREASED_RESPONSE;EFFICACY;INFANTILE MYOFIBROMATOSIS
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801133;A;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
VORTIOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*10;*4/*4 + *4/*10;LADME-PK;INCREASED_CONCENTRATIONS;;
ANTIEPILEPTICS;SCN1A;rs121917953;AA + AT;EFFICACY;INCREASED_RESISTANCE;OTHER;EPILEPSY
NICOTINE;CYP2A6;rs778019189;G;LADME-PK;DECREASED_METABOLISM;;
METHOTREXATE;ENG;rs1800956;G;LADME-PK;DECREASED_CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
METHOTREXATE;PKD1L2;rs16954698;A;LADME-PK;DECREASED_CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4;*1/*2 + *1/*3 + *1/*4 + *2/*4 + *3/*3;DOSAGE;DECREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
ANTIDEPRESSANTS;FKBP5;rs1360780;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;DEPRESSIVE DISORDER
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY, LADME-PK;INCREASED_CONCENTRATIONS;SIDE EFFECT;ADVERSE EVENTS, SIDE EFFECT:CHOLESTASIS, SIDE EFFECT:THROMBOCYTOPENIA
EFAVIRENZ, NEVIRAPINE;NR1I3;rs3003596;AG + GG;EFFICACY;DECREASED_RESPONSE;EFFICACY;HIV INFECTIOUS DISEASE
ANTIDEPRESSANTS;FKBP5;rs4713916;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;DEPRESSIVE DISORDER
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10;*10/*10 + *2/*10;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;BREAST NEOPLASMS
ENDOXIFEN;CYP2D6;CYP2D6 normal metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;BREAST NEOPLASMS
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4;*4/*4;LADME-PK;DECREASED_METABOLISM;;
CLOZAPINE;CYP2D6;rs202102799;C;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA, OTHER:PSYCHOTIC DISORDER
CLOZAPINE;CYP2D6;rs28371726;G;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA, OTHER:PSYCHOTIC DISORDER
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA, OTHER:PSYCHOTIC DISORDER
CLOZAPINE;DRD4;rs762502;C;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;SCHIZOPHRENIA, OTHER:PSYCHOTIC DISORDER
NIFEDIPINE;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;DISEASE;PREGNANCY
CLOZAPINE;DRD4;rs2133251840;del;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;SCHIZOPHRENIA, OTHER:PSYCHOTIC DISORDER
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;CYP1A2 ultrarapid metabolizer;;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA, OTHER:PSYCHOTIC DISORDER
EXENATIDE;SORCS1;rs1416406;GG;EFFICACY;INCREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
LINAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN;KCNJ11;rs2285676;GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
LINAGLIPTIN, SAXAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN;PRKD1;rs57803087;G;EFFICACY;INCREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
CLOZAPINE;CYP1A2;rs72547516;T;;DECREASED_METABOLISM;;
CLOZAPINE;CYP1A2;CYP1A2*8;*8;LADME-PK;DECREASED_METABOLISM;;
MIDAZOLAM;NR1I2;rs2461817;CC;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;RESPIRATORY FAILURE REQUIRING ASSISTED VENTILATION
METHADONE, R-EDDP, S-EDDP;CYP2D6;CYP2D6 intermediate metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;DEATH
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801131;G;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;DOSAGE;DECREASED_DOSE;DISEASE;ULCERATIVE COLITIS, DISEASE:CROHN DISEASE, DISEASE:AUTOIMMUNE HEPATITIS
WARFARIN;CYP2C9;rs1057910;AA;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT
WARFARIN;APOE;rs7412;CC;DOSAGE;INCREASED_DOSE;OTHER;ATRIAL FIBRILLATION, OTHER:PULMONARY EMBOLISM, OTHER:VENOUS THROMBOSIS
METHACHOLINE;ADRB2;rs1042713;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;ASTHMA
NALTREXONE;OPRM1;rs1799971;AG + GG;EFFICACY;DECREASED_RESPONSE;OTHER;TOBACCO USE DISORDER
ACENOCOUMAROL;VKORC1;rs9923231;CT;DOSAGE;DECREASED_DOSE;;
TEMSIROLIMUS;NR1I2;rs3814055;TT;LADME-PK;DECREASED_METABOLISM;DISEASE;URINARY BLADDER NEOPLASMS
TEMSIROLIMUS;ABCB1;rs2032582;CC;LADME-PK;INCREASED_METABOLISM;DISEASE;URINARY BLADDER NEOPLASMS
TACROLIMUS;CYP3A5;rs776746;TT;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;;rs4646457;C;DOSAGE;DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs15524;G;DOSAGE;DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A4;rs12333983;A;DOSAGE;DOSE;DISEASE;KIDNEY TRANSPLANTATION
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;DISEASE;RHEUMATIC HEART DISEASE
FLECAINIDE;SCN4A;rs80338792;T;EFFICACY;INCREASED_RESPONSE;DISEASE;MYOTONIA
ATENOLOL, METOPROLOL;;rs294610;A;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION
ATENOLOL, METOPROLOL;SLC4A1;rs45545233;CC + CT;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;rs3794271;G;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
CAPECITABINE, FLUOROURACIL;DPYD;rs56038477;CT;DOSAGE;DOSE;DISEASE;COLORECTAL NEOPLASMS
SUNITINIB;ABCB1;rs2032582;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;RENAL CELL CARCINOMA
FLUOROURACIL;DPYD;rs17376848;AG + GG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;COLORECTAL NEOPLASMS
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;;
HYDROCHLOROTHIAZIDE;;rs11065987;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
METHADONE;ABCB1;rs1128503;AA;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
ETHANOL;OPRM1;rs553202;T;EFFICACY;INCREASED_RESPONSE;;
ETHANOL;OPRM1;rs524731;A;EFFICACY;INCREASED_RESPONSE;;
S-EDDP;ABCB1;rs1128503;AG;LADME-PK;INCREASED_CONCENTRATIONS;;
NICOTINE;HINT1;rs3852209;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER
S-EDDP;ABCB1;rs1045642;AG;LADME-PK;INCREASED_CONCENTRATIONS;;
OPIOIDS;OPRM1;rs1799971;AG;EFFICACY;DECREASED_RESPONSE;DISEASE;PAIN, POSTOPERATIVE
METHADONE;ABCB1;rs1128503;AG;LADME-PK;DECREASED_CONCENTRATIONS;;
PHENPROCOUMON;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
FLUOXETINE;CYP2D6;rs3892097;CT;EFFICACY;INCREASED_CONCENTRATIONS;EFFICACY;ALCOHOL ABUSE, EFFICACY:MAJOR DEPRESSIVE DISORDER
LEVODOPA;DBH;rs1611115;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;COCAINE DEPENDENCE
VENLAFAXINE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
AXITINIB;OR2B11;rs35305980;A;LADME-PK;CONCENTRATIONS;DISEASE;RENAL CELL CARCINOMA
SULFONAMIDES, UREA DERIVATIVES;KCNJ11;rs5219;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
WARFARIN;VKORC1;rs7294;T;DOSAGE, LADME-PK;INCREASED_DOSE;;
SULFONAMIDES, UREA DERIVATIVES;ABCC8;rs757110;AA + CC;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS
TIPIRACIL HYDROCHLORIDE, TRIFLURIDINE;SLC29A1;rs9394992;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
ANTIDEPRESSANTS, DESIPRAMINE, FLUOXETINE;BDNF;rs61888800;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
AXITINIB;UGT1A10, UGT1A8, UGT1A9;rs3832043;del;LADME-PK;CONCENTRATIONS;DISEASE;RENAL CELL CARCINOMA
AXITINIB;UGT1A7;rs17868323;G;LADME-PK;CONCENTRATIONS;DISEASE;RENAL CELL CARCINOMA
RISPERIDONE;HTR2C;rs3813928;A;EFFICACY;DECREASED_RESPONSE;DISEASE;AUTISM
METHOTREXATE;MTRR;rs1532268;CT + TT;LADME-PK;INCREASED_EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
RISPERIDONE;HTR2A;rs6311;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;AUTISM
AXITINIB;ABCB1;rs1045642;A;LADME-PK;CONCENTRATIONS;DISEASE;RENAL CELL CARCINOMA
AXITINIB;ABCG2;rs2231142;T;LADME-PK;CONCENTRATIONS;DISEASE;RENAL CELL CARCINOMA
AXITINIB;ABCB1;rs2032582;T;LADME-PK;CONCENTRATIONS;DISEASE;RENAL CELL CARCINOMA
VORICONAZOLE;CYP2C19;rs4244285;AA + AG;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;;
ERLOTINIB;EGFR;rs121434568;GT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
METHOTREXATE;ABCB1;rs1045642;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
CYTARABINE;SLC29A1;rs3734703;A;EFFICACY;INCREASED_RESPONSE;DISEASE;LEUKEMIA, MYELOID, ACUTE
SUNITINIB;ABCB1;rs1045642;AA + AG;LADME-PK;INCREASED_CLEARANCE;DISEASE;RENAL CELL CARCINOMA, DISEASE:METASTATIC NEOPLASM
METHOTREXATE;SLC19A1;rs1051266;CC + TT;EFFICACY;DECREASED_RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
SN-38;UGT1A9;rs3832043;TT;DOSAGE;INCREASED_METABOLISM;DISEASE;NON-SMALL CELL LUNG CARCINOMA
EFAVIRENZ;CYP2B6;rs2279345;CC + CT;LADME-PK;INCREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
RISPERIDONE;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;AUTISM
EFAVIRENZ;CYP2B6;rs2279345;CT;LADME-PK;INCREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
GLUCOCORTICOIDS;CRHR1;rs1876828;T;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
ANTIDEPRESSANTS;ERICH3;rs11580409;C;EFFICACY;INCREASED_RESPONSE;;
SN-38;SLCO1B1;rs4149056;CC + CT;DOSAGE;INCREASED_DOSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
SALMETEROL;ADRB2;rs1042713;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;ASTHMA
(S)-METHADONE;CYP3A4;rs2740574;CT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS
VORICONAZOLE;CYP2C19;rs4986893;AA + AG;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;;
METHYLPHENIDATE;GRIN2B;rs2284411;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
WARFARIN;VKORC1;rs17708472;A;DOSAGE, LADME-PK;INCREASED_DOSE;;
FENTANYL;CYP3A4;rs2740574;C;LADME-PK;DECREASED_CLEARANCE;OTHER;BURNS
METHOTREXATE;SLC19A1;rs1051266;TT;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
SALBUTAMOL, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;CRHR2;rs7793837;T;EFFICACY;DECREASED_RESPONSE;DISEASE;ASTHMA
ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;ABCA1;rs2230806;T;EFFICACY;DECREASED_RESPONSE;;
SALBUTAMOL, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;CRHR2;rs7793837;T;EFFICACY;DECREASED_RESPONSE;DISEASE;ASTHMA
ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;CYP2D6;rs3892097;T;EFFICACY;DECREASED_RESPONSE;;
NICARDIPINE, NIMODIPINE;CACNA1B;rs2739258;AG + GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;BIPOLAR DISORDER
METHOTREXATE;MTHFR;rs1801131;TT;EFFICACY;DECREASED_RESPONSE;OTHER;NON-HODGKIN LYMPHOMA, OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA
IMATINIB;CYP3A5;rs776746;C;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
IMATINIB;SLC22A1;rs683369;CG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
SIMVASTATIN;APOA5;rs662799;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;DYSLIPIDAEMIA
IRBESARTAN;APOB;rs1367117;AG;EFFICACY, LADME-PK;RESPONSE;DISEASE;HYPERTENSION
IRBESARTAN;APOB;rs1367117;GG;EFFICACY;RESPONSE;DISEASE;HYPERTENSION
ATORVASTATIN;APOA5;rs662799;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;DYSLIPIDAEMIA
EFAVIRENZ;CYP2A6;rs28399433;C;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;INCREASED_RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
BENAZEPRIL;PRCP;rs2229437;GG + GT;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERTENSION
EFAVIRENZ;UGT2B7;rs28365062;GG;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
EFAVIRENZ;CYP2B6;rs28399499;C;LADME-PK;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY, OTHER;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME
EFAVIRENZ, LAMIVUDINE, TENOFOVIR;CYP2B6;rs2279343;AG + GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;HIV INFECTIOUS DISEASE
METHOTREXATE;MTHFR;rs1801131;GG;EFFICACY;INCREASED_RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
CLOPIDOGREL;ABCB1;rs1045642;G;EFFICACY, OTHER;RESPONSE;DISEASE;ACUTE CORONARY SYNDROME
QUETIAPINE, ZIPRASIDONE;RGS4;rs951439;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
MIDAZOLAM;VDR;rs11568820;CT + TT;LADME-PK;INCREASED_CLEARANCE;;
METHYLDOPA;ARG2;rs3742879;G;EFFICACY;INCREASED_RESPONSE;OTHER;PREGNANCY, OTHER:PRE-ECLAMPSIA
FLUOROURACIL;MTHFR;rs1801133;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
ARIPIPRAZOLE;ABCB1;rs1128503;AA;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;MAJOR DEPRESSIVE DISORDER
OMEPRAZOLE;CYP2C19;rs12248560;TT;DOSAGE, LADME-PK;INCREASED_METABOLISM;OTHER;NO DISEASE
MEPHENYTOIN;CYP2C19;rs12248560;TT;DOSAGE, LADME-PK;INCREASED_METABOLISM;OTHER;NO DISEASE
OMEPRAZOLE;CYP2C19;rs11188072;TT;DOSAGE, LADME-PK;INCREASED_METABOLISM;OTHER;NO DISEASE
MEPHENYTOIN;CYP2C19;rs11188072;TT;DOSAGE, LADME-PK;INCREASED_METABOLISM;OTHER;NO DISEASE
METHADONE;CYP2B6;rs3211371;TT;LADME-PK;INCREASED_CONCENTRATIONS;;
MERCAPTOPURINE, METHOTREXATE;SLCO1B1;rs4149056;CC + CT;DOSAGE;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
GEMCITABINE;CMPK1;rs1044457;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;PANCREATIC NEOPLASMS
DEXMEDETOMIDINE;ADRA2A;rs1800035;CG + GG;EFFICACY;DECREASED_RESPONSE;OTHER;PAIN, POSTOPERATIVE
BUDESONIDE, FLUTICASONE / SALMETEROL, FORMOTEROL, OMALIZUMAB;IL10;rs3024498;CC + CT;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;ASTHMA
DEXMEDETOMIDINE;ADRA2A;rs775887911;CT + TT;EFFICACY;DECREASED_RESPONSE;OTHER;PAIN, POSTOPERATIVE
DEXMEDETOMIDINE;ADRA2A;rs201376588;CT + TT;EFFICACY;DECREASED_RESPONSE;OTHER;PAIN, POSTOPERATIVE
GEMCITABINE;CMPK1;rs35687416;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;PANCREATIC NEOPLASMS
GEMCITABINE;DCTD;rs12507552;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;PANCREATIC NEOPLASMS
BETA BLOCKING AGENTS;;rs139945292;T;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION
ROSUVASTATIN;APOA5;rs662799;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;DYSLIPIDAEMIA
GEMCITABINE;TENT4A;rs274713;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;PANCREATIC NEOPLASMS
METHOTREXATE;FPGS;rs1544105;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
GEMCITABINE;CDC5L;rs992160;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;PANCREATIC NEOPLASMS
METHOTREXATE;TYMS;rs2853539;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;APOA5;rs662799;AA;OTHER;RESPONSE;DISEASE;DYSLIPIDAEMIA
BUDESONIDE, FLUTICASONE / SALMETEROL, FORMOTEROL, OMALIZUMAB;IL17A;rs3819024;AG + GG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;ASTHMA
GEMCITABINE;SH2D5;rs10916852;GT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;PANCREATIC NEOPLASMS
ROSUVASTATIN;CETP;rs708272;A;EFFICACY;DECREASED_RESPONSE;;
ATORVASTATIN;ABCB1;rs1045642;AA;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CORONARY ARTERY DISEASE
ATORVASTATIN;SLCO1B1;rs2306283;AA;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CORONARY ARTERY DISEASE
PHENPROCOUMON;VKORC1;rs9923231;TT;DOSAGE, TOXICITY;DECREASED_DOSE;;
AZATHIOPRINE;TPMT;rs1142345;CT;LADME-PK;DECREASED_METABOLISM;DISEASE;INFLAMMATORY BOWEL DISEASES
AZATHIOPRINE;ITPA;rs1127354;AC;LADME-PK;INCREASED_METABOLISM;DISEASE;INFLAMMATORY BOWEL DISEASES
BUPRENORPHINE;CYP3A4;rs2740574;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;ISCHEMIA, DISEASE:PAIN
PERINDOPRIL;AGTR1;rs5186;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERTENSION
NITRENDIPINE;AGTR1;rs5186;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
LAMOTRIGINE;HNF4A;rs2071197;AA;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;EPILEPSY
LAMOTRIGINE;ABCG2;rs2231142;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;EPILEPSY
LAMOTRIGINE;ABCG2;rs3114020;CC + CT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;EPILEPSY
CYCLOSPORINE;TSPYL1;rs3828743;AG + GG;LADME-PK;INCREASED_CLEARANCE;OTHER;KIDNEY TRANSPLANTATION
GEMCITABINE;CMPK1;rs7543016;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;PANCREATIC NEOPLASMS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
GEMCITABINE;ESR2;rs944050;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;PANCREATIC NEOPLASMS
RISPERIDONE;DRD2;rs1799978;TT;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA
IRINOTECAN;ABCC2;rs2273697;AA + AG;LADME-PK;INCREASED_METABOLISM;DISEASE;COLORECTAL NEOPLASMS
RISPERIDONE;DRD2;rs1799978;T;OTHER;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
LETROZOLE;CYP19A1;rs4646;A;EFFICACY;INCREASED_CLINICAL_BENEFIT;DISEASE;BREAST NEOPLASMS
ANTIEPILEPTICS;ABCC2;rs717620;CT + TT;EFFICACY;INCREASED_RESISTANCE;DISEASE;EPILEPSY
WARFARIN;;rs12777823;A;DOSAGE;DOSE;;
METHOTREXATE;SLCO1B1;rs2306283;AA + AG;LADME-PK;INCREASED_CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;CYSTIC FIBROSIS
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;LADME-PK;DECREASED_CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
CONJUGATED ESTROGENS;SLCO1B1;rs4149056;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;MENOPAUSE
CISPLATIN;ERCC1;rs3212986;A;EFFICACY;DECREASED_RESPONSE;OTHER;OVARIAN NEOPLASMS
ANTIPSYCHOTICS;ABCB1;rs1045642;GG;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;SCHIZOPHRENIA
ANTIPSYCHOTICS;ABCB1;rs2032582;AA;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;SCHIZOPHRENIA
DIAZEPAM;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;ALCOHOL ABUSE
ALPRAZOLAM;CYP3A4;rs35599367;AG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ALCOHOL ABUSE, OTHER:ANXIETY DISORDERS
DIAZEPAM;CYP2C19;rs12248560;CT + TT;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;ALCOHOL ABUSE
CLOZAPINE;POR;rs1057868;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;SCHIZOPHRENIA, OTHER:TOBACCO USE DISORDER
SALBUTAMOL;IGF2R;rs8191725;AG;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
SALBUTAMOL;SLC24A4;rs77441273;AG;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
ALPRAZOLAM;CYP3A4;rs35599367;AG;EFFICACY;DECREASED_RESPONSE;OTHER;ALCOHOL ABUSE, OTHER:ANXIETY DISORDERS
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;IL1B;rs16944;AG;EFFICACY;INCREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;IL1B;rs16944;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
METHOTREXATE;AHRR;rs2292596;G;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
WARFARIN;VKORC1;rs2359612;AA;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
PLATINUM COMPOUNDS;ERCC1;rs11615;AG + GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;OVARIAN NEOPLASMS, OTHER:NEOPLASM OF ESOPHAGUS, OTHER:NEOPLASMS
ULINASTATIN;MMP2;rs243865;T;EFFICACY;DECREASED_RESPONSE;OTHER;PANCREATITIS
ANTIPSYCHOTICS;ABCB1;rs1128503;G;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
ULINASTATIN;MMP9;rs3918242;T;EFFICACY;INCREASED_RESPONSE;OTHER;PANCREATITIS
TACROLIMUS;CYP3A4;rs35599367;AA + AG;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;NR1I2;rs2276707;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
ANTIPSYCHOTICS;ABCB1;rs1045642;G;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
IRINOTECAN;NR1I2;rs10934498;AA;TOXICITY, LADME-PK;DECREASED_EXPOSURE;DISEASE;COLONIC NEOPLASMS
TACROLIMUS;IL10;rs1800896;CC;DOSAGE;DECREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION
OLANZAPINE, PERPHENAZINE;RGS4;rs2842030;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
OLANZAPINE;DRD3;rs324026;C;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;SCHIZOPHRENIA
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;ADH1A;rs6811453;A;EFFICACY;INCREASED_RESISTANCE;DISEASE;LEUKEMIA, MYELOID, ACUTE
RISPERIDONE;RGS4;rs2842030;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
MEASLES VACCINES;TLR3;rs3775291;CT;EFFICACY;DECREASED_RESPONSE;;
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;ADH1A;rs1826909;T;EFFICACY;INCREASED_RESISTANCE;DISEASE;LEUKEMIA, MYELOID, ACUTE
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;;
TAMOXIFEN;ABCC2;rs717620;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
SALBUTAMOL;;rs77149876;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;A;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
CARBAMAZEPINE;SCN1A;rs3812718;TT;DOSAGE;INCREASED_DOSE;DISEASE;EPILEPSY
SALBUTAMOL;PAPPA2;rs77977790;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
NORBUPRENORPHINE;OPRD1;rs569356;GG;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS
TACROLIMUS;CYP3A4;rs2740574;CT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
SALMETEROL;ADRB2;rs1042713;G;EFFICACY;INCREASED_RESPONSE;OTHER;ASTHMA
SALBUTAMOL;;rs116551936;AG;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
SALBUTAMOL;NCOA3;rs115501901;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
LITHIUM;CACNG2;rs2284017;C;EFFICACY;INCREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
SALBUTAMOL;;rs74973995;AG;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
SALBUTAMOL;CRHR2;rs73294475;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
PHENPROCOUMON;CYP3A4;rs2740574;C;DOSAGE;DECREASED_DOSE;;
SALBUTAMOL;ADCY9;rs144315541;AG;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
PERPHENAZINE;MCPH1;rs17570753;A;EFFICACY;RESPONSE;DISEASE;SCHIZOPHRENIA
PERPHENAZINE;CDH13;rs2116971;G;EFFICACY;RESPONSE;DISEASE;SCHIZOPHRENIA
PERPHENAZINE;SKOR2;rs9952628;G;EFFICACY;RESPONSE;DISEASE;SCHIZOPHRENIA
METFORMIN;SLC47A2;rs12943590;AA;EFFICACY, LADME-PK;DECREASED_RESPONSE;DISEASE;DIABETES MELLITUS
QUETIAPINE;KCNMA1;rs35793;G;EFFICACY;RESPONSE;DISEASE;SCHIZOPHRENIA
PERPHENAZINE;MAML3;rs11100483;A;EFFICACY;RESPONSE;DISEASE;SCHIZOPHRENIA
VALPROIC ACID;UGT2B7;rs7668258;CC + CT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;EPILEPSY
METHACHOLINE;RUNX1;rs11702779;AA;OTHER;INCREASED_RESPONSE;DISEASE;ASTHMA
RISPERIDONE;LRP1B;rs874295;G;EFFICACY;RESPONSE;DISEASE;SCHIZOPHRENIA
BEVACIZUMAB;HTRA1;rs11200638;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;MACULAR DEGENERATION
RISPERIDONE;PSMD14;rs9713;A;EFFICACY;RESPONSE;DISEASE;SCHIZOPHRENIA
RISPERIDONE;AGAP1;rs1869295;C;EFFICACY;RESPONSE;DISEASE;SCHIZOPHRENIA
BEVACIZUMAB;ARMS2;rs10490924;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;MACULAR DEGENERATION
VALPROIC ACID;APEH;rs3816877;CC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;EPILEPSY
RISPERIDONE;NPAS3;rs1315115;G;EFFICACY;RESPONSE;DISEASE;SCHIZOPHRENIA
RISPERIDONE;TMEFF2;rs3738883;G;EFFICACY;RESPONSE;DISEASE;SCHIZOPHRENIA
METFORMIN;PCK1;rs4810083;CT + TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
ZIPRASIDONE;CDH4;rs4925300;A;EFFICACY;RESPONSE;DISEASE;SCHIZOPHRENIA
ZIPRASIDONE;LYN;rs1546519;G;EFFICACY;RESPONSE;DISEASE;SCHIZOPHRENIA
BEVACIZUMAB;CFH;rs800292;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;MACULAR DEGENERATION
WARFARIN;CYP2C9;rs1799853;CT;DOSAGE;DECREASED_DOSE;;
ZIPRASIDONE;NALCN;rs9585618;C;EFFICACY;RESPONSE;DISEASE;SCHIZOPHRENIA
ZIPRASIDONE;CNTN4;rs17194378;A;EFFICACY;RESPONSE;DISEASE;SCHIZOPHRENIA
OPIOIDS;COMT;rs4680;GG;DOSAGE;INCREASED_DOSE;DISEASE;NEOPLASMS, DISEASE:PAIN
IMATINIB;SLCO1A2;rs4148978;CT + TT;TOXICITY, LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;GASTROINTESTINAL STROMAL TUMORS
IMATINIB;SLCO1B3;rs4149117;GG;TOXICITY, LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;GASTROINTESTINAL STROMAL TUMORS
HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT + TT;EFFICACY;INCREASED_RESPONSE;;
WARFARIN;CALU;rs2290228;AA;DOSAGE;DECREASED_DOSE;;
OLANZAPINE;;rs12610827;T;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;SCHIZOPHRENIA
REMIFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;SURGERY
FENOFIBRATE;APOB;rs676210;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA
METHACHOLINE;RUNX1;rs11702779;AG + GG;OTHER;INCREASED_RESPONSE;DISEASE;ASTHMA
CITALOPRAM, FLUOXETINE;SERPINE1;rs1799889;G;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
METHOTREXATE;MTR;rs1805087;G;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;NON-HODGKIN LYMPHOMA, OTHER:ACUTE LYMPHOBLASTIC LEUKEMIA
CITALOPRAM, FLUOXETINE, MIRTAZAPINE, PAROXETINE, SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;FKBP5;rs4713916;A;EFFICACY;INCREASED_RESPONSE;DISEASE;MOOD DISORDER
OLANZAPINE;CSMD1;rs17070785;A;EFFICACY;RESPONSE;DISEASE;SCHIZOPHRENIA
OLANZAPINE;PLAGL1;rs2247408;C;EFFICACY;RESPONSE;DISEASE;SCHIZOPHRENIA
SIROLIMUS;CYP3A5;rs15524;AA;LADME-PK;INCREASED_TROUGH CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION
OLANZAPINE;PLAGL1;rs3819811;A;EFFICACY;RESPONSE;DISEASE;SCHIZOPHRENIA
SIROLIMUS;CYP3A5;rs4646453;CC;LADME-PK;INCREASED_TROUGH CONCENTRATION;OTHER;KIDNEY TRANSPLANTATION
ACETAMINOPHEN;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;;
OLANZAPINE;PTPRN2;rs221253;C;EFFICACY;RESPONSE;DISEASE;SCHIZOPHRENIA
IMATINIB;SLC22A1;rs628031;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
WARFARIN;NQO1;rs1800566;AA + AG;DOSAGE;INCREASED_DOSE;;
PERPHENAZINE;PRKCE;rs2278773;C;EFFICACY;RESPONSE;DISEASE;SCHIZOPHRENIA
PERPHENAZINE;;rs11774231;C;EFFICACY;RESPONSE;DISEASE;SCHIZOPHRENIA
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
HYDROCHLOROTHIAZIDE;DOT1L;rs2269879;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
PAROXETINE;ADM;rs11042725;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;;
TILDRAKIZUMAB;ATG5;rs9373839;CT;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;PSORIASIS
TILDRAKIZUMAB;IL17RC;rs708567;CC;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;PSORIASIS
CITALOPRAM;BDNF;rs7124442;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
ARIPIPRAZOLE;ABCB1;rs2032582;AA;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;;
CLOZAPINE;OXT;rs2740204;T;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;;
DIAZEPAM;CYP3A4;rs35599367;GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;ALCOHOL ABUSE
METHOTREXATE;MTHFR;rs1801133;G;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;CROHN DISEASE
METHOTREXATE;DHFR;rs408626;C;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;CROHN DISEASE
REPAGLINIDE;NOS1AP;rs10494366;T;DOSAGE, EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
CITALOPRAM;BDNF;rs7103411;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_RESISTANCE;DISEASE;HIV INFECTIOUS DISEASE
CITALOPRAM;BDNF;rs6265;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
LAMIVUDINE, LOPINAVIR, RITONAVIR, ZIDOVUDINE;ABCC1;rs212091;CC + CT;EFFICACY;INCREASED_RESISTANCE;DISEASE;HIV INFECTIOUS DISEASE
FLUOXETINE;BDNF;rs6265;CT;EFFICACY;INCREASED_CLINICAL_BENEFIT;DISEASE;MAJOR DEPRESSIVE DISORDER
TILDRAKIZUMAB;TNFAIP3;rs610604;GG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;PSORIASIS
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;DECREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
ANTIDEPRESSANTS;ERICH3;rs11580409;CC;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER
CLOPIDOGREL;CYP2C19;rs12248560;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
ARIPIPRAZOLE;ABCB1;rs1045642;AA;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;;
IVACAFTOR;CFTR;rs77932196;A;EFFICACY;INCREASED_RESPONSE;DISEASE;CYSTIC FIBROSIS
PAROXETINE;DRD3;rs6280;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
ENTACAPONE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;PARKINSON DISEASE
CLOZAPINE;CYP2D6;rs1065852;AA;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
CLOZAPINE;CYP2D6;rs16947;GG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
ATORVASTATIN, SIMVASTATIN;ABCG8;rs11887534;CC + CG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;DYSLIPIDAEMIA
IVACAFTOR;CFTR;rs121909011;C;EFFICACY;INCREASED_RESPONSE;DISEASE;CYSTIC FIBROSIS
IMATINIB;ULK3;rs2290573;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
CLOZAPINE;DRD1;rs265976;GT;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;CYSTIC FIBROSIS
INTERFERONS;STAT3;rs4796793;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;RENAL CELL CARCINOMA
TAMOXIFEN;SLCO2B1;rs12422149;AA + AG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;BREAST NEOPLASMS
ACENOCOUMAROL;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_DOSE;;
WARFARIN;VKORC1;rs2359612;AA + AG;DOSAGE;DECREASED_DOSE;;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;DOSAGE, EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
WARFARIN;VKORC1;rs8050894;CG + GG;DOSAGE;DECREASED_DOSE;;
RISPERIDONE;HRH3;rs3787430;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
WARFARIN;;rs12777823;AA + AG;DOSAGE;DECREASED_DOSE;;
WARFARIN;VKORC1;rs2884737;AC + CC;DOSAGE;DECREASED_DOSE;;
WARFARIN;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_DOSE;;
RISPERIDONE;HRH3;rs3787429;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
ACENOCOUMAROL;VKORC1;rs17708472;AA + AG;DOSAGE;INCREASED_DOSE;;
ARIPIPRAZOLE;TAAR6;rs4305746;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
PEGINTERFERON ALFA-2A;IL6;rs1800795;G;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2A;IL6;rs1800796;G;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2A;IL6;rs1800797;G;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
WARFARIN;VKORC1;rs104894540;G;DOSAGE;INCREASED_DOSE;;
ROSUVASTATIN;ABCG2;rs2199936;AA + AG;EFFICACY;INCREASED_RESPONSE;;
WARFARIN;VKORC1;rs104894542;C;DOSAGE;INCREASED_DOSE;;
ILOPERIDONE;CNTF, ZFP91-CNTF;rs1800169;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;;
DISULFIRAM;OPRD1;rs678849;CC;EFFICACY;INCREASED_RESPONSE;OTHER;COCAINE DEPENDENCE
ERYTHROPOIETIN;STIM1;rs1561876;AG + GG;EFFICACY;INCREASED_RESISTANCE;OTHER;KIDNEY DISORDER, OTHER:ANEMIA
LATANOPROST;PTGFR;rs3753380;CC;EFFICACY;INCREASED_RESPONSE;;
RANIBIZUMAB;VEGFA;rs699947;AC + CC;EFFICACY;INCREASED_RESPONSE;DISEASE;MACULAR DEGENERATION
FUROSEMIDE;ABCC4;rs17268282;T;EFFICACY;INCREASED_RESPONSE;DISEASE;HEART FAILURE
METFORMIN;SLC22A1;rs622342;CC;EFFICACY;RESPONSE;OTHER;GENETIC VARIATION AT RS2289669
MORPHINE;COMT;rs737866;T;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;NEOPLASMS
MORPHINE;COMT;rs2075507;G;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;NEOPLASMS
ANTIEPILEPTICS;CYP1A1;rs2606345;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;EPILEPSY
MORPHINE;COMT;rs5746849;A;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;NEOPLASMS
MORPHINE;COMT, TXNRD2;rs7287550;C;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;NEOPLASMS
MORPHINE;COMT;rs6269;A;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;NEOPLASMS
CARBAMAZEPINE;CYP3A4;rs2740574;TT;LADME-PK;INCREASED_CLEARANCE;DISEASE;EPILEPSY
MORPHINE;COMT;rs740603;A;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;NEOPLASMS
MORPHINE;ABCC3;rs4793665;T;LADME-PK;DECREASED_CLEARANCE;;
TACROLIMUS;POR;rs1057868;T;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;CYP2D6;rs35742686;DELT/T;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;DEATH
N-DESMETHYLTRAMADOL, TRAMADOL;CYP3A4;rs35599367;AG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;DEATH
CLOPIDOGREL;CYP2C19;rs4244285;AA;EFFICACY;DECREASED_RESPONSE;OTHER;CORONARY ARTERY DISEASE
CLOPIDOGREL;CYP2C19;rs4986893;AG;EFFICACY;DECREASED_RESPONSE;OTHER;CORONARY ARTERY DISEASE
CLOPIDOGREL;ABCC2;rs717620;CC;EFFICACY;DECREASED_RESPONSE;OTHER;CORONARY ARTERY DISEASE
ATAZANAVIR;SORCS2;rs73208473;A;LADME-PK;DECREASED_EXPOSURE;OTHER;HIV INFECTIOUS DISEASE
WARFARIN;VKORC1;rs104894539;A;DOSAGE;INCREASED_DOSE;;
WARFARIN;VKORC1;rs104894541;C;DOSAGE;INCREASED_DOSE;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;ZNF816;rs9304742;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
CARBAMAZEPINE;UGT2B7;rs28365063;AA;LADME-PK;DECREASED_CLEARANCE;DISEASE;EPILEPSY
CARBAMAZEPINE;NR1I2;rs3814055;T;LADME-PK;DECREASED_CLEARANCE;DISEASE;EPILEPSY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PGLYRP4;rs2916205;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
METHOTREXATE;MTHFR;rs1801133;AA + AG;LADME-PK;INCREASED_EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
SULFONAMIDES, UREA DERIVATIVES;CYP2C9;rs1799853;TT;EFFICACY;INCREASED_RESPONSE;;
SUMATRIPTAN;GNB3;rs5443;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;CLUSTER HEADACHE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;rs2546890;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
DESETHYL HYDROXYCHLOROQUINE;CYP2D6;rs1135840;G;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS
CANNABINOIDS;TRPV1;rs8065080;CC;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;PAIN
RIVAROXABAN;ABCB1;rs4728709;AA + AG;LADME-PK;INCREASED_CLEARANCE;OTHER;ATRIAL FIBRILLATION
CANNABINOIDS;UGT2B7;rs7438135;AA;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;PAIN
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CTNNA2;rs11126740;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
IMATINIB;ABCG2;rs2231142;GT;OTHER, LADME-PK;DECREASED_METABOLISM;DISEASE;NEOPLASMS
DESETHYL HYDROXYCHLOROQUINE;CYP2D6;rs1065852;AA;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS
REPAGLINIDE;KCNJ11;rs5219;T;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
TRAMADOL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER;PAIN, POSTOPERATIVE
REPAGLINIDE;TCF7L2;rs290487;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
MORPHINE;COMT;rs4680;A;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;NEOPLASMS
CARBAMAZEPINE;EPHX1;rs1051740;TT;LADME-PK;DECREASED_METABOLISM;DISEASE;EPILEPSY
MORPHINE;COMT;rs4818;C;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;NEOPLASMS
ERYTHROPOIETIN;ORAI1;rs12320939;GG + GT;EFFICACY;INCREASED_RESISTANCE;OTHER;KIDNEY DISORDER, OTHER:ANEMIA
CARBAMAZEPINE;ABCB1;rs1128503;AA + AG;LADME-PK;INCREASED_CLEARANCE;DISEASE;EPILEPSY
MORPHINE;COMT;rs2239393;A;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;NEOPLASMS
MERCAPTOPURINE;NUDT15;rs116855232;CT;DOSAGE;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
MORPHINE;ARVCF, COMT;rs165728;T;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;NEOPLASMS
CARBAMAZEPINE;ABCB1;rs4148740;AG;LADME-PK;INCREASED_METABOLISM;DISEASE;EPILEPSY
CARBAMAZEPINE;ABCB1;rs4148739;TT;LADME-PK;DECREASED_METABOLISM;DISEASE;EPILEPSY
MORPHINE;ARVCF, COMT;rs174699;T;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;NEOPLASMS
ANTIPSYCHOTICS;DRD2;rs1799732;del;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
HMG COA REDUCTASE INHIBITORS;CETP;rs1532624;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERLIPIDEMIAS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CDKAL1;rs6908425;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
CARBAMAZEPINE;ABCC2;rs2273697;AA + AG;LADME-PK;INCREASED_CLEARANCE;DISEASE;EPILEPSY
HMG COA REDUCTASE INHIBITORS;SIK3;rs533556;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERLIPIDEMIAS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;HLA-C;rs12191877;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
RITODRINE;KCNMB2;rs7624046;TT;EFFICACY;DECREASED_RESPONSE;;
CARBAMAZEPINE;ABCC2;rs4148386;AA + AG;LADME-PK;INCREASED_CLEARANCE;DISEASE;EPILEPSY
WARFARIN;VKORC1;rs61742245;AA + AC;DOSAGE;INCREASED_DOSE;;
CARBAMAZEPINE;ABCC2;rs3740066;CT + TT;LADME-PK;DECREASED_METABOLISM;DISEASE;EPILEPSY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAP3K1;rs96844;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
RITODRINE;KCNMB2;rs9839376;CC;EFFICACY;DECREASED_RESPONSE;;
WARFARIN;GGCX;rs11676382;G;DOSAGE;DECREASED_DOSE;;
CARBAMAZEPINE;NR1I2;rs7643645;G;LADME-PK;INCREASED_METABOLISM;DISEASE;EPILEPSY
MORPHINE;METTL21A;rs2952768;CC;DOSAGE;INCREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
CARBAMAZEPINE;NR1I2;rs4688040;T;LADME-PK;INCREASED_METABOLISM;DISEASE;EPILEPSY
CANNABINOIDS;ABCB1;rs1045642;AG + GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;PAIN
MORPHINE;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
CARBAMAZEPINE;NR1I2;rs2461817;C;LADME-PK;INCREASED_METABOLISM;DISEASE;EPILEPSY
METOPROLOL;ADRB1;rs1801252;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;;
WARFARIN;VKORC1;rs2884737;CC;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;SRP19;rs495794;G;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;;
CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;REEP5;rs153560;G;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
WARFARIN;VKORC1;rs8050894;GG;DOSAGE;DECREASED_DOSE;;
CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;REEP5;rs153549;A;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
ATAZANAVIR;ABCB1;rs1045642;AA + AG;DOSAGE;DOSE;DISEASE;HIV INFECTIOUS DISEASE
ATAZANAVIR;SLCO1B1;rs4149056;TT;DOSAGE;DOSE;DISEASE;HIV INFECTIOUS DISEASE
FLUOROURACIL;DPYD;rs3918290;CT;OTHER, LADME-PK;DECREASED_METABOLISM;DISEASE;NEOPLASMS
ATAZANAVIR;NR1I2;rs2472677;TT;DOSAGE;DOSE;DISEASE;HIV INFECTIOUS DISEASE
WARFARIN;VKORC1;rs61742245;AC;DOSAGE;INCREASED_DOSE;OTHER;WARFARIN MAINTENANCE TREATMENT
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
ACENOCOUMAROL;VKORC1;rs9923231;CT;DOSAGE;DECREASED_DOSE;;
DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;CASP7;rs2227310;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;CASP7;rs4353229;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;CASP7;rs12415607;AA + AC;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;CASP7;rs7921977;CT;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
OLANZAPINE;SLC26A9;rs11240594;A;DOSAGE, EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT
SOLANIDINE;NFIB;rs28379954;CC + CT;LADME-PK;INCREASED_METABOLISM;;
ZIPRASIDONE;EHF;rs286913;A;DOSAGE, EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
CLOZAPINE;SLC6A3;rs2975226;A;DOSAGE, EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
OLANZAPINE;IL1A;rs11677416;C;DOSAGE, EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
CYCLOSPORINE;POR;rs1057868;TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
CARBAMAZEPINE;EPHX1;rs1051740;C;DOSAGE, LADME-PK;INCREASED_METABOLISM;DISEASE;EPILEPSY
PIOGLITAZONE;PTPRD;rs17584499;CC;EFFICACY;INCREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;CC + CT;EFFICACY;INCREASED_DOSE;;
ETHANOL;OPRM1;rs1799971;G;TOXICITY;INCREASED_RESPONSE;OTHER;ALCOHOL ABUSE
ACAMPROSATE;GRIN2B;rs2058878;A;EFFICACY;INCREASED_RESPONSE;DISEASE;ALCOHOL ABUSE
OLANZAPINE;ATP1A2;rs6688363;T;EFFICACY;DECREASED_RESPONSE;OTHER;SCHIZOPHRENIA
RISPERIDONE;;rs8050896;T;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA
RISPERIDONE;TNFRSF11A;rs2980976;A;EFFICACY;DECREASED_RESPONSE;OTHER;SCHIZOPHRENIA
RISPERIDONE;PPA2;rs2636697;G;EFFICACY;DECREASED_RESPONSE;OTHER;SCHIZOPHRENIA
METHOTREXATE;;rs1232027;A;EFFICACY;INCREASED_RESPONSE;DISEASE;ARTHRITIS, PSORIATIC
FENTANYL, HYDROMORPHONE, OPIOIDS, OXYCODONE, TRAMADOL;OPRM1;rs1799971;AA;DOSAGE;INCREASED_DOSE;OTHER;SURGERY
RISPERIDONE;PPA2;rs2636719;A;EFFICACY;DECREASED_RESPONSE;OTHER;SCHIZOPHRENIA
REPAGLINIDE;IGF2BP2;rs4402960;GT + TT;DOSAGE, EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
REPAGLINIDE;IGF2BP2;rs1470579;AC + CC;DOSAGE, EFFICACY;DECREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
DISULFIRAM;MTHFR;rs1801133;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;COCAINE DEPENDENCE
IVACAFTOR;CFTR;rs78655421;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;rs1801274;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ARTHRITIS, PSORIATIC, DISEASE:CROHN DISEASE, DISEASE:PSORIASIS, DISEASE:SPONDYLITIS, ANKYLOSING
ISONIAZID;NAT2;rs4646244;AT;TOXICITY, LADME-PK;DECREASED_CLEARANCE;DISEASE;TUBERCULOSIS
PLATINUM COMPOUNDS;ERCC1;rs11615;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;OVARIAN NEOPLASMS
ISONIAZID;NAT2;rs1799930;AA;TOXICITY, LADME-PK;DECREASED_CLEARANCE;DISEASE;TUBERCULOSIS
HYDROCHLOROTHIAZIDE;BEST3;rs61747221;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
DEFERIPRONE;UGT1A6;rs2070959;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;rs396991;C;EFFICACY;INCREASED_RESPONSE;DISEASE;ARTHRITIS, PSORIATIC, DISEASE:CROHN DISEASE, DISEASE:PSORIASIS, DISEASE:SPONDYLITIS, ANKYLOSING
NIFEDIPINE;ADRA1A;rs1048101;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
DEFERIPRONE;UGT1A6;rs2070959;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
DEFERIPRONE;UGT1A6;rs6759892;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
PIOGLITAZONE;PPARG;rs1801282;CG;EFFICACY;INCREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
PACLITAXEL, PLATINUM COMPOUNDS;CASP7;rs4353229;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
OPIOIDS;TNF;rs1800629;GG;DOSAGE;INCREASED_DOSE;OTHER;NEOPLASMS, OTHER:PAIN
CARBAMAZEPINE;SCN1A;rs3812718;CT;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;EPILEPSY
PACLITAXEL, PLATINUM COMPOUNDS;CASP7;rs2227310;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
RISPERIDONE;TJP1;rs813676;T;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA
OPIOIDS;IL6;rs1800797;A;DOSAGE;DECREASED_DOSE;OTHER;NEOPLASMS, OTHER:PAIN
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;MYOCARDIAL INFARCTION
METHYLPHENIDATE;ADGRL3;rs734644;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
PACLITAXEL, PLATINUM COMPOUNDS;CASP7;rs1127687;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
FLUTICASONE PROPIONATE, MONTELUKAST;CA10;rs967676;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
CARBAMAZEPINE;EPHX1;rs1051740;CT;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;EPILEPSY
CARBAMAZEPINE;EPHX1;rs1051740;CC;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;EPILEPSY
GEMCITABINE, PLATINUM COMPOUNDS;CASP7;rs1127687;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
FLUTICASONE PROPIONATE, MONTELUKAST;;rs1786929;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
CYTARABINE;CDA;rs2072671;CC;TOXICITY, LADME-PK;DECREASED_CLEARANCE;DISEASE;LYMPHOMA, T-CELL
TACROLIMUS;ABCB1;rs2032582;AA;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
CARBAMAZEPINE;SCN1A;rs3812718;TT;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;EPILEPSY
ROSUVASTATIN;ABCG2;rs2231142;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;;
METHYLPHENIDATE;ADGRL3;rs1355368;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
METHYLPHENIDATE;ADGRL3;rs6813183;CC + CG;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
RISPERIDONE;;rs7395555;C;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA
RANIBIZUMAB;CFH;rs1061170;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;MACULAR DEGENERATION
OLANZAPINE;SPOPL;rs10170310;C;EFFICACY;DECREASED_RESPONSE;OTHER;SCHIZOPHRENIA
QUETIAPINE;PDE4D;rs17382202;T;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA
ACENOCOUMAROL;VKORC1;rs9923231;T;DOSAGE;DOSE;;
ACENOCOUMAROL;CYP4F2;rs2108622;T;DOSAGE;DOSE;;
QUETIAPINE;PDE4D;rs17742120;G;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA
QUETIAPINE;PDE4D;rs2164660;A;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA
ACENOCOUMAROL;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE;DISEASE;ATRIAL FIBRILLATION, DISEASE:VENOUS THROMBOEMBOLISM
PERINDOPRIL;AGTR1;rs5182;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
RISPERIDONE;TJP1;rs711355;T;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA
RISPERIDONE;TJP1;rs785423;A;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA
TENOFOVIR ALAFENAMIDE;ABCB1;rs3842;CT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HEPATITIS B VIRUS INFECTION, DISEASE:HIV INFECTIOUS DISEASE
CLOZAPINE;SLC6A4;rs25531;T;EFFICACY;RESPONSE;DISEASE;SCHIZOPHRENIA
RALOXIFENE;UGT1A8;rs1042597;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;MENOPAUSE, DISEASE:SCHIZOPHRENIA
ACENOCOUMAROL, PHENPROCOUMON;VKORC1;rs9923231;T;DOSAGE;DOSE;;
ESOMEPRAZOLE;STAT6;rs1059513;CC + CT;EFFICACY;INCREASED_RESPONSE;OTHER;EOSINOPHILIC ESOPHAGITIS
RISPERIDONE;WBP2NL;rs5758550;A;LADME-PK;DECREASED_CLEARANCE;;
PACLITAXEL, PLATINUM COMPOUNDS;CASP7;rs12415607;AA + AC;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
ADALIMUMAB;CD40LG;rs1126535;T;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
RALOXIFENE;ESR1;rs11543791;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;MENOPAUSE, DISEASE:SCHIZOPHRENIA
PERINDOPRIL;AGTR1;rs275651;AA + AT;EFFICACY;DECREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
LITHIUM;MYO1H;rs7959663;C;EFFICACY;DECREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
INFLIXIMAB;FCGR2A;rs1801274;G;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
LITHIUM;EPHX2;rs59724122;T;EFFICACY;INCREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
LITHIUM;GRAMD1B;rs61123830;A;EFFICACY;DECREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
WARFARIN;VKORC1;rs7294;T;DOSAGE;DECREASED_DOSE;;
LITHIUM;;rs66486766;A;EFFICACY;DECREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
LITHIUM;;rs324899;A;EFFICACY;DECREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
LITHIUM;;rs1611259;T;EFFICACY;DECREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
LITHIUM;;rs6942227;A;EFFICACY;DECREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
NEVIRAPINE;CYP2D6;rs28371706;AA + AG;DOSAGE, LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
NEVIRAPINE;CYP2B6;rs3745274;GT + TT;DOSAGE, LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
CATECHOLAMINES;ADRB1;rs1801253;CC;DOSAGE;DECREASED_DOSE;DISEASE;CORONARY ARTERY DISEASE
ACENOCOUMAROL;APOE;rs429358;CC;DOSAGE;INCREASED_DOSE;DISEASE;ATRIAL FIBRILLATION, DISEASE:VENOUS THROMBOEMBOLISM
PERINDOPRIL;BDKRB1;rs12050217;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
WARFARIN;VKORC1;rs17708472;A;DOSAGE;INCREASED_DOSE;;
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;rs680244;C;OTHER;INCREASED_RESPONSE;DISEASE;TOBACCO USE DISORDER
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;NFATC2;rs3787186;CC + CT;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3, CHRNA5;rs16969968;G;OTHER;INCREASED_RESPONSE;DISEASE;TOBACCO USE DISORDER
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;rs680244;T;OTHER;INCREASED_RESPONSE;DISEASE;TOBACCO USE DISORDER
ALLOPURINOL;ABCG2;rs2231142;T;EFFICACY;DECREASED_RESPONSE;OTHER;GOUT
LITHIUM;FAM177A1;rs79403677;T;EFFICACY;DECREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
CLOPIDOGREL;;rs2487032;A;EFFICACY;DECREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
WARFARIN;VKORC1;rs9923231;A;DOSAGE;DECREASED_DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CHUK;rs11591741;G;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE;;
LITHIUM;ADCY1;rs1521470;A;EFFICACY;DECREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
WARFARIN;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE;;
REPAGLINIDE;KCNQ1;rs2237892;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
LITHIUM;;rs7588746;A;EFFICACY;DECREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
LITHIUM;FAM178B;rs6728642;A;EFFICACY;DECREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
BETA BLOCKING AGENTS;GRK5;rs2230345;AT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;HEART FAILURE
ZILEUTON;PRORP;rs12436663;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;ASTHMA
LITHIUM;ZNF804A;rs62200793;T;EFFICACY;INCREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
LITHIUM;;rs1611255;A;EFFICACY;DECREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
LITHIUM;;rs209474;A;EFFICACY;DECREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
REPAGLINIDE;KCNQ1;rs2237895;AC + CC;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
LITHIUM;;rs3919583;A;EFFICACY;DECREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
PLATINUM COMPOUNDS;XRCC1;rs1799782;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
GLATIRAMER ACETATE;TGFB1;rs1800469;A;EFFICACY;DECREASED_RESPONSE;DISEASE;MULTIPLE SCLEROSIS
ANTIEPILEPTICS;ABCC2;rs3740066;CT + TT;EFFICACY;INCREASED_RESISTANCE;DISEASE;EPILEPSY
N-DESMETHYLTAMOXIFEN;ABCG2;rs2231142;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;BREAST NEOPLASMS
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
GLUCOCORTICOIDS;GLCCI1;rs37973;G;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;;
ANTIEPILEPTICS;ABCC2;rs717620;CT + TT;EFFICACY;INCREASED_RESISTANCE;DISEASE;EPILEPSY
AMLODIPINE;CYP3A4;rs2246709;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
NICOTINE;CYP2B6;rs2279343;G;LADME-PK;INCREASED_METABOLISM;DISEASE;TOBACCO USE DISORDER
TENELIGLIPTIN;FMO3;rs2266780;AG + GG;LADME-PK;DECREASED_CLEARANCE;;
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3, CHRNA5;rs16969968;A;OTHER;INCREASED_RESPONSE;DISEASE;TOBACCO USE DISORDER
QUETIAPINE;COMT;rs4818;C;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
HYDROCHLOROTHIAZIDE;GPR83;rs3758785;GG;EFFICACY;DECREASED_RESPONSE;EFFICACY;ESSENTIAL HYPERTENSION
QUETIAPINE;COMT;rs5993883;T;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
TENELIGLIPTIN;FMO3;rs909530;CT + TT;LADME-PK;DECREASED_CLEARANCE;;
MENOTROPINS;FSHR;rs6166;CT;;DECREASED_DOSE;;
QUETIAPINE;COMT;rs6269;A;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
CANDESARTAN;GPR83;rs3758785;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ESSENTIAL HYPERTENSION
TACROLIMUS;IL6;rs1800795;GG;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION
TENELIGLIPTIN;FMO3;rs2266782;AG + GG;LADME-PK;DECREASED_CLEARANCE;;
PACLITAXEL;ABCB1;rs2032582;CT;LADME-PK;INCREASED_METABOLISM;DISEASE;OVARIAN NEOPLASMS
HYDROCHLOROTHIAZIDE;HSD3B1;rs7553527;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
HYDROCHLOROTHIAZIDE;TTC6;rs177852;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
TENELIGLIPTIN;CYP3A4;rs2242480;CT + TT;LADME-PK;DECREASED_CONCENTRATIONS;;
GLATIRAMER ACETATE;IFNAR1;rs1012335;G;EFFICACY;DECREASED_RESPONSE;DISEASE;MULTIPLE SCLEROSIS
DARUNAVIR;SLCO3A1;rs8027174;GT + TT;LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
ATORVASTATIN;CYP3A4;rs2740574;CC;EFFICACY;DECREASED_RESPONSE;OTHER;CARDIOVASCULAR DISEASE, OTHER:HYPERLIPIDEMIAS
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs121909047;A;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CYSTIC FIBROSIS
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs75961395;AA + AG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CYSTIC FIBROSIS
6-HYDROXY S-WARFARIN;;rs368245720;A;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION, OTHER:VENOUS THROMBOEMBOLISM, OTHER:HEART VALVE DISEASES
ATORVASTATIN;CYP3A5;rs776746;CC;EFFICACY;INCREASED_RESPONSE;OTHER;CARDIOVASCULAR DISEASE, OTHER:HYPERLIPIDEMIAS
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, SERTRALINE;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER
6-HYDROXY S-WARFARIN;PARP14;rs10433340;A;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION, OTHER:VENOUS THROMBOEMBOLISM, OTHER:HEART VALVE DISEASES
METOPROLOL;ADRB1;rs1801253;C;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs121909019;T;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CYSTIC FIBROSIS
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs121909011;T;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CYSTIC FIBROSIS
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs75549581;A;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CYSTIC FIBROSIS
EFAVIRENZ;NR1I3;rs3003596;GG;LADME-PK;INCREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
IMATINIB;ABCG2;rs12505410;G;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
IMATINIB;ABCG2;rs12505410;GG + GT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
TAMOXIFEN;CYP19A1;rs4646;AA + AC;EFFICACY;INCREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
6-HYDROXY R-WARFARIN, 6-HYDROXY S-WARFARIN;GRID2;rs558364281;G;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION, OTHER:VENOUS THROMBOEMBOLISM, OTHER:HEART VALVE DISEASES
IMATINIB;ABCG2;rs13120400;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
METHOTREXATE;SLCO1B1;rs10841753;CT + TT;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
IMATINIB;ABCG2;rs2725252;AC + CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
LACIDIPINE, NIFEDIPINE, NITRENDIPINE;CACNA1C;rs2238032;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
LUMEFANTRINE;CYP3A4;rs2740574;C;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;MALARIA, OTHER:PREGNANCY
QUETIAPINE;HTR1A;rs10042486;TT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
AMITRIPTYLINE, CLOMIPRAMINE, DULOXETINE, IMIPRAMINE, MILNACIPRAN, VENLAFAXINE;BDNF;rs6265;CT + TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER
CHLORPROMAZINE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE;EPM2A;rs1415744;C;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
AMLODIPINE, FELODIPINE;CACNA1C;rs2239050;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
WARFARIN;CYP2C18;rs41291550;A;LADME-PK;DECREASED_METABOLISM;OTHER;ATRIAL FIBRILLATION, OTHER:VENOUS THROMBOEMBOLISM, OTHER:HEART VALVE DISEASES
ATORVASTATIN;CYP3A4;rs2740574;TT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;CARDIOVASCULAR DISEASE, OTHER:HYPERLIPIDEMIAS
CITALOPRAM, FLUOXETINE;GSK3B;rs334558;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
WARFARIN;CYP2C9;rs9332241;T;LADME-PK;DECREASED_METABOLISM;OTHER;ATRIAL FIBRILLATION, OTHER:VENOUS THROMBOEMBOLISM, OTHER:HEART VALVE DISEASES
LUMEFANTRINE;CYP3A5;rs10264272;T;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;MALARIA, OTHER:PREGNANCY
ATORVASTATIN;CYP3A5;rs776746;CC;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;CARDIOVASCULAR DISEASE, OTHER:HYPERLIPIDEMIAS
WARFARIN;FPGS;rs7856096;G;DOSAGE;DECREASED_DOSE;;
WARFARIN;FPGS;rs7856096;G;DOSAGE;DECREASED_DOSE;;
LUMEFANTRINE;CYP3A5;rs776746;C;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;MALARIA, OTHER:PREGNANCY
INFLIXIMAB;FCGR3A;rs396991;A;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
CETUXIMAB;FCGR3A;rs396991;A;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
NALTREXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ALCOHOL ABUSE
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs80034486;CG + GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CYSTIC FIBROSIS
AMLODIPINE, FELODIPINE;CACNA1C;rs2239128;C;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY, LADME-PK;DECREASED_CLEARANCE;DISEASE;COLORECTAL NEOPLASMS
SUNITINIB;CYP3A5;rs776746;T;DOSAGE;DECREASED_DOSE;DISEASE;RENAL CELL CARCINOMA
N-DESMETHYLCLOZAPINE;UGT2B10;rs61750900;GT;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
LUMEFANTRINE;CYP3A4;rs2740574;T;EFFICACY;DECREASED_RESPONSE;DISEASE;MALARIA, DISEASE:PREGNANCY
CLOPIDOGREL;N6AMT1;rs2254638;G;EFFICACY;DECREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
VALPROIC ACID;UGT1A6;rs6759892;TT;LADME-PK;INCREASED_EXPOSURE;OTHER;EPILEPSY
FENTANYL;ASTN2;rs7858836;CT + TT;DOSAGE;DECREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
BENAZEPRIL, IMIDAPRIL;CYP11B2;rs1799998;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;ESSENTIAL HYPERTENSION
FENTANYL;ASTN2;rs958804;CC + CT;DOSAGE;DECREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
VALPROIC ACID;UGT1A6;rs1105879;AA;LADME-PK;INCREASED_EXPOSURE;OTHER;EPILEPSY
VALPROIC ACID;UGT1A6;rs2070959;AA;LADME-PK;INCREASED_EXPOSURE;OTHER;EPILEPSY
TACROLIMUS;CYP3A4;rs35599367;AA + AG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
ETIDRONIC ACID;COL1A1;rs1800012;AA + AC;EFFICACY;DECREASED_RESPONSE;DISEASE;METABOLIC BONE DISORDER
VORICONAZOLE;ABCG2;rs13120400;CC;LADME-PK;INCREASED_TROUGH CONCENTRATION;;
MORPHINE, NORTRIPTYLINE;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESPONSE;OTHER;PAIN
RISPERIDONE;HTR1A;rs6295;CG + GG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
DULOXETINE;;rs4858478;G;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY, LADME-PK;DECREASED_CLEARANCE;DISEASE;COLORECTAL NEOPLASMS
VALPROIC ACID;UGT1A6;rs6759892;GG;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY
DULOXETINE;ZNF385D;rs13093500;T;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER
FOLIC ACID, HYDROXYCHLOROQUINE, METHOTREXATE, SULFASALAZINE;SLC19A1;rs1051266;T;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
DULOXETINE;ZNF385D;rs4334661;T;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
FOLIC ACID, HYDROXYCHLOROQUINE, METHOTREXATE, SULFASALAZINE;MTR;rs1805087;A;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
DULOXETINE;;rs7625956;G;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
TACROLIMUS;CYP3A5;rs4646453;CC;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
TAMOXIFEN;SULT1A1;rs1042028;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
DULOXETINE;ZNF385D;rs7616119;G;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;;rs2933304;T;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
WARFARIN;VKORC1;rs9923231;CT;DOSAGE;INCREASED_DOSE;DISEASE;THROMBOEMBOLISM
METHOTREXATE;SLC19A1;rs1051266;T;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
DULOXETINE;NRXN1;rs4971678;T;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
TRAMADOL;RGL4;rs184199168;A;LADME-PK;DECREASED_METABOLISM;;
DULOXETINE;ZNF385D;rs12630569;G;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
TRAMADOL;;rs72732317;T;LADME-PK;DECREASED_METABOLISM;;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;THROMBOEMBOLISM
BEVACIZUMAB, CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN;VEGFA;rs699947;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
TRAMADOL;HCN1;rs79983226;C;LADME-PK;DECREASED_METABOLISM;;
TRAMADOL;ICA1;rs62435418;A;LADME-PK;DECREASED_METABOLISM;;
ERYTHROPOIETIN;HFE;rs1800562;A;DOSAGE, LADME-PK;DECREASED_DOSE;OTHER;HEMODIALYSIS TREATMENT
DULOXETINE;;rs6700741;C;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
ENALAPRIL;ADRB2;rs1042714;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTROPHY, LEFT VENTRICULAR
ATENOLOL, ENALAPRIL;ADRB2;rs1042714;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTROPHY, LEFT VENTRICULAR
BEVACIZUMAB, CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN;VEGFA;rs3025039;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
ERYTHROPOIETIN;HFE;rs1799945;G;DOSAGE, LADME-PK;DECREASED_DOSE;OTHER;HEMODIALYSIS TREATMENT
TRAMADOL;RFPL4B;rs9384825;T;LADME-PK;DECREASED_METABOLISM;;
DULOXETINE;TEX10;rs6479008;C;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
TACROLIMUS;CYP3A5;rs15524;AA;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
DULOXETINE;TEX10;rs7035619;A;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;TEX10;rs10989064;T;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DIGOXIN;ABCB1;rs1045642;GG;LADME-PK;INCREASED_METABOLISM;;
DULOXETINE;ATP10A;rs12595802;G;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;TEX10;rs7472;G;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
MYCOPHENOLIC ACID;IMPDH2;rs11706052;G;EFFICACY;DECREASED_RESPONSE;;
DULOXETINE;;rs56229625;G;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DIGOXIN;ABCB1;rs2032582;CC;LADME-PK;INCREASED_METABOLISM;;
DULOXETINE;;rs61692318;G;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;;rs62319299;A;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
DULOXETINE;TEX10;rs10124893;G;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;INVS;rs10123866;G;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
ABEMACICLIB, PALBOCICLIB, RIBOCICLIB;ABCB1;rs1045642;A;DOSAGE, TOXICITY;DECREASED_DOSE;OTHER;BREAST NEOPLASMS
DULOXETINE;;rs10007051;C;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CYSTIC FIBROSIS
DULOXETINE;ZNF385D;rs9879065;C;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;;rs55881666;C;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
INFLIXIMAB;;rs2097432;CC + CT;EFFICACY;DECREASED_RESPONSE;OTHER;CROHN DISEASE
VALPROIC ACID;CYP2C9;rs4918758;CC + CT;LADME-PK;INCREASED_EXPOSURE;OTHER;EPILEPSY
DULOXETINE;;rs11933890;A;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
VALPROIC ACID;CYP2C19;rs4244285;AA + AG;LADME-PK;INCREASED_EXPOSURE;OTHER;EPILEPSY
DULOXETINE;ZNF385D;rs9310658;C;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;ZNF385D;rs7653345;A;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
VALPROIC ACID;ABAT;rs1731017;GG;LADME-PK;INCREASED_EXPOSURE;OTHER;EPILEPSY
DULOXETINE;ZNF385D;rs9310657;T;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;ZNF385D;rs9824595;G;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;ZNF385D;rs9873889;C;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;ZNF385D;rs9819548;G;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE;;
CAPECITABINE;CDA;rs532545;CC;EFFICACY;DECREASED_RESPONSE;OTHER;BREAST NEOPLASMS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
HYDRALAZINE / ISOSORBIDE DINITRATE;NOS3;rs1799983;GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;HEART FAILURE
WARFARIN;CYP2C9;rs56165452;C;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;ABCB1;rs1045642;AA;LADME-PK;DECREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;;
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
ADALIMUMAB;CRP;rs1130864;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES
OLANZAPINE;CYP3A43;rs472660;AA;DOSAGE, EFFICACY, TOXICITY, LADME-PK;INCREASED_CLEARANCE;DISEASE;SCHIZOPHRENIA
GLATIRAMER ACETATE;EOMES;rs2371108;T;EFFICACY;INCREASED_RESPONSE;DISEASE;MULTIPLE SCLEROSIS
CARVEDILOL;UGT1A1;rs4148323;A;LADME-PK;DECREASED_METABOLISM;DISEASE;ANGINA PECTORIS
ETOPOSIDE;ABCB1;rs1045642;GG;LADME-PK;INCREASED_METABOLISM;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
ADALIMUMAB;ATG5;rs9373839;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES
DULOXETINE;MIEF2;rs56355515;G;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;MIEF2;rs12603700;G;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
EFAVIRENZ;CYP2B6;rs28399499;C;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
ADALIMUMAB;ATG5;rs510432;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES
TACROLIMUS;ABCB1;rs1045642;GG;LADME-PK;INCREASED_DOSE;DISEASE;TRANSPLANTATION
DULOXETINE;MIEF2;rs3889402;G;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
AZATHIOPRINE;AOX1;rs55754655;G;EFFICACY;DECREASED_RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES
AZATHIOPRINE;AOX1;rs55754655;AG + GG;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
HYDRALAZINE / ISOSORBIDE DINITRATE;CYP11B2;rs1799998;AA;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;HEART FAILURE
DULOXETINE;;rs58042962;G;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
TACROLIMUS;CYP3A4;rs2740574;C;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
DULOXETINE;;rs10771997;T;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
FENOFIBRATE;LPL;rs320;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA
DULOXETINE;FCN2;rs3124955;T;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
FENOFIBRATE;APOA1;rs2727786;CG;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA
DULOXETINE;FCN2;rs3128624;A;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;;rs7306991;A;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
GLATIRAMER ACETATE;CLEC16A;rs6498169;A;EFFICACY;INCREASED_RESPONSE;DISEASE;MULTIPLE SCLEROSIS
TACROLIMUS;CYP3A4;rs2740574;C;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
DIGOXIN;ABCB1;rs1045642;AA;LADME-PK;DECREASED_METABOLISM;;
DULOXETINE;;rs10771999;C;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;;rs10771998;A;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;SKIC3;rs12657120;G;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
ETHOSUXIMIDE;CACNA1H;rs61734410;T;EFFICACY;DECREASED_CLINICAL_BENEFIT;EFFICACY;EPILEPSY
DULOXETINE;SKIC3;rs4639250;G;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;;rs4437856;A;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
ETHOSUXIMIDE;CACNA1I;rs3747178;T;EFFICACY;DECREASED_CLINICAL_BENEFIT;EFFICACY;EPILEPSY
DULOXETINE;TREML4;rs9369266;A;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
AZATHIOPRINE;MOCOS;rs594445;AA + AC;DOSAGE;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
DULOXETINE;TREML4;rs13204353;G;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
LAMOTRIGINE;ABCB1;rs2032582;A;EFFICACY;DECREASED_CLINICAL_BENEFIT;EFFICACY;EPILEPSY
CYCLOSPORINE;CALM1;rs12885713;T;EFFICACY;INCREASED_RESPONSE;OTHER;PSORIASIS
IRBESARTAN;AGT;rs699;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTROPHY, LEFT VENTRICULAR
DULOXETINE;;rs2419128;C;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
METHOTREXATE;SLC19A1;rs1051266;T;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
DULOXETINE;;rs12502866;G;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
METHOTREXATE;GGH;rs3758149;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
DULOXETINE;;rs12094644;T;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
CAPECITABINE;CDA;rs2072671;AA + AC;EFFICACY;DECREASED_RESPONSE;OTHER;BREAST NEOPLASMS
LAMOTRIGINE;CACNA1H;rs2753326;A;EFFICACY;INCREASED_CLINICAL_BENEFIT;EFFICACY;EPILEPSY
RIVAROXABAN;ABCB1;rs4728709;GG;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION
ATENOLOL;ADRA2A;rs1800545;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTROPHY, LEFT VENTRICULAR
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
CYCLOSPORINE;;rs2874116;G;EFFICACY;INCREASED_RESPONSE;OTHER;PSORIASIS
IRBESARTAN;APOB;rs1801701;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTROPHY, LEFT VENTRICULAR
RIVAROXABAN;ABCB1;rs4148738;CC;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION
EFAVIRENZ;CYP2B6;rs28399499;C;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
MEPHENYTOIN;CYP2C19;rs183701923;T;LADME-PK;DECREASED_CLEARANCE;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
MEPHENYTOIN;CYP2C19;rs140278421;A;LADME-PK;DECREASED_CLEARANCE;;
EFAVIRENZ;CYP2B6;rs4803419;T;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;rs34067076;A;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
CHLORPROMAZINE;DRD2;rs1799732;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;rs59410695;A;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
WARFARIN;CYP2C9;rs28371686;G;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;rs28371685;T;DOSAGE;DECREASED_DOSE;;
METHOTREXATE;AMPD1;rs17602729;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
WARFARIN;CYP2C9;rs28371686;G;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;rs56165452;C;DOSAGE;DECREASED_DOSE;;
BENAZEPRIL;AGT;rs7079;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
PLATINUM COMPOUNDS;XRCC3;rs861539;A;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;rs200571120;C;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
OMEPRAZOLE;ABCB1;rs1045642;AA + AG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;GASTROESOPHAGEAL REFLUX
OPIOIDS;OPRM1;rs1799971;AA;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
NELFINAVIR;CYP2C19;rs4244285;AA;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
TOLBUTAMIDE;CYP2C9;rs771237265;C;LADME-PK;DECREASED_CLEARANCE;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;;
METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
TOLBUTAMIDE;CYP2C9;rs762081829;T;LADME-PK;DECREASED_CLEARANCE;;
METFORMIN;SLC22A1;rs628031;A;EFFICACY;DECREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
MEPHENYTOIN;CYP2C19;rs145119820;A;LADME-PK;DECREASED_CLEARANCE;;
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE;;
TOLBUTAMIDE;CYP2C9;rs761895497;C;LADME-PK;DECREASED_CLEARANCE;;
WARFARIN;F7;rs510317;AA + AG;DOSAGE;INCREASED_DOSE;;
FLUOXETINE;HTR1A;rs6295;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
MEPHENYTOIN;CYP2C19;rs61311738;T;LADME-PK;DECREASED_CLEARANCE;;
SULFONAMIDES, UREA DERIVATIVES;TCF7L2;rs7903146;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
BENAZEPRIL;AGT;rs4762;G;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
BENAZEPRIL;AGT;rs699;A;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
FLUOROURACIL, OXALIPLATIN;GSTP1;rs1695;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
ACENOCOUMAROL;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;;
BENAZEPRIL;AGT;rs7079;T;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE;;
FENOFIBRATE;APOA5;rs3135506;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA
PRAVASTATIN, SIMVASTATIN;RHOA;rs11716445;A;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
SULFONAMIDES, UREA DERIVATIVES;KCNJ11;rs587783672;T;EFFICACY;RESPONSE;;
EFAVIRENZ;CYP2B6;rs35303484;AG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;rs72547516;G;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;;
CITALOPRAM;;rs585719;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;DEPRESSION
WARFARIN;GGCX;rs11676382;CG + GG;DOSAGE;DECREASED_DOSE;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;rs566851431;T;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
WARFARIN;;rs12777823;A;LADME-PK;DECREASED_METABOLISM;OTHER;ATRIAL FIBRILLATION, OTHER:VENOUS THROMBOEMBOLISM, OTHER:HEART VALVE DISEASES
WARFARIN;CYP2C9;rs7900194;A;LADME-PK;DECREASED_METABOLISM;OTHER;ATRIAL FIBRILLATION, OTHER:VENOUS THROMBOEMBOLISM, OTHER:HEART VALVE DISEASES
ISONIAZID;CYP2E1;rs6413432;A;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;TUBERCULOSIS
EFAVIRENZ;CYP2B6;rs4803419;TT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;;
WARFARIN;GATA4;rs2645400;TT;DOSAGE;INCREASED_DOSE;;
WARFARIN;CYP2C9;rs28371685;T;LADME-PK;DECREASED_METABOLISM;OTHER;ATRIAL FIBRILLATION, OTHER:VENOUS THROMBOEMBOLISM, OTHER:HEART VALVE DISEASES
WARFARIN;GATA4;rs4841588;TT;DOSAGE;INCREASED_DOSE;;
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;rs7662029;GG;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
BUPRENORPHINE;UGT2B7;rs7439366;CC;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS
METHOTREXATE;SLCO1B1;rs4149056;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;rs7439366;CC;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
METHOTREXATE;SLC19A1;rs2838958;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE, LADME-PK;DECREASED_DOSE;;
SILDENAFIL;VEGFA;rs1570360;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;ERECTILE DYSFUNCTION
SILDENAFIL;VEGFA;rs699947;AA + AC;EFFICACY;DECREASED_RESPONSE;DISEASE;ERECTILE DYSFUNCTION
CAPTOPRIL;ACE2;rs2106809;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
CYCLOPHOSPHAMIDE, DOXORUBICIN, PACLITAXEL, TRASTUZUMAB;FCGR2A;rs1801274;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
TRASTUZUMAB;FCGR3A;rs396991;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
BUPRENORPHINE;UGT2B7;rs7662029;GG;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS
ECULIZUMAB;CR1;rs2274567;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
TACROLIMUS;NR1I2;rs3814055;TT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A4;rs2740574;CT;LADME-PK;INCREASED_EXPOSURE;OTHER;KIDNEY TRANSPLANTATION
MYCOPHENOLIC ACID;UGT1A1;rs4148323;AG;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;;
PHENPROCOUMON;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;;
CLOZAPINE;DRD1;rs686;G;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;rs7438135;AA;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
CLOZAPINE;DRD3;rs6280;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
FOLLITROPIN BETA, MENOTROPINS, THYROTROPIN ALFA, UROFOLLITROPIN;FSHR;rs6166;CT;EFFICACY;DECREASED_RESPONSE;OTHER;INFERTILITY DISORDER
MERCAPTOPURINE;TPMT;rs12199316;G;DOSAGE;INCREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
TICAGRELOR;CYP3A4;rs56324128;CC;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;ACUTE CORONARY SYNDROME
CANDESARTAN;AGTR1;rs5186;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;HEART FAILURE
IRBESARTAN;AGTR1;rs5186;AC;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTROPHY, LEFT VENTRICULAR
WARFARIN;CYP2C9;rs2256871;G;LADME-PK;DECREASED_METABOLISM;OTHER;ATRIAL FIBRILLATION, OTHER:VENOUS THROMBOEMBOLISM, OTHER:HEART VALVE DISEASES
DOCETAXEL, PACLITAXEL;CYP3A5;rs776746;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
CAPECITABINE, FLUOROURACIL, TEGAFUR / GIMERACIL / OTERACIL;DPYD;rs1801159;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE;STOMACH NEOPLASMS
CANDESARTAN;AGTR1;rs5186;AC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEART FAILURE
TICAGRELOR;SLCO1B1;rs113681054;C;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;ACUTE CORONARY SYNDROME
TICAGRELOR;SLCO1B1;rs4149056;T;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;ACUTE CORONARY SYNDROME
GEMCITABINE, PACLITAXEL;SLC29A1;rs760370;A;EFFICACY;DECREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, PAROXETINE, SERTRALINE;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER
WARFARIN;CYP2C19;rs11188082;T;LADME-PK;DECREASED_METABOLISM;OTHER;ATRIAL FIBRILLATION, OTHER:VENOUS THROMBOEMBOLISM, OTHER:HEART VALVE DISEASES
METHYLPHENIDATE;CES1;rs71647871;CT;DOSAGE, LADME-PK;DECREASED_DOSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
TICAGRELOR;UGT2B7;rs61361928;TT;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;ACUTE CORONARY SYNDROME
QUETIAPINE;HTR1A;rs6295;GG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
TICAGRELOR;CYP3A43;rs62471956;G;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;ACUTE CORONARY SYNDROME
ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT
SIMVASTATIN;LEPR;rs1137101;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERLIPIDEMIAS
LAMOTRIGINE;ABCG2;rs2231142;T;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;EPILEPSY
OPIOIDS;IL2;rs2069762;AA;DOSAGE;INCREASED_DOSE;OTHER;PAIN, OTHER:NEOPLASMS
OPIOIDS;BDNF;rs6265;CC;DOSAGE;INCREASED_DOSE;OTHER;PAIN, OTHER:NEOPLASMS
ACENOCOUMAROL, WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT
VORICONAZOLE;CYP3A4;rs4646437;AG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;FUNGAL INFECTIOUS DISEASE
OPIOIDS;IL6;rs1800795;CC;DOSAGE;INCREASED_DOSE;OTHER;PAIN, OTHER:NEOPLASMS
ATENOLOL, IRBESARTAN;AGT;rs4762;AG;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTROPHY, LEFT VENTRICULAR
TENOFOVIR;ABCC4;rs1059751;AA + AG;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;HEPATITIS B, CHRONIC
CAFFEINE;CYP1A1;rs2472297;T;LADME-PK;INCREASED_METABOLISM;;
DOCETAXEL;VEGFA;rs1570360;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
OPIOIDS;IL1B;rs1143634;AA + AG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;PAIN, OTHER:NEOPLASMS
FENOFIBRATE;SCARB1;rs4238001;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA
TENOFOVIR;SLC22A6;rs4149170;TT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HEPATITIS B, CHRONIC
NEVIRAPINE;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
OPIOIDS;OPRD1;rs678849;CC;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;PAIN, OTHER:NEOPLASMS
ACENOCOUMAROL, WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT
IRBESARTAN;AGT;rs699;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTROPHY, LEFT VENTRICULAR
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;CXCL10;rs56061981;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
ATORVASTATIN;ABCB1;rs2032582;T;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
ATORVASTATIN;ABCB1;rs2032582;T;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
ATALUREN;CFTR;rs113993959;T;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
FOLIC ACID;MTHFR;rs1801131;G;LADME-PK;DECREASED_METABOLISM;;
ATALUREN;CFTR;rs75039782;T;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
FOLIC ACID;MTHFR;rs1801133;A;LADME-PK;DECREASED_METABOLISM;;
ATALUREN;CFTR;rs77010898;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
PLATINUM COMPOUNDS;ERCC2;rs1052555;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
FENOFIBRATE;APOA5;rs3135506;CC + CG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA
METHYLPHENIDATE;DRD1;rs5326;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;AUTISM SPECTRUM DISORDER
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
FENTANYL;ABCB1;rs1045642;GG;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
FOLIC ACID, METHOTREXATE;ATIC;rs2372536;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
CORTICOSTEROIDS, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ADAM33;rs2853209;AA;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;ASTHMA
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
LITHIUM;GADL1;rs17026688;T;EFFICACY;INCREASED_RESPONSE;OTHER;BIPOLAR DISORDER
TACROLIMUS;POR;rs1057868;CC;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
FOLIC ACID, METHOTREXATE;ITPA;rs1127354;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
METHOTREXATE;ATIC;rs4673993;C;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
WARFARIN;VKORC1;rs9923231;TT;DOSAGE, LADME-PK;DECREASED_DOSE;;
WARFARIN;GGCX;rs12714145;C;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;;
METHOTREXATE;ADA;rs244076;C;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
METHOTREXATE;ADORA2A;rs5751876;T;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
FOLIC ACID, METHOTREXATE;AMPD1;rs17602729;A;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
RITUXIMAB;FCGR3A;rs396991;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;;
FLUOROURACIL;EGFR;rs2293347;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;STOMACH NEOPLASMS
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE;;
ANTIDEPRESSANTS;TGFBR3;rs12082710;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;DEPRESSION
WARFARIN;VKORC1;rs7294;C;DOSAGE;DECREASED_DOSE;;
METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
ALLOPURINOL;ABCG2;rs2231142;T;DOSAGE;INCREASED_DOSE;DISEASE;GOUT
WARFARIN;VKORC1;rs2884737;C;DOSAGE;DECREASED_DOSE;;
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DECREASED_DOSE;;
RIFAMPIN;AADAC;rs1803155;GG;LADME-PK;DECREASED_EXPOSURE;OTHER;TUBERCULOSIS
CETUXIMAB, PANITUMUMAB;AREG;rs9996584;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
NEVIRAPINE;CYP2B6;rs28399499;CT;LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
CETUXIMAB, PANITUMUMAB;AREG;rs1353295;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
NEVIRAPINE;CYP2B6;rs28399499;CT;TOXICITY, LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
METHOTREXATE;MTHFR;rs1801133;AA + AG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BURKITT LYMPHOMA, DISEASE:LYMPHOMA, T-CELL, DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA
RIFAMPIN;ABCB1;rs3842;CC;LADME-PK;INCREASED_EXPOSURE;OTHER;TUBERCULOSIS
NEVIRAPINE;CYP2B6;rs3745274;GT + TT;TOXICITY, LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
METHOTREXATE;ABCB1;rs1045642;AA;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BURKITT LYMPHOMA, DISEASE:LYMPHOMA, T-CELL, DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA
CLOPIDOGREL;CYP2C19;rs4986893;AG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;HYPERTENSION, OTHER:ACUTE CORONARY SYNDROME
FENTANYL;P2RX7;rs1718125;CT + TT;DOSAGE;INCREASED_DOSE;OTHER;LUNG NEOPLASMS, OTHER:PAIN, POSTOPERATIVE
METHYLPHENIDATE;DRD1;rs4867798;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;AUTISM SPECTRUM DISORDER
METHYLPHENIDATE;DRD3;rs6280;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;AUTISM SPECTRUM DISORDER
METHYLPHENIDATE;DRD4;rs11246226;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;AUTISM SPECTRUM DISORDER
PLATINUM COMPOUNDS;XRCC1;rs25487;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
METHYLPHENIDATE;ADRA2A;rs1800544;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;AUTISM SPECTRUM DISORDER
METHYLPHENIDATE;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;AUTISM SPECTRUM DISORDER
ESTRONE SULFATE;SLCO1B1;rs10841753;C;EFFICACY;DECREASED_CONCENTRATIONS;OTHER;BREAST NEOPLASMS
WARFARIN;GGCX;rs12714145;TT;DOSAGE;INCREASED_DOSE;;
NEVIRAPINE;CYP2B6;rs3745274;GT + TT;LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
CETUXIMAB, PANITUMUMAB;AREG;rs13104811;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
CETUXIMAB, PANITUMUMAB;AREG;rs11942466;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
ANTIDEPRESSANTS;CRHR1;rs28364032;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
TOPIRAMATE;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs4148324;GG + GT;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY
CAPECITABINE, FLUOROURACIL;EXO1;rs1047840;A;EFFICACY;INCREASED_RESPONSE;DISEASE;METASTATIC NEOPLASM
CAPECITABINE, FLUOROURACIL;CYP19A1;rs2236722;G;EFFICACY;DECREASED_RESPONSE;DISEASE;METASTATIC NEOPLASM
CAPECITABINE, FLUOROURACIL;PTEN;rs17431184;C;EFFICACY;INCREASED_RESPONSE;DISEASE;METASTATIC NEOPLASM
CYCLOSPORINE;POR;rs1057868;T;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
CAPECITABINE, FLUOROURACIL;DLG5;rs2289310;T;EFFICACY;INCREASED_RESPONSE;DISEASE;METASTATIC NEOPLASM
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;SLC29A1;rs760370;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
METHOTREXATE;MTHFR;rs1801133;AA + AG;LADME-PK;DECREASED_CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
TIPIRACIL HYDROCHLORIDE, TRIFLURIDINE;SLC29A1;rs760370;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
ETHANOL;ADH1B;rs2018417;A;TOXICITY, LADME-PK;METABOLISM;;
ETHANOL;ADH1B;rs17033;C;TOXICITY, LADME-PK;METABOLISM;;
ETHANOL;ADH1B;rs1229985;G;TOXICITY, LADME-PK;METABOLISM;;
PHENPROCOUMON;PPARA;rs4253728;A;DOSAGE;INCREASED_DOSE;;
ETHANOL;ADH1A;rs931635;A;TOXICITY, LADME-PK;METABOLISM;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
METHADONE;KCNJ6;rs2070995;TT;;INCREASED_DOSE;DISEASE;SUBSTANCE-RELATED DISORDERS
ETHANOL;ADH1C;rs283416;A;TOXICITY, LADME-PK;METABOLISM;;
CAPECITABINE, FLUOROURACIL;ABCB1;rs17160359;T;EFFICACY;INCREASED_RESPONSE;DISEASE;METASTATIC NEOPLASM
ROSIGLITAZONE;PPARG;rs1801282;CG;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
ETHANOL;ADH1C;rs283411;A;TOXICITY, LADME-PK;METABOLISM;;
ETHANOL;ADH1C;rs1662060;C;TOXICITY, LADME-PK;METABOLISM;;
TACROLIMUS;SUMO4;rs237025;AA;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
ACENOCOUMAROL;VKORC1;rs17878544;TT;DOSAGE;DECREASED_DOSE;;
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;G;EFFICACY;DECREASED_RESPONSE;;
ACENOCOUMAROL;VKORC1;rs7200749;AA + AG;DOSAGE;INCREASED_DOSE;;
HMG COA REDUCTASE INHIBITORS;ABCG2;rs2231142;G;EFFICACY;DECREASED_RESPONSE;;
ACENOCOUMAROL;VKORC1;rs61742245;AA + AC;DOSAGE;INCREASED_DOSE;;
WARFARIN;VKORC1;rs7200749;A;DOSAGE;INCREASED_DOSE;;
ACENOCOUMAROL;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE;;
WARFARIN;VKORC1;rs7294;T;DOSAGE;INCREASED_DOSE;;
CITALOPRAM;NEDD4L;rs520210;A;EFFICACY;INCREASED_RESPONSE;DISEASE;DEPRESSION
HMG COA REDUCTASE INHIBITORS;TOMM40;rs2075650;G;EFFICACY;DECREASED_RESPONSE;;
ACENOCOUMAROL;VKORC1;rs55894764;CT + TT;DOSAGE;INCREASED_DOSE;;
VALPROIC ACID;UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs28898617;G;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;EPILEPSY
IVACAFTOR;CFTR;rs78655421;AA + AG;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
METHYLPHENIDATE;PEBP4;rs17685420;T;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;DISEASE;CARDIOVASCULAR DISEASE
VERAPAMIL;ITGAL;rs2230433;C;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;MIGRAINE DISORDER
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HYPERCHOLESTEROLEMIA
PAZOPANIB;KDR;rs34231037;AG;EFFICACY;INCREASED_RESPONSE;DISEASE;RENAL CELL CARCINOMA
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
ETHANOL;ADH7;rs1154461;C;TOXICITY, LADME-PK;METABOLISM;;
HEPATITIS VACCINES;IL4R;rs1805015;C;EFFICACY;INCREASED_RESPONSE;;
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_METABOLISM;OTHER;HIV INFECTIOUS DISEASE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
ETHANOL;ADH1A;rs1229967;C;TOXICITY, LADME-PK;METABOLISM;;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
ETHANOL;ADH1A;rs2276332;C;TOXICITY, LADME-PK;METABOLISM;;
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
BENAZEPRIL, IMIDAPRIL;AGT;rs5051;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
ETHANOL;ADH1A;rs1229976;C;TOXICITY, LADME-PK;METABOLISM;;
URSODEOXYCHOLIC ACID;MGAT5;rs661899;TT;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;CHOLANGITIS
CLOPIDOGREL THIOL METABOLITE H4;CYP2C19;rs4244285;A;LADME-PK;EXPOSURE;;
HEPATITIS VACCINES;IL13;rs1295686;T;EFFICACY;DECREASED_RESPONSE;;
PHENPROCOUMON;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;;
PHENPROCOUMON;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_DOSE;;
TACROLIMUS;ABCB1;rs1045642;AA;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;RHEUMATOID ARTHRITIS
PEGINTERFERON ALFA-2B, RIBAVIRIN;CYP27B1;rs10877012;GT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
DABIGATRAN;CES1;rs8192935;AA + AG;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION
IRINOTECAN;VDR;rs11574077;TT;LADME-PK;INCREASED_METABOLISM;DISEASE;COLORECTAL NEOPLASMS
METHYLPHENIDATE;ADGRL3;rs1868790;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
METHYLPHENIDATE;SNAP25;rs3746544;GG + GT;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
METHYLPHENIDATE;SLC6A3;rs2550948;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
PHENPROCOUMON;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
ATORVASTATIN;SLCO1B1;rs4149056;C;LADME-PK;INCREASED_EXPOSURE;;
INTERFERONS, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
MORPHINE;SLC22A1;rs34059508;AA + AG;LADME-PK;DECREASED_CLEARANCE;;
METHYLPHENIDATE;ADRA2A;rs1800544;G;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
PLATINUM;XRCC1;rs25487;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;LUNG NEOPLASMS
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;;rs10514475;A;EFFICACY;INCREASED_RESPONSE;DISEASE;DEPRESSION
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;PLCB1;rs6108160;A;EFFICACY;INCREASED_RESPONSE;DISEASE;DEPRESSION
WARFARIN;LRP1;rs1800139;TT;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT
METHYLPHENIDATE;ADRA2A;rs1800544;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
WARFARIN;CYP4F2;rs2108622;T;DOSAGE, EFFICACY;INCREASED_DOSE;;
WARFARIN;LRP1;rs1800154;CC;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT
NICOTINE;CYP2A6;rs56113850;T;LADME-PK;DECREASED_CLEARANCE;;
WARFARIN;VKORC1;rs9923231;TT;EFFICACY;INCREASED_RESPONSE;;
INTERFERONS, RIBAVIRIN;IFNL3;rs8099917;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
PHENPROCOUMON;VKORC1;rs2359612;AA + AG;EFFICACY;INCREASED_RESPONSE;;
METHYLPHENIDATE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
WARFARIN;CYP4F2;rs2108622;T;DOSAGE, EFFICACY;INCREASED_DOSE;;
PLATINUM COMPOUNDS;XRCC1;rs1799782;G;EFFICACY;DECREASED_RESPONSE;DISEASE;LUNG NEOPLASMS
MORPHINE;SLC22A1;rs12208357;TT;LADME-PK;DECREASED_CLEARANCE;OTHER;ADENOTONSILLECTOMY
PHENPROCOUMON;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
METHYLPHENIDATE;ADRA2A;rs1800544;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
FLUOROURACIL;LGR5;rs17109924;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;COLONIC NEOPLASMS
ROSUVASTATIN;ABCG2;rs2231142;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;;
MORPHINE;SLC22A1;rs34059508;AA;LADME-PK;DECREASED_CLEARANCE;OTHER;ADENOTONSILLECTOMY
METHYLPHENIDATE;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
MORPHINE;SLC22A1;rs34130495;AA;LADME-PK;DECREASED_CLEARANCE;OTHER;ADENOTONSILLECTOMY
ATORVASTATIN, PRAVASTATIN;KIF6;rs9462535;AA + AC;EFFICACY;INCREASED_RESPONSE;;
CAPECITABINE, FLUOROURACIL;MTHFR;rs1801133;AA + AG;DOSAGE;DECREASED_DOSE;OTHER;NEOPLASMS
ROSUVASTATIN;ABCG2;rs1481012;AG + GG;EFFICACY;INCREASED_RESPONSE;;
SOMATROPIN RECOMBINANT;CDK4;rs2069502;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;TURNER SYNDROME
ATORVASTATIN, PRAVASTATIN;KIF6;rs9471077;AG + GG;EFFICACY;INCREASED_RESPONSE;;
METFORMIN;FMO5;rs7541245;A;EFFICACY;DECREASED_RESPONSE;DISEASE;DIABETES MELLITUS
METHYLPHENIDATE;ADGRL3;rs6858066;A;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
METHYLPHENIDATE;ADGRL3;rs1947274;C;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;DECREASED_RESPONSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
ROSUVASTATIN;USP24;rs17111584;CC + CT;EFFICACY;DECREASED_RESPONSE;;
METHYLPHENIDATE;ADGRL3;rs6551665;G;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
METHYLPHENIDATE;ADGRL3;rs2345039;G;EFFICACY;DECREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
METHYLPHENIDATE;ADGRL3;rs6858066;G;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
METHYLPHENIDATE;ADGRL3;rs1947274;C;EFFICACY;DECREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
METHYLPHENIDATE;SLC6A2;rs5569;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
INTERFERON BETA-1A;RORA;rs4774388;TT;EFFICACY;INCREASED_RESPONSE;OTHER;MULTIPLE SCLEROSIS
METHYLPHENIDATE;SLC6A2;rs28386840;AT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
METHYLPHENIDATE;ADGRL3;rs6551665;G;EFFICACY;DECREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
REMIMAZOLAM;CES1;rs71647871;CT + TT;LADME-PK;DECREASED_METABOLISM;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
NICOTINE;;rs113288603;T;LADME-PK;DECREASED_CLEARANCE;;
ROSUVASTATIN;APOE;rs71352238;CC + CT;EFFICACY;DECREASED_RESPONSE;;
METHYLPHENIDATE;ADRA2A;rs1800544;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
NICOTINE;;rs12461964;A;LADME-PK;DECREASED_CLEARANCE;;
ROSUVASTATIN;APOE;rs7412;CT + TT;EFFICACY;INCREASED_RESPONSE;;
METHYLPHENIDATE;ADRA2A;rs1800544;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
IDARUBICIN;NCF4;rs1883112;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;LEUKEMIA, MYELOID, ACUTE
SIMVASTATIN;ABCC2;rs717620;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
IDARUBICIN;RAC2;rs13058338;AT;EFFICACY;INCREASED_RESPONSE;DISEASE;LEUKEMIA, MYELOID, ACUTE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;MYELOPROLIFERATIVE DISORDER
ROSUVASTATIN;LPA;rs10455872;AG + GG;EFFICACY;DECREASED_RESPONSE;;
ATORVASTATIN;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs887829;T;LADME-PK;INCREASED_METABOLISM;;
METHYLPHENIDATE;BDNF;rs6265;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
EFAVIRENZ;CYP2B6;rs3745274;GG + GT;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE
IVACAFTOR;CFTR;rs78655421;AA + AG;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
ATORVASTATIN;CYP3A7;rs45446698;G;LADME-PK;INCREASED_METABOLISM;;
ATALUREN;CFTR;rs77010898;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
METHYLPHENIDATE;GRM7;rs3792452;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
CLOZAPINE;CYP1A2;rs762551;AA;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;SCHIZOPHRENIA, OTHER:TOBACCO USE DISORDER
EFAVIRENZ;CYP2B6;rs2279343;G;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE
EFAVIRENZ;CYP2B6;rs2279345;T;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE
ATORVASTATIN, PRAVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;INCREASED_RESPONSE;;
METHYLPHENIDATE;ADGRL3;rs6551665;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
ATALUREN;CFTR;rs113993959;T;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
METHYLPHENIDATE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
EFAVIRENZ;ABCB1;rs1045642;AG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE
SOMATROPIN RECOMBINANT;CDK4;rs2270777;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;GROWTH HORMONE DEFICIENCY
IVACAFTOR;CFTR;rs78655421;AG;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
METHYLPHENIDATE;ADRA2A;rs1800544;G;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;;
ATALUREN;CFTR;rs75039782;T;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
ACENOCOUMAROL;VKORC1;rs9923231;CT;DOSAGE;DECREASED_DOSE;;
METFORMIN;PRPF31;rs254271;C;EFFICACY;DECREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
GABAPENTIN;SLC7A5;rs4240803;AG;DOSAGE;INCREASED_DOSE;OTHER;NEUROPATHIC PAIN
ATALUREN;CFTR;rs77010898;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
METFORMIN;NBEA;rs57081354;C;EFFICACY;DECREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
METFORMIN;SLC22A1;rs628031;AA + AG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;LUPUS NEPHRITIS
DRUGS USED IN DIABETES;IRS1;rs1801278;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC1;rs25487;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
METHOTREXATE;MTRR;rs1801394;A;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
SALBUTAMOL;DUSP1;rs881152;G;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC1;rs11615;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
HYDROCHLOROTHIAZIDE;NEDD4L;rs4149601;A;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
METFORMIN;SLC22A1;rs622342;AC + CC;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
WARFARIN;CYP4F2;rs2108622;CT;DOSAGE;INCREASED_DOSE;;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3;rs12980275;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;MYELOPROLIFERATIVE DISORDER
EMTRICITABINE;ABCC2;rs2273897;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE, OTHER:PREGNANCY
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME-PK;DECREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
ATALUREN;CFTR;rs113993959;T;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
GABAPENTIN, PREGABALIN;SLC7A5;rs4240803;AG;EFFICACY;DECREASED_RESPONSE;OTHER;NEUROPATHIC PAIN
MORPHINE;COMT;rs4680;AA;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
METFORMIN;CPA6;rs2162145;T;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
SALBUTAMOL;DUSP1;rs881152;G;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
MIGALASTAT;GLA;rs372966991;T;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE
TACROLIMUS;CYP3A4;rs2242480;CC;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LUNG TRANSPLANTATION
MIGALASTAT;GLA;rs869312146;T;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE
WARFARIN;VKORC1;rs61742245;AA + AC;DOSAGE;INCREASED_DOSE;;
TRAMADOL;SLC22A1;rs34059508;A;DOSAGE;DECREASED_DOSE;DISEASE;PAIN
TACROLIMUS;SLCO1B3;rs4149117;GG + GT;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LUNG TRANSPLANTATION
MIGALASTAT;GLA;rs397515870;G;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE
ESCITALOPRAM;IL11;rs1126757;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;DEPRESSION
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;;
CLOPIDOGREL;CES1;rs2307240;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;ACUTE CORONARY SYNDROME
MIGALASTAT;GLA;rs398123223;G;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE
MIGALASTAT;GLA;rs190347120;A;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE
TACROLIMUS;SLC2A2;rs1499821;CC;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LUNG TRANSPLANTATION
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;;
MIGALASTAT;GLA;rs28935490;T;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE
ABIRATERONE;YBX1;rs10493112;AC + CC;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;PROSTATIC NEOPLASMS
TACROLIMUS;NFATC4;rs1955915;CC + CT;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LUNG TRANSPLANTATION
GRAZOPREVIR;SLCO1B1;rs4149056;C;LADME-PD;INCREASED_EXPOSURE;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION
BISOPROLOL;CYP2D6;rs1080985;CC;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;CARDIOVASCULAR DISEASE
GRAZOPREVIR;SLCO1B1;rs11045819;A;LADME-PD;INCREASED_EXPOSURE;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE;;
WARFARIN;VKORC1;rs9923231;C;LADME-PK;INCREASED_STEADY-STATE CONCENTRATION;;
WARFARIN;VKORC1;rs9923231;C;LADME-PK;INCREASED_DOSE;;
MIGALASTAT;GLA;rs398123212;T;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE
WARFARIN;;rs12777823;AA + AG;DOSAGE;DECREASED_DOSE;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
MIGALASTAT;GLA;rs398123217;C;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE
METHADONE;BDNF, BDNF-AS;rs7127507;C;EFFICACY;DECREASED_RESPONSE;DISEASE;OPIOID-RELATED DISORDERS
O-DESMETHYLTRAMADOL;SLC22A1;rs12208357;T;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;PAIN
MIGALASTAT;GLA;rs397515874;G;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE
MIGALASTAT;GLA;rs727505292;G;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
ENALAPRIL;NOS3;rs2070744;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
METHADONE;BDNF, BDNF-AS;rs11030118;G;EFFICACY;DECREASED_RESPONSE;DISEASE;OPIOID-RELATED DISORDERS
MIGALASTAT;GLA;rs869312399;C;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE
WARFARIN;VKORC1;rs2359612;AG + GG;DOSAGE;INCREASED_DOSE;;
WARFARIN;CYP2C9;rs7089580;T;DOSAGE;DECREASED_DOSE;;
MIGALASTAT;GLA;rs104894828;T;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;;
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;;
METHADONE;BDNF, BDNF-AS;rs1967554;C;EFFICACY;DECREASED_RESPONSE;DISEASE;OPIOID-RELATED DISORDERS
WARFARIN;VKORC1;rs8050894;CG + GG;DOSAGE;DECREASED_DOSE;;
BISOPROLOL;CYP2D6;rs1080985;G;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ACUTE CORONARY SYNDROME
MIGALASTAT;GLA;rs398123226;T;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE
MIGALASTAT;GLA;rs398123226;C;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
WARFARIN;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_DOSE;;
METHADONE;BDNF;rs2030324;G;EFFICACY;DECREASED_RESPONSE;DISEASE;OPIOID-RELATED DISORDERS
MIGALASTAT;GLA;rs727504348;T;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE
BISOPROLOL;CYP2D6;rs3892097;CT + TT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ACUTE CORONARY SYNDROME
BUSULFAN;GSTA1;rs3957357;AA;LADME-PK;INCREASED_CLEARANCE;DISEASE;TRANSPLANTATION
O-DESMETHYLTRAMADOL;SLC22A1;rs34130495;A;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;PAIN
O-DESMETHYLTRAMADOL;SLC22A1;rs34059508;A;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;PAIN
ENALAPRIL;BDKRB2;rs1799722;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERTENSION
METHADONE;BDNF;rs988748;C;EFFICACY;DECREASED_RESPONSE;DISEASE;OPIOID-RELATED DISORDERS
O-DESMETHYLTRAMADOL;SLC22A1;rs55918055;C;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;PAIN
WARFARIN;VKORC1;rs61742245;A;DOSAGE;INCREASED_DOSE;;
MIGALASTAT;GLA;rs869312136;C;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE
TRAMADOL;SLC22A1;rs55918055;C;DOSAGE;DECREASED_DOSE;DISEASE;PAIN
MIGALASTAT;GLA;rs28935195;T;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE
METHADONE;BDNF;rs11030119;G;EFFICACY;DECREASED_RESPONSE;DISEASE;OPIOID-RELATED DISORDERS
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LUNG TRANSPLANTATION
TRAMADOL;SLC22A1;rs12208357;T;DOSAGE;DECREASED_DOSE;DISEASE;PAIN
MIGALASTAT;GLA;rs104894827;A;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE
FENTANYL;CYP3A4;rs2242480;T;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
MIGALASTAT;GLA;rs869312138;C;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE
CELECOXIB;CYP2C9;rs1057910;CC;LADME-PK;DECREASED_METABOLISM;;
BISOPROLOL;CYP3A5;rs776746;TT;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;ACUTE CORONARY SYNDROME
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;;
TRAMADOL;SLC22A1;rs34130495;A;DOSAGE;DECREASED_DOSE;DISEASE;PAIN
MIGALASTAT;GLA;rs1569304898;T;EFFICACY;INCREASED_RESPONSE;OTHER;FABRY DISEASE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1A;rs4149570;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;CROHN DISEASE, DISEASE:INFLAMMATORY BOWEL DISEASES
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR4;rs5030728;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES
METFORMIN;SLC47A1;rs8065082;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;GLUCOSE INTOLERANCE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs4696480;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;ULCERATIVE COLITIS
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNG;rs2430561;AA + AT;EFFICACY;INCREASED_RESPONSE;DISEASE;CROHN DISEASE, DISEASE:INFLAMMATORY BOWEL DISEASES
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;rs352139;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;CROHN DISEASE, DISEASE:INFLAMMATORY BOWEL DISEASES
WARFARIN;VKORC1L1;rs4072879;AA;DOSAGE;DECREASED_DOSE;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs3804099;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs1816702;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CROHN DISEASE
TACROLIMUS;CYP3A4;rs35599367;A;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
SUFENTANIL;OPRM1;rs1799971;G;DOSAGE;DECREASED_DOSE;DISEASE;PAIN
OPIOIDS;ENPP2;rs2249015;AA;DOSAGE;INCREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;APOE;rs429358;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE;ALZHEIMER DISEASE
ROSIGLITAZONE;PAX4;rs6467136;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
ROSIGLITAZONE;PAX4;rs6467136;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
ATORVASTATIN;APOE;rs429358;CT;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
OPIOIDS;ABCB1;rs1045642;AA;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL6;rs10499563;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;ULCERATIVE COLITIS, DISEASE:INFLAMMATORY BOWEL DISEASES
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL17A;rs2275913;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;ULCERATIVE COLITIS, DISEASE:INFLAMMATORY BOWEL DISEASES
LATANOPROST;ABCC4;rs11568658;AC;EFFICACY;DECREASED_RESPONSE;DISEASE;OPEN-ANGLE GLAUCOMA
ADALIMUMAB, ETANERCEPT, INFLIXIMAB, USTEKINUMAB;TNFRSF1B;rs1061622;GG + GT;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CNPY4;rs1554973;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES
BOTULINUM TOXIN TYPE A;CALCA;rs3781719;G;EFFICACY;DECREASED_RESPONSE;OTHER;MIGRAINE DISORDER
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CD14;rs2569190;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;ULCERATIVE COLITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs11938228;AA + AC;EFFICACY;DECREASED_RESPONSE;DISEASE;ULCERATIVE COLITIS, DISEASE:INFLAMMATORY BOWEL DISEASES
BOTULINUM TOXIN TYPE A;TRPV1;rs222749;A;EFFICACY;DECREASED_RESPONSE;OTHER;MIGRAINE DISORDER
OPIOIDS;ENPP2;rs7832704;AA;DOSAGE;INCREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1B;rs4848306;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;ULCERATIVE COLITIS, DISEASE:INFLAMMATORY BOWEL DISEASES
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1RN;rs4251961;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE;ULCERATIVE COLITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;rs6927172;CG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;ULCERATIVE COLITIS, DISEASE:INFLAMMATORY BOWEL DISEASES
HMG COA REDUCTASE INHIBITORS;APOE;rs429358;CC;EFFICACY;INCREASED_RESPONSE;OTHER;ALZHEIMER DISEASE
LOSARTAN;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
PEMETREXED;FOLR3;rs61734430;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA, DISEASE:MESOTHELIOMA
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs4803217;AC + CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
METOPROLOL;GRK4;rs1801058;CT;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERTENSIVE NEPHROSCLEROSIS
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HIV INFECTIOUS DISEASE
FLUOXETINE;HTR2A;rs7997012;GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;INFLAMMATION
DIRECT ACTING ANTIVIRALS, ELBASVIR / GRAZOPREVIR, LEDIPASVIR / SOFOSBUVIR;IFNL3, IFNL4;rs8099917;GG + GT;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION
METOPROLOL;GRK4;rs2960306;GT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERTENSIVE NEPHROSCLEROSIS
TACROLIMUS;ABCC2;rs3740066;CT + TT;LADME-PK;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;ABCC2;rs3740066;CT + TT;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
METHOTREXATE;ABCC2;rs717620;CT + TT;LADME-PK;INCREASED_CLEARANCE;DISEASE;LYMPHOMA
TACROLIMUS;ABCC2;rs717620;CT + TT;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
METOPROLOL;GRK4;rs1024323;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERTENSIVE NEPHROSCLEROSIS
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;INFLAMMATION
WARFARIN;CYP2C19;rs3814637;T;OTHER, LADME-PK;DECREASED_CLEARANCE;;
METHADONE;GAD1;rs3762556;G;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE
WARFARIN;CYP3A4;rs2242480;CT;OTHER, LADME-PK;INCREASED_CLEARANCE;;
INFLIXIMAB;IL1B;rs1143634;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;CROHN DISEASE
METHADONE;GAD1;rs769404;TT;DOSAGE;DECREASED_DOSE;OTHER;HEROIN DEPENDENCE
CLOZAPINE;CYP1A2;rs762551;AA + AC;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
ACENOCOUMAROL;VKORC1;rs9934438;GG;DOSAGE;INCREASED_DOSE;;
CAPECITABINE;DPYD;rs67376798;AT;DOSAGE;DECREASED_DOSE;DISEASE;COLORECTAL NEOPLASMS
CLOZAPINE;UGT1A4;rs2011404;C;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA, OTHER:PSYCHOTIC DISORDER
CAPECITABINE;DPYD;rs3918290;CT;DOSAGE;DECREASED_DOSE;DISEASE;COLORECTAL NEOPLASMS
URIC ACID;VEGFC;rs1002976;C;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HYPERTENSION
LETERMOVIR;SLCO1B1;rs4149032;TT;LADME-PK;DECREASED_EXPOSURE;;
CLOZAPINE;UGT1A1;rs34946978;T;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA, OTHER:PSYCHOTIC DISORDER
METFORMIN;CAPN10;rs3792269;G;EFFICACY;DECREASED_RESPONSE;DISEASE;DIABETES MELLITUS
LETERMOVIR;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_EXPOSURE;;
LETERMOVIR;UGT1A1;rs4148323;AA + AG;LADME-PK;INCREASED_EXPOSURE;;
INTERFERON BETA-1A, INTERFERON BETA-1B;FHIT;rs760316;C;EFFICACY;INCREASED_RESPONSE;DISEASE;MULTIPLE SCLEROSIS
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
GLYBURIDE;FMO2;rs7512785;T;EFFICACY;INCREASED_RESPONSE;;
METHOTREXATE;MTRR;rs1801394;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;JUVENILE RHEUMATOID ARTHRITIS
PROPRANOLOL;ADRB2;rs1042713;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;LIVER CIRRHOSIS
METHOTREXATE;ABCB1;rs1128503;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;JUVENILE RHEUMATOID ARTHRITIS
METHOTREXATE;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;JUVENILE RHEUMATOID ARTHRITIS
CLOZAPINE;ABCB1;rs10248420;G;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;SCHIZOPHRENIA, OTHER:PSYCHOTIC DISORDER
METHOTREXATE;SLC16A7;rs3763980;A;EFFICACY;DECREASED_RESPONSE;DISEASE;JUVENILE RHEUMATOID ARTHRITIS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3, IFNL4;rs12979860;C;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS B, CHRONIC
METHOTREXATE;SLC16A7;rs12231740;T;EFFICACY;DECREASED_RESPONSE;DISEASE;JUVENILE RHEUMATOID ARTHRITIS
METHOTREXATE;ARID5B;rs4948496;CC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
CLOZAPINE;UGT1A1;rs4148323;A;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA, OTHER:PSYCHOTIC DISORDER
FENOFIBRATE;APOE;rs7412;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA
METHOTREXATE;SLCO1B1;rs4149056;TT;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3, IFNL4;rs8099917;T;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS B, CHRONIC
METHADONE;GAD1;rs3762555;G;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;JUVENILE RHEUMATOID ARTHRITIS
METHADONE;GAD1;rs3749034;G;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE
CLOZAPINE;ABCB1;rs7787082;A;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;SCHIZOPHRENIA, OTHER:PSYCHOTIC DISORDER
IGURATIMOD;NAT2;rs1495741;AG + GG;EFFICACY;DECREASED_CLINICAL_BENEFIT;DISEASE;RHEUMATOID ARTHRITIS
INTERFERON BETA-1A, INTERFERON BETA-1B;;rs4278350;T;EFFICACY;INCREASED_RESPONSE;DISEASE;MULTIPLE SCLEROSIS
SITAGLIPTIN, VILDAGLIPTIN;KCNQ1;rs163184;GG + GT;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
IGURATIMOD;ABCG2;rs2231142;GT + TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;DISEASE;RHEUMATOID ARTHRITIS
INTERFERON BETA-1A, INTERFERON BETA-1B;GAPVD1;rs2291858;G;EFFICACY;INCREASED_RESPONSE;DISEASE;MULTIPLE SCLEROSIS
METHADONE;OPRD1;rs204047;GG;DOSAGE;INCREASED_DOSE;;
METHADONE;OPRD1;rs797397;AA;LADME-PK;INCREASED_CONCENTRATIONS;;
METHADONE;OPRD1;rs204047;GG;LADME-PK;INCREASED_CONCENTRATIONS;;
ANTIPSYCHOTICS;ZNF804A;rs1344706;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
PLATINUM COMPOUNDS;XRCC1;rs25487;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
INTERFERON BETA-1A, INTERFERON BETA-1B;GAPVD1;rs10819043;T;EFFICACY;INCREASED_RESPONSE;DISEASE;MULTIPLE SCLEROSIS
INTERFERON BETA-1A, INTERFERON BETA-1B;;rs3133084;A;EFFICACY;INCREASED_RESPONSE;DISEASE;MULTIPLE SCLEROSIS
CAPECITABINE, DOCETAXEL;CYP1A1;rs1048943;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
GLYBURIDE;CYP51A1;rs7793861;G;EFFICACY;INCREASED_RESPONSE;;
INTERFERON BETA-1A, INTERFERON BETA-1B;;rs1448673;G;EFFICACY;INCREASED_RESPONSE;DISEASE;MULTIPLE SCLEROSIS
GLYBURIDE;FMO2;rs7515157;T;EFFICACY;INCREASED_RESPONSE;;
ANASTROZOLE;ABCB1;rs2032582;AA;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
AMISULPRIDE, ANTIPSYCHOTICS, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR1A;rs10042486;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
URIC ACID;BRINP3;rs950569;T;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HYPERTENSION
GLYBURIDE;UGT2B15;rs4148269;G;EFFICACY;INCREASED_RESPONSE;;
INTERFERON BETA-1A, INTERFERON BETA-1B;GAPVD1;rs10760397;C;EFFICACY;INCREASED_RESPONSE;DISEASE;MULTIPLE SCLEROSIS
URIC ACID;PADI4;rs2477134;G;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HYPERTENSION
INTERFERON BETA-1A, INTERFERON BETA-1B;ZNF697;rs10494227;A;EFFICACY;INCREASED_RESPONSE;DISEASE;MULTIPLE SCLEROSIS
DOXORUBICIN;ABCC5;rs1533682;TT;LADME-PK;INCREASED_CLEARANCE;DISEASE;BREAST NEOPLASMS
PLATINUM COMPOUNDS;XRCC3;rs861539;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
GLYBURIDE;MAPK1;rs1803545;A;EFFICACY;INCREASED_RESPONSE;;
GLYBURIDE;ABCC5;rs3749442;A;EFFICACY;INCREASED_RESPONSE;;
GLYBURIDE;SPINK5;rs2303070;T;EFFICACY;INCREASED_RESPONSE;;
GLYBURIDE;BDKRB2;rs5224;A;EFFICACY;INCREASED_RESPONSE;;
GLYBURIDE;MAPK1;rs3729910;G;EFFICACY;INCREASED_RESPONSE;;
IGURATIMOD;ABCB1;rs2032582;CT + TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;DISEASE;RHEUMATOID ARTHRITIS
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE;;
ETHANOL;KLB;rs11940694;A;TOXICITY;DECREASED_DOSE;;
PLATINUM COMPOUNDS;XRCC1;rs1799782;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
GLYBURIDE;ESR1;rs2077647;T;EFFICACY;INCREASED_RESPONSE;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;G;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS, OTHER:AUTOIMMUNE DISEASES, OTHER:PSORIASIS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
ANTIDEPRESSANTS;BDNF;rs6265;C;EFFICACY;INCREASED_RESISTANCE;;
FLUNISOLIDE;TBXT;rs2305089;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
GRANISETRON, PALONOSETRON;ERCC1;rs3212986;AC + CC;EFFICACY;INCREASED_RESPONSE;SIDE EFFECT;NAUSEA, SIDE EFFECT:VOMITING
TACROLIMUS;IL6;rs1800795;GG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;KIDNEY TRANSPLANTATION
VALPROIC ACID;CYP2D6;rs3892097;CT + TT;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;EPILEPSY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs1061622;T;EFFICACY;INCREASED_RESPONSE;OTHER;PSORIASIS
TACROLIMUS;IL6;rs1800795;GG;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;C;EFFICACY;INCREASED_RESPONSE;OTHER;PSORIASIS
TACROLIMUS;CYP3A4;rs4646437;GG;LADME-PK;INCREASED_EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION
RASAGILINE;DRD2;rs1076560;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;PARKINSON DISEASE
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A4;rs2242480;CC;LADME-PK;INCREASED_EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION
RASAGILINE;DRD2;rs2283265;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;PARKINSON DISEASE
TACROLIMUS;CYP3A4;rs4646437;GG;LADME-PK;INCREASED_EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CTLA4;rs4553808;AG + GG;LADME-PK;INCREASED_EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION
ANTIDEPRESSANTS;BDNF-AS;rs10501087;T;EFFICACY;INCREASED_RESISTANCE;;
TACROLIMUS;IL3;rs181781;AA;LADME-PK;INCREASED_EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;DISEASE;LIVER TRANSPLANTATION
LAMOTRIGINE;UGT1A4;rs6755571;CC;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;EPILEPSY
WARFARIN;CYP2C9;rs4917639;C;DOSAGE;DECREASED_DOSE;;
TELAPREVIR;CYP24A1;rs2585428;C;LADME-PK;DECREASED_TROUGH CONCENTRATION;DISEASE;HEPATITIS C VIRUS INFECTION
TACROLIMUS;CTLA4;rs4553808;AA;LADME-PK;INCREASED_EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A4;rs2242480;CC;LADME-PK;INCREASED_EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION
VARENICLINE;CHRNA4;rs1044396;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;TOBACCO USE DISORDER
ESCITALOPRAM;CYP1A2;rs4646425;T;LADME-PK;INCREASED_METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER
ESCITALOPRAM;CYP1A2;rs2069526;G;LADME-PK;INCREASED_METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER
ESCITALOPRAM;CYP1A2;rs4646427;C;LADME-PK;INCREASED_METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER
PLATINUM COMPOUNDS;HSPA5;rs430397;TT;EFFICACY;INCREASED_RESISTANCE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;rs1801274;A;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;rs396991;C;EFFICACY;INCREASED_RESPONSE;OTHER;SPONDYLARTHROPATHIES
EFAVIRENZ;CYP2B6;rs2279343;GG;LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
MORPHINE;ABCB1;rs1045642;AA;LADME-PK;INCREASED_METABOLISM;;
CLOPIDOGREL;P2RY12;rs6785930;AA + AG;EFFICACY;INCREASED_RESISTANCE;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
CLOPIDOGREL;P2RY12;rs6809699;AA + AC;EFFICACY;INCREASED_RESISTANCE;;
EFAVIRENZ;CYP2B6;rs2279343;AG;LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs361525;G;EFFICACY;INCREASED_RESPONSE;OTHER;PSORIASIS
FLUTICASONE PROPIONATE;ORMDL3;rs2872507;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
RITUXIMAB;FCGR3A;rs396991;AC + CC;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
ABATACEPT, RITUXIMAB, TOCILIZUMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;rs1801274;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
VALPROIC ACID;CYP2C9;rs1057910;AC;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;EPILEPSY
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME-PK;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;CALU;rs339097;G;DOSAGE;INCREASED_DOSE;;
ATAZANAVIR / RITONAVIR;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
DEFERASIROX;ABCG2;rs13120400;CT + TT;LADME-PK;INCREASED_EXPOSURE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
ATAZANAVIR / RITONAVIR;CYP3A5;rs776746;CC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
WARFARIN;CYP2C9;rs10509680;T;DOSAGE;DECREASED_DOSE;;
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GOLIMUMAB, INFLIXIMAB;VDR;rs7975232;AA + AC;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
ANTIEPILEPTICS;NR3C1;rs41423247;GG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;EPILEPSY
TACROLIMUS;CYP3A5;rs776746;CT;EFFICACY, LADME-PK;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
DEFERASIROX;ABCC2;rs2273697;AG;LADME-PK;INCREASED_EXPOSURE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;OTHER;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;LIVER TRANSPLANTATION
FLUVASTATIN;APOE;rs7412;CT;EFFICACY;INCREASED_RESPONSE;;
METFORMIN;SLC47A1;rs2289669;A;EFFICACY;DECREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
LAMOTRIGINE;UGT2B7;rs7439366;TT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;EPILEPSY
TACROLIMUS;CYP3A4;rs2740574;CC + CT;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
RITODRINE;PDE4B;rs598961;AA;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;PREMATURE BIRTH
TACROLIMUS;CYP3A4;rs4986910;G;DOSAGE, LADME-PK;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
ACENOCOUMAROL, WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;;
LAMOTRIGINE;UGT2B15;rs1902023;AA;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;EPILEPSY
PLATINUM COMPOUNDS;XPA;rs1800975;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;ABCB1;rs2032582;CC;LADME-PK;INCREASED_CONCENTRATIONS;;
ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;ABCB1;rs1045642;GG;LADME-PK;INCREASED_CONCENTRATIONS;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;ABCB1;rs1128503;GG;LADME-PK;INCREASED_CONCENTRATIONS;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;IL10;rs1800871;AA;LADME-PK;DECREASED_METABOLISM;OTHER;KIDNEY TRANSPLANTATION
ANTIHYPERTENSIVES, HYDRALAZINE, METHYLDOPA, NIFEDIPINE;MMP9;rs3918242;CT;EFFICACY;DECREASED_RESPONSE;DISEASE;GESTATIONAL HYPERTENSION
WARFARIN;CYP2C9;rs1799853;T;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DOSE;;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;DOSE;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;OTHER;RHEUMATIC HEART DISEASE, OTHER:ATRIAL FIBRILLATION, OTHER:HEART VALVE DISEASES, OTHER:CORONARY ARTERY DISEASE
DACLATASVIR;VDR;rs11568820;TT;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;HEPATITIS C VIRUS INFECTION
MORPHINE;COMT;rs4680;AG + GG;EFFICACY;INCREASED_DOSE;;
CLOMIPRAMINE;CYP2D6;rs1080985;CG;EFFICACY;DECREASED_RESPONSE;DISEASE;DEPRESSION
METHYLDOPA;MMP9;rs3918242;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;GESTATIONAL HYPERTENSION
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DOSE;;
DACLATASVIR;CYP24A1;rs2248359;CT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HEPATITIS C VIRUS INFECTION
WARFARIN;VKORC1;rs9923231;A;DOSAGE;DOSE;;
TACROLIMUS;ABCB1;rs1045642;AG + GG;LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
CARBAMAZEPINE, OXCARBAZEPINE;SCN1A;rs3812718;TT;EFFICACY;RESISTANCE;DISEASE;EPILEPSY
METOPROLOL;ADRB1;rs1801252;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;ESSENTIAL HYPERTENSION
METOPROLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;ESSENTIAL HYPERTENSION
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs139304906;C;EFFICACY;INCREASED_CLINICAL_BENEFIT;;
CALCIUM CHANNEL BLOCKERS;NUMA1;rs10898815;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
CARBAMAZEPINE, OXCARBAZEPINE;SCN1A;rs3812718;TT;EFFICACY;RESISTANCE;DISEASE;EPILEPSY
CALCIUM CHANNEL BLOCKERS;TANC2;rs2429427;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
SIBUTRAMINE;GNB3;rs5443;CC;EFFICACY;INCREASED_RESPONSE;OTHER;OBESITY
CARBAMAZEPINE, OXCARBAZEPINE;ABCC2;rs2273697;AG;EFFICACY;RESISTANCE;DISEASE;EPILEPSY
METHOTREXATE;ABCC2;rs765027508;AG;LADME-PK;INCREASED_EXPOSURE;OTHER;LYMPHOMA, B-CELL
BUSULFAN;GSTA1;rs3957356;T;LADME-PK;DECREASED_CLEARANCE;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION
S-EDDP;CYP2B6;rs8192709;CT;LADME-PK;INCREASED_CONCENTRATIONS;;
BUSULFAN;GSTA1;rs3957357;A;LADME-PK;DECREASED_CLEARANCE;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION
SIMVASTATIN;UGT1A9;rs12052787;T;EFFICACY;INCREASED_RESPONSE;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY, LADME-PK;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
SIMVASTATIN;UGT1A9;rs2003569;A;EFFICACY;INCREASED_RESPONSE;;
PLATINUM COMPOUNDS;ERCC4;rs1799801;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
PLATINUM COMPOUNDS;ERCC1;rs11615;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY, LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;rs3892097;TT;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;DEPRESSION
PLATINUM COMPOUNDS;ERCC3;rs3738948;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
TEGAFUR;CYP2A6;rs8192720;AA + AG;LADME-PK;INCREASED_METABOLISM;;
ANTIPSYCHOTICS, CHLORPROMAZINE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE;MTHFR;rs1801133;AG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;SCHIZOPHRENIA
OXYCODONE;UGT2B7;rs7439366;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;NEOPLASMS, DISEASE:PAIN
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;;
BUPROPION;CYP2B6;rs3745274;T;LADME-PK;INCREASED_EXPOSURE;OTHER;MAJOR DEPRESSIVE DISORDER
RISPERIDONE;HRH4;rs4483927;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
ATENOLOL;GRK4;rs2960306;T;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERTENSION
ATENOLOL;GRK4;rs1024323;T;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERTENSION
CALCIUM CHANNEL BLOCKERS;PICALM;rs588076;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
DELEOBUVIR, FALDAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
WARFARIN;CYP2C9;rs9332131;del;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;PULMONARY EMBOLISM
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;rs28371686;G;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;PULMONARY EMBOLISM
PROPOFOL;GABRA2;rs11503014;CC;OTHER;DECREASED_RESPONSE;;
WARFARIN;HNF4A;rs3212198;T;DOSAGE;INCREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
CODEINE, TRAMADOL;CYP1B1;rs1056836;C;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;PAIN
ERLOTINIB, GEFITINIB;EGFR;rs121434568;G;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
WARFARIN;NR1I3;rs2501873;TT;DOSAGE;INCREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
VERAPAMIL;PCDHB8;rs3733694;G;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;MIGRAINE DISORDER
RIVAROXABAN;POR;rs1057868;TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION
VERAPAMIL;PCDHB6;rs17844444;A;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;MIGRAINE DISORDER
WARFARIN;VKORC1;rs72547529;T;DOSAGE;INCREASED_DOSE;;
WARFARIN;VKORC1;rs72547529;T;DOSAGE;INCREASED_DOSE;;
WARFARIN;VKORC1;rs72547529;T;DOSAGE;INCREASED_DOSE;;
CAPECITABINE, CETUXIMAB, OXALIPLATIN;KRAS;rs61764370;AC;EFFICACY;INCREASED_RESPONSE;DISEASE;RECTAL NEOPLASMS
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
SIMVASTATIN ACID;SLCO1B1;rs4149056;CT;LADME-PK;INCREASED_EXPOSURE;;
LOSARTAN;AGTR1;rs5186;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;LIVER CIRRHOSIS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
HEROIN;OPRM1;rs9479757;AG;DOSAGE;INCREASED_DOSE;DISEASE;HEROIN DEPENDENCE
5-HYDROXYINDOLE-3-ACETIC ACID, SEROTONIN;MAOB;rs1799836;T;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;MAJOR DEPRESSIVE DISORDER
ANTIDEPRESSANTS;GRIK4;rs1954787;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
RIVAROXABAN;ABCB1;rs4148738;CT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION
5-HYDROXYINDOLE-3-ACETIC ACID, SEROTONIN;MAOB;rs1799836;TT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;MAJOR DEPRESSIVE DISORDER
APIXABAN;POR;rs1057868;T;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION
OXCARBAZEPINE;UGT1A9;rs2741049;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;SEIZURES
CODEINE, TRAMADOL;CYP1B1;rs1056837;A;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;PAIN
CANDESARTAN;CYP11B2;rs1799998;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
3-HYDROXYCOTININE;;rs4105144;CC + CT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;TOBACCO USE DISORDER
HYDROCODONE, OXYCODONE;CYP2D6;rs35742686;DELT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;PAIN
3-HYDROXYCOTININE;EGLN2;rs3733829;AA + AG;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;TOBACCO USE DISORDER
HYDROCODONE, OXYCODONE;MACROD2;rs76026520;G;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;PAIN
MERCAPTOPURINE;NUDT15;rs116855232;CT;DOSAGE;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
BENAZEPRIL;MTHFR;rs1801133;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
DEFERASIROX;CYP1A1;rs2606345;AC + CC;LADME-PK;INCREASED_TROUGH CONCENTRATION;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
PITRAKINRA;IL4R;rs1029489;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;DISEASE;LIVER TRANSPLANTATION
CIPROFLOXACIN;CYP1A2;rs762551;AA + AC;;INCREASED_CLEARANCE;OTHER;INFECTIOUS DISEASE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_DOSE;DISEASE;LIVER TRANSPLANTATION
RADIOTHERAPY;CACNA2D3;rs11130424;AG + GG;EFFICACY;INCREASED_RESISTANCE;OTHER;NASOPHARYNGEAL NEOPLASMS
HYDROXYUREA;MAP3K5;rs9483947;CC;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;BETA-THALASSEMIA AND RELATED DISEASES
ANTIHYPERTENSIVES;CLNK;rs13144136;G;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
HYDROXYUREA;MAP3K5;rs9376230;CC;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;BETA-THALASSEMIA AND RELATED DISEASES
IMATINIB;ABCB1;rs1128503;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
IMATINIB;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
ATORVASTATIN;ABCC2;rs717620;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
LENALIDOMIDE, THALIDOMIDE;FGF2;rs308395;CG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;MULTIPLE MYELOMA
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
METHOTREXATE;ABCC2;rs717620;CT + TT;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
ANTIDEPRESSANTS;MAOA;rs979605;AA;LADME-PK;DECREASED_CLINICAL_BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER
METHOTREXATE;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
ANTIDEPRESSANTS;GRIK4;rs1954787;C;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
ETHANOL;ALDH2;rs671;AG;OTHER;INCREASED_EXPOSURE;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
HYDROCHLOROTHIAZIDE;NEDD4L;rs292449;CC + CG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
PITRAKINRA;IL4R;rs8832;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
TACROLIMUS;CYP3A5;rs776746;T;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
PITRAKINRA;IL4R;rs3024530;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
PITRAKINRA;IL4R;rs1110470;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
PITRAKINRA;IL4R;rs2239347;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
BENAZEPRIL;MTR;rs1805087;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;ESSENTIAL HYPERTENSION
PITRAKINRA;IL4R;rs1805010;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
VORICONAZOLE;ABCC2;rs717620;CT + TT;LADME-PK;INCREASED_TROUGH CONCENTRATION;;
ACENOCOUMAROL, PHENPROCOUMON;VKORC1;rs9934438;GG;DOSAGE, TOXICITY;INCREASED_DOSE;;
MYCOPHENOLATE MOFETIL;SLCO1B3;rs7311358;A;LADME-PK;DECREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
MORPHINE;ABCC3;rs4793665;CC;LADME-PK;INCREASED_METABOLISM;;
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8105790;C;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
ATORVASTATIN;SLCO1B1;rs4149056;CT;LADME-PK;INCREASED_EXPOSURE;;
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8103142;C;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
MEMANTINE;NR1I2;rs1523130;CT + TT;LADME-PK;DECREASED_CLEARANCE;DISEASE;DEMENTIA
BENAZEPRIL;ADRB2;rs1042713;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ESSENTIAL HYPERTENSION
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs11881222;G;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs7248668;A;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
AMISULPRIDE;ANKS1B;rs7968606;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs28416813;C;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs4803219;C;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
MORPHINE;OPRM1;rs1799971;AG;DOSAGE;INCREASED_DOSE;DISEASE;NEOPLASMS
ESCITALOPRAM;;rs2069521;A;LADME-PK;INCREASED_METABOLISM;DISEASE;MAJOR DEPRESSIVE DISORDER
IMATINIB;CYP3A5;rs776746;CC;LADME-PK;INCREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
ROSUVASTATIN;SCARB1;rs4238001;CC;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;MYOCARDIAL ISCHEMIA
IMATINIB;ABCB1;rs1045642;AA;LADME-PK;INCREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
IMATINIB;CYP3A5;rs776746;CC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
LACOSAMIDE;ABCC2;rs2273697;GG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;EPILEPSY
IMATINIB;ABCB1;rs1045642;AA;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE;DYSLIPIDAEMIA
OLANZAPINE;SV2C;rs11960832;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
CORTICOSTEROIDS;TBX21;rs2240017;CG;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
METHOTREXATE;ABCC1;rs2238476;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
ANTIDEPRESSANTS;HTR2A;rs6314;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP2D6;rs1065852;A;EFFICACY;INCREASED_RESPONSE;DISEASE;EPILEPSY
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP2C9;rs9332120;C;EFFICACY;INCREASED_RESPONSE;DISEASE;EPILEPSY
TACROLIMUS;CYP3A5;rs776746;C;LADME-PK;DECREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP2D6;rs3892097;C;EFFICACY;INCREASED_RESPONSE;DISEASE;EPILEPSY
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP3A4;rs2740574;C;EFFICACY;INCREASED_RESPONSE;DISEASE;EPILEPSY
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;DISEASE;LIVER TRANSPLANTATION
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP3A4;rs2687116;C;EFFICACY;INCREASED_RESPONSE;DISEASE;EPILEPSY
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;LIVER TRANSPLANTATION
DULOXETINE;ANO2;rs61908411;C;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;ANO2;rs61908409;C;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;ANO2;rs61908410;T;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;ANO2;rs78615940;A;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;ANO2;rs78482393;G;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;ANO2;rs61908405;C;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;ANO2;rs61908406;G;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ARG1;rs2781659;A;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;ACUTE CORONARY SYNDROME
DULOXETINE;ANO2;rs61908404;C;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;ANO2;rs61908408;A;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;ANO2;rs61908407;A;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;ANO2;rs17786412;G;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
DULOXETINE;ANO2;rs17786400;A;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
METHADONE;ABCB1;rs9282564;C;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS
DULOXETINE;ANO2;rs61908403;G;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;ANO2;rs61908402;T;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;ANO2;rs17724452;C;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
GLATIRAMER ACETATE;PVT1;rs2114358;A;EFFICACY;INCREASED_RESPONSE;DISEASE;MULTIPLE SCLEROSIS
DULOXETINE;;rs7316769;G;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;ANO2;rs17724494;C;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
WARFARIN;CYP2C9;rs56165452;CT;DOSAGE;DECREASED_DOSE;;
METHADONE;ABCB1;rs1045642;A;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS
DULOXETINE;ANO2;rs17786394;T;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DULOXETINE;ANO2;rs17724464;G;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
METHADONE;UGT2B7;rs7439366;CT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS
TENOFOVIR;ABCC4;rs1751034;TT;LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;;
PEMETREXED, PLATINUM COMPOUNDS;CCND1;rs9344;A;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;LUNG NEOPLASMS
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DECREASED_DOSE;;
METOPROLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEART FAILURE
WARFARIN;VKORC1;rs7294;T;DOSAGE;INCREASED_DOSE;;
LIRAGLUTIDE;GLP1R;rs10305420;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;OBESITY, DISEASE:POLYCYSTIC OVARY SYNDROME
LAMOTRIGINE;CACNA1H;rs2753325;A;EFFICACY;INCREASED_CLINICAL_BENEFIT;EFFICACY;EPILEPSY
AZATHIOPRINE;TPMT;TPMT low activity;;LADME-PK;DECREASED_DOSE;;
FLUOROURACIL;DPYD;rs3918290;CT;LADME-PK;DECREASED_METABOLISM;DISEASE;NEOPLASMS
FLUOROURACIL;DPYD;rs2297595;CC + CT;LADME-PK;DECREASED_METABOLISM;DISEASE;NEOPLASMS
ASPIRIN;GP1BA;rs6065;CT + TT;EFFICACY;INCREASED_RESPONSE;;
FLUOROURACIL;DPYD;rs1801160;CT + TT;LADME-PK;DECREASED_METABOLISM;DISEASE;NEOPLASMS
FLUOROURACIL;DPYD;rs1801265;GG;LADME-PK;DECREASED_METABOLISM;DISEASE;NEOPLASMS
LACOSAMIDE;ABCC2;rs717620;CC;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;EPILEPSY
ANASTROZOLE;;rs11648166;G;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;;
LACOSAMIDE;ABCC2;rs2273697;A;EFFICACY;INCREASED_RESISTANCE;OTHER;EPILEPSY
LACOSAMIDE;ABCC2;rs717620;T;EFFICACY;INCREASED_RESISTANCE;OTHER;EPILEPSY
ANASTROZOLE;;rs28845026;T;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT
CYCLOPHOSPHAMIDE;CYP2B6;rs4802101;C;LADME-PK;DECREASED_METABOLISM;DISEASE;LUPUS ERYTHEMATOSUS
APIXABAN;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;DISEASE;ATRIAL FIBRILLATION
METHOTREXATE;ARID5B;rs10994982;A;LADME-PK;DECREASED_CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
OXYCODONE;OPRM1;rs1799971;AG + GG;EFFICACY;DECREASED_RESPONSE;OTHER;PAIN, POSTOPERATIVE
CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;A;LADME-PK;DECREASED_METABOLISM;DISEASE;LUPUS ERYTHEMATOSUS
IMATINIB;ABCB1;rs1045642;AG + GG;LADME-PK;INCREASED_TROUGH CONCENTRATION;OTHER;GASTROINTESTINAL STROMAL TUMORS
FENOFIBRATE;PPARA;rs4253778;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS
METHOTREXATE;SLC22A11;rs11231809;AT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
METHOTREXATE;ABCC1;rs246240;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
HMG COA REDUCTASE INHIBITORS;HMGCR;rs3846662;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;FAMILIAL HYPERCHOLESTEROLEMIA
METHOTREXATE;ABCC1;rs3784864;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;LUPUS NEPHRITIS
4-HYDROXYCYCLOPHOSPHAMIDE;CYP3A5;rs776746;CC + CT;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;LUPUS NEPHRITIS
CYCLOPHOSPHAMIDE;CYP2B6;rs7254579;C;LADME-PK;METABOLISM;DISEASE;LUPUS ERYTHEMATOSUS
HMG COA REDUCTASE INHIBITORS;;rs445925;A;EFFICACY;INCREASED_RESPONSE;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;G;EFFICACY;DECREASED_RESPONSE;;
FENOFIBRATE;IL6;rs1800795;CC + CG;EFFICACY;INCREASED_RESPONSE;OTHER;PATIENTS WITH A HIGH RISK OF CARDIOVASCULAR DISEASE
RANIBIZUMAB;NRP1;rs2070296;T;EFFICACY;DECREASED_RESPONSE;DISEASE;MACULAR DEGENERATION
ATORVASTATIN;CETP;rs708272;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;MICB;rs3828913;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
METHOTREXATE;ABCG2;rs13120400;CC;EFFICACY;INCREASED_RESPONSE;SIDE EFFECT;PSORIASIS
NICOTINE;DBH;rs77905;GG;DOSAGE;DECREASED_DOSE;DISEASE;TOBACCO USE DISORDER
WARFARIN;VKORC1;rs9923231;CC + CT;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT
NICOTINE;MAOA;rs1137070;TT;DOSAGE;INCREASED_DOSE;DISEASE;TOBACCO USE DISORDER
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;DOSAGE;DECREASED_DOSE;;
OMEPRAZOLE, PANTOPRAZOLE;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;HELICOBACTER INFECTIONS
DEFERASIROX;CYP24A1;rs2248359;TT;LADME-PK;METABOLISM;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
DEFERASIROX;VDR;rs7975232;AA;LADME-PK;METABOLISM;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
FLUVOXAMINE, MILNACIPRAN, PAROXETINE;HTR1A;rs1364043;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DEFERASIROX;VDR;rs2228570;G;LADME-PK;METABOLISM;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
ANTIPSYCHOTICS;GRM3;rs6465084;AA;TOXICITY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
METFORMIN;SLC47A1;rs2289669;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
WARFARIN;CYP4F2;rs2108622;CC + CT;DOSAGE;DECREASED_DOSE;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
METFORMIN;SLC47A1;rs2289669;AA;LADME-PK;DECREASED_CLEARANCE;DISEASE;DIABETES MELLITUS, TYPE 2
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
BETA BLOCKING AGENTS;GRK5;rs2230345;AA + AT;EFFICACY;RESPONSE;DISEASE;HEART FAILURE
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
EFAVIRENZ;NR1I3;rs2307424;G;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
EFAVIRENZ;NR1I3;rs2307424;AG;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
ANTIHYPERTENSIVES;ATP2B1;rs12817819;CT + TT;EFFICACY;INCREASED_RESISTANCE;DISEASE;CORONARY ARTERY DISEASE, DISEASE:HYPERTENSION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
WARFARIN;EPHX1;rs1051741;CT;DOSAGE;DECREASED_DOSE;;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8103142;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs11881222;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;;
ISONIAZID;NAT2;rs1799930;AA;LADME-PK;INCREASED_EXPOSURE;DISEASE;HIV INFECTIOUS DISEASE, DISEASE:TUBERCULOSIS
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;;
MERCAPTOPURINE;NUDT15;rs73189762;T;DOSAGE;DECREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
WARFARIN;PRSS53, VKORC1;rs7294;CT;DOSAGE;INCREASED_DOSE;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
ISONIAZID;NR1I2;rs2472677;TT;LADME-PK;INCREASED_EXPOSURE;DISEASE;HIV INFECTIOUS DISEASE, DISEASE:TUBERCULOSIS
AMLODIPINE, FELODIPINE;CACNA1C;rs2238032;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
ISONIAZID;SLCO1B1;rs4149032;CC;LADME-PK;DECREASED_EXPOSURE;DISEASE;HIV INFECTIOUS DISEASE, DISEASE:TUBERCULOSIS
CALCIUM CHANNEL BLOCKERS;CACNA1C;rs2239128;C;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
MORPHINE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_DOSE;;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs2900478;A;EFFICACY;DECREASED_RESPONSE;;
CALCIUM CHANNEL BLOCKERS;CACNA1C;rs2239050;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
HMG COA REDUCTASE INHIBITORS;CELSR2;rs646776;C;EFFICACY;INCREASED_RESPONSE;;
VALPROIC ACID;UGT2B7;rs12233719;GG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;EPILEPSY
EFAVIRENZ;CYP2A6;rs28399454;T;LADME-PK;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
EFAVIRENZ;CYP2B6;rs28399499;C;LADME-PK;METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
CALCIUM CHANNEL BLOCKERS;CACNA1C;rs2238032;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;DISEASE;VENOUS THROMBOEMBOLISM
PHENPROCOUMON, WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;;
EFAVIRENZ;CYP2B6;rs2279343;GG;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
ATAZANAVIR;ABCB1;rs1045642;GG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;rs7900194;A;DOSAGE;DECREASED_DOSE;;
EFAVIRENZ;CYP2B6;rs2279343;AG;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
VALPROIC ACID;UGT2B7;rs7668258;CT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;EPILEPSY
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;rs28371686;G;DOSAGE;DECREASED_DOSE;;
WARFARIN;APOC1, APOE;rs429358;T;DOSAGE;DECREASED_DOSE;OTHER;HAPLOTYPE EPSILON2
VALPROIC ACID;UGT2B7;rs7668258;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;EPILEPSY
WARFARIN;APOC1, APOE;rs7412;T;DOSAGE;DECREASED_DOSE;OTHER;HAPLOTYPE EPSILON2
INFLIXIMAB;;rs2097432;CC + CT;EFFICACY;INCREASED_DISCONTINUATION;EFFICACY;CROHN DISEASE
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;;
PHOTODYNAMIC THERAPY;CFH;rs1061170;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;MACULAR DEGENERATION
VALPROIC ACID;UGT2B7;rs7439366;TT;LADME-PK;CONCENTRATIONS;DISEASE;EPILEPSY
RISPERIDONE;ABCG2;rs2231142;GT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;;
FLUOXETINE;HTR1B;rs9361233;CC + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
EFAVIRENZ;CYP2B6;rs8192709;CC;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
INFLIXIMAB;;rs73277969;T;EFFICACY;INCREASED_DISCONTINUATION;EFFICACY;CROHN DISEASE
IVACAFTOR;CFTR;rs121908757;C;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
IVACAFTOR;CFTR;rs121909005;G;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
ASPIRIN, CLOPIDOGREL;CYP2C19;rs12248560;T;;INCREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
IVACAFTOR;CFTR;rs121908755;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
ASPIRIN, PRASUGREL;PEAR1;rs2768759;AC + CC;EFFICACY;DECREASED_RESPONSE;;
CYCLOSPORINE;ABCB1;rs2032582;AC + CC;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
ASPIRIN, CLOPIDOGREL, PRASUGREL;PEAR1;rs12041331;AA + AG;EFFICACY;INCREASED_RESPONSE;;
CYCLOSPORINE;CYP3A4;rs4646437;AG + GG;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
HYDRALAZINE / ISOSORBIDE DINITRATE;GNB3;rs5443;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HEART FAILURE
IVACAFTOR;CFTR;rs397508453;C;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
WARFARIN;VKORC1;rs72547529;T;EFFICACY;DECREASED_RESPONSE;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;INCREASED_CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION
IVACAFTOR;CFTR;rs121909013;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
IVACAFTOR;CFTR;rs121909041;C;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
TACROLIMUS;CYP3A4;rs2242480;T;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
IVACAFTOR;CFTR;rs74503330;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
NEVIRAPINE;CYP1A2;rs762551;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HIV INFECTIOUS DISEASE
FENTANYL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;PAIN
ANASTROZOLE, LETROZOLE, TAMOXIFEN;CYP19A1;rs4646;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;BREAST NEOPLASMS, DISEASE:MENOPAUSE
IVACAFTOR;CFTR;rs267606723;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
SEROTONIN;ERICH3;rs696692;T;OTHER;DECREASED_CONCENTRATIONS;DISEASE;DEPRESSIVE DISORDER
IVACAFTOR;CFTR;rs80282562;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
TACROLIMUS;ABCB1;rs1045642;AG + GG;DOSAGE;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
CYCLOSPORINE;CYP3A4;rs4646437;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;KIDNEY TRANSPLANTATION
ANASTROZOLE, LETROZOLE, TAMOXIFEN;CYP19A1;rs4646;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
PLATINUM COMPOUNDS;ERCC2;rs1799793;CT + TT;EFFICACY;INCREASED_RESISTANCE;OTHER;NON-SMALL CELL LUNG CARCINOMA
SEROTONIN;TSPAN5;rs11947402;G;OTHER;DECREASED_CONCENTRATIONS;DISEASE;DEPRESSIVE DISORDER
NEVIRAPINE;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TRAF1;rs3761847;G;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
THALIDOMIDE;CTNNB1;rs4533622;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;MULTIPLE MYELOMA
WARFARIN;VKORC1;rs9934438;AG;DOSAGE;INCREASED_DOSE;DISEASE;ATRIAL FIBRILLATION, DISEASE:CARDIOMYOPATHIES, DISEASE:HEART VALVE REPLACEMENT, DISEASE:PERIPHERAL VASCULAR DISEASES, DISEASE:PULMONARY EMBOLISM, DISEASE:VENOUS THROMBOSIS
FENTANYL;OPRM1;rs1799971;AG + GG;DOSAGE;DECREASED_DOSE;DISEASE;PAIN
IVACAFTOR;CFTR;rs193922525;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
CYCLOPHOSPHAMIDE, DEXAMETHASONE, THALIDOMIDE;CTNNB1;rs4135385;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;MULTIPLE MYELOMA
OPIOIDS;IL17A;rs2275913;A;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
PLATINUM COMPOUNDS;CYP1A1;rs1048943;CC + CT;EFFICACY;INCREASED_RESISTANCE;OTHER;NON-SMALL CELL LUNG CARCINOMA
WARFARIN;CYP4F2;rs2108622;C;DOSAGE;DECREASED_DOSE;DISEASE;VENOUS THROMBOEMBOLISM
TACROLIMUS;ABCB1;rs2032582;AC + CC;DOSAGE;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;DISEASE;VENOUS THROMBOEMBOLISM
ANTIDEPRESSANTS, CITALOPRAM, ESCITALOPRAM;ERICH3;rs11580409;C;EFFICACY;INCREASED_RESPONSE;DISEASE;DEPRESSIVE DISORDER
ETHANOL;OPRM1;rs1799971;AG + GG;OTHER;DECREASED_DOSE;;
CYCLOSPORINE;ABCB1;rs2032582;AC + CC;DOSAGE;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A7;rs10211;TT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;
WARFARIN;VKORC1;rs9923231;C;DOSAGE, EFFICACY;INCREASED_DOSE;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE, EFFICACY;INCREASED_RESPONSE;;
TACROLIMUS;ABCB1;rs1045642;GG;LADME-PK;INCREASED_DOSE;OTHER;LIVER TRANSPLANTATION
ACETAMINOPHEN, TRAMADOL;OPRM1;rs1799971;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;NEUROPATHIC PAIN
RITUXIMAB;FCGR2A;rs1801274;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
METHADONE;CYP2B6;rs3745274;T;LADME-PK;DECREASED_CLEARANCE;DISEASE;OPIOID-RELATED DISORDERS
COTININE;UGT2B10;rs2942857;CC;LADME-PK;DECREASED_CLEARANCE;DISEASE;TOBACCO USE DISORDER
FENTANYL;;rs6961071;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;PAIN, POSTOPERATIVE
RITUXIMAB;FCGR3A;rs396991;AC + CC;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
WARFARIN;VKORC1;rs2359612;G;DOSAGE;INCREASED_DOSE;;
CYCLOPHOSPHAMIDE, DOXORUBICIN, FEC100, FLUOROURACIL;ALDH1A1;rs13959;AG + GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;BREAST NEOPLASMS
TACROLIMUS;POR;rs1057868;CC;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
COUMARIN;CYP2A6;rs1801272;TT;OTHER, LADME-PK;DECREASED_METABOLISM;;
COUMARIN;CYP2A6;rs1801272;TT;LADME-PK;DECREASED_METABOLISM;;
METHADONE;ABCB1;rs2032582;CC;LADME-PK;DECREASED_CLEARANCE;DISEASE;OPIOID-RELATED DISORDERS
NICOTINE;CYP2A6;rs5031016;G;LADME-PK;DECREASED_METABOLISM;;
TOCILIZUMAB;FCGR3A;rs396991;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
CARVEDILOL;ADRB2;rs1042714;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HEART FAILURE
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
FENTANYL;;rs13093031;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;PAIN, POSTOPERATIVE
ATORVASTATIN, LOVASTATIN, SIMVASTATIN;CYP3A5;rs776746;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;ARTERIOSCLEROSIS
COTININE;UGT2B10;rs2942857;CC;LADME-PK;INCREASED_EXPOSURE;DISEASE;TOBACCO USE DISORDER
CLOPIDOGREL;ABCB1;rs1045642;A;EFFICACY;INCREASED_RESPONSE;OTHER;ACUTE CORONARY SYNDROME
CISPLATIN;ERCC1;rs11615;A;EFFICACY;DECREASED_RESPONSE;OTHER;OVARIAN NEOPLASMS
WARFARIN;VKORC1;rs2884737;C;DOSAGE;DECREASED_DOSE;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
WARFARIN;PRSS53, VKORC1;rs7294;TT;DOSAGE;INCREASED_DOSE;;
WARFARIN;VKORC1;rs8050894;G;DOSAGE;DECREASED_DOSE;;
PHENOBARBITAL;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESISTANCE;DISEASE;EPILEPSY
TACROLIMUS;FMO3;rs1800822;CC;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
FENOFIBRATE;CRP;rs1417938;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;METABOLIC SYNDROME
PRAVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE;DYSLIPIDAEMIA
IVACAFTOR;CFTR;rs397508442;T;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
FLUOXETINE;HTR1B;rs9361235;CC + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
N-DESMETHYLCLOZAPINE;UGT2B10;rs61750900;T;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
WARFARIN;NQO1;rs10517;GG;DOSAGE;DECREASED_DOSE;;
FENOFIBRATE;CRP;rs3091244;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;METABOLIC SYNDROME
PRAVASTATIN;MMP3;rs35068180;A/del + AA;EFFICACY;INCREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
N-DESMETHYLCLOZAPINE;UGT1A4;rs2011425;G;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
FENOFIBRATE;CRP;rs3091244;GG + GT;EFFICACY;INCREASED_RESPONSE;DISEASE;METABOLIC SYNDROME
FENTANYL;ABCB1;rs1128503;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;NEOPLASMS, DISEASE:PAIN
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;DISEASE;CARDIOVASCULAR DISEASE
CLOZAPINE;CYP2C18;rs1126545;T;LADME-PK;DECREASED_METABOLISM;OTHER;SCHIZOPHRENIA
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;;
SIMVASTATIN;SLCO1B1;rs4149056;C;EFFICACY;DECREASED_RESPONSE;;
DESLORATADINE, MIZOLASTINE;FCER1A;rs2298805;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;URTICARIA
ATORVASTATIN;CYP3A5;rs17161788;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;G;EFFICACY;DECREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;SELE;rs3917412;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;COLONIC NEOPLASMS
ATORVASTATIN;CYP3A5;rs776746;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
OPIOIDS;;rs2952768;CC;EFFICACY;DECREASED_RESPONSE;OTHER;PAIN, POSTOPERATIVE
HMG COA REDUCTASE INHIBITORS;PCSK9;rs11591147;T;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
IMATINIB;CYP3A4;rs28371759;AG;EFFICACY;INCREASED_RESPONSE;OTHER;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
DIGOXIN;ABCB1;rs2032582;CC;LADME-PK;INCREASED_CLEARANCE;DISEASE;HEART FAILURE
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;COLONIC NEOPLASMS
PLATINUM;ERCC5;rs17655;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR, IVACAFTOR / TEZACAFTOR;CFTR;rs75389940;AG + GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CYSTIC FIBROSIS
CARVEDILOL;UGT2B7;rs12233719;T;LADME-PK;DECREASED_CLEARANCE;DISEASE;HEART DISEASES
BUPROPION, NICOTINE, VARENICLINE;CHRNA5;rs2036527;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER
BUPROPION, NICOTINE, VARENICLINE;CHRNA5;rs16969968;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER
CARVEDILOL;UGT2B7;rs28365063;G;LADME-PK;DECREASED_CLEARANCE;DISEASE;HEART DISEASES
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
TACROLIMUS;FMO3;rs909530;CC;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
DIGOXIN;ABCB1;rs2032582;AA + AT;LADME-PK;DECREASED_CLEARANCE;DISEASE;HEART FAILURE
LUMACAFTOR;CFTR;rs121909047;AA;EFFICACY;RESPONSE;;
METHADONE;CDH2;rs8094439;AA;EFFICACY;INCREASED_RESPONSE;;
PERTUSSIS VACCINES;TLR4;rs4986790;AA;EFFICACY;INCREASED_RESPONSE;;
TACROLIMUS;POR;rs1057868;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;;
METHADONE;CDH2;rs17446819;CC;EFFICACY;INCREASED_RESPONSE;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;;
SORAFENIB;ABCG2;rs2231137;CT;LADME-PK;CONCENTRATIONS;DISEASE;HEPATOCELLULAR CARCINOMA
NICOTINE;CYP2A6;rs376817657;CT + TT;LADME-PK;DECREASED_METABOLISM;;
SORAFENIB;ABCG2;rs2231142;GT;LADME-PK;CONCENTRATIONS;DISEASE;HEPATOCELLULAR CARCINOMA
IVACAFTOR;CFTR;rs397508602;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
IMATINIB;SLC22A1;rs683369;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
FENOFIBRATE;GCKR;rs780094;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA
IVACAFTOR / LUMACAFTOR;CFTR;rs121909011;T;EFFICACY;RESPONSE;;
IMATINIB;ABCB1;rs1045642;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;;
FENTANYL;OPRM1;rs1799971;GG;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
IVACAFTOR / LUMACAFTOR;CFTR;rs74551128;A;EFFICACY;RESPONSE;;
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;;
BILIRUBIN;UGT1A1;rs887829;TT;LADME-PK;INCREASED_CONCENTRATIONS;;
WARFARIN;CYP2C9;rs1799853;CT;DOSAGE;DECREASED_DOSE;;
METHOTREXATE;GGH;rs3758149;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
MERCAPTOPURINE;NUDT15;rs186364861;A;DOSAGE;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
FENOFIBRATE;APOA5;rs662799;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA
IMIQUIMOD;TLR7;rs179008;A;EFFICACY;INCREASED_RESPONSE;DISEASE;BASAL CELL CARCINOMA
MERCAPTOPURINE;NUDT15;rs116855232;T;DOSAGE;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
METHOTREXATE;GGH;rs11545077;CC + CT;EFFICACY;INCREASED_RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
WARFARIN;VKORC1;rs9923231;T;DOSAGE, OTHER;DECREASED_DOSE;;
FENOFIBRATE;APOA5;rs3135506;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA
CLONIDINE;GNB3;rs5443;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;LIVER CIRRHOSIS
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
CLOZAPINE;UGT2B10;rs61750900;T;LADME-PK;DECREASED_METABOLISM;OTHER;SCHIZOPHRENIA
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
OPIOIDS;TAOK3;rs1277441;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;NEOPLASMS, OTHER:PAIN
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
OPIOIDS;TAOK3;rs795484;TT;DOSAGE;DECREASED_RESPONSE;OTHER;NEOPLASMS, OTHER:PAIN
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
FENTANYL;OPRM1;rs1799971;GG;DOSAGE;INCREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
WARFARIN;CYP2C9;rs1799853;T;LADME-PK;DECREASED_METABOLISM;;
IVACAFTOR;CFTR;rs121909005;G;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
OPIOIDS;TAOK3;rs795484;CT + TT;DOSAGE;INCREASED_DOSE;OTHER;NEOPLASMS, OTHER:PAIN
FENTANYL;ABCB1;rs1128503;AA;DOSAGE;INCREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
IVACAFTOR;CFTR;rs121908757;C;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
TENOFOVIR;ABCC4;rs3742106;AC + CC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
VITAMIN B12 AND FOLIC ACID;MTHFR;rs1801133;A;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;HYPERHOMOCYSTEINEMIA, OTHER:STROKE
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY, LADME-PK;INCREASED_EXPOSURE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
CAPTOPRIL;AGTR1;rs5186;AC + CC;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTP1;rs1695;A;EFFICACY;INCREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;;
DAUNORUBICIN;CBR1;rs25678;CC;LADME-PK;DECREASED_EXPOSURE;DISEASE;LEUKEMIA, MYELOID, ACUTE
IVACAFTOR;CFTR;rs78655421;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
MERCAPTOPURINE;TPMT;rs1142345;CC;DOSAGE;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
CITALOPRAM;CYP2C19;rs4244285;AG;EFFICACY;DECREASED_RESPONSE;OTHER;ALCOHOL ABUSE, OTHER:MAJOR DEPRESSIVE DISORDER
BILIRUBIN;SLCO1B1, SLCO1B3, SLCO1B7;rs1910167;C;LADME-PK;INCREASED_CONCENTRATIONS;;
CITALOPRAM;CYP2C19;rs4244285;AG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ALCOHOL ABUSE, OTHER:MAJOR DEPRESSIVE DISORDER
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
ATENOLOL;GNB3;rs5443;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;ESSENTIAL HYPERTENSION
ETANERCEPT;PSORS1C1;rs2233945;C;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
TACROLIMUS;POR;rs1057868;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
MERCAPTOPURINE;ABCC4;rs2274407;AA;DOSAGE;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE, DISEASE:TUBERCULOSIS
DISULFIRAM;TPH2;rs4290270;AA + AT;EFFICACY;INCREASED_RESPONSE;OTHER;COCAINE DEPENDENCE
ATENOLOL;GNB3;rs11064426;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;ESSENTIAL HYPERTENSION
ENALAPRIL;NR3C2;rs5522;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
ATENOLOL;GNB3;rs2301339;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ESSENTIAL HYPERTENSION
ATENOLOL;GNB3;rs5443;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;ESSENTIAL HYPERTENSION
MERCAPTOPURINE;NUDT15;rs116855232;TT;DOSAGE;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
ATENOLOL;GNB3;rs11064426;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;ESSENTIAL HYPERTENSION
ACENOCOUMAROL;CYP2C9;rs4086116;T;DOSAGE;DECREASED_DOSE;;
ATENOLOL;GNB3;rs11064426;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;ESSENTIAL HYPERTENSION
ETANERCEPT;STAT4;rs7574865;T;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
ATENOLOL;GNB3;rs2301339;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ESSENTIAL HYPERTENSION
METHOTREXATE;GGH;rs11545076;AC + CC;EFFICACY;INCREASED_RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
ALLOPURINOL;ABCG2;rs2231142;T;EFFICACY;DECREASED_RESPONSE;DISEASE;GOUT
PRAVASTATIN;SLCO1B1;rs4149015;AG;EFFICACY, LADME-PK;DECREASED_RESPONSE;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
IVACAFTOR, TEZACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
ATORVASTATIN, HMG COA REDUCTASE INHIBITORS, PRAVASTATIN, SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERLIPIDEMIAS
FENOFIBRATE;ABCA1;rs2230806;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA
SERTRALINE;HTR2A;rs6313;AA + AG;DOSAGE;INCREASED_DOSE;OTHER;DEPRESSION, OTHER:ANXIETY DISORDERS
FENOFIBRATE;ABCA1;rs2230808;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA
PLATINUM COMPOUNDS;NUP107;rs79419059;C;EFFICACY;INCREASED_RESISTANCE;DISEASE;OVARIAN NEOPLASMS
FENOFIBRATE;ABCA1;rs2230806;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA
VENLAFAXINE;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;ANXIETY DISORDERS
WARFARIN;NQO1;rs1800566;AA;DOSAGE;DECREASED_DOSE;;
KETOPROFEN;CYP2C9;rs1799853;CC;EFFICACY;INCREASED_RESPONSE;OTHER;PAIN, POSTOPERATIVE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION
ETANERCEPT;TNF;rs1800629;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
ANTIDEPRESSANTS;CHL1;rs1516338;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;BIPOLAR DISORDER, DISEASE:DEPRESSIVE DISORDER, DISEASE:MAJOR DEPRESSIVE DISORDER
ADALIMUMAB;TANK;rs1267067;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;rs15524;AA;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
ADALIMUMAB;VEGFA;rs25648;T;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
DACLATASVIR, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
CARVEDILOL;ADRB1;rs1801253;GG;DOSAGE;INCREASED_DOSE;DISEASE;HEART FAILURE
TACROLIMUS;CYP3A5;rs4646450;GG;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
INFLIXIMAB;TNF;rs361525;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
METHOTREXATE;SLCO1B1;rs11045879;CC + CT;LADME-PK;INCREASED_EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A4;rs4646437;GG;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
HYDROCHLOROTHIAZIDE;VASP;rs10995;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
ADALIMUMAB;TNFAIP3;rs2230926;T;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
METHOTREXATE;SLC19A1;rs2838958;AA + AG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
SIMVASTATIN, SIMVASTATIN ACID;SLCO1B1;rs4149056;C;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HYPERCHOLESTEROLEMIA
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;;
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;;
IVACAFTOR;CFTR;rs121908757;C;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
METHOTREXATE;SLC19A1;rs3788200;AG + GG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
LITHIUM;NR1D1, THRA;rs2314339;T;EFFICACY;DECREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE;;
NALTREXONE;OPRM1;rs1799971;AG;EFFICACY;INCREASED_RESPONSE;OTHER;AMPLIFICATION OF SEXUAL BEHAVIOR, OTHER:PARKINSON DISEASE
TACROLIMUS;CYP3A5;rs776746;CT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;DISEASE;VENOUS THROMBOEMBOLISM
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
ATENOLOL;GNB3;rs2301339;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ESSENTIAL HYPERTENSION
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;ERCC2;rs13181;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;STOMACH NEOPLASMS
ACENOCOUMAROL;APOE;rs429358;C;DOSAGE;DECREASED_DOSE;DISEASE;VENOUS THROMBOEMBOLISM
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;;
WARFARIN;VKORC1;rs8050894;CG + GG;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE;DECREASED_DOSE;;
WARFARIN;VKORC1;rs2359612;AA + AG;DOSAGE;DECREASED_DOSE;;
ATAZANAVIR;SORCS2;rs73208473;A;LADME-PK;DECREASED_EXPOSURE;DISEASE;HIV INFECTIOUS DISEASE
ROSUVASTATIN;ABCG2;rs2231142;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;;
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;ERCC1;rs11615;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;STOMACH NEOPLASMS
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;STOMACH NEOPLASMS
METHADONE;CNR1;rs806368;CT + TT;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE
METHADONE;TPH2;rs1386493;GG;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE
MORPHINE;UGT2B7;rs7439366;CT + TT;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;NEOPLASMS, OTHER:PAIN
ATORVASTATIN, SIMVASTATIN;KIF6;rs20455;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
EFAVIRENZ;CYP2B6;rs35303484;GG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
METHADONE;CYP2B6;rs16974799;CT;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE
LAMIVUDINE, NEVIRAPINE;ABCB1;rs1045642;A;EFFICACY;RESPONSE;DISEASE;HIV INFECTIOUS DISEASE
METHADONE;OPRL1;rs2229205;CT;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE
ROSUVASTATIN;KIF6;rs20455;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
ADRENERGICS, INHALANTS;;rs34548976;T;EFFICACY;DECREASED_RESPONSE;DISEASE;ASTHMA
TOPIRAMATE;GRIK1;rs2832407;AA + AC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;ALCOHOL-RELATED DISORDERS
CISPLATIN, GEMCITABINE;CDA;rs2072671;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
TOPIRAMATE;GRIK1;rs2832407;AA + AC;EFFICACY;DECREASED_RESPONSE;DISEASE;ALCOHOL-RELATED DISORDERS
LAMIVUDINE, NEVIRAPINE, ZIDOVUDINE;ABCB1;rs2032582;A;EFFICACY;RESPONSE;DISEASE;HIV INFECTIOUS DISEASE
ATORVASTATIN;KIF6;rs20455;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
CISPLATIN, GEMCITABINE;ERCC1;rs11615;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
FLUVASTATIN;ABCB1;rs1922242;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
GLICLAZIDE;KCNQ1;rs2237897;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
WARFARIN;CYP4F11;rs1060467;G;DOSAGE;DECREASED_DOSE;;
CARBOPLATIN, TAXANES;VEGFA;rs9369421;CC + CT;EFFICACY;INCREASED_RESPONSE;;
TACROLIMUS;CYP3A4;rs35599367;AA + AG;LADME-PK;DECREASED_CLEARANCE;OTHER;KIDNEY TRANSPLANTATION
EFAVIRENZ;CYP2A6;rs28399433;AC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
FLUVASTATIN;CETP;rs4783961;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;OTHER;KIDNEY TRANSPLANTATION
TACROLIMUS;ABCB1;rs9282564;CC + CT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
METHOTREXATE;MTRR;rs1801394;AG + GG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
TENOFOVIR;IFNL3, IFNL4;rs12979860;C;LADME-PK;INCREASED_CLEARANCE;OTHER;HIV INFECTIOUS DISEASE
GLUCOCORTICOIDS;ABCB1;rs1128503;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;CROHN DISEASE
METFORMIN;SLC22A1;rs622342;A;EFFICACY;INCREASED_RESPONSE;EFFICACY;DIABETES MELLITUS
GLUCOCORTICOIDS;ABCB1;rs1045642;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;CROHN DISEASE
HYDROXYUREA;BCL11A;rs1427407;T;EFFICACY;INCREASED_RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
HYDROXYUREA;BCL11A;rs766432;C;EFFICACY;INCREASED_RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
WARFARIN;CYP2C9;rs2860905;A;DOSAGE;DECREASED_DOSE;;
FENTANYL;UGT2B7;rs7439366;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;PAIN, POSTOPERATIVE
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE, EFFICACY;DECREASED_DOSE;;
TIOTROPIUM;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
LUMEFANTRINE;ABCC2;rs8187710;AA;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;MALARIA
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs80034486;G;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CYSTIC FIBROSIS
ATORVASTATIN;APOE;rs7412;CT;EFFICACY;INCREASED_RESPONSE;;
METHADONE;ABCB1;rs1045642;AG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;;
CLOPIDOGREL;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESISTANCE;DISEASE;HYPERTENSION
MORPHINE;UGT2B7;rs7439366;CT + TT;EFFICACY;DECREASED_RESPONSE;OTHER;NEOPLASMS, OTHER:PAIN
VALPROIC ACID;UGT1A6;rs2070959;AG + GG;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;EPILEPSY
VALPROIC ACID;UGT1A6;rs1105879;AC + CC;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;EPILEPSY
CLOZAPINE;HTR2A;rs6314;AA + AG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;SCHIZOPHRENIA
FLUVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE;;
PRAVASTATIN;ACE;rs4341;CG + GG;EFFICACY;INCREASED_RESPONSE;;
PRAVASTATIN;LPL;rs328;GG;EFFICACY;INCREASED_RESPONSE;;
LOVASTATIN;CETP;rs708272;AG;EFFICACY;INCREASED_RESPONSE;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
FENTANYL;UGT2B7;rs10028494;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;PAIN, POSTOPERATIVE
METHOTREXATE;MTHFR;rs1801133;AA;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
NICOTINE;CHRNA3;rs1051730;A;LADME-PK;INCREASED_DOSE;;
FLUVASTATIN;LIPC;rs1800588;CC + CT;EFFICACY;INCREASED_RESPONSE;;
CLOZAPINE;CYP1A1;rs2472297;T;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
METHYLPHENIDATE;CES1;rs114119971;CG;DOSAGE;DECREASED_DOSE;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
SIMVASTATIN;LIPC;rs1800588;CT;EFFICACY;INCREASED_RESPONSE;;
CISPLATIN, FLUOROURACIL, OXALIPLATIN;VEGFA;rs25648;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;STOMACH NEOPLASMS
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;DISEASE;CARDIOVASCULAR DISEASE
ATORVASTATIN;ABCB1;rs2032582;CC;EFFICACY;INCREASED_RESPONSE;;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
ATORVASTATIN;SLCO1B1;rs4149036;AC + CC;EFFICACY;INCREASED_RESPONSE;;
ATORVASTATIN;CYP3A5;rs776746;CC + CT;EFFICACY;INCREASED_RESPONSE;;
PERTUSSIS VACCINES;TLR4;rs2770150;GG;EFFICACY;DECREASED_RESPONSE;;
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs6025211;CC + TT;EFFICACY;INCREASED_RESPONSE;OTHER;LIVER CANCER
TACROLIMUS;ABCB1;rs2032582;AA + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;NEPHROTIC SYNDROME
LOVASTATIN;SLCO1B1;rs2291073;GT + TT;EFFICACY;INCREASED_RESPONSE;;
SUFENTANIL;CYP3A4;rs2242480;CT + TT;DOSAGE;DECREASED_DOSE;OTHER;PAIN
TACROLIMUS;ABCB1;rs1128503;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;NEPHROTIC SYNDROME
CATECHOLAMINES, METFORMIN;SLC22A3;rs8187725;T;OTHER, LADME-PK;DECREASED_METABOLISM;;
LOVASTATIN;LDLR;rs688;TT;EFFICACY;INCREASED_RESPONSE;;
AMLODIPINE;CACNA1C;rs2239050;GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;HYPERTENSION
FLUVASTATIN;CYP3A4;rs4986910;AG;EFFICACY;INCREASED_RESPONSE;;
NALTREXONE;ADH1C;rs698;C;EFFICACY;INCREASED_RESPONSE;OTHER;ALCOHOL ABUSE
NALTREXONE;ADH1B;rs2066702;A;EFFICACY;DECREASED_RESPONSE;OTHER;ALCOHOL ABUSE
LOVASTATIN;LDLR;rs5925;CC;EFFICACY;INCREASED_RESPONSE;;
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs9679162;TT;EFFICACY;INCREASED_RESPONSE;OTHER;LIVER CANCER
FLUOXETINE;HTR2A;rs6313;GG;EFFICACY;DECREASED_RESPONSE_TIME;OTHER;DEPRESSION, OTHER:ANXIETY DISORDERS
NALTREXONE;ALDH2;rs671;G;EFFICACY;INCREASED_RESPONSE;OTHER;ALCOHOL ABUSE
VARENICLINE;CYP2B6;rs8109525;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER
TACROLIMUS;ABCB1;rs1128503;AG;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;CYP2C9;rs7089580;T;DOSAGE;INCREASED_DOSE;;
CLOPIDOGREL;P2RY12;rs2046934;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;CORONARY DISEASE
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;
TACROLIMUS;ABCB1;rs1045642;AA;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;CYP2C19;rs3814637;C;DOSAGE;DOSE;;
TACROLIMUS;ABCB1;rs2032582;AA;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;CYP2C9;rs4917639;A;DOSAGE;DOSE;;
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DOSE;;
TACROLIMUS;CYP3A7;rs2257401;CG + GG;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;
CLOPIDOGREL;P2RY12;rs3732759;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;CORONARY DISEASE
ANTIBIOTICS, ESOMEPRAZOLE;ABCB1;rs1045642;AA;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;HELICOBACTER INFECTIONS
CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE;VEGFA;rs833061;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;MULTIPLE MYELOMA
DOLUTEGRAVIR;ABCG2;rs2231142;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
CLOPIDOGREL;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED_RESISTANCE;;
CISPLATIN, FLUOROURACIL;GALNT14;rs9679162;GG;EFFICACY;INCREASED_RESPONSE;OTHER;LIVER CANCER
CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE;KDR;rs2305948;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;MULTIPLE MYELOMA
CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE;KDR;rs1870377;AT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;MULTIPLE MYELOMA
MORPHINE;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;LIVER CANCER, OTHER:PAIN
SORAFENIB;GALNT14;rs9679162;GG;EFFICACY;INCREASED_RESPONSE;OTHER;HEPATITIS C VIRUS INFECTION, OTHER:LIVER CANCER
MYCOPHENOLIC ACID;ABCC2;rs2273697;A;LADME-PK;DECREASED_EXPOSURE;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;OTHER;LIVER TRANSPLANTATION
MYCOPHENOLIC ACID;ABCC2;rs717620;T;LADME-PK;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION
FENTANYL;ATF2;rs7583431;A;EFFICACY;INCREASED_RESPONSE;DISEASE;PAIN, POSTOPERATIVE
MYCOPHENOLIC ACID;ABCC2;rs717620;T;LADME-PK;EXPOSURE;OTHER;KIDNEY TRANSPLANTATION
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;NR1I2;rs3814055;CT + TT;DOSAGE;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
AFLIBERCEPT, RANIBIZUMAB;ANO2;rs2110166;TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;MACULAR DEGENERATION
TACROLIMUS;NR1I2;rs3814055;CT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
VENLAFAXINE;SLC6A2;rs2242446;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
MYCOPHENOLIC ACID;ABCC2;rs2273697;A;LADME-PK;DECREASED_EXPOSURE;OTHER;KIDNEY TRANSPLANTATION
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
BOCEPREVIR, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;C;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;CHRNA7;rs6494223;T;EFFICACY;INCREASED_RESPONSE;DISEASE;ALZHEIMER DISEASE
ADALIMUMAB;FCGR2A;rs1801274;A;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
FLUOROURACIL;ENOSF1;rs2612091;CC;EFFICACY;INCREASED_RESPONSE;OTHER;STOMACH NEOPLASMS
ALLOPURINOL;SLC22A12;rs505802;T;DOSAGE;INCREASED_DOSE;OTHER;GOUT
ALLOPURINOL;PDZK1;rs12129861;C;DOSAGE;INCREASED_DOSE;OTHER;GOUT
DACLATASVIR, SOFOSBUVIR;HINT1;rs7728773;CT + TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;DOSAGE;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;IL6;rs1800795;G;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
LITHIUM;;rs78015114;T;EFFICACY;INCREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
BUPRENORPHINE;OPRD1;rs678849;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;OPIOID-RELATED DISORDERS
CARBAMAZEPINE, PHENOBARBITAL, PHENYTOIN, VALPROIC ACID;SCN2A;rs17183814;A;EFFICACY;RESISTANCE;;
LITHIUM;;rs79663003;T;EFFICACY;INCREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
APREMILAST;CYP3A4, TMEM130;rs1203844;C;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;PSORIASIS
APREMILAST;CYP3A4;rs35599367;A;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;PSORIASIS
ATORVASTATIN;MYLIP;rs9370867;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
LITHIUM;;rs75222709;T;EFFICACY;INCREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
LITHIUM;;rs74795342;G;EFFICACY;INCREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
APREMILAST;PDE4D;rs295943;T;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;PSORIASIS
METHYLPHENIDATE;ADRA2A;rs1800544;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
SIMVASTATIN;SCAP;rs12487736;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY
CAFFEINE;CYP1A2;rs2069514;AA + AG;OTHER, LADME-PK;DECREASED_METABOLISM;;
APREMILAST;CDKN2B, CDKN2B-AS1;rs1063192;G;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;PSORIASIS
PRAVASTATIN;LIPC;rs1800588;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE;OTHER;TOTAL KNEE OR HIP ARTHROPLASTY
EFAVIRENZ;CYP2B6;rs28399499;CT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
(R)-METHADONE;NR1I3;rs2307424;GG;LADME-PK;INCREASED_CLEARANCE;OTHER;HIV INFECTIOUS DISEASE
OLANZAPINE;HTR2A;rs6314;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
(S)-METHADONE;CYP2B6;rs2279343;G;LADME-PK;DECREASED_CLEARANCE;OTHER;HIV INFECTIOUS DISEASE
SIMVASTATIN;ABCB1;rs1128503;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;CT;TOXICITY;INCREASED_DISCONTINUATION;DISEASE;INFLAMMATORY BOWEL DISEASES
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
(R)-METHADONE;NR1I3;rs3003596;GG;LADME-PK;INCREASED_CLEARANCE;OTHER;HIV INFECTIOUS DISEASE
BEVACIZUMAB;CFH;rs1061170;CT;DOSAGE;INCREASED_DOSE;DISEASE;MACULAR DEGENERATION
METHADONE;OPRD1;rs678849;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;OPIOID-RELATED DISORDERS
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;CT;DOSAGE;DECREASED_DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES
BEVACIZUMAB;ARMS2;rs10490924;GT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;MACULAR DEGENERATION
SIMVASTATIN;ABCB1;rs2032582;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
WARFARIN;NQO1;rs1800566;AA + AG;DOSAGE;INCREASED_DOSE;;
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_CONCENTRATIONS;;
DEFERASIROX;ABCC2;rs2273697;AG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
BUDESONIDE;;rs2392165;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER;ASTHMA
THIORIDAZINE;CYP2D6;rs1080985;CC + CG;LADME-PK;DECREASED_METABOLISM;;
DEFERASIROX;CYP1A2;rs2470890;CC + CT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;DOSAGE;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
DEFERASIROX;CYP1A2;rs762551;AC + CC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
OLANZAPINE;DRD2;rs1076560;AA + AC;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
DEFERASIROX;CYP1A1;rs2606345;AC + CC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
DEFERASIROX;UGT1A1;rs887829;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
CARBAMAZEPINE;ABCB1;rs1128503;A;LADME-PK;INCREASED_CLEARANCE;OTHER;EPILEPSY
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;FCGR2A;rs1801274;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
CAPECITABINE;MTHFR;rs1801133;GG;LADME-PK;INCREASED_EXPOSURE;DISEASE;NEOPLASMS
DACLATASVIR, SOFOSBUVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION
BUPRENORPHINE;;rs6973474;T;EFFICACY;INCREASED_RESPONSE;OTHER;OPIOID-RELATED DISORDERS
CARBAMAZEPINE;ABCB1;rs2032582;A;LADME-PK;INCREASED_CLEARANCE;OTHER;EPILEPSY
METHOTREXATE;SLC19A1;rs2838958;A;LADME-PK;DECREASED_CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
BUPRENORPHINE;;rs13169373;T;EFFICACY;INCREASED_RESPONSE;OTHER;OPIOID-RELATED DISORDERS
HALOPERIDOL;CYP2D6;rs3892097;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;ALCOHOLIC PSYCHOSIS, DISEASE:ALCOHOL ABUSE, DISEASE:ALCOHOL-RELATED DISORDERS
CARBAMAZEPINE;ABCB1;rs1045642;A;LADME-PK;INCREASED_CLEARANCE;OTHER;EPILEPSY
NEVIRAPINE;CYP2B6;rs28399499;C;LADME-PK;INCREASED_CONCENTRATIONS;;
IMATINIB;SLC22A1;rs628031;GG;LADME-PK;DECREASED_CLEARANCE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
NICOTINE;CHRNA5;rs16969968;A;DOSAGE;INCREASED_DOSE;DISEASE;TOBACCO USE DISORDER
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;LIVER TRANSPLANTATION
BUPRENORPHINE;;rs62368105;G;EFFICACY;INCREASED_RESPONSE;OTHER;OPIOID-RELATED DISORDERS
BUPRENORPHINE;;rs11782370;T;EFFICACY;INCREASED_RESPONSE;OTHER;OPIOID-RELATED DISORDERS
METHOTREXATE;ABCC4;rs7317112;G;LADME-PK;DECREASED_CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;FCGR3A;rs396991;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
METHOTREXATE;SLCO1B1;rs2306283;G;LADME-PK;INCREASED_CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
BUPRENORPHINE;;rs7205113;T;EFFICACY;INCREASED_RESPONSE;OTHER;OPIOID-RELATED DISORDERS
ETANERCEPT;IL10;rs1800896;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
BUPRENORPHINE;ADAMTSL2;rs756770;A;EFFICACY;INCREASED_RESPONSE;OTHER;OPIOID-RELATED DISORDERS
(R)-METHADONE;ABCB1;rs2032582;AA;LADME-PK;DECREASED_CLEARANCE;OTHER;HIV INFECTIOUS DISEASE
ETANERCEPT;TGFB1;rs1800471;CG;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
ATORVASTATIN;SLCO1B1;rs2306283;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
EFAVIRENZ, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS;CYP2B6;rs3745274;T;EFFICACY;INCREASED_RESPONSE;DISEASE;HIV INFECTIOUS DISEASE
EFAVIRENZ;CYP2B6;rs2279345;CC + CT;LADME-PK;INCREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
EFAVIRENZ;CYP2B6;rs3745274;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HIV INFECTIOUS DISEASE, DISEASE:TUBERCULOSIS
METHOTREXATE;SLCO1B1;rs4149056;TT;LADME-PK;INCREASED_EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
XK469;AOX1;rs10931910;G;LADME-PK;DECREASED_CLEARANCE;DISEASE;NEOPLASMS
SIMVASTATIN;PON1;rs662;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CORONARY DISEASE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE, DISEASE:TUBERCULOSIS
MERCAPTOPURINE;NUDT15;rs116855232;T;DOSAGE;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
ETANERCEPT;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
MERCAPTOPURINE;TPMT;rs1142345;CT;DOSAGE;DECREASED_DOSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
NEVIRAPINE;CYP2B6;rs3745274;T;LADME-PK;INCREASED_CONCENTRATIONS;;
BUCINDOLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEART FAILURE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
TACROLIMUS;CYP3A4;rs4986907;CT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
NEVIRAPINE;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
PHENPROCOUMON;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE;;
WARFARIN;CYP4F2;rs2189784;AG + GG;DOSAGE;INCREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
PHENPROCOUMON;EPHX1;rs1051740;CC;DOSAGE, LADME-PK;DECREASED_DOSE;;
ASPIRIN, DICLOFENAC, IBUPROFEN, INDOMETHACIN, KETOROLAC, NAPROXEN;TNF;rs1800629;A;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;MIGRAINE WITHOUT AURA
PHENPROCOUMON;PROC;rs1799808;CC;DOSAGE, LADME-PK;INCREASED_DOSE;;
LAMOTRIGINE;UGT2B7;rs7668258;CT + TT;LADME-PK;INCREASED_STEADY-STATE CONCENTRATION;DISEASE;EPILEPSY
INFLIXIMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
IMATINIB;SLC22A4;rs1050152;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;GASTROINTESTINAL STROMAL TUMORS
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
IMATINIB;SLC22A5;rs2631367;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;GASTROINTESTINAL STROMAL TUMORS
IMATINIB;SLC22A5;rs2631372;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;GASTROINTESTINAL STROMAL TUMORS
ETANERCEPT;TNF;rs1799724;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
WARFARIN;EPHX1;rs2260863;CG;DOSAGE;INCREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
WARFARIN;APOE;rs7412;CC;DOSAGE;DECREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
CYCLOPHOSPHAMIDE;CYP2B6;rs2279343;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-HODGKIN LYMPHOMA
WARFARIN;CYP3A4;rs28371759;AA;DOSAGE;DECREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;DECREASED_RESPONSE;;
WARFARIN;CYP1A2;rs2069514;GG;DOSAGE;DECREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
IMATINIB;ABCC4;rs9561765;AG;EFFICACY;INCREASED_RESPONSE;DISEASE;GASTROINTESTINAL STROMAL TUMORS
WARFARIN;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE;;
WARFARIN;SLC15A2;rs1143671;TT;DOSAGE;DECREASED_DOSE;;
LAMOTRIGINE;UGT1A4;rs2011425;GG + GT;LADME-PK;DECREASED_STEADY-STATE CONCENTRATION;DISEASE;EPILEPSY
WARFARIN;EPHX1;rs2260863;CC;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION
RITONAVIR;NR1I2;rs1523130;CC + CT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;;
L-TRYPTOPHAN;SLC22A2;rs316019;CC;LADME-PK;INCREASED_CLEARANCE;;
WARFARIN;VKORC1;rs9923231;AA;DOSAGE;INCREASED_DOSE;OTHER;ATRIAL FIBRILLATION
PHENPROCOUMON;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;;
RITONAVIR;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
RITONAVIR;ABCB1;rs2032582;AC + CC;LADME-PK;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
ERENUMAB;RAMP1;rs13386048;A;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;MIGRAINE WITH AURA, OTHER:MIGRAINE WITHOUT AURA
ADALIMUMAB, INFLIXIMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;OTHER;SPONDYLITIS, ANKYLOSING
SIROLIMUS;POR;rs1057868;CT + TT;LADME-PK;DECREASED_TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION
OLANZAPINE;BDNF;rs6265;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
RITONAVIR;NR1I2;rs6785049;AA + AG;LADME-PK;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
ERENUMAB;RAMP1;rs6431564;G;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;MIGRAINE WITH AURA, OTHER:MIGRAINE WITHOUT AURA
INFLIXIMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
LOSARTAN;SLC22A12;rs1529909;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERTENSION, DISEASE:HYPERURICEMIA
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;;
ERENUMAB;RAMP1;rs12465864;G;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;MIGRAINE WITH AURA, OTHER:MIGRAINE WITHOUT AURA
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
LOSARTAN;SLC22A12;rs3825016;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERTENSION, DISEASE:HYPERURICEMIA
ADALIMUMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
SIROLIMUS;IL10;rs1800896;CC;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
CYCLOSPORINE;ABCB1;rs9282564;CT;TOXICITY, LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HEART TRANSPLANTATION
CLADRIBINE, CYTARABINE;RRM1;rs1042919;AT;EFFICACY;DECREASED_RESPONSE;DISEASE;LEUKEMIA, MYELOID, ACUTE
CLADRIBINE, CYTARABINE;RRM2B;rs1265138;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;LEUKEMIA, MYELOID, ACUTE
FLUOROURACIL;DPYD;rs1801265;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_EXPOSURE;DISEASE;COLONIC NEOPLASMS
CLADRIBINE, CYTARABINE;RRM1;rs2898950;AC + CC;EFFICACY;INCREASED_RESPONSE;DISEASE;LEUKEMIA, MYELOID, ACUTE
INTERFERON ALFA-2A, RECOMBINANT, INTERFERON ALFA-2B, RECOMBINANT, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
BUPROPION;CYP2B6;rs2279343;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;TOBACCO USE DISORDER
INTERFERON ALFA-2A, RECOMBINANT, INTERFERON ALFA-2B, RECOMBINANT, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
CLADRIBINE, CYTARABINE;RRM1;rs1561876;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;LEUKEMIA, MYELOID, ACUTE
COTININE;PSMA4;rs57064725;A;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;TOBACCO USE DISORDER
METHOTREXATE;ATIC;rs16853826;GG;TOXICITY;INCREASED_DISCONTINUATION;DISEASE;RHEUMATOID ARTHRITIS
METHOTREXATE;ABCC1;rs35592;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
COTININE;CHRNA5;rs16969968;A;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;TOBACCO USE DISORDER
INFLIXIMAB;TNFRSF10A;rs20575;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
CLADRIBINE, CYTARABINE;RRM2;rs1130609;GT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;LEUKEMIA, MYELOID, ACUTE
INTERFERON ALFA-2A, RECOMBINANT, INTERFERON ALFA-2B, RECOMBINANT, RIBAVIRIN;FTO;rs9939609;AA + AT;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION, DISEASE:HIV INFECTIOUS DISEASE
VITAMIN K AND ANALOGUES;CYP4F2;rs2108622;T;LADME-PK;DECREASED_METABOLISM;;
COTININE;;rs77107237;G;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;TOBACCO USE DISORDER
CLOZAPINE;DTNBP1;rs742105;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
CLADRIBINE, CYTARABINE;RRM2;rs5030743;CG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;LEUKEMIA, MYELOID, ACUTE
COTININE;CHRNB4;rs10851907;A;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;TOBACCO USE DISORDER
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
SIROLIMUS;ABCB1;rs1045642;AA + AG;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;SLCO1B3;rs7311358;AA;DOSAGE;DECREASED_DOSE;;
WARFARIN;SLC15A2;rs1143672;AA;DOSAGE;DECREASED_DOSE;;
INTERFERON ALFA-2A, RECOMBINANT, INTERFERON ALFA-2B, RECOMBINANT, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
WARFARIN;SLCO1B3;rs4149117;GG;DOSAGE;DECREASED_DOSE;;
ETANERCEPT;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
COTININE;CHRNA3;rs7170068;A;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;TOBACCO USE DISORDER
SUNITINIB;ABCB1;rs1045642;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;RENAL CELL CARCINOMA
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE, EFFICACY;DECREASED_DOSE;;
INTERFERON ALFA-2A, RECOMBINANT, INTERFERON ALFA-2B, RECOMBINANT, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
FLUPENTHIXOL;NFKB1;rs230504;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
MONTELUKAST;SLCO2B1;rs12422149;AG;EFFICACY, LADME-PK;DECREASED_RESPONSE;DISEASE;ASTHMA
DEFERASIROX;CYP24A1;rs927650;CT + TT;LADME-PK;DECREASED_METABOLISM;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;;
DEFERASIROX;CYP24A1;rs2585428;CT + TT;LADME-PK;DECREASED_METABOLISM;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
FLUPENTHIXOL;NFKB1;rs3774959;AG;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
ANTIDEPRESSANTS;TPH2;rs10879346;C;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
METHOTREXATE POLYGLUTAMATE;IMPDH1;rs4731448;GG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
CARBOPLATIN, CISPLATIN;EIF3A;rs3740556;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
METHOTREXATE POLYGLUTAMATE;CEP72;rs924607;TT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
TACROLIMUS;IL10;rs1800896;TT;DOSAGE;DECREASED_DOSE;DISEASE;LIVER TRANSPLANTATION
MIRTAZAPINE, VENLAFAXINE;TPH2;rs1487278;C;EFFICACY;INCREASED_RESPONSE;DISEASE;DEPRESSION
TACROLIMUS;ABCB1;rs1045642;GG;DOSAGE;INCREASED_DOSE;DISEASE;LIVER TRANSPLANTATION
BILIRUBIN;UGT1A1;rs4124874;GG + GT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;NEOPLASMS
CARBOPLATIN, CISPLATIN;EIF3A;rs3740556;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;LUNG NEOPLASMS
DEFERASIROX;CYP24A1;rs2248359;CT + TT;LADME-PK;DECREASED_METABOLISM;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
FLUPENTHIXOL;NFKB1;rs230493;AT;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
METHOTREXATE POLYGLUTAMATE;SLCO1B3;rs7311358;AA + AG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
NICOTINE;FMO3;rs2266780;AA;LADME-PK;INCREASED_METABOLISM;;
PAZOPANIB;VEGFA;rs699947;A;EFFICACY;DECREASED_RESPONSE;DISEASE;RENAL CELL CARCINOMA
METHOTREXATE POLYGLUTAMATE;FSTL5;rs3749598;AA + AC;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
METHOTREXATE POLYGLUTAMATE;ATG16L1;rs2241880;AG + GG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
FLUOROURACIL;DPYD;rs3918290;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
TACROLIMUS;CYP3A5;rs776746;CT;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
THEOPHYLLINE;CYP1A2;rs2069514;AA + AG;OTHER, LADME-PK;DECREASED_METABOLISM;DISEASE;ASTHMA
INFLIXIMAB;TNFRSF10A;rs20575;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;ARTHRITIS, PSORIATIC
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNFRSF1A;rs767455;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;ARTHRITIS, PSORIATIC
PAZOPANIB;VEGFA;rs2010963;G;EFFICACY;DECREASED_RESPONSE;DISEASE;RENAL CELL CARCINOMA
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNFRSF10A;rs20575;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNFRSF1A;rs767455;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
PAZOPANIB;VEGFA;rs833061;T;EFFICACY;DECREASED_RESPONSE;DISEASE;RENAL CELL CARCINOMA
ETANERCEPT;PTTG1;rs2431697;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
CISPLATIN, GEMCITABINE;CMPK1;rs4492666;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
BUPROPION, NICOTINE, VARENICLINE;CHRNA5;rs503464;A;EFFICACY;INCREASED_RESPONSE;DISEASE;TOBACCO USE DISORDER
VORICONAZOLE;NR1I2;rs6785049;GG;LADME-PK;INCREASED_CONCENTRATIONS;;
ETANERCEPT;HLA-B;rs13437088;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
ETANERCEPT;MAP3K1;rs96844;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
CLOZAPINE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
CLOZAPINE;HTR1A;rs6295;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
ETANERCEPT;GBP6;rs928655;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
ATORVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;DECREASED_RESPONSE;;
ETANERCEPT;IL12B;rs2546890;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
TEMOZOLOMIDE;ABCB1;rs1128503;AA + AG;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;GLIOMA
IVACAFTOR;SLC26A9;rs7512462;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;CYSTIC FIBROSIS
GEMCITABINE;DCK;rs66878317;AG + GG;LADME-PK;INCREASED_CLEARANCE;;
VORICONAZOLE;NR1I2;rs3814057;CC;LADME-PK;INCREASED_CONCENTRATIONS;;
NICOTINE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;TOBACCO USE DISORDER
MILNACIPRAN;ADRA2A;rs1800544;CC + CG;EFFICACY;INCREASED_RESPONSE;DISEASE;DEPRESSIVE DISORDER
PLATINUM COMPOUNDS;IGF2, IGF2-AS, INS-IGF2;rs4244809;GG;EFFICACY;DECREASED_RESISTANCE;DISEASE;OVARIAN NEOPLASMS
VORICONAZOLE;FMO3;rs2266780;AA;LADME-PK;INCREASED_CONCENTRATIONS;;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs2306283;GG;EFFICACY;INCREASED_RESPONSE;;
FLUVOXAMINE;FGF2;rs1449683;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE;DEPRESSIVE DISORDER
VORICONAZOLE;POR;rs10954732;GG;LADME-PK;INCREASED_CONCENTRATIONS;;
PLATINUM COMPOUNDS;INS-IGF2;rs3842761;GG;EFFICACY;DECREASED_RESISTANCE;DISEASE;OVARIAN NEOPLASMS
MILNACIPRAN;HTR1A;rs6295;CC + CG;EFFICACY;INCREASED_RESPONSE;DISEASE;DEPRESSIVE DISORDER
VALPROIC ACID;SCN2A;rs17183814;AA + AG;EFFICACY;INCREASED_RESISTANCE;OTHER;EPILEPSY
VALPROIC ACID;SCN1A;rs2298771;TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;EPILEPSY
VORICONAZOLE;NR1I2;rs2461817;AA;LADME-PK;DECREASED_CONCENTRATIONS;;
VORICONAZOLE;NR1I2;rs3732359;GG;LADME-PK;INCREASED_CONCENTRATIONS;;
METHOTREXATE;ABCC2;rs3740066;TT;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;OSTEOSARCOMA
CISPLATIN, GEMCITABINE;RRM1;rs720106;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
VORICONAZOLE;NR1I2;rs7643645;AA;LADME-PK;INCREASED_CONCENTRATIONS;;
SIMVASTATIN;SLCO1B1;rs2306283;AA;EFFICACY;INCREASED_RESPONSE;;
CISPLATIN, GEMCITABINE;RRM1;rs232043;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
CISPLATIN, GEMCITABINE;CMPK1;rs11211524;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
SIMVASTATIN;SLCO1B1;rs2306283;GG;EFFICACY;INCREASED_RESPONSE;;
CISPLATIN, GEMCITABINE;RRM1;rs2284449;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
ACENOCOUMAROL;GGCX;rs11676382;G;DOSAGE;DECREASED_DOSE;;
ACENOCOUMAROL;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;;
ACENOCOUMAROL;VKORC1;rs7294;T;DOSAGE;INCREASED_DOSE;;
METHOTREXATE;NR1I2;rs6785049;G;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;OSTEOSARCOMA
RITUXIMAB;TGFB1;rs1800470;AG;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
RITUXIMAB;TGFB1;rs1800471;CG;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12980275;A;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;T;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
SIMVASTATIN;CYP3A4;rs35599367;A;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERCHOLESTEROLEMIA
PIOGLITAZONE;ADIPOQ;rs2241766;GT;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS
MORPHINE;OPRM1;rs1799971;GG;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
MORPHINE;OPRM1;rs1799971;GG;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
ACENOCOUMAROL;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
ROSUVASTATIN;CYP3A5;rs776746;C;EFFICACY;INCREASED_RESPONSE;DISEASE;MYOCARDIAL INFARCTION
METHOTREXATE;GSK3B;rs3732361;A;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;OSTEOSARCOMA
NALOXONE;OPRM1;rs1799971;AG + GG;OTHER;INCREASED_RESPONSE;;
TIPIFARNIB;ABCB1;rs1128503;AA;OTHER, LADME-PK;DECREASED_METABOLISM;;
ETANERCEPT;ZNF816;rs9304742;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
ROSUVASTATIN;ABCG2;rs2231142;T;EFFICACY;INCREASED_RESPONSE;DISEASE;MYOCARDIAL INFARCTION
EFAVIRENZ;CYP2B6;rs3745274;GG;DOSAGE;INCREASED_DOSE;DISEASE;HIV INFECTIOUS DISEASE
NALTREXONE;OPRM1;rs1799971;G;EFFICACY;INCREASED_RESPONSE;DISEASE;ALCOHOL ABUSE
ANTIPSYCHOTICS;NRG1;rs13250975;G;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;DISEASE;HEART DISEASES
METHOTREXATE;SLCO1A2;rs4149009;CC + CT;LADME-PK;DECREASED_CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
ANTIPSYCHOTICS;;rs2513265;A;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
ANTIPSYCHOTICS;ADCY2;rs1544938;C;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
ANTIPSYCHOTICS;NRG1;rs17716295;A;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
NICOTINE;CHRNA5;rs16969968;GG;OTHER;DECREASED_DOSE;DISEASE;TOBACCO USE DISORDER
METHADONE;DAO;rs55944529;TT;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE
ANTIPSYCHOTICS;CCL2;rs4795893;G;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
ANTIPSYCHOTICS;CCL2;rs4586;T;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
METHADONE;DAO;rs55944529;TT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HEROIN DEPENDENCE
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, SERTRALINE;HTR2A;rs3803189;GG + GT;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE, OTHER:MALARIA
IVACAFTOR;CFTR;rs121908755;A;EFFICACY;INCREASED_RESPONSE;;
METHADONE;DRD1;rs5326;TT;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE
IVACAFTOR;CFTR;rs121908757;C;EFFICACY;INCREASED_RESPONSE;;
IVACAFTOR;CFTR;rs80282562;A;EFFICACY;INCREASED_RESPONSE;;
RIFAMPIN;SLCO1B1;rs4149056;CT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;TUBERCULOSIS
METHYLPHENIDATE;CYP2D6;rs1065852;GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs11045819;CC;EFFICACY;DECREASED_RESPONSE;;
METHYLPHENIDATE;CYP2D6;rs1135840;CG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
IVACAFTOR;CFTR;rs121909041;C;EFFICACY;INCREASED_RESPONSE;;
PRAVASTATIN;SLCO1B1;rs2306283;GG;EFFICACY;DECREASED_RESPONSE;;
WARFARIN;CYP2C9;rs1057910;AA;DOSAGE;INCREASED_DOSE;;
IVACAFTOR;CFTR;rs193922525;A;EFFICACY;INCREASED_RESPONSE;;
WARFARIN;VKORC1;rs7196161;AA + AG;DOSAGE;INCREASED_DOSE;;
IVACAFTOR;CFTR;rs267606723;A;EFFICACY;INCREASED_RESPONSE;;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;;
IVACAFTOR;CFTR;rs74503330;A;EFFICACY;INCREASED_RESPONSE;;
IVACAFTOR;CFTR;rs121909005;G;EFFICACY;INCREASED_RESPONSE;;
IVACAFTOR;CFTR;rs121909013;A;EFFICACY;INCREASED_RESPONSE;;
SUNITINIB;GLP1R;rs6923761;A;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;RENAL CELL CARCINOMA, OTHER:GASTROINTESTINAL STROMAL TUMORS
DOXORUBICIN;ABCB1;rs1128503;AA;LADME-PK;DECREASED_METABOLISM;DISEASE;BREAST NEOPLASMS
ATOMOXETINE;CYP2D6;rs1135840;CC;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
BETA BLOCKING AGENTS;GRK5;rs3740563;A;EFFICACY;DECREASED_RESPONSE;OTHER;CORONARY ARTERY DISEASE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNG;rs2069705;G;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
MONTELUKAST;MLLT3;rs6475448;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
BETA BLOCKING AGENTS;GRK5;rs10787959;A;EFFICACY;DECREASED_RESPONSE;OTHER;CORONARY ARTERY DISEASE
BUPROPION;;rs1908557;C;EFFICACY;DECREASED_RESPONSE;DISEASE;DEPRESSION
BETA BLOCKING AGENTS;GRK5;rs11198893;A;EFFICACY;DECREASED_RESPONSE;OTHER;CORONARY ARTERY DISEASE
RIFAMPIN;CYP27B1;rs4646536;AG + GG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;TUBERCULOSIS
CORTICOSTEROIDS;ST13;rs138335;G;EFFICACY;DECREASED_RESPONSE;DISEASE;ASTHMA
RIFAMPIN;VDR;rs1544410;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;TUBERCULOSIS
DOCETAXEL;CYP3A4;rs2740574;C;LADME-PK;INCREASED_CLEARANCE;DISEASE;NEOPLASMS
BETA BLOCKING AGENTS;ADRB1;rs1801253;GG;EFFICACY;DECREASED_RESPONSE;OTHER;HEART FAILURE
METHADONE;CYP2B6;rs3745274;GG + GT;DOSAGE;INCREASED_DOSE;DISEASE;HEROIN DEPENDENCE
DOCETAXEL;CYP3A5;rs776746;T;LADME-PK;INCREASED_CLEARANCE;DISEASE;NEOPLASMS
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;C;EFFICACY;DECREASED_RESPONSE;DISEASE;CARDIOVASCULAR DISEASE
RAMIPRIL;ADRB2;rs2053044;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
OPIOIDS;COMT;rs4680;GG;DOSAGE;INCREASED_DOSE;OTHER;BREAST NEOPLASMS, OTHER:PAIN, POSTOPERATIVE
METHADONE;NGF;rs2239622;AA;DOSAGE;DECREASED_DOSE;DISEASE;OPIOID-RELATED DISORDERS
NICOTINE;CYP1A2;rs35694136;T/del + del/del;EFFICACY;INCREASED_EXPOSURE;OTHER;URINARY BLADDER NEOPLASMS
METHADONE;CYP2B6;rs2279343;AA + AG;DOSAGE;INCREASED_DOSE;DISEASE;HEROIN DEPENDENCE
GEMCITABINE;NT5C3A;rs3750117;AA;OTHER, LADME-PK;INCREASED_CLEARANCE;DISEASE;NEOPLASMS
GEMCITABINE;NT5C2;rs11598702;TT;OTHER, LADME-PK;DECREASED_CLEARANCE;DISEASE;NEOPLASMS
FENTANYL, REMIFENTANIL;PGAP6;rs199670311;T;EFFICACY;INCREASED_DOSE;DISEASE;PAIN
OLANZAPINE;UGT1A4;rs2011425;GT;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;SCHIZOPHRENIA
ANTIDEPRESSANTS;ADCY9;rs2230739;CC;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER
DABIGATRAN;CES1;rs2244613;GG + GT;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;STROKE
ANTIPSYCHOTICS;PI4KA;rs165854;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
ANTIPSYCHOTICS;GRM3;rs1468412;AA + AT;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
BUDESONIDE, CORTICOSTEROIDS, FLUTICASONE / SALMETEROL, FLUTICASONE PROPIONATE;ZNF432;rs3752120;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;ASTHMA
AZATHIOPRINE;ITPA;rs1127354;AA + AC;EFFICACY;INCREASED_RESPONSE;DISEASE;SYSTEMIC LUPUS ERYTHEMATOSUS
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;ERBB2;rs1136201;G;EFFICACY;DECREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
ANTIPSYCHOTICS;SLC1A3;rs1529461;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
ANTIPSYCHOTICS;GRM3;rs2299214;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;RNF8;rs2284922;A;EFFICACY;INCREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
ANTIPSYCHOTICS;GRM3;rs6465084;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;BARD1;rs2070096;A;EFFICACY;DECREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
GEMCITABINE;CDA;rs1048977;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;ERBB3;rs2229046;C;EFFICACY;DECREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
CORTICOSTEROIDS;ST13;rs138337;G;EFFICACY;DECREASED_RESPONSE;DISEASE;ASTHMA
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;ERBB3;rs773123;A;EFFICACY;DECREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
ANTIPSYCHOTICS;SLC1A4;rs10211524;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
RISPERIDONE;GRM3;rs2299214;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME-PK;INCREASED_CONCENTRATIONS;;
PRAVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;;
SUFENTANIL;COMT;rs4680;AA;DOSAGE, EFFICACY;DECREASED_DOSE;;
FLUINDIONE;VKORC1;rs9923231;TT;LADME-PK;DOSE;;
APREMILAST;LEPR, LEPROT;rs1045895;AA + AG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;PSORIASIS
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;;
OPIOIDS;ABCB1;rs1045642;AA;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;NEOPLASMS, DISEASE:PAIN
CARBOPLATIN, CISPLATIN;AKT1;rs2494752;AG;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
QUINAPRIL;AGT;rs699;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
OPIOIDS;KCNJ6;rs6517442;CC;DOSAGE;INCREASED_DOSE;OTHER;LOW BACK PAIN
OLANZAPINE;CYP1A2;rs35694136;T/del;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;SCHIZOPHRENIA
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE;NEOPLASMS, DISEASE:PAIN
OLANZAPINE;CYP1A2;rs762551;AA;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;SCHIZOPHRENIA
FENTANYL;OPRM1;rs1799971;GG;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
PHENPROCOUMON;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE;;
CAPECITABINE, FLUOROURACIL, TEGAFUR;TYMS;rs183205964;C;TOXICITY;INCREASED_DISCONTINUATION;DISEASE;NEOPLASMS
KETOPROFEN;CYP2C9;rs1057910;AC;EFFICACY;INCREASED_RESPONSE;OTHER;PAIN, POSTOPERATIVE
ATORVASTATIN;ABCB1;rs1045642;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;CORONARY ARTERY DISEASE
IMATINIB;SLC22A1;rs683369;CC;LADME-PK;INCREASED_CLEARANCE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
CAFFEINE;CYP1A2;rs762551;AA;OTHER, LADME-PK;INCREASED_METABOLISM;;
IMATINIB;SLC22A1;rs683369;CC;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
ETANERCEPT;TNFRSF1B;rs1061622;GT;EFFICACY;DECREASED_RESPONSE;DISEASE;SPONDYLITIS, ANKYLOSING
FENTANYL, REMIFENTANIL;SLC9A9;rs4839603;GG;EFFICACY;DECREASED_DOSE;DISEASE;PAIN
EFAVIRENZ;ABCB1;rs1045642;GG;EFFICACY, LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
EFAVIRENZ;CYP2B6;rs3745274;T;EFFICACY;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
EFAVIRENZ;ABCB1;rs1045642;AA;EFFICACY, LADME-PK;INCREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
APREMILAST;PDE4B;rs12745871;T;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;PSORIASIS
ATORVASTATIN;SCARB1;rs5888;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
APREMILAST;TSPAN16;rs322144;C;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;PSORIASIS
PRAVASTATIN;FCAR;rs11666735;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;MYOCARDIAL INFARCTION
CYCLOPHOSPHAMIDE, EPIRUBICIN;GSTP1;rs1695;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
FENOFIBRATE;APOA1;rs964184;G;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTRIGLYCERIDEMIA
ANTIEPILEPTICS;SCN1A;rs10188577;CT;EFFICACY;INCREASED_RESISTANCE;DISEASE;EPILEPSY
APREMILAST;DOCK6;rs12979813;G;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;PSORIASIS
DAPTOMYCIN;ABCB1;rs1045642;AA;LADME-PK;INCREASED_CONCENTRATIONS;;
DAPTOMYCIN;ABCB1;rs1045642;AA;LADME-PK;DECREASED_CLEARANCE;;
NALTREXONE;DBH;rs1611115;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;ALCOHOL ABUSE
GEMCITABINE;SLC28A2;rs11854484;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
ANTINEOPLASTIC AGENTS;ABCG2;rs2231142;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
GEMCITABINE;SLC28A2;rs1060896;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
APREMILAST;EIF3G, P2RY11, PPAN-P2RY11;rs2305795;G;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;PSORIASIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1A;rs767455;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;;
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;OSTEOSARCOMA
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL3;rs1139130;GG;EFFICACY;INCREASED_RESISTANCE;OTHER;TUBERCULOSIS
METHOTREXATE;SLCO1B1;rs11045879;CC + CT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;OSTEOSARCOMA
SUFENTANIL;OPRM1;rs1799971;AG;DOSAGE;INCREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
APREMILAST;ILF3;rs76966440;T;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;PSORIASIS
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;;
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;GSTP1;rs1695;A;EFFICACY;INCREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
SULFASALAZINE;ABCG2;rs2231142;GT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;T;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
WARFARIN;VKORC1;rs9923231;CC + CT;DOSAGE;INCREASED_DOSE;;
TACROLIMUS;ABCB1;rs1128503;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ULCERATIVE COLITIS
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE;;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
WARFARIN;PRSS53, VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;;
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;T;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;VDR;rs2228570;A;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
NORTRIPTYLINE;NOS3;rs1799983;TT;EFFICACY;INCREASED_RESPONSE;OTHER;MIGRAINE WITHOUT AURA, OTHER:MIGRAINE WITH AURA
ALLOPURINOL;GREM2;rs1934341;T;EFFICACY;INCREASED_RESPONSE;;
COTININE;NAT1;rs13253389;AG + GG;LADME-PK;INCREASED_CONCENTRATIONS;;
ALLOPURINOL;GREM2;rs77567654;G;EFFICACY;INCREASED_RESPONSE;;
TACROLIMUS;ABCB1;rs2032582;CC;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
ALLOPURINOL;ABCG2;rs45499402;C;EFFICACY;DECREASED_RESPONSE;;
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
ALLOPURINOL;ABCG2;rs2231142;T;EFFICACY;DECREASED_RESPONSE;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
EXENATIDE;GLP1R;rs10305420;T;EFFICACY;DECREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
TOPIRAMATE;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE;OTHER;MIGRAINE WITHOUT AURA, OTHER:MIGRAINE WITH AURA
LAMOTRIGINE;UGT2B7;rs7668258;TT;LADME-PK;DECREASED_CLEARANCE;DISEASE;EPILEPSY
WARFARIN;VKORC1;rs7294;TT;DOSAGE;INCREASED_DOSE;;
BENAZEPRIL;AGT;rs4762;GG;EFFICACY;RESPONSE;DISEASE;HYPERTENSION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION, DISEASE:HIV INFECTIOUS DISEASE
IMATINIB;ABCB1;rs1128503;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
LAMOTRIGINE;UGT2B7;rs28365063;GG;LADME-PK;INCREASED_CLEARANCE;DISEASE;EPILEPSY
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;;
METHOTREXATE;ABCC4;rs7317112;GG;LADME-PK;INCREASED_CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
BENAZEPRIL;AGTR1;rs2640543;GG;EFFICACY;RESPONSE;DISEASE;HYPERTENSION
ALENDRONATE;MVK;rs10161126;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;BONE DISEASES
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;A;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs80034486;G;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CYSTIC FIBROSIS
SARILUMAB;IL6R;rs11265618;CC;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;LDLR;rs14158;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION, DISEASE:HIV INFECTIOUS DISEASE
BENAZEPRIL;SPTA1;rs2106089;G;EFFICACY;RESPONSE;DISEASE;HYPERTENSION
IMATINIB;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
TACROLIMUS;CYP3A5;rs776746;TT;LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
SARILUMAB;IL6R;rs4329505;TT;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
IMATINIB;ABCB1;rs2032582;C;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
BUPRENORPHINE;OPRD1;rs678849;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;OPIOID-RELATED DISORDERS
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
PHENPROCOUMON;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;NCR3;rs1052248;AT + TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
SALBUTAMOL;COL2A1;rs3809324;GT + TT;LADME-PD;DECREASED_RESPONSE;OTHER;ASTHMA
ANTIPSYCHOTICS;CACNA1C;rs2238087;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
DIURETICS, HYDROCHLOROTHIAZIDE, THIAZIDES, PLAIN;PRKCA;rs4791040;T;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERTENSION
ANTIPSYCHOTICS;CACNA1B;rs2229949;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
ACENOCOUMAROL;STX4;rs10871454;T;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;;
WARFARIN;;rs12777823;AA + AG;DOSAGE;DECREASED_DOSE;;
CORTICOSTEROIDS;GLCCI1;rs37973;GG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;RHINITIS
DEFERASIROX;GC;rs7041;AA;EFFICACY;INCREASED_RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;;
ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
ASPIRIN, CLOPIDOGREL;CYP4F2;rs2108622;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE;ACUTE CORONARY SYNDROME
ACENOCOUMAROL;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;;
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;DISEASE;CARDIOVASCULAR DISEASE
WARFARIN;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;CARDIOVASCULAR DISEASE
INTERFERON BETA-1A, INTERFERON BETA-1B;CD58;rs12044852;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;MULTIPLE SCLEROSIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;rs610604;GG + GT;EFFICACY;INCREASED_RESPONSE;OTHER;ARTHRITIS, PSORIATIC, OTHER:PSORIASIS
MORPHINE;OPRM1;rs1799971;AG + GG;EFFICACY;DECREASED_RESPONSE;;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;DISEASE;CARDIOVASCULAR DISEASE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;rs6920220;AA;EFFICACY;DECREASED_RESPONSE;OTHER;ARTHRITIS, PSORIATIC, OTHER:PSORIASIS
WARFARIN;CYP4F2;rs2108622;CC + CT;DOSAGE;DECREASED_DOSE;DISEASE;CARDIOVASCULAR DISEASE
ANTIPSYCHOTICS;CACNB2;rs12245847;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
TACROLIMUS;CYP3A7;rs2257401;C;LADME-PK;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION, DISEASE:TRANSPLANTATION
DEFERASIROX;UGT1A1;rs887829;CC;EFFICACY;DECREASED_RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES
ANTIPSYCHOTICS;CACNG3;rs1859204;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
TACROLIMUS;CYP3A5;rs776746;C;LADME-PK;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION, DISEASE:TRANSPLANTATION
DEFERASIROX;UGT1A3;rs1983023;TT;EFFICACY;INCREASED_RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES
DEFERASIROX;CYP27B1;rs10877012;GG;EFFICACY;INCREASED_RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
TACROLIMUS;CYP3A4;rs4646437;A;LADME-PK;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION, DISEASE:TRANSPLANTATION
ADALIMUMAB;ATG16L1;rs10210302;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CROHN DISEASE
ANTIPSYCHOTICS;CACNB2;rs982003;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
TACROLIMUS;CYP3A4;rs2242480;T;LADME-PK;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION, DISEASE:TRANSPLANTATION
DEFERASIROX;VDR;rs731236;GG;EFFICACY;INCREASED_RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES
DEFERASIROX;VDR;rs1544410;TT;EFFICACY;INCREASED_RESPONSE;OTHER;BETA-THALASSEMIA AND RELATED DISEASES
TACROLIMUS;CYP3A5;rs41303343;A;LADME-PK;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION, DISEASE:TRANSPLANTATION
CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SLC19A1;rs1051266;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SLCO1B1;rs2306283;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
TACROLIMUS;CYP3A5;rs4646450;A;LADME-PK;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION, DISEASE:TRANSPLANTATION
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
SIMVASTATIN ACID;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_CONCENTRATIONS;;
DIURETICS, HYDROCHLOROTHIAZIDE, THIAZIDES, PLAIN;;rs2776546;A;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
WARFARIN;CYP2C9;rs28371686;CG;DOSAGE;DECREASED_DOSE;;
ANTIPSYCHOTICS;CACNB2;rs10741058;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
ATAZANAVIR;UGT1A1;rs887829;TT;TOXICITY;INCREASED_DISCONTINUATION;DISEASE;HIV INFECTIOUS DISEASE
DIURETICS, HYDROCHLOROTHIAZIDE, THIAZIDES, PLAIN;;rs238;A;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERTENSION
ANTIPSYCHOTICS;CACNA2D3;rs4505744;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
DIURETICS, HYDROCHLOROTHIAZIDE, THIAZIDES, PLAIN;;rs4815273;T;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
IBUPROFEN;CYP2C9;rs1057910;AC;EFFICACY;DECREASED_RESPONSE_TIME;OTHER;PATENT DUCTUS ARTERIOSUS
ANTIPSYCHOTICS;CACNA1E;rs12060765;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
CORTICOSTEROIDS;TAAR6;rs7772821;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
SALBUTAMOL;VEGFA;rs3025039;CT + TT;LADME-PD;DECREASED_RESPONSE;OTHER;ASTHMA
BEVACIZUMAB, RANIBIZUMAB;CFH;rs1061170;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;MACULAR DEGENERATION
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;;
MORPHINE;TAOK3;rs795484;TT;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
PREDNISONE;NR3C1;rs6196;G;EFFICACY;DECREASED_RESISTANCE;DISEASE;NEPHROTIC SYNDROME
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
SN-38;UGT1A1;rs4148323;AA;LADME-PK;DECREASED_METABOLISM;DISEASE;NON-SMALL CELL LUNG CARCINOMA
DOCETAXEL;;rs4842198;G;LADME-PK;INCREASED_METABOLISM;DISEASE;NASOPHARYNGEAL NEOPLASMS
FLUVOXAMINE;HTR2A;rs6311;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;rs3794271;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;DOSAGE, EFFICACY;DECREASED_DOSE;;
PREDNISONE;NR3C1;rs258751;A;EFFICACY;DECREASED_RESISTANCE;DISEASE;NEPHROTIC SYNDROME
LEDIPASVIR, SOFOSBUVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
SN-38;UGT1A9;rs3832043;del/del;LADME-PK;DECREASED_METABOLISM;DISEASE;NON-SMALL CELL LUNG CARCINOMA
PHENYTOIN;CYP2C9;rs28371686;G;OTHER, LADME-PK;DECREASED_METABOLISM;OTHER;NO DISEASE
IMATINIB;ABCG2;rs2231137;CT + TT;DOSAGE;DECREASED_DOSE;OTHER;GASTROINTESTINAL STROMAL TUMORS
PREDNISONE;NR3C1;rs10052957;A;EFFICACY;DECREASED_RESISTANCE;DISEASE;NEPHROTIC SYNDROME
IMATINIB;CYP1A2;rs762551;CC;DOSAGE;DECREASED_DOSE;OTHER;GASTROINTESTINAL STROMAL TUMORS
PHENYTOIN;CYP2C9;rs7900194;A;OTHER, LADME-PK;DECREASED_METABOLISM;OTHER;NO DISEASE
LURASIDONE;HTR1A;rs6295;CG + GG;EFFICACY;DECREASED_RESPONSE;OTHER;SCHIZOPHRENIA
PHENYTOIN;CYP2C9;rs28371685;T;OTHER, LADME-PK;INCREASED_METABOLISM;PK;NO DISEASE
PHENYTOIN;CYP2C9;rs9332131;del;OTHER, LADME-PK;DECREASED_METABOLISM;PK;NO DISEASE
DOCETAXEL;RXRA;rs3132291;A;LADME-PK;INCREASED_METABOLISM;DISEASE;NASOPHARYNGEAL NEOPLASMS
INFLIXIMAB;TNFRSF1B;rs1061622;G;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
CODEINE;OPRM1;rs1799971;AA;DOSAGE;DECREASED_DOSE;;
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
CODEINE;UGT2B7;rs7439366;TT;DOSAGE;DECREASED_DOSE;;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
ANTIPSYCHOTICS;CACNB2;rs4237348;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
TACROLIMUS;CYP3A4;rs2740574;T;LADME-PK;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION, DISEASE:TRANSPLANTATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
ANTIPSYCHOTICS;CACNB4;rs3768652;AA + AC;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
TACROLIMUS;CYP3A4;rs35599367;A;LADME-PK;TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION, DISEASE:TRANSPLANTATION
ANTIPSYCHOTICS;CACNA2D3;rs7427395;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
ANTIPSYCHOTICS;CACNB2;rs1277733;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
SOFOSBUVIR;CES1;rs4513095;A;EFFICACY;DECREASED_RESPONSE;OTHER;CHRONIC HEPATITIS C VIRUS INFECTION
TACROLIMUS;CYP3A5;rs776746;CT;LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
PROPOFOL;SCN9A;rs6746030;AA + AG;OTHER;INCREASED_RESPONSE;;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;DISEASE;TRANSPLANTATION
SALBUTAMOL;PRKG1;rs7081864;A;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;ASTHMA
TACROLIMUS;CYP3A5;rs776746;C;DOSAGE;DECREASED_DOSE;DISEASE;LIVER TRANSPLANTATION
TOCILIZUMAB;IL6R;rs12083537;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
ANTIPSYCHOTICS;BDNF;rs11030104;AG + GG;EFFICACY;INCREASED_RESISTANCE;DISEASE;SCHIZOPHRENIA
SUNITINIB;ABCB1;rs1045642;GG;LADME-PK;INCREASED_EXPOSURE;DISEASE;RENAL CELL CARCINOMA
PROPOFOL;HTR2A;rs6313;AA;DOSAGE;DECREASED_DOSE;;
ANTIPSYCHOTICS;BDNF-AS;rs10501087;CC + CT;EFFICACY;INCREASED_RESISTANCE;DISEASE;SCHIZOPHRENIA
PROPOFOL;GABRA1;rs2279020;GG;OTHER;INCREASED_RESPONSE;;
SUNITINIB;ABCB1;rs1045642;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;RENAL CELL CARCINOMA
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
OPIOIDS;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE;;
TACROLIMUS;CYP3A5;rs776746;CT;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
DOXORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;ABCB1;rs1045642;AA;EFFICACY;DECREASED_RESISTANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
ANTIPSYCHOTICS;BDNF;rs6265;CT + TT;EFFICACY;INCREASED_RESISTANCE;DISEASE;SCHIZOPHRENIA
OPIOIDS;COMT;rs4680;AG;DOSAGE;DECREASED_DOSE;;
METFORMIN, SULFONAMIDES, UREA DERIVATIVES;ABCC8, KCNJ11;rs5219;CT + TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
PALIPERIDONE, RISPERIDONE;NFIB;rs28379954;CT;LADME-PK;INCREASED_CONCENTRATIONS;;
REMIFENTANIL, SEVOFLURANE;ABCB1;rs1128503;GG;EFFICACY;INCREASED_RESPONSE;OTHER;TONSILLECTOMY
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
MORPHINE;TAOK3;rs1277441;GG;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
DOXORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;ABCB1;rs2229109;CT;EFFICACY;INCREASED_RESISTANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
HYDROXYUREA;KLF4;rs2236599;C;EFFICACY;INCREASED_RESPONSE;OTHER;ANEMIA, SICKLE CELL, OTHER:BETA-THALASSEMIA AND RELATED DISEASES
OXYCODONE;OPRM1;rs1799971;GG;DOSAGE;INCREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
TACROLIMUS;CYP3A4;rs2242480;CT + TT;LADME-PK;INCREASED_CLEARANCE;OTHER;HEART TRANSPLANTATION
METHOTREXATE;SLCO1B1;rs11045821;A;EFFICACY, TOXICITY, LADME-PK;DECREASED_CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
METHYLPHENIDATE;SLC6A2;rs28386840;AT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
BILIRUBIN;UGT1A;rs11563250;AG + GG;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;COLORECTAL NEOPLASMS
DEFERASIROX;UGT1A3;rs1983023;CT + TT;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CERS6;rs13393173;A;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
MORPHINE;SLC22A1;rs12208357;CT + TT;LADME-PK;DECREASED_CLEARANCE;;
MIDAZOLAM;CYP3A4;rs35599367;AG;LADME-PK;DECREASED_METABOLISM;DISEASE;NEOPLASMS
MORPHINE;SLC22A1;rs55918055;CC + CT;LADME-PK;DECREASED_CLEARANCE;;
BUPROPION, DRUGS USED IN NICOTINE DEPENDENCE;CYP2A6;rs4803381;T;EFFICACY;INCREASED_RESPONSE;DISEASE;TOBACCO USE DISORDER
METFORMIN;SRR;rs391300;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
METHYLPHENIDATE;SLC6A2;rs5569;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
ERYTHROMYCIN;CYP3A4;rs35599367;AG;LADME-PK;DECREASED_METABOLISM;DISEASE;NEOPLASMS
NICOTINE;CYP2A6;rs4803381;T;LADME-PK;DECREASED_METABOLISM;;
CLOZAPINE;ABCB1;rs7787082;G;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
CAFFEINE;CYP1A2;rs762551;AA + AC;LADME-PK;INCREASED_METABOLISM;;
ATENOLOL;;rs12346562;AA + AC;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
HYDROCHLOROTHIAZIDE;;rs12346562;AA + AC;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERTENSION
ATENOLOL;;rs1104514;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
IVACAFTOR;CFTR;rs121908755;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
MORPHINE;SLC22A1;rs34130495;AA + AG;LADME-PK;DECREASED_CLEARANCE;;
ATENOLOL;;rs10739150;GG + GT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
CLOZAPINE;ABCB1;rs10248420;A;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
DEFERASIROX;UGT1A3;rs3806596;CC;EFFICACY, LADME-PK;INCREASED_RESPONSE;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
TRANDOLAPRIL, VERAPAMIL;PTPRD;rs4742610;T;EFFICACY;RESISTANCE;DISEASE;HYPERTENSION
DEFERASIROX;ABCG2;rs13120400;CC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
EFAVIRENZ;ABCB1;rs3842;CC + CT;LADME-PK;INCREASED_TROUGH CONCENTRATION;DISEASE;HIV INFECTIOUS DISEASE, DISEASE:TUBERCULOSIS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
METFORMIN, SULFONAMIDES, UREA DERIVATIVES;SLC47A1;rs2289669;A;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
SUNITINIB;ABCG2;rs2231142;GT + TT;LADME-PK;INCREASED_EXPOSURE;DISEASE;NEOPLASMS
WARFARIN;VDR;rs11168292;GG;DOSAGE;INCREASED_DOSE;;
4-HYDROXYTAMOXIFEN, ENDOXIFEN;SULT1A2;rs1136703;AA;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
ARA-CTP;SLC28A3;rs17343066;AA;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;LEUKEMIA, MYELOID, ACUTE
WARFARIN;VDR;rs4760658;GG;DOSAGE;INCREASED_DOSE;;
WARFARIN;VDR;rs11168293;TT;DOSAGE;INCREASED_DOSE;;
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;ALPL;rs885814;T;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
ETOPOSIDE;SLIT1;rs2784917;AA;LADME-PK;DECREASED_INHIBITION;;
METHOTREXATE;SLCO1B1;rs4149056;C;EFFICACY, TOXICITY, LADME-PK;DECREASED_CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
METHYLPHENIDATE;SLC6A2;rs5569;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
METHOTREXATE;SLCO1B1;rs2306283;A;EFFICACY, TOXICITY, LADME-PK;DECREASED_CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;;rs1350948;A;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
4-HYDROXYTAMOXIFEN, ENDOXIFEN;SULT1A2;rs1059491;TT;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
METHYLPHENIDATE;SLC6A2;rs28386840;AT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
METHOTREXATE;SLCO1B1;rs4149081;A;EFFICACY, TOXICITY, LADME-PK;DECREASED_CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;EYA4;rs17301249;C;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
METHYLPHENIDATE;SLC6A2;rs28386840;AT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;;
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;;rs12081765;G;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
METHOTREXATE;SLCO1B1;rs11045879;C;EFFICACY, TOXICITY, LADME-PK;DECREASED_CLEARANCE;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
PHENYLEPHRINE;ADRB2;rs1042713;AA;DOSAGE;INCREASED_DOSE;;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT
ANASTROZOLE;CSMD1;rs6990851;G;EFFICACY;INCREASED_RESPONSE;OTHER;BREAST NEOPLASMS
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;ABCC2;rs2273697;AA;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;DEATH
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs6806020;C;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
NICOTINE;CYP2A6;rs28399433;C;LADME-PK;DECREASED_METABOLISM;;
ATORVASTATIN;ABCB1;rs2032582;AA + AC;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
WARFARIN;VKORC1;rs7294;CT + TT;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs1931704;A;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
ACAMPROSATE;CHDH, IL17RB;rs6801605;A;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;ALCOHOL ABUSE
WARFARIN;VKORC1;rs9923231;TT;DOSAGE, EFFICACY;DECREASED_DOSE;OTHER;MECHANICAL HEART VALVE REPLACEMENT
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
PRAVASTATIN;MTTP;rs1800591;GT + TT;EFFICACY;RESPONSE;;
TACROLIMUS;CYP3A5;rs776746;CT;LADME-PK;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;;
COUMARIN;CYP2A6;rs28399433;C;LADME-PK;DECREASED_METABOLISM;;
PEGINTERFERON ALFA-2B, RIBAVIRIN;IL21R;rs3093390;C;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
BEVACIZUMAB, IRINOTECAN;VEGFA;rs1570360;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs7512595;A;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;CARD16;rs1792774;C;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
WARFARIN;CYP2C19;rs3814637;CC;DOSAGE;INCREASED_DOSE;;
WARFARIN;CYP2C9;rs1057910;AA + AC;DOSAGE;INCREASED_DOSE;;
N-DESMETHYLTRAMADOL;ABCC2;rs3740066;TT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;DEATH
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs7750468;G;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
WARFARIN;GGCX;rs699664;CT + TT;DOSAGE;INCREASED_DOSE;;
IVACAFTOR;CFTR;rs75527207;AG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CYSTIC FIBROSIS
ATORVASTATIN;SLCO1B1;rs2306283;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
FENTANYL;ABCC3;rs11079921;C;LADME-PK;INCREASED_CLEARANCE;OTHER;PAIN, OTHER:PREMATURE BIRTH
PEGINTERFERON ALFA-2B, RIBAVIRIN;CARD16;rs1503391;A;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;CASP1;rs557905;T;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs2066911;A;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
HMG COA REDUCTASE INHIBITORS;CFAP44;rs13064411;G;EFFICACY;DECREASED_RESPONSE;;
ATORVASTATIN;CYP7A1;rs3808607;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
PEGINTERFERON ALFA-2B, RIBAVIRIN;CASP1;rs568910;A;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
CODEINE;CYP2D6;rs3892097;TT;LADME-PK;DECREASED_METABOLISM;DISEASE;CHRONIC KIDNEY FAILURE
NICOTINE;CHRNB2;rs2072658;AG;OTHER;INCREASED_RESPONSE;OTHER;DAILY SMOKING
METFORMIN;SLC22A1;rs622342;AC + CC;EFFICACY;DECREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
N-DESMETHYLTRAMADOL;UGT1A8;rs8330;CC;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;DEATH
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
NICOTINE;CHRNA4;rs2229959;C;OTHER;INCREASED_RESPONSE;OTHER;DAILY SMOKING
PEGINTERFERON ALFA-2B, RIBAVIRIN;TUT7;rs17461620;C;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
ACETYLCYSTEINE;TOLLIP;rs3750920;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;PULMONARY FIBROSIS
OXCARBAZEPINE;ABCB1;rs1045642;A;EFFICACY;DECREASED_RESPONSE;DISEASE;EPILEPSY
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
OXCARBAZEPINE;UGT2B7;rs7439366;C;EFFICACY;DECREASED_RESPONSE;DISEASE;EPILEPSY
ARA-CTP;CDA;rs12404655;AG + GG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;LEUKEMIA, MYELOID, ACUTE
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
ARA-CTP;RRM1;rs11030918;CT + TT;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;LEUKEMIA, MYELOID, ACUTE
CLOZAPINE;CYP1A2;rs762551;AA;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
CLOPIDOGREL;CYP3A5;rs776746;CC + CT;EFFICACY;INCREASED_RESISTANCE;DISEASE;STROKE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
ARA-CTP;CTPS1;rs11577910;AG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;LEUKEMIA, MYELOID, ACUTE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
ARA-CTP;CTPS1;rs12067645;AA + AG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;LEUKEMIA, MYELOID, ACUTE
ARA-CTP;CTPS1;rs4364871;CT + TT;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;LEUKEMIA, MYELOID, ACUTE
N-DESMETHYLTRAMADOL;UGT1A8;rs10929303;CC;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;DEATH
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;UGT1A8;rs34650714;CC;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;DEATH
ARA-CTP;SLC28A1;rs11853372;TT;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;LEUKEMIA, MYELOID, ACUTE
ARA-CTP;DCTD;rs4742;GG;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;LEUKEMIA, MYELOID, ACUTE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
ALLOPURINOL;ABCG2;rs2231142;GT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;GOUT
OXCARBAZEPINE;ABCB1;rs1045642;GG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;EPILEPSY
AMANTADINE, ANTICHOLINERGICS, LEVODOPA, SELEGILINE;SLC22A1;rs622342;C;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE;PARKINSON DISEASE
ARA-CTP;DCK;rs4643786;CC + CT;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;LEUKEMIA, MYELOID, ACUTE
CLOZAPINE;CYP1A2;rs762551;AA;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA, OTHER:TOBACCO USE DISORDER
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
MORPHINE-3-GLUCURONIDE, MORPHINE-6-GLUCURONIDE;ABCC3;rs4793665;CC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;SCOLIOSIS, DISEASE:TONSILLECTOMY
TACROLIMUS;ABCB1;rs1128503;GG;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
MORPHINE-3-GLUCURONIDE;ABCC3;rs4148412;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;TONSILLECTOMY
GLUCOSE;CRTC2;rs8450;AA + AG;TOXICITY;INCREASED_CONCENTRATIONS;DISEASE;TRANSPLANTATION
ACENOCOUMAROL;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;rs3794271;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;ARTHRITIS, PSORIATIC
TACROLIMUS;ABCB1;rs1128503;GG;LADME-PK;INCREASED_DOSE;DISEASE;LIVER TRANSPLANTATION
SERTRALINE;GNB3;rs5441;GG;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
FENTANYL;CYP3A4;rs2242480;TT;EFFICACY;INCREASED_RESPONSE;OTHER;PAIN, POSTOPERATIVE
SUFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;LUNG NEOPLASMS, OTHER:PAIN, POSTOPERATIVE
SUFENTANIL;OPRM1;rs1323040;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;LUNG NEOPLASMS, OTHER:PAIN, POSTOPERATIVE
SUFENTANIL;ABCB1;rs1128503;AA + AG;DOSAGE;INCREASED_DOSE;OTHER;LUNG NEOPLASMS, OTHER:PAIN, POSTOPERATIVE
CYCLOSPORINE;ABCB1;rs1045642;A;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
SUFENTANIL;ABCB1;rs2032582;AA + AC;DOSAGE;INCREASED_DOSE;OTHER;LUNG NEOPLASMS, OTHER:PAIN, POSTOPERATIVE
MORPHINE;OPRM1;rs1799971;GG;DOSAGE;INCREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
HDL CHOLESTEROL;CRTC2;rs8450;AA;TOXICITY;DECREASED_CONCENTRATIONS;DISEASE;TRANSPLANTATION
O-DESMETHYLTRAMADOL;SLC22A1;rs34130495;GG;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;DEATH
MYCOPHENOLIC ACID;ABCC2;rs717620;TT;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
METHYLPHENIDATE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
METHYLPHENIDATE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;rs1867351;TT;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;DEATH
PHENYTOIN;CYP2C9;rs12782374;AA + AG;DOSAGE, LADME-PK;DECREASED_DOSE;DISEASE;EPILEPSY
WARFARIN;CYP2C9;rs1057910;C;DOSAGE, LADME-PK;DECREASED_DOSE;;
FENTANYL;ABCC3;rs8077268;T;LADME-PK;INCREASED_CLEARANCE;OTHER;PAIN, OTHER:PREMATURE BIRTH
METHYLPHENIDATE;COMT;rs4680;G;EFFICACY;INCREASED_CLEARANCE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
WARFARIN;CYP2C9;rs1799853;T;DOSAGE, LADME-PK;DECREASED_DOSE;;
PLATINUM COMPOUNDS;XRCC1;rs25487;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;;
CYCLOSPORINE;ABCB1;rs1045642;GG;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
NICOTINE;CYP1A2;rs35694136;T/del + del/del;EFFICACY;DECREASED_EXPOSURE;;
SIROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME-PK;DECREASED_METABOLISM;DISEASE;TRANSPLANTATION
PLATINUM COMPOUNDS;ERCC1;rs3212986;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
MYCOPHENOLIC ACID;UGT2B7;rs7662029;G;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
METHYLPHENIDATE;TH;rs2070762;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;;
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
TACROLIMUS;IL18;rs5744247;CC + CG;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
SIROLIMUS;CYP3A4;rs2740574;CC + CT;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
SIROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
CETUXIMAB;FCGR2A;rs1801274;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
CARBAMAZEPINE;CYP3A4;rs2242480;CC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;EPILEPSY
RISPERIDONE;HTR2C;rs518147;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
CARBAMAZEPINE;CYP3A5;rs776746;CC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;EPILEPSY
SITAGLIPTIN, VILDAGLIPTIN;GLP1R;rs6923761;AA;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
DESETHYLCHLOROQUINE, HYDROXYCHLOROQUINE;CYP2C8;rs7910936;C;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS
CARBAMAZEPINE;ABCB1;rs1045642;GG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;EPILEPSY
CARBAMAZEPINE;EPHX1;rs3738046;CG;LADME-PK;CONCENTRATIONS;DISEASE;EPILEPSY
ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HYPERCHOLESTEROLEMIA
PHENYTOIN;CYP2C9;rs1057910;AC;OTHER, LADME-PK;DECREASED_METABOLISM;DISEASE;EPILEPSY
PHENYTOIN;CYP2C9;rs1799853;CT;LADME-PK;DECREASED_METABOLISM;DISEASE;EPILEPSY
PHENYTOIN;CYP2C19;rs4244285;AG;OTHER, LADME-PK;DECREASED_METABOLISM;DISEASE;EPILEPSY
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION, DISEASE:HIV INFECTIOUS DISEASE
CLOZAPINE;HTR2C;rs6318;C;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
CARBAMAZEPINE;EPHX1;rs2234922;AG + GG;LADME-PK;CONCENTRATIONS;DISEASE;EPILEPSY
CARBAMAZEPINE;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;EPILEPSY
SULFONAMIDES, UREA DERIVATIVES;TCF7L2;rs12255372;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
SIMVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERCHOLESTEROLEMIA
CARBOPLATIN, CISPLATIN, FLUOROURACIL;XRCC1;rs25487;T;EFFICACY;DECREASED_RESPONSE;DISEASE;UTERINE CERVICAL NEOPLASM
TRAMADOL;ABCB1;rs2032582;AA;LADME-PK;INCREASED_EXPOSURE;;
TRAMADOL;ABCB1;rs1045642;AA;LADME-PK;INCREASED_EXPOSURE;;
CARBOPLATIN, CISPLATIN, FLUOROURACIL;SLC19A1;rs12659;A;EFFICACY;DECREASED_RESPONSE;DISEASE;UTERINE CERVICAL NEOPLASM
TRAMADOL;ABCB1;rs1128503;AA;LADME-PK;INCREASED_EXPOSURE;;
TOCILIZUMAB;IL6R;rs12083537;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
CAFFEINE;ADORA1;rs16851030;CC;EFFICACY;INCREASED_RESPONSE;OTHER;APNEA OF PREMATURITY
TOCILIZUMAB;IL6R;rs4329505;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
RISPERIDONE;HTR2C;rs1023574;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
RISPERIDONE;HTR2C;rs9698290;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
DIURETICS, HYDROCHLOROTHIAZIDE, THIAZIDES, PLAIN;PRKCA;rs16960228;A;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
ANTIDEPRESSANTS;RGS17;rs672170;A;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
LITHIUM;NTRK2;rs1387923;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
WARFARIN;CYP2C9;rs7089580;AT;DOSAGE;INCREASED_DOSE;;
WARFARIN;CYP2C9;rs7089580;AT;DOSAGE;INCREASED_CLEARANCE;;
VORICONAZOLE;SLCO1B3;rs4149117;GT + TT;LADME-PK;DECREASED_TROUGH CONCENTRATION;;
LITHIUM;GSK3B;rs334558;G;EFFICACY;INCREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
OXALIPLATIN;TP53;rs1042522;CG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
ANTIDEPRESSANTS;NBEA;rs9315310;T;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
ANTIDEPRESSANTS;CRH;rs4737771;C;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
ANTIDEPRESSANTS;FHIT;rs49411;C;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
ANTIDEPRESSANTS;PARP11;rs2532560;G;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
ANTIDEPRESSANTS;;rs2831440;T;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
SILDENAFIL;GNB3;rs5443;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;ERECTILE DYSFUNCTION
ANTIDEPRESSANTS;MTRF1L;rs766127;G;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
ATORVASTATIN;POR;rs1057868;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;FAMILIAL HYPERCHOLESTEROLEMIA
TACROLIMUS;HSD11B1;rs846908;AA;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
SARILUMAB;IL6R;rs4845625;CC;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
SALVIANOLIC ACID B;NOS3;rs1799983;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;CORONARY DISEASE
BUPROPION;COMT;rs165599;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;SMOKERS
LITHIUM;TPH1;rs1799913;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
BUPROPION;COMT;rs737865;AA;EFFICACY;DECREASED_RESPONSE;OTHER;SMOKERS
LITHIUM;TPH1;rs1800532;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
LITHIUM;CACNG2;rs2284017;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
SALBUTAMOL;CRHR2;rs2267715;G;EFFICACY;DECREASED_RESPONSE;DISEASE;ASTHMA
DESETHYLCHLOROQUINE, HYDROXYCHLOROQUINE;CYP2C8;rs10882521;T;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS
LITHIUM;BCR;rs140504;A;EFFICACY;DECREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
SALMETEROL;ADRB2;rs1042713;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;ASTHMA
WARFARIN;STX1B;rs4889606;AG + GG;DOSAGE;INCREASED_DOSE;;
ADALIMUMAB;HFE;rs2071303;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;CROHN DISEASE
ROSIGLITAZONE;LPIN1;rs10192566;G;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
TACROLIMUS;HSD11B1;rs4844880;AA;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
DESETHYLCHLOROQUINE, HYDROXYCHLOROQUINE;CYP2D6;rs1065852;AA;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS
TACROLIMUS;HSD11B1;rs846910;AA;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
ACENOCOUMAROL;GATA4;rs3735814;AG + GG;DOSAGE;DECREASED_DOSE;;
BETA BLOCKING AGENTS, SELECTIVE, DIURETICS;NEDD4L;rs4149601;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
ANTIDEPRESSANTS;CTNNA3;rs10997242;C;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
ALDOSTERONE ANTAGONISTS, AMILORIDE;NEDD4L;rs4149601;G;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
LITHIUM;DRD1;rs4532;C;EFFICACY;DECREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
ANTIDEPRESSANTS;HTR2A;rs7997012;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
SALBUTAMOL;CRHR2;rs255100;A;EFFICACY;DECREASED_RESPONSE;DISEASE;ASTHMA
ANTIDEPRESSANTS;HTR2A;rs6313;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
ANTIDEPRESSANTS;CACNA1A;rs2112460;A;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
SALBUTAMOL;CRHR2;rs2284220;G;EFFICACY;DECREASED_RESPONSE;DISEASE;ASTHMA
WARFARIN;ORM1;rs17650;AG + GG;DOSAGE;DECREASED_DOSE;;
ANTIDEPRESSANTS;;rs521093;T;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
MORPHINE;UGT2B7;rs7439366;CC;DOSAGE;DECREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
WARFARIN;VKORC1;rs7294;C;DOSAGE;DECREASED_DOSE;;
ANTIDEPRESSANTS;RAPGEF5;rs16873129;C;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
VALPROIC ACID;ABCB1;rs1128503;AA;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;EPILEPSY
ANTIDEPRESSANTS;PON2;rs2299267;G;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
TACROLIMUS;CYP3A5;rs776746;C;LADME-PK;DECREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;C;LADME-PK;DECREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
CISPLATIN;GALNT18;rs7937567;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;URINARY BLADDER NEOPLASMS
EFAVIRENZ;CYP2B6;rs2279343;AG + GG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
RITUXIMAB;;rs3759467;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;VASCULITIS
ANTIPSYCHOTICS, ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE;CYP3A43;rs680055;CG;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOAFFECTIVE DISORDER, DISEASE:SCHIZOPHRENIA
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT;LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_STEADY-STATE CONCENTRATION;DISEASE;LIVER TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;VKORC1;rs9923231;A;DOSAGE;DOSE;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
CORTICOSTEROIDS;HDAC1;rs1741981;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;ASTHMA
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
VINCRISTINE;MTNR1B;rs8192552;AG;LADME-PK;INCREASED_EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA, OTHER:HODGKIN DISEASE, OTHER:RHABDOMYOSARCOMA, OTHER:MEDULLOBLASTOMA, OTHER:GLIOMA
MORPHINE;TLR2;rs3804100;CC + CT;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
TACROLIMUS;CYP3A5;rs776746;CT;OTHER, LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
DOCETAXEL, THALIDOMIDE;CHST3;rs4148947;T;EFFICACY;INCREASED_RESPONSE;DISEASE;PROSTATIC NEOPLASMS
MORPHINE;IL1B;rs1143634;A;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
CISPLATIN;MLLT3;rs10964552;AA + AC;EFFICACY;DECREASED_RESPONSE;DISEASE;URINARY BLADDER NEOPLASMS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;T;DOSAGE, LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
MORPHINE;IL1B;rs1143634;A;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
EFAVIRENZ;CYP2B6;rs28399499;CT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
DOCETAXEL, THALIDOMIDE;CHST3;rs4148950;A;EFFICACY;INCREASED_RESPONSE;DISEASE;PROSTATIC NEOPLASMS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;TT;DOSAGE, LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
ATORVASTATIN;MTTP;rs1800591;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERLIPOPROTEINEMIA TYPE II
NITROGLYCERIN;ALDH2;rs671;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;CONGENITAL HEART DEFECTS
TOCILIZUMAB;GALNT18;rs4910008;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
CISPLATIN;RARS1;rs244898;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;URINARY BLADDER NEOPLASMS
TACROLIMUS;CYP3A5;rs776746;CT;DOSAGE, LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME-PK;DECREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DOSE;DISEASE;STROKE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
RISPERIDONE;ABCB1;rs2235048;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
TACROLIMUS;CYP3A5;rs776746;CT;LADME-PK;INCREASED_DOSE;OTHER;HEART TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME-PK;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
NITROGLYCERIN;ALDH2;rs671;AA + AG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;CONGENITAL HEART DEFECTS, DISEASE:PULMONARY HYPERTENSION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TOCILIZUMAB;CD69;rs11052877;A;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
PHENAZEPAM;CYP2C19;rs12248560;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;ALCOHOL-RELATED DISORDERS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;TT;LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
VINCRISTINE;SNU13;rs6519270;G;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA, OTHER:HODGKIN DISEASE, OTHER:RHABDOMYOSARCOMA, OTHER:MEDULLOBLASTOMA, OTHER:GLIOMA
ATENOLOL;;rs7184292;A;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION
ATENOLOL;XIRP2;rs7606603;C;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION
CYCLOSPORINE;CYP3A7;rs10211;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DOSE;;
CYCLOSPORINE;CYP3A7;rs2257401;CC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;JAK2;rs12343867;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;ULCERATIVE COLITIS
NILOTINIB;GSTP1;rs1695;A;EFFICACY;INCREASED_RESPONSE;OTHER;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
HYDROCHLOROTHIAZIDE;;rs16872401;C;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;rs3212217;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES
CYCLOSPORINE;CYP3A4;rs4646437;GG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
PAROXETINE;ABCB1;rs2032582;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE;DEPRESSION
NILOTINIB;CYP1A1;rs1048943;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;NLRP3;rs10754558;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES
ATENOLOL;;rs7184292;GG;DOSAGE;DECREASED_DOSE;OTHER;HYPERTENSION
ATORVASTATIN;SLCO1B1;rs2306283;GG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;HYPERLIPIDEMIAS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL18;rs1946518;GT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;ULCERATIVE COLITIS
RISPERIDONE;AKT1;rs3803300;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
RISPERIDONE;AKT1;rs2494732;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR1;rs2234711;AG;EFFICACY;DECREASED_RESPONSE;DISEASE;ULCERATIVE COLITIS
IMATINIB;CYP2B6;rs3745274;GG + TT;EFFICACY;INCREASED_RESISTANCE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
WARFARIN;CYP2C19;rs4986893;AA + AG;DOSAGE;DECREASED_DOSE;;
CYCLOSPORINE;CYP3A5;rs776746;CC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;CYP2C19;rs3814637;CT + TT;DOSAGE;DECREASED_DOSE;;
CANNABIDIOL;AOC1;rs12539;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;EPILEPSY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TBX21;rs17250932;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;ULCERATIVE COLITIS
VINCRISTINE;RAB7A;rs4548;CT;LADME-PK;INCREASED_EXPOSURE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA, OTHER:HODGKIN DISEASE, OTHER:RHABDOMYOSARCOMA, OTHER:MEDULLOBLASTOMA, OTHER:GLIOMA
DOCETAXEL, THALIDOMIDE;CHST3;rs730720;C;EFFICACY;INCREASED_RESPONSE;DISEASE;PROSTATIC NEOPLASMS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR2;rs8126756;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;CROHN DISEASE
CANNABIDIOL;SLC15A1;rs1339067;TT;EFFICACY;DECREASED_RESPONSE;OTHER;EPILEPSY
WARFARIN;;rs12772169;T;DOSAGE;DOSE;;
ROSIGLITAZONE;SLCO1B1;rs4149056;C;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;rs3212217;CG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;CROHN DISEASE
CORTICOSTEROIDS FOR SYSTEMIC USE;HDAC1;rs1741981;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;ASTHMA
WARFARIN;NQO1;rs1800566;A;EFFICACY;DECREASED_RESPONSE;DISEASE;THROMBOTIC DISEASE
RISPERIDONE;COMT;rs165599;G;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
WARFARIN;VKORC1;rs9923231;A;DOSAGE;DOSE;;
RISPERIDONE;GRM3;rs724226;G;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;DOSE;;
ATENOLOL, BISOPROLOL, CELIPROLOL, DOXAZOSIN;KCNH2;rs1137617;GG;EFFICACY;RESPONSE;DISEASE;ESSENTIAL HYPERTENSION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR5;rs5744174;AG;EFFICACY;DECREASED_RESPONSE;DISEASE;CROHN DISEASE
MORPHINE;KCNJ6;rs6517442;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;PAIN
METHOTREXATE;ABCG2;rs2231142;GT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;POR;rs1057868;CT + TT;LADME-PK;DECREASED_TROUGH CONCENTRATION;DISEASE;KIDNEY TRANSPLANTATION
MORPHINE, REMIFENTANIL;KCNJ6;rs6517442;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;PAIN
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
LOW DENSITY LIPOPROTEIN;SH2B1;rs3888190;CC;OTHER;INCREASED_CONCENTRATIONS;DISEASE;BIPOLAR DISORDER, DISEASE:DEPRESSIVE DISORDER, DISEASE:PSYCHOTIC DISORDER, DISEASE:SCHIZOAFFECTIVE DISORDER
TACROLIMUS;CYP3A5;rs776746;T;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
ENALAPRIL;VEGFA;rs699947;AA + AC;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
LITHIUM;CACNG2;rs2284018;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
EFAVIRENZ;ABCB1;rs1045642;GG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;;
ANASTROZOLE;;rs1437153;T;EFFICACY;DECREASED_RESPONSE;OTHER;BREAST NEOPLASMS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
DOCETAXEL;ORM2;rs2250242;AA;LADME-PK;INCREASED_CLEARANCE;DISEASE;PROSTATIC NEOPLASMS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
ETANERCEPT, INFLIXIMAB;CARD8;rs2043211;TT;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
METHOTREXATE;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
TACROLIMUS;CYP3A5;rs776746;TT;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR1;rs2234711;AG;EFFICACY;DECREASED_RESPONSE;DISEASE;INFLAMMATORY BOWEL DISEASES
ETANERCEPT, INFLIXIMAB;NLRP3;rs4612666;TT;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
ANASTROZOLE;DLG2;rs2449598;T;EFFICACY;DECREASED_RESPONSE;OTHER;BREAST NEOPLASMS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
TACROLIMUS;CYP3A5;rs776746;T;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;NEPHROTIC SYNDROME
EFAVIRENZ;CYP2B6;rs2279343;GG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A4;rs2242480;CC;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;NEPHROTIC SYNDROME
METHOTREXATE;MTHFR;rs1801133;AA;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
PEGINTERFERON ALFA-2B;HLA-DPA1;rs3077;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS B, CHRONIC
RIVASTIGMINE;BCHE;rs1803274;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;ALZHEIMER DISEASE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE;DECREASED_DOSE;;
METHOTREXATE;ABCB1;rs1045642;AG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
ADALIMUMAB, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;A;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
PRAVASTATIN;LDLR;rs1433099;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;VASCULAR DISEASES
PRAVASTATIN;LDLR;rs2738466;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;VASCULAR DISEASES
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
CANNABIDIOL;ABCC5;rs3749442;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER;EPILEPSY
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs4803217;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION, DISEASE:HIV INFECTIOUS DISEASE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;DISEASE;LIVER TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;DISEASE;LIVER TRANSPLANTATION
SUFENTANIL;NFKBIA;rs696;TT;DOSAGE;INCREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs11881222;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION, DISEASE:HIV INFECTIOUS DISEASE
GLUCOSE;RABEP1;rs1000940;AG + GG;OTHER;DECREASED_CONCENTRATIONS;DISEASE;BIPOLAR DISORDER, DISEASE:DEPRESSIVE DISORDER, DISEASE:PSYCHOTIC DISORDER, DISEASE:SCHIZOAFFECTIVE DISORDER
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;LIVER TRANSPLANTATION
PAROXETINE;BDNF;rs6265;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;LIVER TRANSPLANTATION
REMIFENTANIL;COMT;rs4680;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;PAIN
TACROLIMUS;CYP3A5;rs776746;CT;LADME-PK;INCREASED_CLEARANCE;DISEASE;LIVER TRANSPLANTATION
MORPHINE;COMT;rs4680;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;PAIN
MORPHINE, REMIFENTANIL;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;PAIN
TACROLIMUS;CYP3A5;rs776746;CT;DOSAGE, LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
ANTIPSYCHOTICS;ABCB1;rs2032582;CC;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;SCHIZOPHRENIA
ADALIMUMAB, INFLIXIMAB;TLR2;rs3804099;T;EFFICACY;DECREASED_RESPONSE;OTHER;CROHN DISEASE
ANTIPSYCHOTICS;ABCB1;rs2032582;C;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
MORPHINE;COMT;rs4680;G;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;CORONARY ARTERY DISEASE, EFFICACY:PAIN, POSTOPERATIVE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_EXPOSURE;DISEASE;HIV INFECTIOUS DISEASE
INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8103142;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION, DISEASE:HIV INFECTIOUS DISEASE
TACROLIMUS;CYP3A5;rs776746;T;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;OTHER;HSCT
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs28416813;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION, DISEASE:HIV INFECTIOUS DISEASE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;OTHER;KIDNEY DISEASE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
IMATINIB;ABCG2;rs2231142;GT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs8113007;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION, DISEASE:HIV INFECTIOUS DISEASE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION, DISEASE:HIV INFECTIOUS DISEASE
CLOZAPINE;CHRM1;rs2075748;CC;DOSAGE;DECREASED_DOSE;OTHER;SCHIZOPHRENIA
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CYP1B1;rs1056836;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_EXPOSURE;DISEASE;HIV INFECTIOUS DISEASE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs28416813;G;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
ERENUMAB, FREMANEZUMAB, GALCANEZUMAB;;rs12615320;G;EFFICACY;DECREASED_RESPONSE;OTHER;MIGRAINE WITHOUT AURA, OTHER:MIGRAINE WITH AURA
ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;;
HYDROXYUREA;ASS1;rs10901080;T;EFFICACY;INCREASED_RESPONSE;DISEASE;ANEMIA, SICKLE CELL, DISEASE:BETA-THALASSEMIA AND RELATED DISEASES
ANASTROZOLE;CSMD1;rs6981827;T;EFFICACY;DECREASED_RESPONSE;OTHER;BREAST NEOPLASMS
HYDROXYUREA;ASS1;rs10793902;T;EFFICACY;INCREASED_RESPONSE;DISEASE;ANEMIA, SICKLE CELL, DISEASE:BETA-THALASSEMIA AND RELATED DISEASES
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
DOXORUBICIN;ABCB1;rs2032582;AA;LADME-PK;DECREASED_METABOLISM;DISEASE;BREAST NEOPLASMS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8103142;T;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
TACROLIMUS;CYP3A5;rs776746;CT;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
EPIRUBICIN;NQO1;rs1800566;AA;EFFICACY, TOXICITY;DECREASED_RESPONSE;OTHER;BREAST CANCER CELL LINES
DOCETAXEL, EPIRUBICIN;MDM4;rs1563828;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
GEMCITABINE;CDA;rs2072671;C;LADME-PK;DECREASED_CLEARANCE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
HYDROCHLOROTHIAZIDE;NEDD4L;rs75982813;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
GLICLAZIDE;KCNJ11;rs5219;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
WARFARIN;;rs12777823;AA + AG;DOSAGE;DECREASED_DOSE;;
DOXORUBICIN;ABCB1;rs1045642;AA;LADME-PK;DECREASED_METABOLISM;DISEASE;BREAST NEOPLASMS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
ARIPIPRAZOLE;DRD2;rs6277;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;DISEASE;LIVER TRANSPLANTATION
CAPECITABINE, RADIOTHERAPY;AREG;rs11942466;AA + AC;EFFICACY;DECREASED_RESPONSE;DISEASE;RECTAL NEOPLASMS
(S)-METHADONE;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS
(R)-METHADONE;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS
CAPECITABINE, RADIOTHERAPY;ERCC1;rs11615;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;RECTAL NEOPLASMS
CAPECITABINE, OXALIPLATIN;VEGFA;rs2010963;CG;EFFICACY;DECREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
ARIPIPRAZOLE;ANKK1;rs1800497;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
MORPHINE;COMT;rs4633;C;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;CORONARY ARTERY DISEASE, EFFICACY:PAIN, POSTOPERATIVE
CLOZAPINE;HTR3A;rs1150226;G;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
RISPERIDONE;GRM7;rs2069062;CC;EFFICACY;INCREASED_RESPONSE;;
CLOPIDOGREL;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;ACUTE CORONARY SYNDROME
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
CLOZAPINE;HTR3A;rs2276302;A;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
GLUCOSE;COMT;rs4680;AA + AG;TOXICITY;INCREASED_CONCENTRATIONS;;
CLOZAPINE;HTR3A;rs1062613;C;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
CLOPIDOGREL;ABCB1;rs1045642;AA + AG;LADME-PK;DECREASED_METABOLISM;DISEASE;ACUTE CORONARY SYNDROME
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;PTPRC;rs10919563;G;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_DISCONTINUATION;DISEASE;KIDNEY DISORDER
RISPERIDONE;GRID2;rs1875705;GG;EFFICACY;INCREASED_RESPONSE;;
CLOPIDOGREL;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;ACUTE CORONARY SYNDROME
PACLITAXEL;ABCB1;rs2032582;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
TACROLIMUS;NR1I2;rs2276707;CC;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT;DOSAGE, LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
CAPECITABINE, OXALIPLATIN;VEGFA;rs699947;AC;EFFICACY;DECREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
WARFARIN;PRSS53, VKORC1;rs17886199;A;DOSAGE;DECREASED_DOSE;;
4-HYDROXYATORVASTATIN, 4-HYDROXYATORVASTATIN LACTONE;SLCO2B1;rs12422149;AG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;CORONARY DISEASE
PACLITAXEL;ABCB1;rs2032582;AA + AT;EFFICACY;INCREASED_RESPONSE;DISEASE;OVARIAN NEOPLASMS
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs11881222;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
2-HYDROXYATORVASTATIN LACTONE, 4-HYDROXYATORVASTATIN LACTONE, ATORVASTATIN LACTONE;UGT1A1;rs887829;CC;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;CORONARY DISEASE
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;RGS5;rs1056515;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
SN-38;UGT1A1;rs4148323;AA;DOSAGE;DECREASED_METABOLISM;DISEASE;NEOPLASMS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8105790;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12980275;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
VALPROIC ACID;GABRA1;rs10068980;AA + AG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;EPILEPSY
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
CLOZAPINE;CHRM1;rs1942499;GG;DOSAGE;DECREASED_DOSE;OTHER;SCHIZOPHRENIA
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
ROSUVASTATIN;SCAP;rs12487736;C;EFFICACY;INCREASED_RESPONSE;DISEASE;METABOLIC SYNDROME
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs4803219;CT;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;RALBP1;rs329007;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
ROCURONIUM;ABCB1;rs1128503;AA;EFFICACY;DECREASED_RESPONSE;;
MYCOPHENOLIC ACID;UGT1A9;rs6714486;AA + AT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
ACENOCOUMAROL;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_CLEARANCE;DISEASE;LIVER TRANSPLANTATION
ROCURONIUM;SLCO1B1;rs2306283;AA;EFFICACY;DECREASED_RESPONSE;;
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;G;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PERAMPANEL;CYP3A5, ZSCAN25;rs776746;C;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;EPILEPSY
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;DISEASE;LIVER TRANSPLANTATION
MORPHINE;UGT2B7;rs7438135;AA + AG;LADME-PK;DECREASED_CONCENTRATIONS;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_CLEARANCE;DISEASE;LIVER TRANSPLANTATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GT;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs7248668;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs10853728;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
PRAVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HYPERCHOLESTEROLEMIA
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs10853728;CG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
ACENOCOUMAROL;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE;;
IMATINIB;ABCG2;rs2725252;C;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
PHENPROCOUMON;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;OTHER;MAINTENANCE DOSAGE BY 1.5 MG/WEEK
ATENOLOL, IRBESARTAN;EDN1;rs5370;GT;EFFICACY;INCREASED_RESPONSE;DISEASE;ESSENTIAL HYPERTENSION
PAROXETINE;HTR2A;rs6311;CC;EFFICACY;INCREASED_RESPONSE;OTHER;OBSESSIVE-COMPULSIVE DISORDER
PHENPROCOUMON;CYP2C9;rs4086116;T;DOSAGE;DECREASED_DOSE;OTHER;MAINTENANCE DOSAGE BY 2.2 MG/WEEK
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;APOE;rs7412;C;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERLIPIDEMIAS
IMATINIB;ABCG2;rs2725252;C;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
ATAZANAVIR;NR1I2;rs2472677;CT;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
PRAVASTATIN;SLCO1B1;rs4149015;AG;LADME-PK;INCREASED_METABOLISM;DISEASE;HYPERLIPOPROTEINEMIA TYPE II
APIXABAN;CYP3A5;rs776746;CC + CT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;ATRIAL FIBRILLATION
IMATINIB;ABCG2;rs12505410;G;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
NIACIN;HCAR2;rs2454727;CT + TT;EFFICACY;DECREASED_RESPONSE;;
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;ABCA1;rs12003906;C;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERLIPIDEMIAS
CEFTRIAXONE;ABCG2;rs13120400;TT;LADME-PK;CONCENTRATIONS;DISEASE;CENTRAL NERVOUS SYSTEM INFECTIOUS DISORDER
RIBAVIRIN;ITPA;rs1127354;CC;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;rs776746;CT;LADME-PK;DECREASED_EXPOSURE;DISEASE;KIDNEY TRANSPLANTATION
PRAVASTATIN;SLCO1B1;rs4149015;AG;LADME-PK;INCREASED_RESPONSE;DISEASE;HYPERLIPOPROTEINEMIA TYPE II
CREATINE;MOBP;rs616147;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;AMYOTROPHIC LATERAL SCLEROSIS
PEMETREXED;EXO1;rs1047840;AA + AG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;LUNG NEOPLASMS
PRAVASTATIN;SLCO1B1;rs4149056;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;TRANSPLANTATION
PHENPROCOUMON;STX4;rs10871454;T;DOSAGE;DECREASED_DOSE;OTHER;MAINTENANCE DOSAGE BY 4.8 MG/WEEK
PRAVASTATIN;SLCO1B1;rs4149056;CT;LADME-PK;INCREASED_METABOLISM;DISEASE;TRANSPLANTATION
PROPOFOL;CYP2B6;rs3745274;GT + TT;DOSAGE;DECREASED_DOSE;;
ADALIMUMAB, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;rs352139;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
VALPROIC ACID;CYP2C19;rs4244285;AA + AG;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;MYELODYSPLASTIC SYNDROMES
APIXABAN;ABCG2;rs2231142;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;ATRIAL FIBRILLATION
IVACAFTOR;CFTR;rs121908755;A;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
3,4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;rs2242446;TT;OTHER;DECREASED_RESPONSE;;
ATENOLOL;AGT;rs699;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
3,4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;rs1861647;GG;OTHER;INCREASED_RESPONSE;;
3,4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;rs36029;AA;OTHER;INCREASED_RESPONSE;;
ATENOLOL;AGT;rs5051;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
TEMOZOLOMIDE;ABCB1;rs2229109;CT;EFFICACY;DECREASED_RESPONSE;OTHER;GLIOMA
FOLLITROPIN BETA, UROFOLLITROPIN;FSHR;rs6166;T;TOXICITY;INCREASED_RESPONSE;;
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;HLA-E;rs1264457;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
REPAGLINIDE;SLC30A8;rs13266634;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
DISULFIRAM;ADRA1A;rs1048101;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;COCAINE DEPENDENCE
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;ATP5F1E;rs1059150;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
SIROLIMUS;ABCB1;rs1045642;AG;LADME-PK;INCREASED_CONCENTRATIONS;;
MERCAPTOPURINE;NUDT15;rs116855232;TT;DOSAGE;DECREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
DEXMEDETOMIDINE;CYP2A6;rs28399433;C;LADME-PK;DECREASED_CLEARANCE;;
IRBESARTAN;CYP2C9;rs1799853;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
FENTANYL;CALCA;rs145837941;GG;DOSAGE;INCREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
NITRIC OXIDE;NAMPT;rs1319501;TT;EFFICACY;INCREASED_CONCENTRATIONS;OTHER;PRE-ECLAMPSIA
TOCILIZUMAB;GALNT18;rs4910008;CC + CT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
BUPRENORPHINE;OPRD1;rs529520;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;OPIOID-RELATED DISORDERS
NICOTINE;;rs12459249;C;LADME-PK;DECREASED_METABOLISM;;
WARFARIN;GGCX;rs2592551;AA + AG;DOSAGE;INCREASED_DOSE;DISEASE;ATRIAL FIBRILLATION
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;DEPRESSION
ESCITALOPRAM;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;DEPRESSION
ATOMOXETINE, DESVENLAFAXINE, DULOXETINE, SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;DEPRESSION
TOCILIZUMAB;IL6;rs2069840;CC;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
ANTIDEPRESSANTS;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;DEPRESSION
BENAZEPRIL;MTHFR;rs1801131;G;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERTENSION
FLUOXETINE, PAROXETINE;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
BENAZEPRIL;MTHFR;rs1801133;G;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERTENSION
IRBESARTAN;CYP2C9;rs1057910;AC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;ESSENTIAL HYPERTENSION
PAROXETINE;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
FENTANYL;CALCA;rs145837941;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;PAIN, POSTOPERATIVE, OTHER:CAESARIAN SECTION
EFAVIRENZ;CYP2B6;rs28399499;CC + CT;LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
PEMETREXED;CAMKK2;rs1653586;GT;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;LUNG NEOPLASMS
ABIRATERONE;SRD5A2;rs523349;CC;EFFICACY;INCREASED_RESPONSE;OTHER;PROSTATIC NEOPLASMS
BUPRENORPHINE;OPRD1;rs581111;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;OPIOID-RELATED DISORDERS
CARBOPLATIN, LONAFARNIB, PACLITAXEL;FNTB;rs11623866;GG;EFFICACY;RESPONSE;DISEASE;OVARIAN NEOPLASMS
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
METHOTREXATE;ABCG2;rs12505410;GG;LADME-PK;INCREASED_CLEARANCE;DISEASE;OSTEOSARCOMA
ESCITALOPRAM;BMP5;rs41271330;A;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
ESCITALOPRAM;BMP5;rs41271330;AA + AG;EFFICACY;INCREASED_DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER
METHOTREXATE;ABCG2;rs13137622;GT + TT;LADME-PK;INCREASED_CLEARANCE;DISEASE;OSTEOSARCOMA
METHOTREXATE;ABCG2;rs13120400;CC;LADME-PK;INCREASED_CLEARANCE;DISEASE;OSTEOSARCOMA
AMLODIPINE;CYP3A4;rs2740574;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
TACROLIMUS;IL18;rs1946518;GG + GT;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION
TACROLIMUS;IL10;rs1800896;TT;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION
RIVASTIGMINE;BCHE;rs1803274;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;ALZHEIMER DISEASE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
EFAVIRENZ;CYP2B6;rs35303484;G;LADME-PK;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
VALPROIC ACID;CYP2C9;rs1057910;C;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;EPILEPSY
METHOTREXATE;MTHFR;rs1801133;AG + GG;LADME-PK;INCREASED_STEADY-STATE CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
AZATHIOPRINE;NUDT15;rs116855232;TT;TOXICITY;DECREASED_DOSE;DISEASE;LEUKOPENIA
CLOZAPINE;NFIB;rs28379954;CT;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION
METFORMIN;SLC22A1;rs594709;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
IRINOTECAN;TDP1;rs2401863;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
METFORMIN;SLC47A1;rs2289669;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
TACROLIMUS;IL18;rs5744247;CC + CG;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION
METHOTREXATE;SLC19A1;rs1051266;TT;LADME-PK;INCREASED_STEADY-STATE CONCENTRATION;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
DEXMEDETOMIDINE;CYP2D6;rs16947;GG;DOSAGE;INCREASED_DOSE;OTHER;SURGERY
CARBAMAZEPINE;CYP1A2;rs762551;AA;LADME-PK;INCREASED_CLEARANCE;DISEASE;EPILEPSY
RIVAROXABAN;CYP3A4;rs2242480;T;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION
CYCLOSPORINE, TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME-PK;INCREASED_CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION
METHOTREXATE;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs4148324;GG + GT;LADME-PK;DECREASED_CLEARANCE;DISEASE;OSTEOSARCOMA
EFAVIRENZ;ABCB1;rs3842;C;LADME-PK;CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
CYCLOSPORINE, TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME-PK;DECREASED_DOSE;OTHER;LIVER TRANSPLANTATION
DEXMEDETOMIDINE;WBP2NL;rs5758550;AG + GG;TOXICITY;INCREASED_RESPONSE;OTHER;SURGERY
MEMANTINE, RIVASTIGMINE;BCHE;rs1803274;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;ALZHEIMER DISEASE
IVACAFTOR;CFTR;rs75527207;AA;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE;DECREASED_DOSE;;
WARFARIN;GGCX;rs699664;CC;DOSAGE;INCREASED_DOSE;;
METHOTREXATE;MTHFR;rs1801131;GT;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
CLOPIDOGREL;ABCB1;rs1045642;AA;LADME-PK;DECREASED_EXPOSURE;;
TACROLIMUS;POR;rs1057868;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;VKORC1;rs9934438;GG;DOSAGE;INCREASED_DOSE;;
RIVASTIGMINE;BCHE;rs1803274;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;LEWY BODY DISEASE
FENTANYL;CALCA;rs145837941;GG;DOSAGE;INCREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
APIXABAN;ABCG2;rs2231142;G;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs1061622;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
DEXMEDETOMIDINE;CYP1A2;rs762551;AC + CC;LADME-PK;INCREASED_CLEARANCE;OTHER;SEDATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs3397;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
LATANOPROST;PTGFR;rs3766355;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;GLAUCOMA, DISEASE:OCULAR HYPERTENSION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs1061631;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
METHOTREXATE;MTHFR;rs1801133;AG;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs3397;C;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
METHADONE;NECTIN4;rs11265549;AA;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS
OPIOID ANESTHETICS, OTHER GENERAL ANESTHETICS, VOLATILE ANESTHETICS;OPRM1;rs1799971;GG;EFFICACY;INCREASED_RESPONSE;;
OPIOID ANESTHETICS, OTHER GENERAL ANESTHETICS, VOLATILE ANESTHETICS;ABCG2;rs2231142;TT;EFFICACY;INCREASED_RESPONSE;;
METHADONE;NECTIN4;rs11265549;AA;DOSAGE;DECREASED_DOSE;OTHER;OPIOID-RELATED DISORDERS
DEXMEDETOMIDINE;KCNMA1;rs16934182;AA + AG;DOSAGE;DECREASED_DOSE;OTHER;SURGERY
DABIGATRAN;CES1;rs2244613;GG + GT;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION
ATORVASTATIN;ABCG8;rs11887534;CC + CG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
CAPECITABINE;DPYD;rs3918290;CT;DOSAGE;DOSE;DISEASE;NEOPLASMS
CAPECITABINE;DPYD;rs56038477;CT;DOSAGE;DOSE;DISEASE;NEOPLASMS
CAPECITABINE;DPYD;rs67376798;AT;DOSAGE;DOSE;DISEASE;NEOPLASMS
DEXMEDETOMIDINE;ADRA2A;rs1800544;GG;DOSAGE;DECREASED_DOSE;OTHER;SURGERY
TAMOXIFEN-N-GLUCURONIDE;UGT1A4;rs2011425;GG + GT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
IMATINIB;CYP2B6;rs3745274;GG + GT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
ATORVASTATIN;CYP7A1;rs3808607;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
METHOTREXATE;ATIC;rs4673993;CC;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
BENAZEPRIL;AGT;rs7079;GG;EFFICACY;RESPONSE;DISEASE;HYPERTENSION
WARFARIN;CYP2C9;rs9332098;GG;DOSAGE;INCREASED_DOSE;;
CANNABIDIOL;;rs6729738;CC;EFFICACY;INCREASED_RESPONSE;OTHER;EPILEPSY
METHOTREXATE;MTHFR;rs1801133;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
DEXMEDETOMIDINE;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RESPONSE;OTHER;SURGERY
WARFARIN;CYP2C9;rs9332092;TT;DOSAGE;INCREASED_DOSE;;
HYDROCHLOROTHIAZIDE;TXNDC11;rs3784921;G;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION
WARFARIN;CYP2C9;rs1057910;CC;LADME-PK;DECREASED_CLEARANCE;;
PAROXETINE;CYP1A2;rs762551;A;LADME-PK;INCREASED_DOSE;DISEASE;MAJOR DEPRESSIVE DISORDER
WARFARIN;CYP2C9;rs1799853;TT;LADME-PK;DECREASED_CLEARANCE;;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
DEXMEDETOMIDINE;KCNMA1;rs16934182;AA + AG;TOXICITY;INCREASED_RESPONSE;OTHER;SURGERY
TOPOTECAN;ABCG2;rs4148157;AA + AG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BRAIN NEOPLASMS
EFAVIRENZ;CYP2B6;rs28399499;CC + CT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
RIVAROXABAN;CYP3A4;rs2246709;G;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION
DULOXETINE;KMT2E;rs117986340;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
RIVASTIGMINE;ACHE;rs2571598;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;ALZHEIMER DISEASE
MORPHINE;OPRM1;rs1799971;AG + GG;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
DULOXETINE;NCAM1;rs2303377;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
RIVAROXABAN;CYP3A5;rs776746;T;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;HEART TRANSPLANTATION
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
DULOXETINE;ZNF385D;rs4261893;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
EFAVIRENZ;CYP2B6;rs2279343;AG + GG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
RIVAROXABAN;CYP3A4;rs3735451;C;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION
WARFARIN;VKORC1;rs2359612;GG;DOSAGE;INCREASED_DOSE;;
WARFARIN;VKORC1;rs7294;TT;DOSAGE;INCREASED_DOSE;;
DEXMEDETOMIDINE;;rs141294036;CC;TOXICITY;INCREASED_RESPONSE;OTHER;SURGERY
AMPHETAMINE;CDH13;rs3784943;AG + GG;EFFICACY;INCREASED_RESPONSE;;
EVEROLIMUS;CYP3A4;rs35599367;AG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
PRAVASTATIN;SLCO1B1;rs4149056;CT;EFFICACY;DECREASED_RESPONSE;DISEASE;CORONARY STENOSIS
DEXMEDETOMIDINE;KCNMB1;rs11739136;CC + CT;EFFICACY;INCREASED_RESPONSE;OTHER;SURGERY
MORPHINE;UGT2B7;rs7668282;CC + CT;LADME-PK;DECREASED_METABOLISM;DISEASE;ANEMIA, SICKLE CELL
MIVACURIUM;BCHE;rs755648929;AG;EFFICACY;INCREASED_RESPONSE;;
SUCCINYLCHOLINE;BCHE;rs772583466;CT;EFFICACY;INCREASED_RESPONSE;;
EFAVIRENZ;CYP2A7P1, CYP2B6;rs3745274;T;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;PREGNANCY
DABIGATRAN;CES1;rs8192935;GG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION
ETHANOL;OPRM1;rs1799971;AG + GG;DOSAGE;DECREASED_DOSE;;
METHOTREXATE;CLCN6, MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
METHOTREXATE;C1orf167, CLCN6, MTHFR;rs1801131;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
METHOTREXATE;MTR;rs1805087;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
RANIBIZUMAB;CXCL8;rs4073;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;MACULAR DEGENERATION
ETHANOL;OPRM1;rs10485057;AA;DOSAGE;INCREASED_DOSE;;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;;
OPIOIDS;COMT;rs4680;AA + AG;DOSAGE;DECREASED_DOSE;OTHER;PAIN, OTHER:NEOPLASMS
METHOTREXATE;BIRC5;rs9904341;CG;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
ACENOCOUMAROL;VKORC1;rs9934438;GG;EFFICACY;DECREASED_RESPONSE;;
SALBUTAMOL;;rs17834628;A;EFFICACY;INCREASED_RESPONSE;;
NICOTINE;CHRNA3;rs1051730;A;DOSAGE;DECREASED_DOSE;OTHER;TOBACCO USE DISORDER
ABIRATERONE, PREDNISOLONE;TSPYL1;rs3828743;A;EFFICACY;DECREASED_RESPONSE;DISEASE;PROSTATIC NEOPLASMS
PLATINUM;RICTOR;rs6878291;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
CLOZAPINE;DRD2;rs2514218;T;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
METHOTREXATE;FASTKD3, MTRR;rs1801394;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
RANIBIZUMAB;KDR;rs2071559;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;MACULAR DEGENERATION
ETHANOL;OPRM1;rs1799971;AG;OTHER;INCREASED_RESPONSE;OTHER;ALCOHOL ABUSE
BUSULFAN;GSTA1;rs3957356;CT;LADME-PK;DECREASED_CLEARANCE;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION
METHOTREXATE;ATIC;rs12995526;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
CLOZAPINE;HTR3A;rs1062613;T;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
METHOTREXATE;ATIC;rs7563206;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE;DECREASED_DOSE;;
METHOTREXATE;ATIC;rs2372536;CC + CG;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
METHOTREXATE;ATIC;rs4673993;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
CANDESARTAN;KCNK3;rs1275988;C;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION
RISPERIDONE;NR1I2;rs1523130;CC;LADME-PK;DECREASED_CLEARANCE;DISEASE;BIPOLAR DISORDER, DISEASE:DEPRESSION, DISEASE:SUBSTANCE-RELATED DISORDERS
SUFENTANIL;ABCB1;rs1045642;GG;DOSAGE;INCREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
ADALIMUMAB;IL17F;rs763780;TT;EFFICACY;INCREASED_RESPONSE;;
IMMUNOGLOBULINS;CASP3, PRIMPOL;rs113420705;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;MUCOCUTANEOUS LYMPH NODE SYNDROME
SUFENTANIL;COMT;rs4680;AA;DOSAGE;INCREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
WARFARIN;VKORC1;rs7294;CC;DOSAGE;DECREASED_CONCENTRATIONS;OTHER;HEART VALVE REPLACEMENT
IMMUNOGLOBULINS;COQ8B, ITPKC;rs28493229;CC + CG;EFFICACY;DECREASED_RESPONSE;DISEASE;MUCOCUTANEOUS LYMPH NODE SYNDROME
USTEKINUMAB;IL17F;rs763780;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
WARFARIN;CYP2C9;rs1057910;AA;DOSAGE;INCREASED_DOSE;OTHER;HEART VALVE REPLACEMENT
INFLIXIMAB;IL17F;rs763780;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
EFAVIRENZ;CYP2B6;rs3745274;TT;DOSAGE, LADME-PK;DECREASED_DOSE;DISEASE;HIV INFECTIOUS DISEASE
HYDROCHLOROTHIAZIDE;CSK;rs1378942;C;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION
SALBUTAMOL;;rs35661809;G;EFFICACY;INCREASED_RESPONSE;;
ANTIPSYCHOTICS;DRD3;rs6280;CT + TT;EFFICACY;INCREASED_RESISTANCE;OTHER;MOOD DISORDER, OTHER:SCHIZOPHRENIA
HYDROCHLOROTHIAZIDE;PDE3A;rs12579720;C;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION
CANDESARTAN;SULT1C3;rs6722745;T;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION
ATENOLOL;STN1;rs4387287;A;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION
METFORMIN;;rs10783050;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS
METFORMIN;IL1B;rs1143623;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;;
WARFARIN;VKORC1;rs9923231;TT;LADME-PK;DECREASED_CONCENTRATIONS;;
CISPLATIN, PACLITAXEL;TP53;rs1042522;CG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;STOMACH NEOPLASMS
RIFAPENTINE;ABCB1;rs1045642;AA + AG;LADME-PK;INCREASED_CLEARANCE;;
BEVACIZUMAB, PEGAPTANIB, RANIBIZUMAB;VEGFA;rs2010963;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;CHOROIDAL NEOVASCULARIZATION
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;NQO1;rs1800566;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;METASTATIC NEOPLASM, DISEASE:STOMACH NEOPLASMS
WARFARIN;VKORC1;rs9923231;CT;EFFICACY;INCREASED_DOSE;OTHER;LEFT VENTRICULAR DYSFUNCTION
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;PON1;rs662;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;METASTATIC NEOPLASM, DISEASE:STOMACH NEOPLASMS
RISPERIDONE;NR1I2;rs2276707;CC;LADME-PK;DECREASED_CLEARANCE;DISEASE;BIPOLAR DISORDER, DISEASE:DEPRESSION, DISEASE:SUBSTANCE-RELATED DISORDERS
EFAVIRENZ;CYP2B6;rs28399499;C;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE
WARFARIN;VKORC1;rs9923231;CT;EFFICACY;DECREASED_RESPONSE;OTHER;LEFT VENTRICULAR DYSFUNCTION
RITUXIMAB;FCGR3A;rs396991;C;EFFICACY;INCREASED_RESPONSE;OTHER;AUTOIMMUNE DISEASES
NICOTINE;CHRNA3, CHRNA5;rs16969968;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER
CLOZAPINE;HTR3A;rs2276302;G;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
IMATINIB;ABCB1;rs2032582;AT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
IMATINIB;ABCG2;rs2231142;T;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
TELMISARTAN;GNB3;rs5443;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;ESSENTIAL HYPERTENSION
EFAVIRENZ;CYP2B6;rs8192719;T;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE
LITHIUM, VALPROIC ACID;;rs2769605;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
CISPLATIN, FLUOROURACIL;GNAS;rs7121;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;NEOPLASM OF ESOPHAGUS
ATENOLOL, METOPROLOL;ZMAT4;rs1367094;T;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE
ATENOLOL, HYDROCHLOROTHIAZIDE, METOPROLOL;LRRC15;rs11313667;del;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
ONDANSETRON;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;;
LITHIUM, OLANZAPINE;DRD2;rs1800497;GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;BIPOLAR DISORDER
HMG COA REDUCTASE INHIBITORS;;rs247616;T;EFFICACY;INCREASED_RESPONSE;;
BOCEPREVIR, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;KLRC1;rs7301582;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
HYDROCHLOROTHIAZIDE;PRKAG2;rs10224002;A;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION
AGOMELATINE, MELATONIN RECEPTOR AGONISTS, SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;DEPRESSIVE DISORDER
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;KLRD1;rs2302489;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
HYDROCHLOROTHIAZIDE;PLCE1;rs932764;A;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
METOPROLOL;;rs1446468;T;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION
ATENOLOL;RRP1B;rs9306160;T;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION
ATENOLOL;TBX2;rs8068318;C;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION
AMISULPRIDE;DRD2;rs1079597;C;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
USTEKINUMAB;NFKBIA;rs2145623;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
HYDROCHLOROTHIAZIDE;ADO;rs10995311;C;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION
PLATINUM COMPOUNDS;XBP1;rs2269577;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
CANDESARTAN;DOT1L, PLEKHJ1;rs740406;A;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION
USTEKINUMAB;ADAM33;rs2787094;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
HYDROCHLOROTHIAZIDE;NUCB2;rs757081;C;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION
USTEKINUMAB;;rs1975974;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
EXENATIDE;KCNQ1;rs163184;G;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE, DISEASE:TUBERCULOSIS
USTEKINUMAB;AGBL4;rs191190;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
NORTRIPTYLINE;SLC39A14;rs17060812;C;EFFICACY;INCREASED_RESPONSE;DISEASE;DEPRESSION
ACENOCOUMAROL;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE;;
USTEKINUMAB;CHUK;rs11591741;CC + CG;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
USTEKINUMAB;HTR2A;rs6311;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
WARFARIN;VKORC1;rs9923231;CC + CT;DOSAGE;INCREASED_DOSE;;
HYDROCHLOROTHIAZIDE;C5orf56;rs12521868;G;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION
CANDESARTAN;SH2B3;rs3184504;T;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
CARBAMAZEPINE;CYP3A5;rs776746;CC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;EPILEPSY
APIXABAN;ABCG2;rs2231142;GG + GT;LADME-PK;INCREASED_CLEARANCE;DISEASE;ATRIAL FIBRILLATION
CARBAMAZEPINE;CYP3A5;rs15524;AA;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;EPILEPSY
PAROXETINE;COMT;rs4680;A;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
CAPECITABINE, PACLITAXEL;TP53;rs1042522;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;STOMACH NEOPLASMS
SUFENTANIL;CYP3A4;rs2242480;CC;DOSAGE;INCREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
TRIGLYCERIDES;CYP19A1;rs749292;A;OTHER;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS, DISEASE:MENOPAUSE
HDL CHOLESTEROL;CYP19A1;rs1062033;G;OTHER;INCREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS, DISEASE:MENOPAUSE
EFAVIRENZ;CYP2B6;rs28399499;C;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
CLOBAZAM;POR;rs1057868;TT;LADME-PK;INCREASED_CLEARANCE;DISEASE;EPILEPSY
WARFARIN;CYP2C9;rs1057910;AA;DOSAGE;INCREASED_DOSE;DISEASE;HEART VALVE DISEASES
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;OTHER;HEART VALVE REPLACEMENT
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
NORTRIPTYLINE;PPM1A;rs2273623;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;DEPRESSION
AMILORIDE, SPIRONOLACTONE;CYP4A11;rs1126742;GG;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;TT;DOSAGE;DECREASED_DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES
DEFERASIROX;UGT1A3;rs3806596;CC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
LOPINAVIR;CYP3A5;rs776746;C;LADME-PK;INCREASED_TROUGH CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE
PROPOFOL;CYP2B6;rs2279343;AA + AG;LADME-PK;DECREASED_CLEARANCE;;
SPIRONOLACTONE;CYP4A11;rs3890011;CC;EFFICACY;DECREASED_RESPONSE;OTHER;HYPERTENSION
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
ATAZANAVIR;NR1I2;rs2472677;TT;LADME-PK;INCREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION
RIFAMPIN;AADAC;rs1803155;AA;LADME-PK;DECREASED_CLEARANCE;OTHER;TUBERCULOSIS
APATINIB, APATINIB METABOLITE M1-1;CYP2C9;rs1934968;GG;LADME-PK;INCREASED_EXPOSURE;OTHER;NEOPLASMS
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;rs11075995;AT + TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;NEOPLASMS
AMPRENAVIR;SLCO1B1;rs4149056;C;LADME-PK;DECREASED_TROUGH CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE
ACAMPROSATE;;rs77583603;G;EFFICACY;DECREASED_RESPONSE;OTHER;ALCOHOL ABUSE
EVEROLIMUS;CYP3A5;rs776746;CC + CT;LADME-PK;DECREASED_CLEARANCE;DISEASE;HEART TRANSPLANTATION
NALTREXONE;;rs12749274;A;EFFICACY;DECREASED_RESPONSE;OTHER;ALCOHOL ABUSE
DEFERASIROX;ABCG2;rs13120400;CC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;BETA-THALASSEMIA AND RELATED DISEASES
FLUVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;INCREASED_CLINICAL_BENEFIT;;
FLUVASTATIN;APOE;rs429358;CC;EFFICACY;INCREASED_CLINICAL_BENEFIT;;
DOXORUBICIN;CBR1;rs20572;CC;LADME-PK;INCREASED_CLEARANCE;DISEASE;BREAST NEOPLASMS
DEHYDROARIPIPRAZOLE;CYP1A2;rs762551;AA;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
CLOZAPINE;CYP1A2;rs762551;AA;LADME-PK;DECREASED_EXPOSURE;OTHER;SCHIZOPHRENIA, OTHER:TOBACCO USE DISORDER
ETHANOL;OPRM1;rs1799971;AA;DOSAGE;INCREASED_DOSE;;
PREDNISOLONE;GATA3;rs3824662;AA;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
TACROLIMUS;GSTM3;rs7483;TT;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;LIVER TRANSPLANTATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;rs1051792;AG;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
ADALIMUMAB;TNF;rs1799724;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;rs1051792;GG;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
FLUOXETINE;HTR1B;rs130058;AA + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;MENTAL DISORDERS
ADALIMUMAB;TNF;rs1800629;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
CLOZAPINE;CYP1A2;rs762551;AA;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;SCHIZOPHRENIA
FLUVASTATIN;APOE;rs7412;TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;;
ADALIMUMAB;TNF;rs361525;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
CARBAMAZEPINE;CYP1A2;rs762551;AA;LADME-PK;INCREASED_CLEARANCE;OTHER;EPILEPSY
MORPHINE;SLC6A4;rs1042173;CC;DOSAGE;DECREASED_DOSE;OTHER;LUNG NEOPLASMS, OTHER:PAIN
FLUOROURACIL;ABCA2;rs2271862;G;LADME-PK;INCREASED_CLEARANCE;OTHER;COLORECTAL NEOPLASMS
FLUOXETINE;TPH2;rs4570625;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;MENTAL DISORDERS
5'-DEOXY-5-FLUOROURIDINE;ABCG5;rs6720173;C;LADME-PK;INCREASED_CLEARANCE;OTHER;COLORECTAL NEOPLASMS
METHOTREXATE;ADORA2A-AS1;rs17004921;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
ANTIEPILEPTICS;ABCB1;rs2032582;AA;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;EPILEPSY
ANTIEPILEPTICS;ABCB1;rs1045642;AA;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;EPILEPSY
ATENOLOL, HYDROCHLOROTHIAZIDE;;rs35123024;C;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERTENSION
ATENOLOL, HYDROCHLOROTHIAZIDE;ALDH1A2;rs261316;T;EFFICACY;DECREASED_RESPONSE;DISEASE;HYPERTENSION
CISPLATIN;REV3L;rs462779;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;OSTEOSARCOMA
CISPLATIN;REV1;rs3087403;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;OSTEOSARCOMA
ANTIEPILEPTICS;SCN1A;rs2298771;CC + CT;EFFICACY;INCREASED_RESISTANCE;OTHER;EPILEPSY
LOPINAVIR;SLCO1B1;rs4149056;C;LADME-PK;INCREASED_TROUGH CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE
FENTANYL;OPRM1;rs9384179;AA;DOSAGE, EFFICACY;INCREASED_DOSE;SIDE EFFECT;PAIN, POSTOPERATIVE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;LIVER TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;LIVER TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
FLUVASTATIN;CYP2C9;rs1057910;AC;LADME-PK;INCREASED_CONCENTRATIONS;;
FENTANYL;KCNJ6;rs2835859;TT;DOSAGE, EFFICACY;INCREASED_DOSE;SIDE EFFECT;PAIN, POSTOPERATIVE
ABIRATERONE;HSD3B1;rs1047303;AC;LADME-PK;INCREASED_METABOLISM;OTHER;PROSTATIC NEOPLASMS
FENTANYL;;rs2952768;CC;DOSAGE, EFFICACY;INCREASED_DOSE;SIDE EFFECT;PAIN, POSTOPERATIVE
FENTANYL;;rs11959113;AA;DOSAGE, EFFICACY;INCREASED_DOSE;SIDE EFFECT;PAIN, POSTOPERATIVE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;HEART TRANSPLANTATION
CYCLOPHOSPHAMIDE;GSTA1;rs3957356;CT;EFFICACY, TOXICITY, LADME-PK;DECREASED_RESPONSE;DISEASE;LUPUS NEPHRITIS
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
BILIRUBIN;SOD2;rs4880;GG;TOXICITY;INCREASED_CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;HEART TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
METHYLPHENIDATE;SLC6A2;rs5569;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
TACROLIMUS;POR;rs1057868;CT + TT;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;HEART TRANSPLANTATION
IVACAFTOR;CFTR;rs77010898;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;CYSTIC FIBROSIS
DOCETAXEL, DOXORUBICIN;AKR1C3;rs1937840;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;BREAST NEOPLASMS
ANTIDEPRESSANTS;GRIK4;rs1954787;TT;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;MAJOR DEPRESSIVE DISORDER
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HEMATOPOIETIC STEM CELL TRANSPLANTATION
ANTIDEPRESSANTS;GRIK4;rs1954787;C;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;OTHER;AN INTERNATIONAL NORMALIZED RATIO (INR) OF 2.0-3.0
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;VKORC1;rs7294;T;DOSAGE;INCREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
WARFARIN;CYP2C9;rs1057910;A;DOSAGE;INCREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_DOSE;;
BUPRENORPHINE;OPRM1;rs2075572;CC + CG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS
SELECTIVE SEROTONIN (5HT1) AGONISTS;PRDM16;rs2651899;C;EFFICACY;INCREASED_RESPONSE;OTHER;MIGRAINE WITH AURA, OTHER:MIGRAINE WITHOUT AURA
AFATINIB;NR1I2;rs6785049;AA + AG;LADME-PK;DECREASED_CLEARANCE;OTHER;NON-SMALL CELL LUNG CARCINOMA
WARFARIN;CYP2C9;rs4917639;C;DOSAGE;DECREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
LOPINAVIR;SLCO1B1;rs4149056;CT;LADME-PK;INCREASED_EXPOSURE;OTHER;HIV INFECTIOUS DISEASE
NALTREXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ALCOHOL ABUSE
ANTIDEPRESSANTS;ABCB1;rs1128503;A;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER
METHADONE;COMT;rs933271;CC + CT;EFFICACY;INCREASED_RESPONSE;OTHER;OPIOID-RELATED DISORDERS
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs2070959;AG;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;EPILEPSY
METHOTREXATE;MTHFR;rs1801131;GT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
VALPROIC ACID;GRIN2B;rs1019385;AC;DOSAGE, LADME-PK;DECREASED_DOSE;DISEASE;EPILEPSY
VALPROIC ACID;GRIN2B;rs1019385;CC;DOSAGE, LADME-PK;DECREASED_DOSE;DISEASE;EPILEPSY
METHOTREXATE;SLC19A1;rs1051266;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
CARBAMAZEPINE, CLOBAZAM, ETHOSUXIMIDE, LAMOTRIGINE, LEVETIRACETAM, OXCARBAZEPINE, VALPROIC ACID;SCN1A;rs2298771;C;EFFICACY;INCREASED_RESPONSE;DISEASE;EPILEPSY
LOPINAVIR;SLCO1B1;rs4149056;C;LADME-PK;INCREASED_TROUGH CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE
VALPROIC ACID;UGT1A6;rs1105879;AC;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;EPILEPSY
FLUVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE;;
EVEROLIMUS;CYP3A5;rs776746;CT;LADME-PK;DECREASED_TROUGH CONCENTRATION;OTHER;BREAST NEOPLASMS, OTHER:KIDNEY NEOPLASMS, OTHER:NEUROENDOCRINE TUMORS
WARFARIN;CYP4F2;rs2108622;C;DOSAGE;DECREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
AMISULPRIDE;SNAP25;rs8636;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
CLOPIDOGREL;ABCA1;rs2487032;A;LADME-PK;INCREASED_METABOLISM;;
CLOPIDOGREL;N6AMT1;rs2254638;G;LADME-PK;DECREASED_METABOLISM;;
TENOFOVIR;ABCG2;rs2231142;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
SIROLIMUS;ABCB1;rs2032582;A;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION
ANTIPSYCHOTICS;NRXN1;rs12467557;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
ANTIPSYCHOTICS;NRXN1;rs10490162;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
CLOPIDOGREL;CYP2C19;rs4986893;AA;EFFICACY;DECREASED_RESPONSE;;
DABIGATRAN;CES1;rs8192935;GG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;ATRIAL FIBRILLATION
ADALIMUMAB, CERTOLIZUMAB PEGOL, GOLIMUMAB, INFLIXIMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;BEHCET SYNDROME
CLOPIDOGREL;CYP2C19;rs4244285;AA;EFFICACY;DECREASED_RESPONSE;;
TACROLIMUS;CYP3A5;rs776746;CC;OTHER, LADME-PK;DECREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
BEVACIZUMAB;CFH;rs1061170;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;MACULAR DEGENERATION
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs2070959;GG;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;EPILEPSY
CISPLATIN, FLUOROURACIL;DPYD;rs3918290;CT;EFFICACY;DECREASED_RESPONSE;DISEASE;HEAD AND NECK NEOPLASMS
CISPLATIN, DOCETAXEL, IRINOTECAN;XRCC3;rs861539;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;STOMACH NEOPLASMS
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs6759892;GG;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;EPILEPSY
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs6759892;GT;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;EPILEPSY
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
VALPROIC ACID;UGT1A6;rs1105879;CC;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;EPILEPSY
10-MONOHYDROXY OXCARBAZEPINE;INSR;rs2396185;C;LADME-PK;DECREASED_CLEARANCE;OTHER;EPILEPSY
ETHANOL;OPRM1;rs1799971;AG;EFFICACY;INCREASED_RESPONSE;OTHER;ALCOHOL ABUSE
RISPERIDONE;HTR1A;rs6295;GG;DOSAGE, EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
FENTANYL;CACNA1E;rs3845446;CC + CT;DOSAGE;DECREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
FENTANYL;LAMB3;rs2076222;G;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE;PAIN, POSTOPERATIVE
CETUXIMAB;VEGFA;rs833061;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
CETUXIMAB;VEGFA;rs1570360;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
CISPLATIN, FLUOROURACIL, MITOXANTRONE;MECP2;rs1734791;A;EFFICACY;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA
CISPLATIN, FLUOROURACIL, MITOXANTRONE;MECP2;rs1734787;A;EFFICACY;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA
CISPLATIN, FLUOROURACIL, MITOXANTRONE;MECP2;rs17435;A;EFFICACY;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs5906072;T;EFFICACY;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA
PROCHLORPERAZINE;ANKK1, DRD2;rs1800497;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER;NAUSEA
PROCHLORPERAZINE;DRD2;rs1079597;CT + TT;EFFICACY;DECREASED_RESPONSE;OTHER;NAUSEA
METFORMIN;ATM;rs11212617;AC;EFFICACY;INCREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
MORPHINE;OPRK1;rs1051660;A;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE;PAIN
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs12613732;G;EFFICACY;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs5009910;C;EFFICACY;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA
ATORVASTATIN;HMGCR;rs17671591;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
ESCITALOPRAM;TPH1;rs1800532;GT + TT;EFFICACY;DECREASED_RESPONSE;OTHER;DEPRESSION
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs6752303;C;EFFICACY;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs10209881;C;EFFICACY;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA
DABIGATRAN;CES1;rs2244613;GG;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;ATRIAL FIBRILLATION
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs12999804;A;EFFICACY;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA
TACROLIMUS;CYP3A4;rs2740574;TT;DOSAGE;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
APATINIB, APATINIB METABOLITE M1-1;CYP2C9;rs34532201;TT;LADME-PK;INCREASED_EXPOSURE;OTHER;NEOPLASMS
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs5934731;C;EFFICACY;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs715171;C;EFFICACY;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs4932551;C;EFFICACY;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs7170769;T;EFFICACY;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs6458232;C;EFFICACY;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs7608731;C;EFFICACY;RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs758900656;A;LADME-PD;INCREASED_CLINICAL_BENEFIT;;
ALLOPURINOL, FEBUXOSTAT;AOX1;rs3731722;G;DOSAGE;DOSE;DISEASE;GOUT
PAZOPANIB;CYP3A4;rs35599367;AG;LADME-PK;DECREASED_CLEARANCE;OTHER;NEOPLASMS
RITUXIMAB;IL2;rs6822844;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;AUTOIMMUNE DISEASES
TACROLIMUS;CYP3A5;rs776746;TT;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
RITUXIMAB;IL2;rs6822844;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;SYSTEMIC LUPUS ERYTHEMATOSUS
ALLOPURINOL, FEBUXOSTAT;AOX1;rs11678615;T;DOSAGE;DOSE;DISEASE;GOUT
METHOTREXATE;MTHFR;rs1801131;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
ALLOPURINOL, FEBUXOSTAT;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs34650714;T;DOSAGE;DECREASED_DOSE;DISEASE;GOUT
ALLOPURINOL, FEBUXOSTAT;XDH;rs1884725;G;DOSAGE;DECREASED_DOSE;DISEASE;GOUT
ALLOPURINOL, FEBUXOSTAT;AOX1;rs75995567;T;DOSAGE;INCREASED_DOSE;DISEASE;GOUT
WARFARIN;CYP4F2;rs2108622;T;DOSAGE, LADME-PK;DOSE;;
WARFARIN;VKORC1;rs9923231;T;DOSAGE, LADME-PK;DOSE;;
WARFARIN;GGCX;rs699664;T;DOSAGE, LADME-PK;DOSE;;
METFORMIN;SLC22A1;rs622342;AC;EFFICACY;INCREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
PROPOFOL, REMIFENTANIL;ABCB1;rs1128503;GG;EFFICACY;INCREASED_RESPONSE;;
METHOTREXATE;ABCC3;rs4148416;TT;LADME-PK;INCREASED_CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
TACROLIMUS;CYP3A4;rs2740574;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
METHOTREXATE;SLC19A1;rs17004785;CG;LADME-PK;INCREASED_CLEARANCE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
DONEPEZIL;BCHE;rs1803274;T;EFFICACY;INCREASED_RESPONSE;DISEASE;ALZHEIMER DISEASE
CISPLATIN, DOXORUBICIN, METHOTREXATE;MTHFD1;rs2236225;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;OSTEOSARCOMA
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs9679162;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATOCELLULAR CARCINOMA
PAROXETINE;GDNF;rs2973049;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
PAROXETINE;GDNF;rs2216711;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL17RA;rs4819554;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
ATOMOXETINE;SLC6A2;rs3785143;T;EFFICACY;DECREASED_RESPONSE;DISEASE;ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY
PAROXETINE;BDNF;rs6265;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;rs396991;AC + CC;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
ROSUVASTATIN;CETP;rs5882;G;EFFICACY;INCREASED_RESPONSE;;
DISULFIRAM;DBH;rs1611115;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;ALCOHOL ABUSE
RIVAROXABAN;CYP3A5;rs776746;TT;LADME-PK;INCREASED_STEADY-STATE CONCENTRATION;OTHER;ATRIAL FIBRILLATION
RISPERIDONE;COMT;rs9606186;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
RIVAROXABAN;ABCB1;rs1045642;AA + AG;LADME-PK;INCREASED_CLEARANCE;OTHER;ATRIAL FIBRILLATION
TACROLIMUS;C6;rs10052999;CC + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
WARFARIN;VKORC1;rs9934438;GG;DOSAGE;INCREASED_DOSE;;
TACROLIMUS;C6;rs9200;CC + CT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
CISPLATIN, DOXORUBICIN, METHOTREXATE;ABCC2;rs717620;CT + TT;EFFICACY;DECREASED_RESPONSE;OTHER;OSTEOSARCOMA
RISPERIDONE;RGS4;rs2661319;C;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
LAMOTRIGINE;SLC22A1;rs628031;AA + AG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;EPILEPSY
RISPERIDONE;ANKK1;rs1800497;A;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
TACROLIMUS;CYP3A4;rs2740574;CT;LADME-PK;INCREASED_DOSE;OTHER;TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
CISPLATIN, DOXORUBICIN, METHOTREXATE;GSTP1;rs1695;AG + GG;EFFICACY;DECREASED_RESPONSE;OTHER;OSTEOSARCOMA
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
PHENYTOIN;CYP2C9;rs1057910;C;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;EPILEPSY
CARBAMAZEPINE;SCN1A;rs3812718;TT;DOSAGE;INCREASED_DOSE;DISEASE;EPILEPSY
PHENYTOIN;SCN1A;rs3812718;T;DOSAGE;INCREASED_DOSE;DISEASE;EPILEPSY
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;;
INDINAVIR;CYP3A4;rs2740574;CC;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
TACROLIMUS;ABCB1;rs2032582;T;LADME-PK;DECREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
ALPHA-HYDROXYMETOPROLOL;CYP2D6;rs28371738;A;LADME-PK;INCREASED_CONCENTRATIONS;;
RIVAROXABAN;ABCB1;rs1128503;AG + GG;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION
FLUVOXAMINE, MILNACIPRAN, PAROXETINE;HTR1A;rs6295;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
LANSOPRAZOLE;ABCB1;rs1045642;G;OTHER, LADME-PK;INCREASED_METABOLISM;;
FLUVOXAMINE, MILNACIPRAN, PAROXETINE;HTR1A;rs10042486;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
LAMOTRIGINE;ABCG2;rs2231142;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;EPILEPSY
RIVAROXABAN;ABCB1;rs1045642;AG + GG;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION
RIVAROXABAN;ABCB1;rs4148738;T;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;ATRIAL FIBRILLATION
PHENYTOIN;CYP2C9;rs1934969;AT + TT;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;EPILEPSY
DEXAMETHASONE, DIPHENHYDRAMINE, PACLITAXEL, RANITIDINE;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;HEAD AND NECK NEOPLASMS
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;DISEASE;ATRIAL FIBRILLATION, DISEASE:HEART VALVE REPLACEMENT, DISEASE:PULMONARY HYPERTENSION, DISEASE:PULMONARY EMBOLISM, DISEASE:VENOUS THROMBOSIS
HMG COA REDUCTASE INHIBITORS;APOC1;rs4420638;G;EFFICACY;DECREASED_RESPONSE;DISEASE;CARDIOVASCULAR DISEASE, DISEASE:HYPERCHOLESTEROLEMIA
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE;DECREASED_DOSE;DISEASE;ATRIAL FIBRILLATION, DISEASE:HEART VALVE REPLACEMENT, DISEASE:PULMONARY HYPERTENSION, DISEASE:PULMONARY EMBOLISM, DISEASE:VENOUS THROMBOSIS
PHOTODYNAMIC THERAPY;F13A1;rs5985;AA + AC;EFFICACY;DECREASED_RESPONSE;DISEASE;CHOROIDAL NEOVASCULARIZATION
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE;DISEASE;ATRIAL FIBRILLATION, DISEASE:HEART VALVE REPLACEMENT, DISEASE:PULMONARY HYPERTENSION, DISEASE:PULMONARY EMBOLISM, DISEASE:VENOUS THROMBOSIS
CITALOPRAM;TPH1;rs1800532;GT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
HMG COA REDUCTASE INHIBITORS;NPC1L1;rs2072183;G;EFFICACY;DECREASED_RESPONSE;DISEASE;CARDIOVASCULAR DISEASE, DISEASE:HYPERCHOLESTEROLEMIA
HMG COA REDUCTASE INHIBITORS;SORT1;rs629301;T;EFFICACY;DECREASED_RESPONSE;DISEASE;CARDIOVASCULAR DISEASE, DISEASE:HYPERCHOLESTEROLEMIA
MERCAPTOPURINE;NUDT15;rs116855232;CT;DOSAGE;DECREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
MYCOPHENOLIC ACID;UGT1A9;rs3832043;del;LADME-PK;DECREASED_METABOLISM;DISEASE;KIDNEY TRANSPLANTATION
BISOPROLOL;ACY3;rs2514036;T;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
MYCOPHENOLIC ACID;SLCO1B1;rs2306283;AA + AG;LADME-PK;DECREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
IMATINIB;BCL2L11;rs724710;T;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
FLUOROURACIL;DPYD;rs3918290;CT;LADME-PK;DECREASED_CLEARANCE;DISEASE;COLORECTAL NEOPLASMS
METOPROLOL;SEPTIN3;rs56234624;G;LADME-PK;INCREASED_CONCENTRATIONS;;
ALEMTUZUMAB, CHLORAMBUCIL, CYCLOPHOSPHAMIDE, FLUDARABINE, PREDNISONE, RITUXIMAB, VINCRISTINE;CXCL12;rs1801157;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL
MYCOPHENOLIC ACID;ABCC2;rs3740066;CT;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION
GEMCITABINE;RRM1;rs9937;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;PANCREATIC NEOPLASMS
TACROLIMUS;ABCB1;rs1045642;AA + AG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;LUNG TRANSPLANTATION
BEVACIZUMAB;CXCL8;rs4073;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;MACULAR DEGENERATION
GEMCITABINE;RRM1;rs183484;AC;EFFICACY, TOXICITY;DECREASED_RESPONSE;DISEASE;PANCREATIC NEOPLASMS
HYDROCHLOROTHIAZIDE;NEDD4L;rs4149601;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
SN-38;UGT1A1;rs4148323;AA;DOSAGE;INCREASED_CONCENTRATIONS;OTHER;NON-SMALL CELL LUNG CARCINOMA
COTININE GLUCURONIDE;UGT1A9;rs12471326;CT;LADME-PK;INCREASED_CONCENTRATIONS;;
NICOTINE;CYP2A6;rs145014075;GT;LADME-PK;INCREASED_CONCENTRATIONS;;
BEVACIZUMAB, RANIBIZUMAB;VEGFA;rs3025000;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;MACULAR DEGENERATION
GRANISETRON;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE;SIDE EFFECT;NAUSEA, SIDE EFFECT:VOMITING
WARFARIN;VKORC1;rs9923231;CC + CT;DOSAGE;INCREASED_DOSE;OTHER;HEART FAILURE
CARBAMAZEPINE;SCN1A;rs3812718;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;EPILEPSY
BEVACIZUMAB, RANIBIZUMAB;VEGFA;rs3025000;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;MACULAR DEGENERATION
CARBAMAZEPINE;SCN1A;rs3812718;TT;DOSAGE;INCREASED_DOSE;DISEASE;EPILEPSY
ETANERCEPT;CD84;rs6427528;AG;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
LOPINAVIR;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_TROUGH CONCENTRATION;OTHER;HIV INFECTIOUS DISEASE
CARBAMAZEPINE;SCN1A;rs2298771;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;EPILEPSY
METHADONE;OPRM1;rs10485058;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;OPIOID-RELATED DISORDERS
CARBAMAZEPINE;GABRA1;rs2290732;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;EPILEPSY
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;;
USTEKINUMAB;IL12B;rs3213094;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
GEMCITABINE;CDA;rs2072671;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;PANCREATIC NEOPLASMS
TOCILIZUMAB;IL6R;rs11265618;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
TOCILIZUMAB;IL6R;rs12083537;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
EFAVIRENZ;ABCB1;rs2032582;AA;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
ALFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;DISEASE;PAIN
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
EFAVIRENZ;ABCB1;rs1045642;AA;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
CETUXIMAB;FCGR3A;rs396991;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;HEAD AND NECK NEOPLASMS
CETUXIMAB;FCGR2A;rs1801274;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HEAD AND NECK NEOPLASMS
EFAVIRENZ;HNF4A;rs1884613;CC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
METHADONE;ALDH5A1;rs2760118;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;OPIOID-RELATED DISORDERS
ATAZANAVIR;UGT1A1;rs887829;TT;TOXICITY;INCREASED_DISCONTINUATION;;
PLATINUM COMPOUNDS;XRCC1;rs25487;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS, DISEASE:STOMACH NEOPLASMS
OLANZAPINE;CHAT;rs1880676;A;DOSAGE, EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
RAMIPRIL;ACE;rs4359;CC + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
RAMIPRIL;ACE;rs4344;AA + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERTENSION
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;DOSE;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;GLOMERULONEPHRITIS, MEMBRANOUS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
OXYCODONE;OPRD1;rs581111;AA + AG;EFFICACY;DECREASED_RESPONSE;;
PEGINTERFERON ALFA-2B, RIBAVIRIN;KLRK1;rs1049174;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
CITALOPRAM;CRHR2;rs2270007;CC + CG;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
RIFAMPIN;NR1I2;rs3732357;AA + AG;LADME-PK;DECREASED_EXPOSURE;OTHER;TUBERCULOSIS
METHOTREXATE;SLC19A1;rs1051266;CT + TT;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;OSTEOSARCOMA
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
OXYCODONE;;rs6848893;CT;EFFICACY;DECREASED_RESPONSE;;
PLATINUM COMPOUNDS;ATP7B;rs9535826;G;EFFICACY;INCREASED_RESPONSE;DISEASE;LUNG NEOPLASMS
DEXAMETHASONE;NR3C1;rs6198;CC;EFFICACY;INCREASED_TIME TO RESPONSE;OTHER;COVID-19
ANTIDEPRESSANTS;HTR2A;rs6313;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;BIPOLAR DISORDER, OTHER:DEPRESSION, OTHER:MAJOR DEPRESSIVE DISORDER
PLATINUM COMPOUNDS;ATP7B;rs9535828;A;EFFICACY;INCREASED_RESPONSE;DISEASE;LUNG NEOPLASMS
DEXAMETHASONE;NR3C1;rs33388;AA;EFFICACY;INCREASED_TIME TO RESPONSE;OTHER;COVID-19
RISPERIDONE;CCL2;rs4795893;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
RISPERIDONE;CCL2;rs4586;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
METHOTREXATE;FPGS;rs1544105;TT;EFFICACY;INCREASED_RESPONSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
ACENOCOUMAROL;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
METHOTREXATE;FPGS;rs1544105;TT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
DEXAMETHASONE;NR3C1;rs33389;TT;EFFICACY;INCREASED_TIME TO RESPONSE;OTHER;COVID-19
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;ABCA1;rs769705621;AAAA;EFFICACY;DECREASED_RESPONSE;OTHER;FAMILIAL HYPERCHOLESTEROLEMIA
CORTICOSTEROIDS, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ADRB2;rs1042713;A;EFFICACY;DECREASED_RESPONSE;DISEASE;ASTHMA
RISPERIDONE;CCL2;rs2857657;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
LAMOTRIGINE;UGT1A4;rs2011425;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;EPILEPSY
MERCAPTOPURINE;ITPA;rs1127354;A;LADME-PK;METABOLISM;DISEASE;ACUTE LYMPHOBLASTIC LEUKEMIA
LAMOTRIGINE;UGT1A4;rs2011425;TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;EPILEPSY
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;;
EFAVIRENZ;CYP2B6;rs28399499;CC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
NICOTINE;CHRNB3;rs4950;G;EFFICACY, OTHER;INCREASED_RESPONSE;OTHER;SMOKERS
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
PLATINUM COMPOUNDS;HMGB1;rs1412125;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;LUNG NEOPLASMS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;rs352139;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
NICOTINE;CHRNB3;rs13280604;G;EFFICACY, OTHER;INCREASED_RESPONSE;OTHER;SMOKERS
WARFARIN;VKORC1;rs749671;G;DOSAGE;INCREASED_DOSE;;
DEXAMETHASONE;CYP3A4;rs35599367;AG;EFFICACY;INCREASED_TIME TO RESPONSE;OTHER;COVID-19
PLATINUM COMPOUNDS;HMGB1;rs2249825;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;LUNG NEOPLASMS
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
EFAVIRENZ;CYP2B6;rs2279343;G;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
CISPLATIN, RADIOTHERAPY;XRCC1;rs25487;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;NASOPHARYNGEAL NEOPLASMS, DISEASE:TOBACCO USE DISORDER
LOSARTAN;ACE;rs4291;AT + TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;HYPERTENSION
VEGF/VEGFR (VASCULAR ENDOTHELIAL GROWTH FACTOR) INHIBITORS;VEGFA;rs699947;AC + CC;EFFICACY;INCREASED_RESPONSE;OTHER;MACULAR DEGENERATION
ACENOCOUMAROL;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
OXYCODONE;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE;;
ADALIMUMAB, INFLIXIMAB;IL12B;rs2546890;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
TACROLIMUS;CYP3A4;rs2740574;T;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
ADALIMUMAB, INFLIXIMAB;IVL;rs6661932;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
OPIOIDS;COMT;rs4680;AA + AG;DOSAGE;INCREASED_DOSE;OTHER;PAIN
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
USTEKINUMAB;TIRAP;rs8177374;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
NICOTINE;OPRM1;rs1799971;AG + GG;OTHER;INCREASED_EXPOSURE;OTHER;SCHIZOPHRENIA
USTEKINUMAB;TLR5;rs5744174;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs11938228;AA + AC;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;LY96;rs11465996;CG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs4696480;AT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
TACROLIMUS;CYP3A5;rs776746;C;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS, USTEKINUMAB;IL1B;rs1143623;CG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
WARFARIN;ABCB1;rs1045642;A;DOSAGE;INCREASED_DOSE;;
WARFARIN;APOE;rs429358;CC + CT;DOSAGE;DECREASED_DOSE;;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS, USTEKINUMAB;IL1B;rs1143627;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
REPAGLINIDE;NR1I2;rs2276706;GG;LADME-PK;DECREASED_METABOLISM;;
COTININE;OPRM1;rs510769;T;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE
RISPERIDONE;COMT;rs9606186;C;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
REPAGLINIDE;NR1I2;rs3814058;CC;LADME-PK;DECREASED_METABOLISM;;
ATEZOLIZUMAB, BEVACIZUMAB;IL7;rs16906115;AA;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;HEPATOCELLULAR CARCINOMA
COTININE;OPRM1;rs12209447;T;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE
RISPERIDONE;COMT;rs2020917;C;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
COTININE;OPRM1;rs3798676;T;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DECREASED_DOSE;;
FENTANYL;ABCB1;rs1045642;AA;DOSAGE;DECREASED_DOSE;;
RISPERIDONE;COMT;rs933271;C;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
COTININE;OPRM1;rs553202;T;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE
COTININE;OPRM1;rs1074287;G;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE
METHADONE;OPRD1;rs529520;AA + AC;DOSAGE;INCREASED_DOSE;DISEASE;HEROIN DEPENDENCE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION
COTININE;OPRM1;rs1799971;A;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE
COTININE;OPRM1;rs6912029;T;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE
PREDNISONE;EDNRA;rs5333;CC + CT;EFFICACY;INCREASED_RESISTANCE;DISEASE;NEPHROTIC SYNDROME
REPAGLINIDE;NR1I2;rs3814058;CC;LADME-PK;INCREASED_METABOLISM;;
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;TLR4;rs1927907;CC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;LIVER TRANSPLANTATION
PAZOPANIB;NR1I2;rs3814055;T;EFFICACY;DECREASED_RESPONSE;DISEASE;RENAL CELL CARCINOMA
ACENOCOUMAROL;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;DISEASE;ATRIAL FIBRILLATION
ADALIMUMAB, INFLIXIMAB;ZNF816;rs9304742;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
ACENOCOUMAROL;CALU;rs1043550;G;DOSAGE;INCREASED_DOSE;DISEASE;ATRIAL FIBRILLATION
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HIV INFECTIOUS DISEASE
TACROLIMUS;IL18;rs1946518;GG + GT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
ADALIMUMAB, INFLIXIMAB;NFKBIA;rs2145623;CC + CG;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
ADALIMUMAB, INFLIXIMAB;TNFRSF1B;rs1061624;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
REPAGLINIDE;NR1I2;rs2276706;GG;LADME-PK;INCREASED_METABOLISM;;
ADALIMUMAB, INFLIXIMAB;SLC9A8;rs645544;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
FLUOROURACIL, PLATINUM COMPOUNDS, RADIOTHERAPY;XRCC4;rs10040363;G;EFFICACY;DECREASED_RESPONSE;DISEASE;STOMACH NEOPLASMS
FENTANYL, REMIFENTANIL;OPRM1;rs79910351;TT;EFFICACY;DECREASED_RESPONSE;;
FLUOROURACIL, PLATINUM COMPOUNDS, RADIOTHERAPY;XRCC4;rs2075685;T;EFFICACY;DECREASED_RESPONSE;DISEASE;STOMACH NEOPLASMS
MYCOPHENOLIC ACID;SLCO1B1;rs4149056;TT;LADME-PK;INCREASED_EXPOSURE;OTHER;KIDNEY TRANSPLANTATION
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE;;
SIMVASTATIN;PPARA;rs4253728;AA + AG;LADME-PK;DECREASED_CLEARANCE;;
FLUOROURACIL, PLATINUM COMPOUNDS, RADIOTHERAPY;ERCC1;rs2298881;A;EFFICACY;INCREASED_RESPONSE;DISEASE;STOMACH NEOPLASMS
COTININE;OPRM1;rs563649;T;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE
COTININE;OPRM1;rs2075572;G;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE
SIMVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE;;
COTININE;OPRM1;rs7748401;G;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE
COTININE;OPRM1;rs495491;G;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE
COTININE;OPRM1;rs10457090;G;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE
COTININE;OPRM1;rs3778152;G;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE
PRAVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE;;
COTININE;OPRM1;rs589046;T;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;HEROIN DEPENDENCE
METHOTREXATE;NR1I2;rs3814055;T;LADME-PK;DECREASED_METABOLISM;DISEASE;OSTEOSARCOMA
METHOTREXATE;SLCO1B1;rs2306283;AA + AG;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
METHOTREXATE;ABCC3;rs4793665;C;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;OSTEOSARCOMA
METHOTREXATE;NR1I2;rs7643038;G;LADME-PK;DECREASED_METABOLISM;DISEASE;OSTEOSARCOMA
METHOTREXATE;ABCB1;rs9282564;C;LADME-PK;INCREASED_CONCENTRATIONS;;
METHOTREXATE;ABCG2;rs2231142;T;LADME-PK;DECREASED_METABOLISM;DISEASE;OSTEOSARCOMA
GLUCOCORTICOIDS;;rs17446593;AA;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;THROMBOCYTOPENIA
SUNITINIB;CYP3A5;rs776746;CC;LADME-PK;DECREASED_CLEARANCE;;
CLOZAPINE;NTRK2;rs10465180;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;SCHIZOPHRENIA
SIMVASTATIN;CYP3A5;rs776746;TT;LADME-PK;INCREASED_CLEARANCE;;
SIMVASTATIN ACID;SLCO1B1;rs4149056;CT;LADME-PK;DECREASED_CLEARANCE;;
SIMVASTATIN;SLCO2B1;rs12422149;AA;LADME-PK;INCREASED_CLEARANCE;;
WARFARIN;CYP2C9;rs9332238;G;DOSAGE;INCREASED_DOSE;;
CLOPIDOGREL;P2RY12;rs6809699;AA + AC;EFFICACY;INCREASED_RESISTANCE;OTHER;CORONARY DISEASE
EFAVIRENZ;CYP2B6;rs3745274;T;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE
DOXORUBICIN;CBR1;rs20572;CC;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;ADRA2A;rs1800544;CG;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
ERLOTINIB;ABCB1;rs1045642;AA;TOXICITY, LADME-PK;DECREASED_CLEARANCE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
ERLOTINIB;ABCB1;rs1128503;AA;TOXICITY, LADME-PK;DECREASED_CLEARANCE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
NICOTINE;CYP2A6;rs28399468;A;LADME-PK;DECREASED_METABOLISM;;
METHOTREXATE;ABCC1;rs28364006;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
DOLUTEGRAVIR;NR1I2;rs2472677;TT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE
ERLOTINIB;ABCB1;rs2032582;AA;TOXICITY, LADME-PK;DECREASED_CLEARANCE;DISEASE;NON-SMALL CELL LUNG CARCINOMA
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;;
LOSARTAN;AGTR1;rs5186;CC;EFFICACY;DECREASED_RESPONSE;DISEASE;ESSENTIAL HYPERTENSION
CLOPIDOGREL;KDR;rs2305948;T;EFFICACY;DECREASED_RESPONSE;DISEASE;CORONARY DISEASE
LAMOTRIGINE;UGT2B7;rs7668258;CT + TT;DOSAGE;INCREASED_DOSE;OTHER;EPILEPSY
MERCAPTOPURINE;NUDT15;rs73189762;T;DOSAGE;DECREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
METFORMIN;ARFGEF3;rs143276236;AC;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
TRASTUZUMAB;ERBB2;rs1136201;G;TOXICITY;RESPONSE;;
DOXORUBICIN;CBR1;rs9024;GG;LADME-PK;INCREASED_CLEARANCE;DISEASE;BREAST NEOPLASMS
METFORMIN;PRKAB2;rs7541245;A;EFFICACY;DECREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;DOSAGE;DECREASED_DOSE;DISEASE;INFLAMMATORY BOWEL DISEASES, DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
TACROLIMUS;POR;rs1057868;CT + TT;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
DOXORUBICIN;CBR1;rs9024;GG;LADME-PK;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS
DOXORUBICIN;CBR1;rs9024;GG;LADME-PK;DECREASED_EXPOSURE;DISEASE;BREAST NEOPLASMS
PRAMIPEXOLE;DRD3;rs6280;T;EFFICACY;INCREASED_RESPONSE;;
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE;;
WARFARIN;VKORC1;rs7196161;GG;DOSAGE;DECREASED_DOSE;;
ANTIDEPRESSANTS, BENZODIAZEPINE DERIVATIVES, MIRTAZAPINE, SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GAL;rs948854;C;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
TACROLIMUS;CYP3A5;rs776746;CC;LADME-PK;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;VKORC1;rs9934438;GG;DOSAGE;INCREASED_DOSE;;
SUFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;PREGNANCY
WARFARIN;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE;;
TACROLIMUS;CYP3A5;rs41303343;A;DOSAGE, LADME-PK;DECREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
METFORMIN;SLC22A1;rs628031;GG;EFFICACY;INCREASED_RESPONSE;OTHER;DIABETES MELLITUS, TYPE 2
TACROLIMUS;CYP3A5;rs10264272;T;DOSAGE, LADME-PK;DECREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
WARFARIN;VKORC1;rs2884737;AA;DOSAGE;INCREASED_DOSE;;
WARFARIN;VKORC1;rs61742245;A;DOSAGE;INCREASED_DOSE;;
TACROLIMUS;CYP3A5;rs776746;C;DOSAGE, LADME-PK;DECREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
MYCOPHENOLIC ACID;ABCC2;rs717620;CC;LADME-PK;INCREASED_EXPOSURE;OTHER;KIDNEY TRANSPLANTATION
WARFARIN;PRSS53, VKORC1;rs2359612;A;DOSAGE;DECREASED_DOSE;;
CAFFEINE;CYP1A2;rs762551;AA;OTHER, LADME-PK;INCREASED_METABOLISM;DISEASE;TOBACCO USE DISORDER
DOXORUBICIN;CBR1;rs20572;CC;LADME-PK;DECREASED_EXPOSURE;DISEASE;BREAST NEOPLASMS
WARFARIN;GGCX;rs11676382;CG;DOSAGE;DECREASED_DOSE;;
CAFFEINE;CYP1A2;rs762551;AA;OTHER, LADME-PK;INCREASED_METABOLISM;OTHER;HEAVY COFFEE CONSUMPTION
METHOTREXATE;ATIC;rs2372536;GG;EFFICACY;DECREASED_RESPONSE;OTHER;RHEUMATOID ARTHRITIS
TACROLIMUS;CYP3A4;rs35599367;AA + AG;LADME-PK;DECREASED_CLEARANCE;OTHER;LIVER TRANSPLANTATION
TACROLIMUS;CYP3A4;rs2740574;C;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A4;rs35599367;A;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_CLEARANCE;OTHER;LIVER TRANSPLANTATION
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
WARFARIN;PRSS53, VKORC1;rs7294;T;DOSAGE;INCREASED_DOSE;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL9;rs2069885;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;SPONDYLITIS, ANKYLOSING
RITUXIMAB;FCGR3A;rs396991;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;NEUROMYELITIS OPTICA
PREDNISOLONE;CD40;rs1883832;CC;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;THROMBOCYTOPENIA
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_METABOLISM;OTHER;LIVER TRANSPLANTATION
METFORMIN;SLC47A1;rs2289669;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
ERENUMAB;CALCRL;rs6710852;G;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;MIGRAINE WITH AURA, OTHER:MIGRAINE WITHOUT AURA
TACROLIMUS;ABCB1;rs2032582;AA + TT;DOSAGE, LADME-PK;DECREASED_CLEARANCE;OTHER;LIVER TRANSPLANTATION
WARFARIN;VKORC1;rs7294;CC;DOSAGE;DECREASED_DOSE;;
HALOTHANE;RYR1;rs118192161;T;OTHER;INCREASED_RESPONSE;;
WARFARIN;VKORC1;rs8050894;CC;DOSAGE;INCREASED_DOSE;;
WARFARIN;VKORC1;rs2359612;GG;DOSAGE;INCREASED_DOSE;;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL5;rs2069812;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;SPONDYLITIS, ANKYLOSING
BETA BLOCKING AGENTS, SELECTIVE;BST1;rs28404156;A;EFFICACY;INCREASED_RESPONSE;OTHER;HYPERTENSION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;HEPATITIS C VIRUS INFECTION, DISEASE:HIV INFECTIOUS DISEASE
TAMOXIFEN;CYP19A1;rs4646;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;BREAST NEOPLASMS, DISEASE:MENOPAUSE
BISPHOSPHONATES;FDPS;rs2297480;T;EFFICACY;INCREASED_RESPONSE;DISEASE;OSTEOPOROSIS
SIMVASTATIN;CETP;rs5882;A;EFFICACY;INCREASED_RESPONSE;DISEASE;HYPERCHOLESTEROLEMIA
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;APOE;rs405509;TT;EFFICACY;INCREASED_RESPONSE;OTHER;MAJOR DEPRESSIVE DISORDER
METHOTREXATE;ABCG2;rs17731538;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;C;EFFICACY;INCREASED_RESPONSE;DISEASE;CROHN DISEASE, DISEASE:INFLAMMATORY BOWEL DISEASES, DISEASE:PSORIASIS, DISEASE:SPONDYLARTHROPATHIES
CYCLOSPORINE;UMOD;rs12917707;GT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;KIDNEY TRANSPLANTATION
MODAFINIL;ABCB1;rs2032582;AC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;NARCOLEPSY
MODAFINIL;ABCB1;rs1045642;AG;EFFICACY;INCREASED_RESPONSE;DISEASE;NARCOLEPSY
WARFARIN;MYC;rs4645962;CT;DOSAGE;DECREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
WARFARIN;MYC;rs4645943;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
CARBAMAZEPINE;EPHX1;rs2234922;G;DOSAGE, LADME-PK;DECREASED_METABOLISM;DISEASE;EPILEPSY
MODAFINIL;ABCB1;rs1128503;AG;EFFICACY;INCREASED_RESPONSE;DISEASE;NARCOLEPSY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs361525;G;EFFICACY;INCREASED_RESPONSE;DISEASE;CROHN DISEASE, DISEASE:INFLAMMATORY BOWEL DISEASES, DISEASE:PSORIASIS, DISEASE:SPONDYLARTHROPATHIES
BISPHOSPHONATES;FDPS;rs11264359;A;EFFICACY;INCREASED_RESPONSE;DISEASE;OSTEOPOROSIS
WARFARIN;MYC;rs4645974;CC;DOSAGE;INCREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;G;EFFICACY;INCREASED_RESPONSE;DISEASE;CROHN DISEASE, DISEASE:INFLAMMATORY BOWEL DISEASES, DISEASE:PSORIASIS, DISEASE:SPONDYLARTHROPATHIES
ATORVASTATIN, SIMVASTATIN;ABCC2;rs717620;T;EFFICACY;DECREASED_DOSE;;
LEFLUNOMIDE;DHODH;rs3213422;CC;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
ANTIPSYCHOTICS;DRD2;rs1799732;G;EFFICACY;INCREASED_RESISTANCE;OTHER;MOOD DISORDER, OTHER:SCHIZOPHRENIA
IMATINIB;SLC22A4;rs1050152;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
RISPERIDONE;HTR2A;rs6313;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA
ANTIPSYCHOTICS;HTR2A;rs7997012;AG;EFFICACY;INCREASED_RESISTANCE;OTHER;MOOD DISORDER, OTHER:SCHIZOPHRENIA
METHADONE;CYP2B6;rs3745274;TT;DOSAGE, LADME-PK;DECREASED_DOSE;DISEASE;HEROIN DEPENDENCE
METHADONE;ABCB1;rs1045642;AA + AG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;OPIOID-RELATED DISORDERS
OLANZAPINE;HTR2A;rs6313;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DOSE;;
OLANZAPINE;HTR2A;rs6313;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA
CARBAMAZEPINE;EPHX1;rs1051740;CC;LADME-PK;INCREASED_METABOLISM;DISEASE;EPILEPSY
EFAVIRENZ;CYP2B6;rs3745274;GG;LADME-PK;INCREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
CARBAMAZEPINE;EPHX1;rs2234922;GG;LADME-PK;INCREASED_METABOLISM;DISEASE;EPILEPSY
AZATHIOPRINE, MERCAPTOPURINE;ITPA;rs7270101;AC + CC;TOXICITY, LADME-PK;INCREASED_METABOLISM;DISEASE;INFLAMMATORY BOWEL DISEASES, DISEASE:ACUTE LYMPHOBLASTIC LEUKEMIA
IMATINIB;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
IMATINIB;SLC22A4;rs1050152;TT;EFFICACY;DECREASED_RESPONSE;DISEASE;CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
ETHANOL;OPRM1;rs3778150;CC + CT;;DECREASED_RESPONSE;;
CARBAMAZEPINE;ABCB1;rs1045642;AG;LADME-PK;INCREASED_DOSE;DISEASE;EPILEPSY
ANTIEPILEPTICS;ABCB1;rs1045642;AG;EFFICACY;INCREASED_RESISTANCE;DISEASE;EPILEPSY
RALOXIFENE;COMT;rs737865;AG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE DISORDER
PACLITAXEL;ABCC2;rs717620;CT;TOXICITY;DECREASED_DOSE;SIDE EFFECT;PERIPHERAL NERVOUS SYSTEM DISEASES
RALOXIFENE;COMT;rs737865;AA;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE DISORDER
BUPRENORPHINE;OPRD1;rs678849;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER;OPIOID-RELATED DISORDERS
METHADONE;ABCB1;rs2032582;AC;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS
ETHANOL;OPRM1;rs1799971;AG + GG;OTHER;INCREASED_EXPOSURE;;
ANTIEPILEPTICS;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESISTANCE;DISEASE;EPILEPSY
RISPERIDONE;TNIK;rs7627954;CC;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA
RALOXIFENE;COMT;rs4818;CG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE DISORDER
METHADONE;CYP3A4;rs35599367;AG;LADME-PK;DECREASED_CLEARANCE;DISEASE;OPIOID-RELATED DISORDERS
SUNITINIB;ABCB1;rs2032582;AA + AT;DOSAGE, TOXICITY;INCREASED_DOSE;DISEASE;RENAL CELL CARCINOMA
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;OTHER;SYSTEMIC LUPUS ERYTHEMATOSUS
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNF;rs1800629;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
SUNITINIB;ABCB1;rs1128503;AA;DOSAGE, TOXICITY;INCREASED_DOSE;DISEASE;RENAL CELL CARCINOMA
METHADONE;ABCB1;rs1045642;AA;LADME-PK;INCREASED_CLEARANCE;DISEASE;OPIOID-RELATED DISORDERS
METHADONE;ABCB1;rs1128503;AG;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;OPIOID-RELATED DISORDERS
METHADONE;POR;rs1057868;CT + TT;LADME-PK;INCREASED_CLEARANCE;DISEASE;OPIOID-RELATED DISORDERS
METHADONE;CYP2B6;rs2279343;AA;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE
DOLUTEGRAVIR;ABCG2;rs2231142;TT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE
METHADONE;CYP2B6;rs3745274;GG;DOSAGE;INCREASED_DOSE;OTHER;HEROIN DEPENDENCE
PREDNISOLONE;TLR4;rs4986791;T;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;THROMBOCYTOPENIA
PERAMPANEL;CYP3A4;rs4986908;CG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;EPILEPSY
TELBIVUDINE;TK2;rs3826160;CC + CT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;HEPATITIS B, CHRONIC
WARFARIN;EPHX1;rs1877724;TT;DOSAGE;DECREASED_DOSE;;
NEVIRAPINE;CYP2B6;rs3745274;TT;TOXICITY, LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
ETHANOL;OPRM1;rs3778150;CC + CT;DOSAGE;INCREASED_DOSE;;
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;RESPONSE;DISEASE;CYSTIC FIBROSIS
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;INCREASED_RESPONSE;;
NEVIRAPINE;CYP2B6;rs3745274;T;OTHER, LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
NEVIRAPINE;CYP2C19;rs12768009;AA;OTHER, LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;;
ESCITALOPRAM;CYP2C18;rs11188059;G;LADME-PK;DECREASED_CONCENTRATIONS;;
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;PRKCE;rs6720975;T;EFFICACY;INCREASED_RESPONSE;OTHER;ALZHEIMER DISEASE
ESCITALOPRAM;CYP2C18;rs2860840;T;LADME-PK;DECREASED_CONCENTRATIONS;;
EFAVIRENZ;CYP2B6;rs2279345;TT;LADME-PK;DECREASED_METABOLISM;DISEASE;HIV INFECTIOUS DISEASE
PERAMPANEL;CYP3A4;rs2242480;CT + TT;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;EPILEPSY
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;;rs17798800;T;EFFICACY;DECREASED_RESPONSE;DISEASE;ALZHEIMER DISEASE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;;
PREDNISOLONE;TLR4;rs4986790;G;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;THROMBOCYTOPENIA
METHADONE;ABCB1;rs2032582;CC;DOSAGE;DECREASED_DOSE;OTHER;HEROIN DEPENDENCE
METHADONE;ABCB1;rs1045642;AA;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;HEROIN DEPENDENCE
SN-38;ABCB1;rs12720066;AC + CC;LADME-PK;DECREASED_EXPOSURE;DISEASE;COLORECTAL NEOPLASMS
ANTIPSYCHOTICS;GABRB1;rs4627835;T;DOSAGE;INCREASED_DOSE;DISEASE;SCHIZOAFFECTIVE DISORDER, DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;GABRB1;rs16860087;A;DOSAGE;INCREASED_DOSE;DISEASE;SCHIZOAFFECTIVE DISORDER, DISEASE:SCHIZOPHRENIA
WARFARIN;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE;OTHER;A STABLE INTERNATIONAL NORMALIZED RATIO OF BETWEEN TWO AND THREE
SN-38;ABCC1;rs35621;CT + TT;LADME-PK;INCREASED_EXPOSURE;DISEASE;COLORECTAL NEOPLASMS
CARBAMAZEPINE;ABCB1;rs1045642;AA;DOSAGE;INCREASED_DOSE;OTHER;EPILEPSY
LITHIUM;ASIC2;rs11869731;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
SN-38;ABCC1;rs6498588;AT + TT;LADME-PK;INCREASED_EXPOSURE;DISEASE;COLORECTAL NEOPLASMS
CAPECITABINE, FLUOROURACIL;HLA-G;rs9380142;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
ANTIDEPRESSANTS;MAPK1;rs8136867;AG;EFFICACY;INCREASED_RESPONSE;DISEASE;MENTAL DISORDERS
WARFARIN;VKORC1;rs8050894;G;DOSAGE;DECREASED_DOSE;;
CAPECITABINE, FLUOROURACIL;HLA-G;rs17179108;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
WARFARIN;VKORC1;rs9923231;CC;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE;HEART DISEASES
PHENYTOIN;CYP2C9;rs9332238;A;LADME-PK;INCREASED_CONCENTRATIONS;;
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;CHAT;rs3793790;G;EFFICACY;INCREASED_RESPONSE;DISEASE;ALZHEIMER DISEASE
FLUVOXAMINE;COMT;rs4680;GG;EFFICACY;DECREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
LITHIUM;OR52E2;rs16909440;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
LITHIUM;OR52J3;rs2499984;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;INCREASED_RESPONSE;;
ANTIDEPRESSANTS;CREB1;rs889895;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;MAJOR DEPRESSIVE DISORDER
DOLUTEGRAVIR;UGT1A1;rs887829;CT + TT;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE, OTHER:TUBERCULOSIS
LITHIUM;;rs16973410;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;BIPOLAR DISORDER
MERCAPTOPURINE;TPMT;rs1142345;C;EFFICACY;EXPOSURE;DISEASE;LEUKEMIA
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;INCREASED_RESPONSE;;
DOLUTEGRAVIR;AADAC;rs1803155;AG + GG;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE, OTHER:TUBERCULOSIS
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;CHAT;rs2177370;A;EFFICACY;INCREASED_RESPONSE;DISEASE;ALZHEIMER DISEASE
METHOTREXATE;ATIC;rs2372536;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
ZIDOVUDINE;UGT2B7;rs28365062;G;LADME-PK;INCREASED_METABOLISM;;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DOSE;DISEASE;ATRIAL FIBRILLATION, DISEASE:VENOUS THROMBOEMBOLISM
CHOLESTEROL;APOE;rs429358;TT;TOXICITY;INCREASED_CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
METHADONE;DRD2;rs6275;AA;DOSAGE, LADME-PK;DECREASED_DOSE;DISEASE;HEROIN DEPENDENCE
METFORMIN;SLC47A2;rs12943590;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
ATENOLOL, CARVEDILOL, DILTIAZEM, METOPROLOL, VERAPAMIL;ADRB1;rs1801253;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE;ATRIAL FIBRILLATION
METHADONE;DRD2;rs1799978;CC;DOSAGE, LADME-PK;DECREASED_DOSE;DISEASE;HEROIN DEPENDENCE
METFORMIN;SLC22A2;rs316019;AA + AC;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
CARBAMAZEPINE;ABCB1;rs1128503;AA + AG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;EPILEPSY
CARBAMAZEPINE;ABCB1;rs2032582;AA + AC;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;EPILEPSY
ERYTHROMYCIN;ABCC2;rs717620;TT;OTHER, LADME-PK;INCREASED_METABOLISM;;
WARFARIN;GGCX;rs11676382;CG + GG;DOSAGE;DECREASED_DOSE;;
CARBAMAZEPINE;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;EPILEPSY
ABIRATERONE, DUTASTERIDE;HSD3B1;rs1047303;AC;EFFICACY;DECREASED_RESPONSE;OTHER;PROSTATIC NEOPLASMS
AZATHIOPRINE;PACSIN2;rs2413739;CT + TT;EFFICACY;DECREASED_RESPONSE;OTHER;IRRITABLE BOWEL SYNDROME
SILDENAFIL;NOS3;rs2070744;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;ERECTILE DYSFUNCTION
NEVIRAPINE;CYP2B6;rs3745274;TT;TOXICITY, LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
ABIRATERONE;SRD5A2;rs523349;CC;LADME-PK;INCREASED_METABOLISM;OTHER;PROSTATIC NEOPLASMS
TRIGLYCERIDES;CYP19A1;rs10046;A;OTHER;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS, DISEASE:MENOPAUSE
TRIGLYCERIDES;CYP19A1;rs3759811;C;OTHER;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS, DISEASE:MENOPAUSE
WARFARIN;VKORC1;rs7196161;A;DOSAGE;DOSE;DISEASE;ATRIAL FIBRILLATION, DISEASE:PULMONARY EMBOLISM, DISEASE:STROKE, DISEASE:VENOUS THROMBOSIS
HDL CHOLESTEROL;CYP19A1;rs1008805;G;OTHER;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS, DISEASE:MENOPAUSE
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
TRIGLYCERIDES;CYP19A1;rs2289105;C;OTHER;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS, DISEASE:MENOPAUSE
WARFARIN;VKORC1;rs7196161;G;DOSAGE;DOSE;;
METHOTREXATE;SLC19A1;rs1051296;AC + CC;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
HDL CHOLESTEROL;CYP19A1;rs10046;G;OTHER;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS, DISEASE:MENOPAUSE
FENTANYL;CYP3A4;rs2242480;T;DOSAGE;DECREASED_DOSE;OTHER;PAIN, POSTOPERATIVE
HDL CHOLESTEROL;CYP19A1;rs2289105;T;OTHER;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS, DISEASE:MENOPAUSE
LEFLUNOMIDE;ESR1;rs2234693;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
NEVIRAPINE;CYP2B6;rs3745274;GT;TOXICITY, LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
LEFLUNOMIDE;ESR1;rs9340799;AA;EFFICACY;INCREASED_RESPONSE;DISEASE;RHEUMATOID ARTHRITIS
USTEKINUMAB;C9orf72;rs774359;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
METHOTREXATE;GGH;rs3758149;GG;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
HDL CHOLESTEROL;CYP19A1;rs4646;A;OTHER;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS, DISEASE:MENOPAUSE
USTEKINUMAB;IL13;rs848;AA + AC;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
TRIGLYCERIDES;CYP19A1;rs700518;C;OTHER;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS, DISEASE:MENOPAUSE
USTEKINUMAB;ZNF816;rs9304742;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
TRIGLYCERIDES;CYP19A1;rs4775936;C;OTHER;DECREASED_CONCENTRATIONS;DISEASE;BREAST NEOPLASMS, DISEASE:MENOPAUSE
WARFARIN;GGCX;rs11676382;CG + GG;DOSAGE;DECREASED_DOSE;;
USTEKINUMAB;STAT4;rs7574865;GT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
USTEKINUMAB;SLC22A4;rs1050152;CT;EFFICACY;INCREASED_RESPONSE;DISEASE;PSORIASIS
ETHANOL;OPRM1;rs1799971;AG + GG;OTHER;INCREASED_RESPONSE;OTHER;ALCOHOL ABUSE
NICOTINE;CHRNA5;rs16969968;GG;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER
WARFARIN;STX1B;rs72800847;AA + AG;DOSAGE;DECREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
WARFARIN;CYP1A1;rs3826041;CC;DOSAGE;INCREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
VARENICLINE;CHRNA5;rs16969968;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER;TOBACCO USE DISORDER
WARFARIN;DNMT3A;rs2304429;TT;DOSAGE;INCREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
WARFARIN;NQO1;rs10517;AA;DOSAGE;INCREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
RALOXIFENE;ESR1;rs2234693;TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;SCHIZOPHRENIA, OTHER:SCHIZOAFFECTIVE DISORDER
ACENOCOUMAROL, PHENPROCOUMON;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;;
FENTANYL;DRD1;rs966775;AG + GG;EFFICACY;INCREASED_CONCENTRATIONS;OTHER;PAIN, POSTOPERATIVE
FLUTICASONE / SALMETEROL;CHRM2;rs8191992;A;EFFICACY;RESPONSE;DISEASE;ASTHMA
METHOTREXATE;MTHFR;rs1801133;AA + AG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;NON-HODGKIN LYMPHOMA
WARFARIN;VKORC1;rs9923231;A;DOSAGE;DOSE;;
PHENPROCOUMON;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;;
WARFARIN;CYP2C9;rs1057910;AA;DOSAGE;INCREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
ARIPIPRAZOLE, RISPERIDONE;DRD2;rs2514218;CC;EFFICACY;INCREASED_RESPONSE;OTHER;PSYCHOTIC DISORDER, OTHER:SCHIZOAFFECTIVE DISORDER, OTHER:SCHIZOPHRENIA
VORICONAZOLE;ABCG2;rs2231142;GT + TT;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LEUKEMIA, OTHER:LYMPHOMA, OTHER:MYELODYSPLASTIC SYNDROMES
WARFARIN;STX1B;rs4889606;AG + GG;DOSAGE;DECREASED_DOSE;;
WARFARIN;UGT1A1;rs887829;CC;DOSAGE;DECREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
WARFARIN;CYP4F2;rs2108622;CC + CT;DOSAGE;DECREASED_DOSE;DISEASE;HEART VALVE REPLACEMENT
AZATHIOPRINE, MERCAPTOPURINE;ITPA;rs1127354;AA + AC;LADME-PK;DECREASED_METABOLISM;DISEASE;INFLAMMATORY BOWEL DISEASES
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION, OTHER:HEART VALVE REPLACEMENT, OTHER:PULMONARY EMBOLISM
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SHMT1;rs1979277;A;EFFICACY;INCREASED_RESPONSE;DISEASE;COLORECTAL NEOPLASMS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL6;rs1800795;G;EFFICACY;DECREASED_RESPONSE;DISEASE;PSORIASIS
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE;INCREASED_DOSE;OTHER;ATRIAL FIBRILLATION, OTHER:HEART VALVE REPLACEMENT, OTHER:PULMONARY EMBOLISM
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;OTHER;ATRIAL FIBRILLATION, OTHER:HEART VALVE REPLACEMENT, OTHER:PULMONARY EMBOLISM
PLATINUM COMPOUNDS;;rs6983267;GG + GT;EFFICACY;INCREASED_RESPONSE;DISEASE;LUNG NEOPLASMS
METFORMIN;SLC22A2;rs316009;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER;PAIN, OTHER:PAIN, POSTOPERATIVE
ATORVASTATIN;SLCO1B1;rs4149056;C;LADME-PK;INCREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;HYPERCHOLESTEROLEMIA
CYCLOSPORINE;CYP3A4;rs35599367;AA + AG;TOXICITY, LADME-PK;DECREASED_CLEARANCE;DISEASE;KIDNEY TRANSPLANTATION
PLATINUM COMPOUNDS;MALAT1;rs619586;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE;LUNG NEOPLASMS
PLATINUM COMPOUNDS;HOTAIR;rs7958904;CC + CG;EFFICACY;DECREASED_RESPONSE;DISEASE;LUNG NEOPLASMS
PLATINUM COMPOUNDS;H19;rs2839698;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE;LUNG NEOPLASMS
TACROLIMUS;CYP3A4;rs35599367;AG;DOSAGE;DECREASED_DOSE;DISEASE;KIDNEY TRANSPLANTATION
CARBAMAZEPINE;EPHX1;rs1051740;C;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;EPILEPSY
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_DOSE;;
FLUTICASONE / SALMETEROL;CHRM2;rs6962027;A;EFFICACY;RESPONSE;DISEASE;ASTHMA
NICOTINE;OPRM1;rs1799971;AG + GG;OTHER;INCREASED_EXPOSURE;;
BETA BLOCKING AGENTS;ADRB1;rs1801253;C;EFFICACY;INCREASED_RESPONSE;OTHER;CARDIOMYOPATHY, DILATED
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_DOSE;DISEASE;STROKE
BETA BLOCKING AGENTS;ADRB2;rs1042713;A;EFFICACY;INCREASED_RESPONSE;OTHER;CARDIOMYOPATHY, DILATED
FLUTICASONE / SALMETEROL;CHRM2;rs6962027;A;EFFICACY;RESPONSE;DISEASE;ASTHMA
CARBAMAZEPINE;EPHX1;rs2234922;G;DOSAGE, LADME-PK;INCREASED_DOSE;DISEASE;EPILEPSY
FLUTICASONE PROPIONATE;CRHR1;rs1876831;T;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
RISPERIDONE;TNIK;rs2088885;AA;EFFICACY;INCREASED_RESPONSE;OTHER;SCHIZOPHRENIA
FLUTICASONE PROPIONATE;CRHR1;rs1876828;T;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
METFORMIN;CSMD1;rs2617102;AC + CC;EFFICACY;DECREASED_RESPONSE;DISEASE;DIABETES MELLITUS
FLUTICASONE PROPIONATE;CRHR1;rs1876829;C;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
FLUTICASONE PROPIONATE;CRHR1;rs739645;G;EFFICACY;INCREASED_RESPONSE;DISEASE;ASTHMA
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DOSE;;
NEVIRAPINE;CYP2B6;rs3745274;T;TOXICITY, LADME-PK;DECREASED_CLEARANCE;DISEASE;HIV INFECTIOUS DISEASE
NICOTINE;POR;rs1057868;CT + TT;LADME-PK;INCREASED_METABOLISM;PK;CYP2A6 NORMAL, BUT NOT REDUCED, METABOLIZERS
CARBAMAZEPINE;SCN1A;rs3812718;TT;LADME-PK;INCREASED_METABOLISM;DISEASE;EPILEPSY
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE;DISEASE;ATRIAL FIBRILLATION
VORICONAZOLE;CYP2C18;rs2860840;T;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LEUKEMIA, OTHER:LYMPHOMA, OTHER:MYELODYSPLASTIC SYNDROMES
VORICONAZOLE;CYP2C18;rs11188059;G;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;LEUKEMIA, OTHER:LYMPHOMA, OTHER:MYELODYSPLASTIC SYNDROMES
REMIFENTANIL;ABCB1;rs1045642;GG;DOSAGE;INCREASED_DOSE;;
WARFARIN;GGCX;rs12714145;CT + TT;DOSAGE;DECREASED_DOSE;OTHER;ATRIAL FIBRILLATION, OTHER:HEART VALVE REPLACEMENT, OTHER:PULMONARY EMBOLISM
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_DOSE;DISEASE;ATRIAL FIBRILLATION
REMIFENTANIL;ABCB1;rs1045642;GG;EFFICACY;DECREASED_RESPONSE;;
FLUOROURACIL;DPYD;rs1801159;CC + CT;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;COLORECTAL NEOPLASMS
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;DISEASE;ATRIAL FIBRILLATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE;CHRONIC HEPATITIS C VIRUS INFECTION
CARBAMAZEPINE;SCN1A;rs3812718;TT;LADME-PK;INCREASED_DOSE;DISEASE;EPILEPSY
NALTREXONE;OPRM1;rs1799971;AA;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;OPIOID-RELATED DISORDERS
ASPIRIN;P2RY1;rs1371097;T;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;STROKE
GEMCITABINE;CMPK1;rs1044457;TT;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;NON-SMALL CELL LUNG CARCINOMA
TACROLIMUS;SLC7A8;rs7141505;AC + CC;LADME-PK;DECREASED_METABOLISM;OTHER;LIVER TRANSPLANTATION
MERCAPTOPURINE;NUDT15;rs55713253;CC;DOSAGE;INCREASED_DOSE;OTHER;ACUTE LYMPHOBLASTIC LEUKEMIA
CYCLOPHOSPHAMIDE, DOXORUBICIN, PACLITAXEL;ABCC2;rs145008610;AA;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;BREAST NEOPLASMS
DEOXY-THIOGUANOSINE TRIPHOSPHATE, THIOGUANOSINE TRIPHOSPHATE;TPMT;rs1142345;CT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;INFLAMMATORY BOWEL DISEASES
AZATHIOPRINE;PACSIN2;rs2413739;CC + CT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;INFLAMMATORY BOWEL DISEASES
CLOPIDOGREL CARBOXYLIC ACID;ABCB1;rs1045642;AA + AG;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;CARDIOVASCULAR DISEASE
BREXPIPRAZOLE;CYP2D6;CYP2D6 intermediate metabolizer;;LADME-PK;DECREASED_METABOLISM;OTHER;SCHIZOPHRENIA
BREXPIPRAZOLE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
THIORIDAZINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3/*4 + *4/*4 + *4/*5 + *4/*6;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;MENTAL DISORDERS
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*17, CYP2D6*29, CYP2D6*34, CYP2D6*39, CYP2D6*41;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_CONCENTRATIONS;OTHER;MALARIA, VIVAX
CYCLOSPORINE;CYP3A5;rs776746;CT;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;OTHER;KIDNEY TRANSPLANTATION
RISPERIDONE;CYP2D6;CYP2D6*17;*17;LADME-PK;INCREASED_METABOLISM;OTHER;SCHIZOPHRENIA, OTHER:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY, OTHER:AUTISM, OTHER:BIPOLAR DISORDER
RISPERIDONE;CYP2D6;CYP2D6*29;*29;LADME-PK;DECREASED_METABOLISM;OTHER;SCHIZOPHRENIA, OTHER:ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY, OTHER:AUTISM, OTHER:BIPOLAR DISORDER
DULAGLUTIDE, LIRAGLUTIDE, SEMAGLUTIDE;GLP1R;rs6923761;GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;DIABETES MELLITUS, TYPE 2
N-DESMETHYLCLOZAPINE;SLCO1B1;rs4149056;CC + CT;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;SCHIZOPHRENIA
NORCLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;LADME-PK;DECREASED_CLEARANCE;OTHER;EPILEPSY
ARTEMETHER, LUMEFANTRINE;CYP2B6;rs3745274;GT;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;MALARIA
4-ENE VALPROIC ACID;CPT1A;rs2228502;GG;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;EPILEPSY
TACROLIMUS;SULT1E1;rs3775770;CC;LADME-PK;DECREASED_METABOLISM;OTHER;LIVER TRANSPLANTATION
DEXTROMETHORPHAN;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;DECREASED_METABOLISM;;
METHOTREXATE;ATIC;rs4673991;CC + CT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
QUETIAPINE;CYP3A4;CYP3A4*22;*22;LADME-PK;INCREASED_EXPOSURE;OTHER;LIVER CIRRHOSIS
METHOTREXATE;ATIC;rs4673993;CT + TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
METHOTREXATE;ADA;rs2057638;GT + TT;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
METHOTREXATE;ATIC;rs2372536;CC + CG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
METHOTREXATE;ADA;rs6017375;CG + GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
METHOTREXATE;ADA;rs371927;AA;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;RHEUMATOID ARTHRITIS
PROPOFOL;UGT1A9;rs72551330;CT;LADME-PK;DECREASED_CLEARANCE;;
PROPOFOL;UGT1A9;rs2741045;CC;LADME-PK;INCREASED_CLEARANCE;;
LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*1;;INCREASED_CLINICAL_BENEFIT;;
CODEINE, HYDROCODONE, OXYCODONE, TRAMADOL;CYP2D6;CYP2D6 poor metabolizer;;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;PAIN
ZUCLOPENTHIXOL;CYP2D6;CYP2D6 normal metabolizer;;LADME-PK;DECREASED_DOSE-ADJUSTED TROUGH CONCENTRATIONS;;
SITAGLIPTIN;GLP1R;rs6923761;GG;EFFICACY;INCREASED_CLINICAL_BENEFIT;OTHER;HYPERTENSION, OTHER:DIABETES MELLITUS
SALBUTAMOL;ADRB2;rs1042717;AA;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;ASTHMA
SALBUTAMOL;ADRB2;rs1042714;GG;EFFICACY;DECREASED_CLINICAL_BENEFIT;OTHER;ASTHMA
THIORIDAZINE;CYP2D6;CYP2D6 poor metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;DEPRESSION
ZUCLOPENTHIXOL;CYP2D6;CYP2D6 intermediate metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;MENTAL DISORDERS
PERPHENAZINE;CYP2D6;CYP2D6 intermediate metabolizer;;LADME-PK;INCREASED_CONCENTRATIONS;OTHER;MENTAL DISORDERS
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CDKAL1;rs7754840;CC;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CDKAL1;rs7756992;GG;EFFICACY;INCREASED_RESPONSE;DISEASE;DIABETES MELLITUS
SITAGLIPTIN, VILDAGLIPTIN;GLP1R;rs6923761;AA;EFFICACY;DECREASED_RESPONSE;DISEASE;DIABETES MELLITUS, TYPE 2
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2C19;CYP2C19*17;*17;EFFICACY;INCREASED_RESISTANCE;OTHER;SCHIZOPHRENIA, OTHER:MENTAL DISORDERS, OTHER:NEUROTIC DISORDER, OTHER:PERSONALITY DISORDER
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME-PK;INCREASED_CONCENTRATIONS;DISEASE;MAJOR DEPRESSIVE DISORDER
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2D6;CYP2D6*3;*3;EFFICACY;INCREASED_RESISTANCE;OTHER;SCHIZOPHRENIA, OTHER:MENTAL DISORDERS, OTHER:NEUROTIC DISORDER, OTHER:PERSONALITY DISORDER
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP1A2;CYP1A2*30;*30;EFFICACY;INCREASED_RESISTANCE;OTHER;SCHIZOPHRENIA, OTHER:MENTAL DISORDERS, OTHER:NEUROTIC DISORDER, OTHER:PERSONALITY DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;DOSAGE;INCREASED_DOSE;OTHER;LIVER TRANSPLANTATION
TACROLIMUS;CYP3A4;rs35599367;AG;DOSAGE;DECREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION
TACROLIMUS;CYP3A4;rs2740574;CC + CT;DOSAGE;INCREASED_DOSE;OTHER;KIDNEY TRANSPLANTATION
EFAVIRENZ;CYP2B6;rs4803419;C;LADME-PK;DECREASED_CONCENTRATIONS;OTHER;HIV INFECTIOUS DISEASE, OTHER:MISSED DOSE
ANTIDEPRESSANTS;SLC22A3;rs2292334;AG + GG;DOSAGE;INCREASED_DOSE;OTHER;DEPRESSION
